A farkon barkewar cutar, Shugaba Donald Trump da babban jami'in Fadar White House Peter Navarro shirya da kyauta na allurai miliyan 63 na hydroxychloroquine (HCQ) zuwa tarin magungunan Amurka don yaƙar Covid-19. Gwamnati ta fara tabbatar da HCQ a cikin Maris 2020, bayan Trump, bisa shawarar likitocinsa da masu ba shi shawara na kimiyya, ya yaba wa HCQ a matsayin "mai matukar karfafa gwiwa," "mai karfi," da kuma "mai sauya wasa." Yayin da HCQ (da kuma ta analogue mai kama da tsari chloroquine) ba FDA-ya nuna don Covid-19 ba, sananne ne cewa yana da takamaiman aikin sarrafa magunguna don hana ƙwayoyin cuta shiga cikin sel, Abubuwan sinadarai waɗanda aka yi amfani da su don amfanin rigakafin cutar tun daga 1934.
Bayan shawarar Trump, ba zato ba tsammani HCQ ta zo karkashin wani mummunan harin da bai dace ba daga jami'an tarayya, 'yan jaridu, wadanda ake kira "masu binciken gaskiya," da kuma malaman jami'a. Yawancin hare-haren sun ƙunshi bayanan karya game da ilimin harhada magunguna da amincin HCQ ko ƙoƙarin Trump na samar da HCQ ga majinyata masu cancanta.
FDA ta fara ba da izinin amfani da gaggawa (EUA) don HCQ a cikin Maris 2020, amma janye izini a ranar 15 ga Yuni, 2020, yana mai cewa maganin shine "mai yuwuwa yayi tasiri a cikin kula da COVID-19 ga [Amurka] amfani masu izini.” Kusan lokaci guda, FDA kuma rubuta rahoton da ake tambaya a tsarin da ke sukar amincin HCQ. Labarin FDA ya dogara ne akan bincike na farko da na lokaci-lokaci, kuma ba nunin amincin tarihi ba ko kuma bisa dacewa da amfani da magani na HCQ dosing, rubutawa, lokaci, da tsawon lokaci. FDA sai da alama tana lakafta bincikenta a matsayin tabbatacce, a alamance ta rufe kofa kan la'akari da sabbin binciken.
Ƙididdigar Tsaro na FDA Hydroxychloroquine Dangane da: Sanannun Magungunan Ƙarfafawa, da Amfani da Ba a Kula da Lafiya na asibiti
Bisa ga taƙaitaccen taƙaitaccen shafi 15 mara kyau Bayanan aminci na HCQ wanda aka buga a ranar 19 ga Mayu, 2020, FDA ta yi la'akari da bayanai daga Tsarin Bayanan Guba na Kasa (NPDS) wanda ke nufin da alama ya haɗa da amfani da marasa sinadarai da/ko HCQ mai sarrafa kansa da/ko bayanan wuce gona da iri a cikin kimantawar asibiti.
Babu shakka, wuce gona da iri ko duk wani wanda ba a kula da shi ta hanyar likita ba, bincikar kansa, da/ko yin alluran kai na wani Magungunan sayan magani yana da babban yuwuwar haifar da munanan al'amura, musamman saboda maganin rigakafi/tsawon lokacin HCQ da/ko chloroquine ba a bayyana nan da nan ga jama'a ba. Na lura, "idan ya zubar da jini yana kaiwa" - nau'in labarai masu ban sha'awa Rahoton ya haifar da damuwa da matsananciyar damuwa da Amurkawa tare da rashin cikawa ko kuskuren watsawa da bayanin mace-mace don kaiwa ga sarrafa "tankin kifi" da kansa. chloroquine mai dauke da kayayyakin tsaftacewa na dauke da wasu sinadarai don magance kansu daga yiwuwar bayyanar Covid-19. Wannan ya haifar da rashin lafiya mai tsanani saboda shayar da guba mai guba ko kuma wuce gona da iri, wani lokacin har ya kai ga mutuwa.
Dogaro mai Tsanani akan Bayanan Bayanan Tsarin Ba da Rahoto na Abubuwan da suka faru na FDA
A cikin rahotonta, FDA ta kuma yi la'akari da Tsarin Rahoton Abubuwan da suka faru (FAERS) wanda a cewarsa Table 6 kawai ya ƙunshi kusan 256 m rahotannin aukuwa mara kyau a cikin tsawon watanni biyar a duk duniya lokacin da aka gudanar don Covid-19. Na lura, yawancin rahotannin da FDA ta ambata sun haɗa da allurai waɗanda ko dai ba a san su ba da / ko kuma sun kasance a ko'ina daga 2x zuwa 6x matsakaicin iyakar kulawa na HCQ don wani Alamar asibiti ta FDA da shawarwarin kashi na masana'anta. A saman wannan, ya bayyana cewa FDA ba ta la'akari da HCQ ba Tsarin tushe/gishiri ko mahimmancin nauyi na tushen HCQ (a kan ma'aunin MG/kg) kamar yadda bai bayyana don yin bincike ko ba da rahoton ma'aunin marasa lafiya ba. Ba a sani ba idan an yi la'akari da duk wani aikin tantancewar gabobin a matsayin wani ɓangare na tarin amincin su ko kimantawa - muhimmin la'akari tunda HCQ shine. hanta metabolized da kuma really excreted, tare da gyare-gyaren sashi mai yuwuwar da ake buƙata don aikin hanta ko aikin koda da ba ta da iyaka.
Wadannan da wasu mahimman abubuwan ragewa da an buƙaci su don ingantaccen kimanta lafiyar HCQ ta FDA.
Da alama FDA ta haɗa da Sanann Maganganun Magunguna-Magungunan Magunguna da Ƙwararren Ingancin da Ba a sani ba daga Rugujewar Magungunan Intanet:
Ingantacciyar hulɗar miyagun ƙwayoyi da magunguna, wasu sun kafa har zuwa 1980s, ya faru a cikin mutanen da suka sami HCQ ta hanyar kewaya tashoshi na al'ada na haƙuri / rubutawa. Baya ga rashin daidai / wuce kima kashi / tsawon lokacin da aka yi amfani da shi, rahoton na FDA yayi cikakken bayani game da yadda HCQ ya bayyana cewa an ba da shi daga kantin magunguna na ketare waɗanda ke da tarihin samar da magungunan mabukaci tare da ƙarancin inganci. masu guba masu guba.
A cikin rahotonta, FDA ta nuna cewa yawancin lokuta masu haɗari (69% na 331 jimlar rahotannin aminci na HCQ) sun haɗa da maza tare da matsakaicin shekaru a farkon 60s, duk da haka FDA ta yi amfani da waɗannan binciken marasa kyau don bada shawara game da amfani da HCQ kowane rukunin shekaru.
A saman wannan, Page 7 na rahoton ya nuna mafi yawan 109 tsanani HCQ m cardiac m aukuwa lokuta lokuta da FDA aka ambata kuma kai tsaye contraindicated da kyau kafa FDA da/ko manufacturer dosing jagororin ga HCQ.
Musamman:
- 92 daga cikin 109 masu tsanani na cututtukan zuciya (84%) sun ba da rahoton amfani da aƙalla wasu magunguna guda ɗaya wanda ke tsawaita tazarar QT.
- 75 (69%) na cututtukan zuciya sun ba da rahoton yin amfani da azithromycin lokaci guda.
- 22/25 [88%] na m shari'o'in da aka ruwaito amfani da wani concomitant QT-tsawaita magani.
A wasu kalmomi, FDA ta haɗa da sanannun, rashin lafiya na asibiti, dogon lokaci, hulɗar miyagun ƙwayoyi, amfani da rashin amfani, da/ko rubuta kurakurai a cikin ɓata amincin HCQ.
Yana da kyau a ce kashi 84% na abubuwan da suka faru na zuciya (kuma mai yiwuwa yawancin sauran abubuwan da suka faru na HCQ da aka ba da rahoton da aka jera a cikin bayanin FDA) za a iya hana su ta hanyar ilimin haƙuri na asibiti, kulawar asibiti da ya dace, da kuma bayar da shawarwari / shawarwarin magunguna na magani na sanannen inganci daga kantin Amurka, ciki har da ma'auni na likitancin zuciya don yin hulɗar magani. Har ma da ƙarin abubuwan da suka faru za a iya hana su tare da taƙaitaccen tarihin tarihin zuciya da/ko na'urar lantarki. A hakika, Lopinavir/ritonavir (Paxlovid), wanda ake amfani dashi don magance Covid, yana da ingantaccen tasirin tsawaitawa na QT. kamar HCQ, amma tun da gargadi game da mu’amalar miyagun kwayoyi An sanar da su sosai kuma an ba da Paxlovid a ƙarƙashin kulawar likita/magunguna, rahotannin cututtukan zuciya da ba a saba gani ba, guje wa cututtukan zuciya da sauran matsalolin aminci.
Babu wani magani da ya taɓa dacewa ga kowane mutum ɗaya, kuma ba kowa ba ne ya cancanci a yi masa allura tare da HCQ don dalilai masu tushe da suka haɗa da aikin gabobin jiki, yanayin zuciya, da/ko haɗarin kafa abubuwan da ba su dace ba. Koyaya, ana iya rage mu'amalar muggan ƙwayoyi da miyagun ƙwayoyi ta hanyar daidaita kashi da/ko dakatar da wasu magunguna na ɗan lokaci na ɗan gajeren lokacin da ake buƙatar HCQ don hana ko kula da farkon bayyanar Covid-19. Na dabam daga waccan, sauran gargaɗin FDA game da aminci da aka bayyana a cikin rahoton nata sun bayyana a maimakon haka suna bayyana waɗanda ke da alaƙa da dozin na dogon lokaci da ba a buƙata don Covid-19 da wuri- ko alamun fallasa ko na wucin gadi da kuma ko'ina a faɗi "dakatar da yaduwar".
Hydroxychloroquine shine Haƙiƙa Amintacce Idan An Yi Amfani Da Kyau:
Bayan yawaitar cutar amai da gudawa na amfani da HCQ ba tare da izini ba, saƙo mai haske daga FDA ta Amurka ga jama'ar Amurka game da amincin amfanin HCQ yakamata ya faru amma bai yi ba. Madadin haka, FDA ta yi shuru, ba ta gargadi masu amfani musamman game da bin tsarin likitancin Amurka da kantin magani ba, kuma ta bar Amurkawa su yi (wani lokaci m) kurakuran amfani da HCQ. FDA ta fitar da sanarwar sa ido da gaske tana bayyana HCQ a matsayin "mara lafiya" ga Covid-19. FDA ta yi wannan sanarwar aminci duk da CDC ta inganta amfani da HCQ a cikin 2019 a matsayin lafiya kuma "wani in mun gwada da kyau jure magani. "
A zahiri, ana ɗaukar HCQ da aminci ga alamun COVID-19 waɗanda CDC ta faɗi cewa "Ana iya rubuta HCQ ga manya da yara na kowane zamani. Hakanan za a iya ɗauka ta hanyar lafiya ta mata masu ciki da masu shayarwa.” CDC tana magana akan amfani da HCQ na dogon lokaci don jiyya na cututtukan cututtuka.
Idan CDC ta ɗauki shi lafiya don dogon lokaci magani, yana da ma'ana kawai a ɗauka cewa tabbas zai kasance lafiya ga gajere amfani da saurin yaɗa cututtuka kamar Covid-19.
Daruruwan sauran karatu (wanda aka jera a cikin littafin littafin wannan takarda) an nuna su da wuya kawai suna ba da rahoton matsalolin tsaro a cikin ƙayyadadden lokacin HCQ da aka gudanar don Covid-19. Daga cikin waɗancan, kusan dukkansu ƙanana ne, kuma daga cikin waɗannan, duk sun bayyana sun yanke shawarar daina shan magani. Takaitattun rahotannin aminci na HCQ an yi dalla-dalla a cikin taƙaitattun abubuwan da ke biye da kowace magana a cikin littafin littafin.
Duplicity FDA: FAERS Yayi Yayi kyau don Muzgunawa Tsaron Hydroxychloroquine, amma BA YA KYAUTATA Amincewar allurar mRNA:
Dogaro mai nauyi na FDA akan rahotannin AERS wajen wulakanta HCQ a cikin rahotonta ba kawai ba ba da son zuciya ba - ya kasance m.
A baya, FDA da NIH sun sha tsawatar amfani da FAERS a matsayin suna da "ba a tabbatar ba"Da kuma"ba kafa dalili ba"Kuma"dangantaka ba dalili ba ne” a matsayin uzuri ga alama a zaɓi watsi da haɗin kai, da kuma yadda FAERS "Ba za a iya kafa ƙimar abin da ya faru tare da rahoton [FAERS] ba"da kuma yadda binciken FAERS ya kasance"babu tabbataccen hujja na alaƙar da ke tsakanin fallasa ga samfurin da abin da aka ruwaito. "
Saboda haka, ta asusun FDA, kowane ɗayan shari'o'in 256 na HCQ FAERS da ake zaton ingantacce da aka ambata a cikin rahotanni na iya kasancewa:
1) Karin gishiri,
2) Ba a yarda a yi amfani da shi don ƙididdigewa ko nuna adadin abin da ya faru ba, (wanda manema labarai suka yi duk da haka),
3) An danganta shi da abubuwan da ba HCQ ba da
4) *Idan* aka yi amfani da shi don ƙididdige ƙididdigewa, yuwuwar ƙididdige adadin abubuwan da suka faru na lokuta 291 worldwide zai wakilci wani ɗan ƙaramin dangi mara kyau abin da ya faru, amma ba mu san hakan ba saboda FDA ba ta bayar ko kimanta lamuran 291 ba tare da jimlar adadin marasa lafiya. A takaice dai, adadi na 291 shine lamba, amma menene denominator?
FDA ta dogara da shawararta ta aminci a kan roƙon duniya na jimillar rahotanni 331 daga duk tushe (kasuwanci mai yawa wanda ya kasance a fili rashin amfani da rashin dacewa na asibiti da / ko overdoses da / ko a cikin mutane sama da shekaru 60), sama da kimanin watanni biyar, ciki har da rahotannin 256 na duniya a cikin FAERS, ciki har da: 25 jimlar rahotanni a cikin dukan wallafe-wallafen 20 da aka buga na 11S. "wasu" rahotanni na asali nebulous. An yanke hukuncin HCQ/chloroquine ɗari ɗaya da tara a matsayin "masu haɗari na zuciya" kuma ƙarin 113 "masu tsanani marasa zuciya."
Babu wata alama da aka ba da cewa abubuwan da ba su da kisa ba su da cikakkiyar warwarewa sakamakon dakatarwar amfani da HCQ na ɗan gajeren lokaci ko kuma cikakken tsarin jiyya don hanawa ko kula da Covid-19.
Kamar yadda a bayyane yake, munanan abubuwan da suka faru suna da abubuwa masu ragewa. Ana ɗaukar HCQ a matsayin magani mai aminci tare da ƙananan rahotannin aukuwa mara kyau. A zahiri, cikakken bincike don jimlar adadin rahotannin abubuwan da suka faru na HCQ/chloroquine a cikin shekaru 55 da suka gabata na amfani da duniya (ciki har da ƙananan abubuwan da ba su da kyau da kuma abubuwan da suka faru da suka samo asali daga sanannun hulɗar miyagun ƙwayoyi) a cikin bayanan FDA AERS sun nuna babban adadin lokuta 32,011 bisa ga sabuntawar bayanan kwanan nan a cikin 2024. Amfani da asibiti na asibiti sinadarai na HCQ sun kasance kusan shekaru 100, amma aminci da kuma bayanan tattara bayanan abubuwan da suka faru sun kasance kawai a kusa da 1969.
Amincin Dangi na Hydroxychloroquine's 32,011 vs> 1,000,000 mRNA Rahoton FDA:
Yayin da rahotannin abubuwan da ba su dace ba 32,011 ba su da mahimmanci, kwatanta hakan da na fiye da miliyan 1 m rahotannin aukuwa an ƙaddamar da shi ga Tsarin Bayar da Maganganun Halittun Alurar rigakafin Alurar riga kafi (VAERS) don harbin mRNA Covid-19, duka, tun daga 2021 (watau ~ 3.5 shekaru) - kuma ba a duk duniya ba - amma a Amurka kadai, tare da dubun dubatan waɗancan miliyan da aka san suna da tsanani, dindindin, da/ko masu mutuwa.
A gaskiya ma, adadin duniya mutuwar an ruwaito daga allurar mRNA (bisa 37,500) a cikin shekaru ukunsa a kasuwa ya zarce jimlar adadin abubuwan da suka faru mara kyau da suka faru a cikin tarihin shekaru 55 na amfani da HCQ. Na bayanin kula, yawancin abubuwan da suka faru na HCQ masu alaƙa da amfani da HCQ na ɗan gajeren lokaci sun kasance ƙanana, kuma sun haɗa da abubuwa kamar tashin zuciya, rage cin abinci, da gajiya, wadanda suke da mummunan al'amuran da ke hade da magunguna daban-daban.
Duk da haka, a daidai lokacin da aka ba da rahoton bala'in bala'in mRNA, wani ƙwararrun ƙwararrun Amurka. Gaskiyar-Checkers" akai-akai sun yi amfani da megaphone ɗin su don tsawatar da Amurkawa cewa HCQ ba shi da lafiya." Manyan cibiyoyin bincike na likita da masu binciken gaskiya sun gaya wa Amurkawa cewa yawancin rahotannin abubuwan da suka faru na mRNA da mutuwar kwatsam da rahotannin asibiti na ciwon daji sune "ba dalili ba"kuma a saman wannan, ana kuma harbin Covid mRNA"Tabbatar da Safe"Da kuma"Ba Haɗari ba"Da kuma"KADA KA BUKATAR A janye A Kasuwa” [Kasuwanci nasu].
Ba ya buƙatar zama kwararre a cikin cututtukan cututtukan ƙwayar cuta don bambance rashin daidaituwa tsakanin ci gaba da EUA wanda ke biye da cikakkiyar yarda ga novel mRNA Covid injections tare da. daruruwan dubban na abubuwan da ba su da kyau, idan aka kwatanta da saurin janyewar HCQ EUA bayan 331 worldwide Rahoton abubuwan da ba su dace ba na HCQ, yalwar da alama suna da alaƙa da rashin dacewa/amfani/dosing/ dubawa.
Manyan Labarun Jarida da ke ayyana Hydroxychloroquine a matsayin mara lafiya ga Covid-19:
Kafin cire HCQ's EUA, da alama sosai hadewa da kuma babu shakka sun daidaita Saƙon ya fito kan HCQ daga jaridun Amurka, wanda ya sa ya zama kamar shawarar HCQ ba wai kawai shawarar Trump ba.unsafe"amma kuma"bai yi aiki ba"don Covid-19. Harvard, Stanford, da Scripps masana kimiyya (bi da bi) sun gargadi Amurkawa ta hanyar Washington Post Labari kokarin Trump na daukar HCQ shine "matsananciyar wahala"Da kuma"Idan da akwai bege [HCQ], wannan ita ce mutuwar ta"Da kuma"Abu ɗaya ne ba a sami fa'ida ba, amma [HCQ] yana nuna cutarwa daban-daban. "
Masana kimiyya da aka ambata a sama suna magana ne Lancet da kuma New England Journal of Medicine labaran da aka yi la'akari da su a matsayin hanya don sukar shawarar Trump na aiwatar da HCQ na Covid-19. Daga baya editocin mujallu sun janye wallafe-wallafen biyu saboda yaudara.
An janye su daga mujallu lokacin da marubutan su "ya ki bayarwa [masu duba] samun damar duk bayanan da suka nema"Bayan fitowar lokacin da aka tambayi sakamakon da masana kimiyya a waje suka yi tambaya dalilin da yasa HCQ, tare da irin wannan rikodin tarihin tarihi ba zato ba tsammani ya bayyana rashin aminci ga marasa lafiya na Covid-19. Tambayoyi sun haifar da bincike wanda a ƙarshe ya nuna cewa babu wani marubucin littafin. ko kuma Mujallar "masu bita-tsara" sun taba ganin bayanan marasa lafiya 96,032 tun da farko, domin bai taba wanzuwa ba. Tambaya mai mahimmanci ita ce: me ya sa wadanda ake kira "masu bita-bita" suka ba da izinin buga sakamakon binciken lafiya da bai dace ba ga HCQ kafin su tabbatar da waɗannan binciken?
Bayan gyarawa, Lancet ta Editan Richard Horton, ya ce ya kadu tare da marubutan, suna kiran binciken HCQ-lambasting "misali mai ban mamaki na rashin da'a na bincike a tsakiyar yanayin gaggawa na lafiya na duniya.” Editan Lancet ya yi “…uzuri ga editoci da masu karatun littafin Lancet ga matsalolin da wannan ya haifar. "
Haka manema labarai da ba su da wata damuwa game da sanya wa gwamnatin Trump lakabi da kuskure don ƙoƙarin ci gaba da HCQ da daidaita saƙon a kansa ya kusan yin shiru kuma ba shakka bai yi ba. daidaitawa or daidaita duk wani gyara da suka yarda da cewa ba su tabbatar da bayanan da ake tambaya ba duk da cewa rayukan mutane na cikin hadari.
An sani a yau cewa jaridu da jaridu ba kawai ba ne ba daidai ba amma ba daidai ba, game da bayanin da suka yi da kuma hanyoyin da suka yi amfani da su don cimma matsayarsu duk da cewa sun bayar. "Gaskiyar gaskiya," kasancewa "akan duba gaskiya" da kuma isar da "gaskiya na gaske," da/ko da'awar zama"bincike-bincike na tsara. "
Sakamakon Buga Bayanan Hydroxychloroquine na Karya?
Abubuwan da aka janye yanzu sun kasance da farko sun rubuta su Mandeep Mehra MD, farfesa a Makarantar Kiwon Lafiya ta Harvard wanda kuma ke aiki a matsayin darekta na Brigham da Cibiyar Zuciya da Zuciya ta Asibitin Mata. A gefe guda, Dr. Mehra yana riƙe muƙamai/mukamai biyu har zuwa yau, a cikin abin da ya zama duk ma saba tsarin na Harvard da sauran fitattun jami'an jami'o'in da ke rike da matsayi masu daraja da riba duk da zamba da / ko rashin kwarewa.
Mawallafi na biyu a kan takardun biyu shine Sapan Desai MD, wanda ya yi iƙirarin samun manyan bayanai na marasa lafiya mafi girma a duniya, karkashin rusasshiyar sa yanzu Kamfanin na tushen Illinois, Surgisphere. Kamar yadda ya fito, bayanan sa wanda ya ba da rahoton illolin da ke da alaƙa da HCQ tsakanin marasa lafiya da Covid-19 bai taba wanzuwa ba, da kuma "masu bitar takwarorinsu" a matakin da ake zaton "manyan matakin" Lancet, Da kuma New England Journal of Medicine wanda aikin sa shine yin bitar bayanan da gaske bai taba tabbatar da duk wani binciken cutar da ake tambaya ba wanda ya bambanta da tarihin aminci na HCQ a cikin cututtukan autoimmune da zazzabin cizon sauro, kamar yadda dalla-dalla a cikin ɗimbin wallafe-wallafe tare da bayanan AERS na FDA.
Marubucin takarda na uku, Farfesa Frank Ruschitzka MD, (kamar Harvard's Mehra) har yanzu yana rike da Shugabancin Cibiyar Zuciya ta Jami'ar da Sashen Nazarin Cardiology a Asibitin Jami'ar da ke Zürich, Switzerland.
Marubuci na hudu akan takarda, Amit Patel MD yana da alaƙa da Sapan Desai ta hanyar aure. Shi ne kawai marubucin da aka "hukumta" kai tsaye don buga bayanan zamba, yana da "An amince da juna" don samun matsayinsa na wanda ba a biya shi ba, a matsayin malami a Jami'ar Utah, ƙarewa.
Karin bincike kan Sapan Desai da wasu suka samu da yawa, munanan abubuwan da suka faru na zamba na likita tare da yawaitar faruwar hakan rashin aiki na asibiti da kuma sakaci gabaninsa Lancet bugu - wani abu da ya kamata a bibiyar takwarorin mujallu da kuma la'akari da shi yayin nazarin bayanansa don bugawa.
Ko da yake an ƙyale Dr. Desai ya ba da lasisin likitansa da son rai a Ohio da Illinois, ya bayyana yana da alaƙa da abubuwan da suka shafi kula da marasa lafiya. Wani bincike na intanet bai nuna wani karar da ke kan Dr. Desai ba saboda buga bayanan likita da zamba. Babu tabbas idan Dr. Desai ko wasu mawallafa suna fuskantar tuhume-tuhume na aikata laifuka don ƙaryata mummunan binciken asibiti game da HCQ.
Ba a san ko me zai faru ba idan wasu ɓangarorin sun sami “masu bita-tsara” na mujallu sakamakon barin waɗannan bayanan HCQ na aminci na yaudara.
Ƙaddamar da Makaho na Ƙirar Jarida ta Lay Press Bugawa:
'Yan siyasa kuma "amintattun 'yan jarida"tare da ilimi ko horo a kimiyya - balle kuma babu tushe a cikin ilimin harhada magunguna - balle kuma babu wani tushe a cikin rikitattun magungunan bincike, cututtukan cututtukan cuta, ko kimantawar asibiti na amincin magunguna - cikin farin ciki ya yi tsalle ya soki shawarar HCQ na Trump, dangane da wallafe-wallafen mujallu da ba a tantance ba ko kuma cikin zamba.
Ga kadan daga cikin da yawa ambato:
- The New York Times ya ce kokarin Trump na HCQ ya kasance "Wataƙila ba don komai ba"kuma tasan yadda"Kwararrun likitoci a duk faɗin ƙasar… sun yaba da janyewar FDA na [amfani da gaggawa] hawaye” a cikin magana game da HCQ.
- Dan jaridan Jamhuriyar Arizona da ba shi da tabbas EJ Montini, wanene na shekaru da, da kyar ke iya rubuta labarin da ba ya bata wa Trump rai ba, wanda kuma aka yi ra'ayi kan amincin miyagun kwayoyi, yana mai kiran mabiyan Trump "hydroxychloroquine kook"ya kara da kwatankwacinsa ga kwararrun likitocin Trump (watau har da naku da gaske) a matsayin "coterie ko bootlicking minions” [SIC] Montini ya amince da farfagandar da wasu ‘yan jarida suka yi game da Lancet da New England Journal of Medicine a matsayin ba komai ba ga hikimar Littafi Mai-Tsarki, fiye da kowane shawara, tattaunawa, ko bincike mai mahimmanci.
Idan wani ya manta game da ainihin furucin da Shugaba Trump ya yi, a hankali. m shawara Bayanan sun nuna cewa HCQ na iya zama da amfani ga Covid-19, ga ainihin bayanansa da ya yi yayin taron manema labarai:
Trump ya fada kai tsaye yayin wani taron manema labarai a ranar 20 ga Maris, 2020 cewa ya ba da shawarar amfani da HCQ don jinya da wuri.a farkon" na Covid-19 cututtuka a 0:22 a cikin bidiyon da ke sama. Trump ya yi daidai da ya ba da shawarar cewa saboda a yau, akwai shaidu da yawa cewa jiyya da wuri (ko ma rigakafi) tare da HCQ yana da tasiri sosai ga Covid-19.
A yayin taron manema labarai na Maris 2020 da kuma tsayawa tare da Trump, Fauci ya bayyana daidai da cewa "[HCQ] guba ba su da yawa, kuma ta fuskoki da yawa, ana iya juyawa"A 1:50.
Bayan shawarwarin Trump da tarin samfura na gaba, HCQ ta sami wani abin ban mamaki, da alama an haɗa kai, faɗuwa daga tagomashi.
Da farko, Fauci ya canza ra'ayinsa game da bayaninsa na Maris 2020 bayan buga a ciki New England na Medicine on Bari 1, 2020 (daga baya an ja da baya), hanyoyin magance matsalar FDA a cikin bita kan Bari 19, 2020 (wanda aka tattauna a sama), da kuma Lancet ta bugawa akan Bari 22nd, 2020 (daga baya an janye).
Duk da shaidar tarihi na HCQ yana da aminci da inganci, likitoci, 'yan siyasa, da ƙungiyoyi, suna ɗaukar jagorancinsu daga labarun da ba daidai ba daga Fauci, 'yan jaridu, da wallafe-wallafen likita, sun garzaya don yin ɓarna da rashin kuskuren anti-HCQ a saman labarun anti-Trump mai tausayawa.
Wadannan su ne kadan daga cikin dozin a kan dozin:
- Watanni hudu bayan bayyana ainihin akasin hakan yayin bidiyon taron manema labarai na sama, a ranar 29 ga Yuli, 2020, Dr. Anthony Fauci ya gaya wa CNBC cewa akwai "babu shaida yana da tasiri.” Fauci shima ya canza ba zato ba tsammani, ya kara da cewa HCQ na Covid-19 "bai yi ma'anar kimiyya ba.” Da alama ba a tantancewa ba ko kallon sama (karya kuma yanzu an janye) Jaridar New England da kuma Lancet karshe.
- Josh Cohen, a Forbes.com Babban marubucin fannin kiwon lafiya na PhD (wanda ke da ilimin tattalin arziki) daga baya ya ba da labarin wani op-ed na rashin hankali wanda ya danganta da wani bincike daga Faransa yana bayyana cewa shawarar HCQ na Trump. zai iya zama "Yana da alaƙa da Mutuwar 17,000"...sai dai Cohen ya bar"zai iya zama”bangare. Forbes ta Tufts- Harvard- da Jami'ar Pennsylvania- horarwa "Kiwon lafiya Analyst" (wanda kuma yayi ra'ayi akan sauyin yanayi da dokar rage hauhawar farashin kayayyaki) cikakken sakaci da ambaton cewa irin wannan adadin an yi cikakken ka'ida, hasashe, kuma ƙiyasin ya kasance. karin magana na karshen zamani"tausayi amfani"scenario inda HCQ zai iya samun, a zahiri ya haifar da karuwar mace-mace da kashi 11%. Ya kuma hukunta "rashin tabbas, yanayin gwaji na hydroxychloroquine"Duk da cewa ba gwaji ba kuma tabbataccen binciken asibiti ya wanzu kafin a buga labarin nasa. Forbes ' taken labarin mai ruɗi mai ban tsoro wanda maimakon zama "bincike" da alama yana yin daidai da rubuce-rubucen da ba" manazarta kiwon lafiya " The Hill da kuma POLITICO. The bugu na asali wanda Cohen's (da Hill's da kuma Siyasa) labarin ya dogara, ya kasance (a cikin abin da ya zama sanannen tsari) janyewa bisa bukatar babban editan mujallar bugawa biyo bayan binciken masu biyan mujallu wanda ya gano manyan nakasu a cikin bayanan binciken (da sauran kasawa). Duk da haka, abubuwan da ke sama (ban da sauran) labaran labarai suna ci gaba da kasancewa kai tsaye da kan layi, suna tattara labarai daga jama'a waɗanda suka yi imanin cewa gaskiya ne kuma na yanzu, har yanzu ana amfani da su azaman magana akan Trump. Za a sake gyara waɗannan tsoffin tsoffin op-eds abada faruwa?
- Likita kuma fitaccen masanin harkokin likitanci Dr. Vinay Prasad, Jami'ar California a San Francisco masanin cututtukan daji ya bayyana ta hanyar a MedpageToday.com op-ed: "Kuma, ee, bari mu kwanta: hydroxychloroquine baya aiki ga COVID,"Yayin da yake kuka a cikin wannan labarin na MedPageToday cewa kowa ma an ba da izinin a ba da murya ga bangaren adawa a cikin muhawarar Covid-19. Kamar sauran mutane, Prasad ya rufe kofa sakamakon binciken farko. madadin jiyya na Covid-19 kamar HCQ don ba da murya ga "lebur-kasa.” Dr. Prasad ya kuma bayyana ta hanyar a Washington Post op-ed cewa "Hukuncin likitancin Trump ba daidai ba ne. Misalin da ya kafa ya fi muni.” Ya kuma bayyana ta shafin Twitter/X cewa "Gwamnatin da ta gabata tana son hydroxychloroquine da ivermectin da sauran magungunan wauta marasa inganci. "
- Sashen Nazarin Cututtuka na Jami'ar Yale Dr. bai nuna wata fa'ida ba don rage yiwuwar mutuwa ko saurin murmurewa."Wasikarsa da aka ambata ta kasance a kan layi, tana nunawa sosai a sakamakon binciken intanet har yau." Dr. Dr. Harvey Risch, fitaccen masanin cututtukan cututtuka da abokin aikin Yale, yayin da ya kasa yin hakan kai tsaye haɗa littafin Dr. Risch haka kuma ba a lissafta wani laifi na musamman kan tsarin binciken Dr. Risch ba. A lokacin, binciken da aka gudanar da kyau ya ci karo da maganar Dr. Vermund da ra'ayinsa game da HCQ, tare da da yawa akan ƙarin karatu tun lokacin da aka sake shi, amma babu sabuntawa ko sake dubawa daga Dr. Vermund da ke magance waɗannan bayanai masu kyau.
- WHO ta ce HCQba shi da wani tasiri mai ma'ana akan mace-mace ko asibiti"da" sun ba da shawara mai karfi game da amfani da hydroxychloroquine" da kuma cewa "…kada kuyi la'akari da wannan magani mai dacewa. "
Duk da yake akwai wani yunƙuri mai ban sha'awa da tallata jama'a don tozarta shirin HCQ na Trump, babu ƙaramin ƙoƙari don kimanta abin da ake faɗa, gyara bayanan, ko kuma sadar da zance da ƙididdiga marasa kuskure game da HCQ biyo bayan koma bayan labarin ko kuma yayin da sabbin bayanai suka fito suna cin karo da tsoffin bayanai.
Covid-19 babban gwaji ne na kimiyyar likitanci, amma maimakon ɗaukar lokaci don rage yanke shawara da tsayawa, mai da hankali, da dogaro da haƙiƙa, kimiyya, da tushen asibiti, amintattun jami'an tarayya, likitoci, da masana kimiyya na Amurka sun firgita kuma a maimakon haka cikin ƙwazo ya yi tsalle zuwa tsada, sabon labari "saurin sauri" kan shawarar kamfanoni, masu riba. A gigice kaɗan ne suka ja da baya, kaɗan kuma suka yi shiru. Wannan hali ya yi daidai da bayanan 2019 da ke nuna hakan 91 kashi na likitocin likitanci sun yi imani da cewa samfuran da aka yarda da FDA suna da lafiya gaba ɗaya kuma koyaushe suna amfanar marasa lafiya.
Kamar yadda aka bayyana a sarari tare da amincewar Big Pharma Covid-19, mutane na iya yin amfani da bayanan kimiyya don haɓaka labari, amma ci gaba da tarin bincike na gaskiya, tare da ƙarin binciken, kuma magudi a ƙarshe ya zama mai wahala, idan ba zai yiwu ba. Gaskiyar kimiyya daga ƙarshe tana haskakawa. Cikakkun shaida ta hanyar bincike-saɓanin binciken annoba game da aminci da ingancin samfuran Covid-19 a ƙarshe sun bayyana.
Masana kimiyyar ilimin kimiyya na gaskiya ba su dauki makauniyar umarnin tafiya daga 'yan jaridu, WHO, hukumomin tarayya, Anthony Fauci, gwamnonin jihohi, ko wani ba. Mun bincikar bayanan ta hanyar dabara da haƙiƙa kuma mun bar binciken binciken asibiti na zahiri ya yi magana da kansu. Haƙiƙa ce ta kowane masanin kimiyya kamata sun biyo baya, maimakon hanzarta zuwa ga ƙarshe - annoba ko a'a - da hauka fahimtar farko, mai sheki, sabon abu na Big Pharma, sannan kuma ba da izini da sauri ga marasa lafiya da 'yan ƙasa ta hanyar umarni, buƙatun ma'aikata, ko kuzarin kuɗi.
Ana Zaluntar Likitoci da Magunguna don Rubutu da Rarraba HCQ:
Likitoci kamar kaina da suka bayar da shawarar wani madadin magani kamar ivermectin ko HCQ sun kasance mãsu, izgili a kan layi ta hanyar "'yan jarida masu amintacce" da kuma "masu binciken gaskiya" a matsayin wani ɓangare na "maƙarƙashiyar dama." Duk wanda bai yarda da Covid-19 mRNA ko wasu jiyya da labarai na Big Pharma Covid-19 ba an dakatar da shi, kora, da kuma fashewa a matsayin "anti-kimiyya" a duk duniya kuma cikin isa ga stratosphere ta hanyar intanet. Kuma idan hakan bai isa ba, bai ƙare a nan ba.
Bayan likitoci da masu hada magunguna sun rasa su jobs, sunayensu, ayyukansu, inshora, kuɗi, lasisi, kuma sana'o'i sun lalace. Wannan saboda a lokuta da yawa, ko da bayan sun rasa ayyukansu, jihar likita da / ko allunan kantin magani tare da faffadan iko mai fa'ida tare da kasafin kuɗaɗen masu biyan haraji marasa iyaka sun ƙaddamar da ƙararrakin shari'a game da lasisin su, suna ɗaukar tsananta wa "lakabin-lakabi" na Covid-19 (ciki har da ivermectin da HCQ) lokacin da sauran jiyya na "off-label" ba-Cibiyoyin bincike na Covid-19 sun kasance kusan kusan kowane bangare na kusan kowane aikin likita da kantin magani. A saman haka, 'yan jaridu na Amurka da "masu binciken gaskiya" sun ware kuma suka nemi kunyata masu bayarwa ta labaran kan layi.
Tun daga watan Mayu 2024, Amurkawa sun koya ta hanyar ɗan Republican Rahoton Majalisar Shari'a da kuma Elon Musk's siyan Twitter cewa Facebook, YouTube da Amazon, cewa babban labarin Covid-19, hukunci, da ba da izini an daidaita shi ta hanyar Fadar White House ta Biden ta hanyar barazanar doka kai tsaye.
Abin mamaki shine, Fadar White House ta Amurka ce ta tilasta kamfanoni masu zaman kansu su yi la'akari da ainihin gaskiyar a yanzu-wanda aka tabbatar da su zama magunguna masu tasiri (ciki har da HCQ) yayin da suke ba da shawara da / ko yin amfani da littafi, magunguna masu tsada na Big Pharma, kuma manema labaru kayan aiki ne kawai don ci gaba da ƙarfafa ayyukan ta'addanci na Fadar White House.
LOKACI YANA DA MATSALAR Idan Ya zo Ga Nasara Maganin Hydroxychloroquine don Covid-19:
Bayanan da ba su dace ba da ke kewaye da HCQ da alama an taƙaita su ga Amurka da sauran ƙasashen Yamma. An nuna HCQ yana da amfani don hana kamuwa da cutar Covid-19 na farko lokacin da aka yi aiki a matsayin ka'idar magani da wuri, wanda shine dalilin da ya sa HCQ (ko chloroquine) ya kasance. an karɓa don maganin Covid-19 a lokacin farkon cutar annoba, aƙalla a wani ɓangare, ta Kasashen 42 (ƙasashe 58 lokacin da suka haɗa da ƙungiyoyin kiwon lafiya masu zaman kansu).
Yawancin binciken da gwamnatin Amurka, jami'an ilimi, da manyan jami'an Pharma suka ambata sun yi watsi da wani muhimmin mahimmanci amma mahimmancin ilimin harhada magunguna: Duk wani Magungunan maganin ƙwayoyin cuta (ciki har da: ƙwayoyin cuta, ƙwayoyin cuta, ƙwayoyin cuta) ba su da fa'ida sosai idan aka aiwatar da su a ƙarshen matakan kamuwa da cuta, wanda a lokacin kamuwa da cuta mai saurin kwafi zai mamaye mutum. Jiyya na farko/nan da nan shine ma'aunin asibiti don maganin duk kamuwa da cuta, ko da kuwa cutar ta kasance: mura, mura, HIV, ko Covid-19. Lokaci yana da mahimmanci musamman don yin la'akari lokacin da ake kula da tsofaffi / marasa lafiya.
Duk da haka, An yi watsi da magani da wuri a cikin ɗimbin mujallolin likitanci da aka yi bita na ƙwararru, gami da (sake) na Amurka. New England Journal of Medicine. Fitattun guda biyu, waɗanda aka ambata sosai, ana nuna misalai a ƙasa:
SOLIDARITY New England Journal of Medicine (Littafi Mai Tsarki #377)
In Yuni na 2020, da New England Journal of Medicine an buga wani tsari mara kyau Gwajin SOLIDARITY Farashin HCQ. Binciken HCQ mara kyau ne saboda masu gudanar da binciken SOLIDARITY sun yi amfani da HCQ jinkirin jinkiri Hanyar don kula da marasa lafiya na Covid-19, duk da farkon magani kasancewar ma'aunin kulawa na asibiti.
SOLIDARITY wani buɗaɗɗen lakabin RCT ne (babu hannun mai sarrafa placebo) gwaji wanda ya nuna: 19% mafi girma mace-mace (p=0.23). SOLIDARITY yayi amfani da 954 matuƙar matuƙar mataki, mai mahimmanci (64% na marasa lafiya sun riga sun kasance akan iskar oxygen / iska) marasa lafiya don gudanar da HCQ. Bayanai sun nuna karuwa a cikin mace-macen HCQ a kwanaki 5-7, wanda yayi daidai da ~90% na yawan mace-mace. Kusan yawan mace-macen da ke cikin wannan binciken ya samo asali ne daga waɗancan sosai marigayi-mataki marasa lafiya na numfashi ana gudanar da HCQ. Yawan adadin HCQ shima ya yi girma sosai kuma masu gudanar da binciken sun yi ba suna bayyana don daidaita allurai dangane da nauyin haƙuri, ma'ana cewa yuwuwar yawan adadin adadin mai guba daga mafi girman allurai na iya faruwa a cikin marasa lafiya da ƙananan nauyi.
Marubutan na WHO suna magana ne game da ƙarancin mace-mace a cikin ƴan kwanakin farko don ba da shawarar rashin guba, amma da alama sun gaza yin la'akari da tsawon rabin rayuwar HCQ. Ilimin harhada magunguna/pharmacokinetics na chloroquine metabolism suna da rikitarwa, tare da rabin rayuwa yana ƙaruwa tare da haɓaka sashi. Bugu da ƙari, an ba da adadin adadin marasa lafiya da ba a bayyana ba fiye da chloroquine mai guba a matsayin madadin HCQ.
Gyarawa New England Journal of Medicine (Littafi Mai Tsarki #383)
FADAWA (Rantomized Ekimantawa na COVID-19ErapY) gwajin da aka buga Disamba na 2020 bai sami wani fa'ida mai mahimmanci ba sosai marigayi mataki, (kwanaki 9 bayan bayyanar cututtuka) a cikin marasa lafiya marasa lafiya tun lokacin da kwayar cutar ta riga ta mamaye marasa lafiya. Kamar yadda yake a cikin gwajin SOLIDARITY, jinyar da aka jinkirta don Covid-19 ko wasu cututtukan ƙwayar cuta ba shine ma'aunin kulawa ba.
Sakamakon mara kyau na iya kasancewa saboda guba daga yawan adadin da ba a saba amfani da shi ba (9.2g duka a cikin kwanaki 10) wanda aka nuna a cikin labarin baya da za a hade da karuwa a cikin haɗari. Marubuta ba su bayar da rahoton sakamako ba dangane da nauyi, BMI, ko yanayin rashin daidaituwa kamar su ciwon sukari da HCQ yakamata a yi amfani da su bisa nauyi. Kamar SOLIDARITY, marubuta sun yi ba daidaita sashi na HCQ dangane da nauyin haƙuri, ma'ana cewa mai guba na iya kasancewa mafi girma a cikin marasa lafiya na ƙananan nauyi. Bayanai sun nuna karuwa a cikin mace-macen HCQ a ranakun 5-8, daidai da ~85% na yawan abin da aka gani a rana ta 28 (ana ganin irin wannan karu a cikin gwajin SOLIDARITY).
Marubuta sun lura: “ba mu lura da yawan mace-mace a cikin kwanaki 2 na farko na jiyya ba…"amma sun kasa yin la'akari da yawan adadin da aka yi amfani da su a saman kimanin sa'o'i 1,000 zuwa 1,200 na rabin rayuwar HCQ. Gudanar da magani a kowace rana tare da tsawon rabin rayuwa yana nufin cewa za a kai ga matakan HCQ da yawa daga baya, kamar yadda ya taru. Bugu da ƙari, marasa lafiya a cikin wannan gwaji sun kasance marigayi magani kuma suna da rashin lafiya sosai (matsakaicin 9 days posting wani karin iskar oxygen, 60%). Extracorporeal membrane oxygenation (injin oxygenation na jini, babban haɗari na likita tare da 17% mace-mace). mahimmi, dogon jerin DOGARA na rashin daidaituwar hanyoyin. (Labarin intanet ne "fassara ta atomatik" daga Faransanci)
Tasirin Hydroxychloroquine yana da fa'ida a cikin Nazarin Jiyya na Farko:
Duk da farkon jiyya shine ma'aunin jiyya, masu bincike sun yi watsi da shi bisa tsari, bita-bita na 'yan jarida na "top-tier", da 'yan jaridu. A cewar wani binciken bincike na raguwa 39 da wuri magani karatu a c19early.com, sun nuna 66% mai ban mamaki [kewayon: 54-74%] ƙananan haɗari. Sha bakwai daga cikin waɗannan karatun 39 sun nuna 76% [61-85%] ƙasa mutuwa da 16 nazarin ya nuna 41% [28-51%] ƙananan abin da ya faru na kwantar da marasa lafiya.
Lateaiwatar da aiwatar da jiyya kuma ya yi nasara, amma ƙasa da haka, tare da 22% [18-26%] ƙananan haɗari daga nazarin 264. Latti sosai magani ya kasance ba shi da amfani kuma har ma da cutarwa, musamman a yawan allurai - kamar yadda za a sa ran tare da kusan kowane magungunan da aka ba da kari ga marasa lafiya na ƙarshen zamani kowane iri.
Don kwatanta wannan tasirin a gani, a nan akwai kwatance biyu waɗanda ke ba da cikakken bayani game da karatun jiyya na farko (Row 1) tare da duk binciken binciken HCQ (Row 2). Duk da yake HCQ gabaɗaya yana da alaƙa da sakamako mai kyau, binciken farko na jiyya yana da mafi kyawun sakamako, (kamar yadda yake yawanci ga sauran magungunan rigakafin ƙwayoyin cuta). Sakamako mara kyau babu shakka sun faru amma yawanci sakamakon jinkirin jiyya ne, jinkirin ganewar asali, rashin daidaituwa / tsawon lokaci, da/ko in ba haka ba yunƙurin kula da Covid-19 bayan kwafin ƙwayar cuta ya sami kwafi na kwanaki.
LOKACI NE KOMAI idan aka zo wani matakin maganin maganin rigakafi. Wannan ma'aunin magani na farko ya kasance mai zaman kansa daga ko na mura na yanayi, mura, AIDS, ko Covid-19. BABBAN: Hoton da ke sama shi ne ɓarna na HCQ binciken farko na jiyya idan aka kwatanta da duk karatun HCQ. LOWER: Gabaɗaya magana, nazarin mara kyau yana da alaƙa da yin watsi da lokaci / ƙarshen-mataki / yawan aiwatar da HCQ.
Jiyya na Ƙarshe da Ba daidai ba An Fassara Ba daidai ba azaman Hydroxychloroquine Yin Cutarwa da/ko "Ba Ya Taimako:"
Rahotannin da aka watsar da manema labarai na mummunan sakamako masu alaƙa da HCQ sun nuna lokacin da bai dace ba na HCQ a cikin hanyar "maganin marigayi" (ko wani lokacin ma sosai karatun jiyya na marigayi) da/ko nazarin da ke son yin watsi da/ba tantance jinkirin jiyya na HCQ bayan tabbatar da ganewar asali. 'Yan jarida, ba su da masaniya a cikin ilimin harhada magunguna ko ma'auni na magani, sun yi watsi da lokacin HCQ, dosing, duration, da sauran mahimman fa'idodin yayin da suke yin watsi da mummunan yanayi a kan Trump da shawarwarinsa na HCQ. Labarin su ya samo asali ne daga abin da ya zama kamar saƙon haɗin gwiwa da kuma mujallu na "manyan-matakin" da ƙwararrun ƙwararrun su "masu bitar takwarorinsu" waɗanda su ma sun yi watsi da mahimman batutuwa tare da kashi na HCQ, tsawon lokaci, da/ko jinkirin gudanarwa.
Fiye da rabin duk karatun asibiti na HCQ a cikin littafin littafin da ke ƙasa sun yi watsi da ƙa'idodin asibiti na gudanarwa na farko da saduwa da ma'anar rashin tasiri, jinkirin jinkiri - kuma duk da haka lokacin da aka haɗa tare a matsayin wani ɓangare na meta-bincike, HCQ. har yanzu ya nuna ɗan ƙaramin gabaɗaya (22% [18 26%) ƙarancin haɗari) ingantaccen tasiri.
An ƙayyadadden jinkirin jiyya a cikin cikakken littafin littafi da taƙaitattun abubuwan da suka biyo baya.
Gabaɗaya Nazarin Negative Bias a cikin Ayyukan Hydroxychloroquine?
Daya daga cikin son zuciya daga 'yan jaridu da jami'an tarayya na iya kasancewa saboda karin auna binciken da ake yi na nuna son kai da aka buga a Amurka. Abin mamaki, aƙalla nazari ɗaya na bayanai ya nuna hakan An gano nazarin HCQ daga Arewacin Amurka sau 2.4 mafi kusantar bayar da rahoton sakamako mara kyau fiye da duk karatu daga sauran duniya, hade.
Ya nuna cewa binciken guda ɗaya wanda ke da sakamako mara kyau da ke da alaƙa da HCQ (a ƙarshen 2020 kamar yadda Trump yake kan ofis yana haɓaka HCQ) yana da alaƙa da marubutan likita / kimiyya. yana da tarihin ba da gudummawa ga Jam'iyyar Democrat.
Irin wannan ƙin yarda na binciken wani abu ne wanda galibi zai ba da garantin binciken kimiyya na taka tsantsan, musamman saboda kuɗin masu biyan haraji na iya ba da tallafi kai tsaye ko a kaikaice aƙalla wani yanki na kusan dukkanin binciken asibiti na Amurka. Duk da haka, ba a ko da wani bincike da aka gabatar, wanda ya rage a yi.
Me game da Binciken Cochrane na Hydroxychloroquine?
Duk da yake sake dubawa na Cochrane kuma galibi ana dogara ne akan tunani don tarin nazarin da yawa, binciken Cochrane HCQ kawai yayi bita. Nazarin 14, (kuma an bincika 12 daga cikinsu kawai). Binciken ƙarshe na Cochrane na bayanan ya dawo a cikin Satumba 2020, yana watsi da> 90% na bayanan HCQ da ke akwai. Yaushe Cochrane zai sabunta bita don haɗa ɗaruruwan karatun asibiti na gaba? Wanene ya sani, amma a nan ne c19 ku bincike ya shigo cikin wasa wanda ya kwafi hanyoyin Cochrane (DerSimonian da Laird bazuwar tasirin tasirin), amma ya faɗaɗa shi don haɗawa. dukan akwai karatun asibiti, yana ba da tabbataccen amsa, na yau da kullun. Cikakken jerin 400+ HCQ nazarin asibiti da aka bincika an haɗa su a cikin littafin littafi.
Tare da Cochrane, 'yan jarida suna da alama sun yi watsi da babban adadin bayanan asibiti a lokacin da kuma yanzu; maimakon haka, yin amfani da zaɓin sakamako don dacewa da labarin anti-HCQ, anti-Trump. HCQ (tare da wasu jiyya da aka sake maimaitawa) yakamata a yi la'akari da su da / ko aiwatar da su azaman jiyya na farko da/ko madadin placebo, da/ko masu kwatanta fasahar mRNA ko akan wasu tsada, sabbin jiyya na Covid-19, gami da paxlovid da Remdesivir.
Dangane da waɗannan bayanan, da alama HCQ ɗin zai kasance mafi girma daga duka madaidaicin aminci da inganci - kuma tare da wadatar "bayar da" Trump - kyauta.
Kyauta, Ba da gudummawar Hydroxychloroquine vs Mai Tsada, Ra'ayin Nazarin Remdesivir na Novel:
Duk da yake yin watsi da ingantaccen binciken HCQ da aiwatar da ka'idodin hanyoyin magani da wuri da aka yi watsi da su tare da HCQ, remdesivir ya kasance. FDA ta amince kuma ta amince da ita don maganin Covid-19 dangane da binciken Afrilu 2020 wanda bai haifar da sakamako mai kyau ba..
Duk da haka, FDA ta amince da remdesivir ta wata hanya, kuma ba tare da tuntubar kwamitin shawarwarin da aka nada ba.
Irin wannan amincewar gaggawa ta faru a cikin EU, kafin a fitar da bayanan gwaji na WHO mara kunya, kuma a bayyane yake. yayin da m sakamakon gwaji da aka sani ga manufacturer. Gangamin tallan tallace-tallacen na Gileyad ya ci gaba duk da ingantaccen inganci da rashin bayyana gaskiya a cikin yardawar FDA/EU.
Gwajin SOLIDARITY, wanda kuma ya ƙunshi hannu wanda ya yi nazarin remdesivir, ya nuna cewa remdesivir. bai rage mace-mace ba ko rage lokacin da ake ɗaukar marasa lafiya don murmurewa daga Covid-19.
Gabatarwar abubuwan tarawa, na yau da kullun yana nuna hakan babu wani ci gaba mai mahimmanci ko ma'anar asibiti tare da amfani da remdesivir.
A cikin ƴan ingantattun karatu, ƙaramin haɓakar mace-mace marasa mahimmanci yana ɓacewa tare da tsawon lokaci mai tsayi. Duk da haka, an ƙarfafa asibitocin kuɗi don jawo hankalin marasa lafiya su yi amfani da remdesivir ta hanyar ba da wani abin mamaki. 20% "ƙarfafa" biyan kuɗi daga Medicare akan duk lissafin asibiti ga marasa lafiya waɗanda suka yarda da karɓar remdesivir da kuma ƙarin biyan kuɗi ga asibiti idan mai haƙuri na Covid-19 ya sami iska ta inji. A ƙarshe, wannan ya yi aiki ga kowane asibiti da ke karɓa "aƙalla" $100,000 "bonus" kowane majiyyaci, dalar Amurka ta biya.
Ba kamar cikakken m kuma samuwan karatun HCQ ga kowa don bincika ba, bayanan binciken Remdesivir da saƙon hukuma sun bayyana ta hanyar masana kimiyya. m, rashin adalci, rashin cikawa, da rashin gaskiya. Binciken binciken daki-daki 8.6% ƙarin mutuwar a cikin rukunin Remdesivir fiye da a cikin rukunin placebo. Sakamakon wannan binciken, ya nuna a ranar 28, 7.2% (22 daga 158) a cikin hannun Remdesivir ya mutu, yayin da 7.8% (10 daga 78) a cikin hannun placebo ya mutu.
Remdesivir karatu kuma yana da metric "mutuwa” an cire shi daga farkon ƙarshen ƙarshensa a cikin abin da ya zama sanannen tsarin FDA na kasa gargaɗin Amurkawa game da abubuwan da ba su da kyau yayin ba da izinin Big Pharma Hanyar tattara bayanan lafiyar ƙwayoyi ta skew ta hanyar kawai ba buƙatar tattara ta ba. Bambanci a cikin adadin mutuwa, ɗaya daga cikin matakan farko na asali, ba shi da mahimmanci a ƙididdiga, yana nuna kawai a raguwar raguwa daga kashi 11 cikin 8 na marasa lafiya da aka ba wa placebo zuwa kashi XNUMX cikin marasa lafiya da aka ba da remdesivir.
Bayanan asibiti da ke akwai ba su goyi bayan amincewar remdesivir ba, balle kuma amincewar Fadar White House mai karfi, balle kuma tallafin biyan haraji da gwamnatin tarayya ta amince da shi ga asibitoci, daga masu biyan haraji. Rikicin da ya shafi amincewa da kuɗaɗen da masu biyan haraji ke bayarwa sun rikitar da isassun mutane har ta kai ga an yi suka a cikin littattafan da ba na likitanci ba kamar su. kimiyya.org.
Layin ƙasa: Remdisivir ya kasance (wataƙila) ba lafiya kuma ba tasiri, ko da yake an gwada shi akan sigogin haƙuri na "farkon magani", sabanin nazarin HCQ, da har yanzu ya nuna mummunan sakamako. Daga nan jami'an FDA da masu duba lafiyar likita suka ƙaddamar da shi don amincewa. Ba kamar HCQ da Trump ya bayar ba wanda ke da tabbataccen tabbataccen shaida don fa'ida a farkon jiyya, Remdisivir yana da iyakataccen tarihin asibiti (tare da shekarun HCQ na 55 na tarihin asibiti), ba shi da fa'ida, kuma ba shi da aminci, kuma saboda wasu yarjejeniyar da ba a fayyace ba, yana da ƙwaƙƙwaran kuɗi na ƙarfafa gwamnatinsa, wanda ke ba da lissafin asibiti. tsada sosai.
Shekaru Hudu Bayan haka: Dagewa, Ba daidai ba, 2024 Da'awar "Hydroxychloroquine Baya Aiki don Covid-19"
Ya zuwa wannan rana, akwai wasu manyan cibiyoyin likitanci, makarantun likitanci, da sauran ƙungiyoyi waɗanda har yanzu suna da shafukan yanar gizo masu aiki, suna bayyana a fili a shafi na farko na sakamakon binciken intanet, suna ci gaba da ba da shawarwari don maganin remdesivir yayin lokaci guda suna sake bayyana labarin da ba daidai ba game da yadda bai kamata a yi amfani da HCQ don Covid-19 ba.
Dukkanin sakamakon da ke ƙasa ya fito sosai (a shafin farko na sakamako) biyo bayan binciken intanet na yau da kullun don sunan wurin da kalmomin "hydroxychloroquine covid" a cikin Yuli 2024.
Duk da ɗimbin haƙiƙa, bayanan duniya na ainihi suna bayyana in ba haka ba tsawon shekaru yanzu, ga mutane da yawa labarin Big Pharma/White House. Sikeli ba zai taɓa faɗuwa daga idanunsu ba. Lallai, babu makafi kamar waɗanda ba za su… bincika shaidar asibiti da kwatanta hanyoyin tantancewa ba.
Musamman: Anan akwai jerin manyan cibiyoyin kiwon lafiya waɗanda har yanzu ba su daɗe, tropes ba daidai ba game da HCQ. Kodayake duk bayanan gidan yanar gizon da ke ƙasa ba daidai ba ne, wasu sun “fi kuskure” fiye da wasu kamar yadda Wataƙila Orwell ya ce. Anan zaɓi ne kawai:
Hanyar haɗin FDA nan da nan da ke sama ta ci gaba da sake maimaita kafaffen abubuwan da suka faru na cututtukan zuciya da kuma hulɗar miyagun ƙwayoyi da ke da alaƙa da amfani da HCQ, kamar yadda bayanin kula lafiyar sa tattauna a baya.
Yalwar Bayanan Kimiyya Yana Nuna Aminci da Tasirin HCQ don Covid-19:
Yawai kamar binciken kimiyya guda biyu na Cochrane a jere yana nuna cewa duka masks da aka wajabta, gami da abin rufe fuska na tiyata, da kuma abin rufe fuska N-/KN-95 kusan lalle ba shi da inganci don hana watsawar Covid-19, bayanan binciken sun yi ta ɓarna kan lokaci game da fa'idodin HCQ jim kaɗan bayan Covid-19 ya fara yaduwa. Waɗancan binciken daga ƙarshe sun taru cikin ɗumbin shaidun asibiti a gabanmu a yau, yana nuna cewa HCQ shine. gaskiya tasiri don rigakafin Covid-19 da magani. Ba ƙari ba ne a ce HCQ zai taimaka wa miliyoyin mutane.
Don fayyace shaidar, yayin da nake da ɓarkewar karatun HCQ akan kwamfutata, ofis da ɗakin kwana, kunnen kare da abinci, akwai Meta-bincike mai ladabi-gabatar wanda ke amfani da tsarin nazari iri ɗaya wanda Cochrane amfani reviews. Ya ba da cikakken bayani game da yadda tattara: sama da bincike 400, wanda masana kimiyya sama da 8,000 suka gudanar, wanda ya haɗa da marasa lafiya sama da 525,000 a cikin ƙasashe 58, ya nuna cewa ingantaccen amfanin asibiti na HCQ na Covid-19 ya haifar da ilimin kididdiga muhimmanci ƙananan haɗari ga 1) mace-mace, 2) asibiti, 3) dawo da, 4) kaso, kuma 5) kariya daga kamuwa da cuta.
Na lura, wannan ba kawai a ceri-taba slash Texas sharpshooter kuskuren zaɓin binciken bayanai; yana wakiltar tarin duk akwai na asibiti data.
Bita da Ƙimar Duk Nazarin Nazari da Yake Samu:
A cikin shirya gardama, ana buƙatar yin la'akari duk halaltattun bayanai akwai - ba kawai zaɓin taƙaitaccen binciken da masu ba da labarai suka yi ba ko kuma kawai dogara ga binciken daga zaɓaɓɓun mujallolin likitanci na “top-tier”. Ba asiri ba ne cewa "manyan-tier" mujallolin karɓa muhimmanci tallafawa daga Big Pharma don biyan kuɗin sa, wanda a yanzu ya haɗa da ƙarin, ba sequitur kai tsaye kamar gwaji”rabon hankali na wucin gadi.” Kamar yadda ya bayyana a cikin shekaru goma da suka gabata, kuma mafi bayyana a ƙarƙashin Covid-19, binciken da aka buga a cikin mujallolin "manyan matakin" ciki har da New England Journal of Medicine, The Journal of the American Medical Association da Lancet Ba Littafi Mai Tsarki ba ne sama da zargi, kuma yana iya zama matattu ba daidai ba.
Shi ya sa yana da mahimmanci a sami tabbaci daga madaidaicin tushe. Akwai ingantattun bayanan asibiti da ake bugawa, gami da bayanai daga wasu ƙasashe da/ko bayanan da aka buga a cikin ƙananan mujallu (ba tare da tallafin Big Pharma ba) waɗanda suka cancanci kulawar asibiti da cututtukan cututtuka. A gaskiya ma, masu ilimin kimiyya waɗanda ke ciyar da rayuwarsu a cikin binciken likita za su gaya muku cewa ba manyan suna ba, ƙananan karatu, abubuwan lura, da / ko bayanan nazarin duniya lokacin da aka bincika su a hade ba kawai sun cancanci la'akari ba - amma yana iya zama. Kara nuna inganci da amincin magani. A wasu kalmomi, jimillar shaida daga mahara, da aka tsara, da ƙananan, ainihin duniya, rahotanni na shari'a, jerin shari'o'i, da / ko gwaje-gwajen kallo na iya zama alamar da ta fi ƙarfin tasiri na asibiti / ƙididdiga fiye da na ɗaya ko wasu ƙananan gwaje-gwaje masu banƙyama.
Ya zuwa yau akwai sama da karatun asibiti sama da 400 da ke nazarin amfani da HCQ a cikin Covid-19 tare da duka biyun da aka gano mara kyau da inganci. An ba da cikakken littafin tarihin duk nazarin, da taƙaitaccen binciken da aka bincika a cikin nau'i na littafin tarihin da aka tsara a ƙarshen wannan labarin.
Jeri da bita na bayanan da littafin littafin ya keɓance binciken da aka sani cewa samfuran bincike ne na yaudara, gami da waɗanda Elshafie, Dabbau#1, Dabbau#2, Abd-Salam, da abin da aka ambata Desai Lancet da kuma New England Journal of Medicine wallafe-wallafe.
Kyakkyawa da Mummuna na Manyan Gwaje-gwajen da Aka Sarrafa Bazuwar (RCTs):
Gwaje-gwajen da aka Sarrafa bazuwar (RCTs) an fi son a zahiri idan an tsara su da gudanar da su yadda ya kamata. Koyaya, zamanin Covid-19 ya fallasa munanan ra'ayi a cikin irin waɗannan gwaje-gwajen, gami da amma ba'a iyakance ga: jinkirin jiyya (kowane maganin rigakafin kamuwa da cuta na kowane kamuwa da cuta, gami da Covid-19 dole ne a fara shi da sauri), ka'idojin da aka tsara don gazawa, sauye-sauye na tsakiyar karatu zuwa ƙa'idar binciken, bincike na son zuciya da gabatarwa, rashin bayyana gaskiya a cikin bayanai, da fitar da jama'a cikin tuhuma.
Kamar yadda aka nuna a nan, son rai a kan mahimman ƙira na bincike da ƙarancin kulawar kulawa na iya haifar da ƙarshen binciken asibiti ba daidai ba. Kowane binciken asibiti na HCQ yana buƙatar kimanta shi akan cancantar mutum don yuwuwar son zuciya da/ko ruɗani, ko bazuwar, duniyar gaske, na lura, babba, ko ƙananan gwaji.
Manyan RCTs da ake zargin suna samar da Babban Pharma-wanda aka kirkira-wasa na "Maganin Tushen Shaida" da aka buga a cikin mujallolin "manyan matakin" sau da yawa suna bayyana masu tursasawa - musamman saboda su ne abin da 'yan jarida ke mayar da hankali a kai - amma a baya-bayan nan, ya bayyana a fili cewa masu ilimin kimiyya masu alhakin dole ne su yi nazarin hanyoyin da aka yi amfani da su fiye da babban matakin taƙaitaccen bayani, da kuma duba ƙarin bayanan da ba na RCT ba don tabbatar da binciken.
Wata matsala tare da manyan RCTs shine sabanin kalmomi na ainihi da nazarin kallo, ba kawai kowa zai iya gudanar da manyan RCTs ba. Shingayen sun hada da su akai-akai muhimmanci mafi tsada, mai cin lokaci, kuma yana buƙatar sadaukarwa, ƙwararrun ma'aikatan tallafi. Wannan yana hana ƙwararrun likitocin da ba su da kuɗi waɗanda ke da ƙananan ayyuka / kayan aiki ko likitocin da ke da buƙatun aiki waɗanda ke da mai da hankali kan alhakin kulawa kai tsaye sabanin binciken asibiti.
Duk da yake ana samun tallafin tarayya don ƙoƙarin RCT, waɗannan tallafin suna da gasa sosai kuma suna da iyaka ga takamaiman cututtuka ko batutuwa waɗanda a ƙarshe ana ba da su ga takamaiman wurare tare da ma'aikatan tallafi da aka ambata a baya, abubuwan more rayuwa, da dai sauransu. Wadancan manyan cibiyoyin da/ko ma'aikatansu ayan a haɗa ta wata hanya ko wata zuwa Babban Pharma kudade.
Lokacin da Covid-19 ta bulla, biliyoyin daloli masu biyan haraji An bai wa Big Pharma. Irin wannan amana kamar ta yaudari likitoci da masana kimiyya marasa da'a don ƙirƙirar abin ƙarfafawa don nuna rashin tasiri ko aminci ga samfuran jerika masu tsada, yayin da bi da bi ke nuna inganci ga wani labari, tsada, samfuran kasuwanci da aka haƙa a matsayin wata hanya ta samun ƙarin kuɗin masu biyan haraji. Manyan masana kimiyya na Pharma za a iya kwadaitar da su don nuna fa'ida ga samfuransu dangane da fasahar da ake da su, mara tsada, ko mafi yawan samuwa. Wannan yanayin ba wai kawai ya shafi jiyya na Covid-19 kamar HCQ ko ivermectin ba, amma ga adadi mai kyau. dukan binciken likitancin bincike.
Irin waɗannan ra'ayoyin na iya haifar da rashin daidaituwa a cikin RCT tare da binciken asibiti na ainihi. Kamar yadda lamarin yake tare da binciken HCQ mara kyau, da/ko wasu binciken da suka danganci yardawar Covid-19, yana da mahimmanci a bincika dalilan dalilin. Abin takaici, ya bayyana cewa babu kaɗan zuwa FDA/CDC/NIH ko sha'awar fadar White House don gano gaskiya. Shaidar da aka nuna a nan ra'ayi ne na farko kan abin da ya kamata bincike ya bincika.
Kuna iya Gudu (Tare da Labarin Ƙarya) amma Ba za ku Iya Ɓoyewa ba (Daga Bayanan): Binciken Duk Bayanan Clinical na Hydroxychloroquine:
Meta-bincike yana haɗa nazari don yin nazari mai faɗi. Wannan nau'in dabara daidai ne, ingantacce, kuma masana ilimin cututtuka, masu kididdiga, da sauran fannonin likitanci/kimiyya suna mutunta shi sosai. A haƙiƙa, nazarin HCQ na yanzu a cikin littafin tarihin nan yana amfani da tsarin bincike iri ɗaya wanda Cochrane ke amfani da shi akai-akai don ba da cikakken hoto na tasiri a cikin karatu.
Wadannan binciken kididdiga daga binciken asibiti baya ga ingantaccen ilimin kwayoyin halitta da hanyoyin magani na yadda HCQ ke da tasiri don hana shigar da ƙwayoyin cuta da yawa cikin sel. Don dalilai na kiyaye tsayin wannan bita, ba za a tattauna tsarin aikin HCQ ba a nan.
Meta-bincike wanda ya haɗu da RCT da na lura/ainihin-amfani da karatu a duk faɗin wurare da yawa sun zama mafi ƙarfi. Dogara akan wani gwajin mutum ɗaya yana ƙarƙashin yuwuwar ruɗani, gazawa, kurakurai, son zuciya, rashin iyawa, har ma da zamba.
A zane daidaita daga a Nature bazawa A ƙasa yana misalta yanayin da ƙaramin karatu huɗu waɗanda ƙila ba su isar da mahimmancin ƙididdiga ɗaya ɗaya ba (watau suna da ap>0.05), amma suna iya nuna ƙaƙƙarfan shaida tare da mahimmancin ƙididdiga lokacin da aka bincika a hade ta hanyar nazarin meta:
Har zuwa yau, da DerSimonian da kuma ta bazuwar tasirin meta-bincike samfurin gudanar da c19 ku manazarta suna nuna tasirin fa'idar asibiti na HCQ don maganin Covid-19 tare da tabbas p<0.00000000001 (wato, ɗaya a cikin sextillion ɗaya) sama da duka> 400 karatun HCQ.
RCTs don takamaiman sakamako kamar mace-mace, asibiti, da murmurewa kowanne yana nuna fa'ida mai ƙarfi tare da ap<0.0001.
Amfanin sakamako na HCQ ya haɗa da jinkirin jiyya da sauran nazarin sakamakon mummunan sakamako, duk da jinkirin jinkirin da ba shi da tasiri sosai. Jinkiri da/ko jinkiri (kuma wani lokacin sosai An yi amfani da jiyya a cikin fiye da rabin (n=264) na nazarin HCQ a cikin littafin tarihin da ke ƙasa. Na bayanin kula, adadi mai yawa na marigayi / marigayi / jinkirin nazarin jiyya da aka tattara a cikin meta-bincike har yanzu ya ƙare yana nuna wasu fa'idodi masu fa'ida na gudanarwar HCQ, yana nuna ƙarfin ingancin sa. Abubuwan da za su iya ruɗawa na iya haɗawa da kwafi na hoto, adadin ɗaukar hoto na hoto, bambance-bambancen ƙwayar cuta / maye gurbi, a saman yawan alƙaluma, immunologic, da sauran dalilai. Gujewa jinkirin jiyya wata mahimmanci ce da aka koyar da wuri a duka kantin magani da makarantun likitanci.
Ƙididdigar Kuɗi na La'antar Shawarwari na Hydroxychloroquine na Trump a cikin Faɗin Babban Madadin Pharma:
Yayin da shawarar Trump ta yin amfani da HCQ ta yi mummunar bama bamai, labari, tsadaddiyar jiyya na Big Pharma tare da taƙaitaccen bayanai an haɓaka, (kuma an gwada su da placebo maimakon jiyya ciki har da HCQ ko ivermectin) kuma an sake dubawa cikin sauri, FDA ta Amurka ta ba da izini kuma an saya tare da bashin mai biyan haraji ta Fadar White House. Duk da taƙaitaccen binciken, Paxlovid ($1,400 ta hanyar magani), Remdisivir ($ 3,120 a kowace hanya), da Molnupiravir ($ 700 a kowace hanya) sun kasance Fadar White House ta amince duk da cewa Trump ya riga ya tabbatar da HCQ for free. Ina rantsuwa da karshen 2021 kadai, Fadar White House ta riga ta kashe fiye da dala biliyan 10.6 kawai akan Paxlovid kadai kuma daga baya ya sayi ƙari. Dukkan jiyya na Covid-19 na Fadar White House ba su da inganci / binciken aminci na dogon lokaci idan aka kwatanta da HCQ.
Don hangen nesa: sama da dala biliyan 10.6 da gwamnati ta kashe akan Paxlovid kawai ta hanyar 2021 kadai zai iya siyan kusan 353,000 $30,000 Toyota Camry SEs (samfurin da ya fi shahara) ga Amurkawa marasa galihu da suka yi asarar motocinsu saboda tabarbarewar tattalin arziki.
Har ma mafi muni: bisa ga binciken da aka yi kwanan nan, (kuma kamar remdesivir) Paxlovid baya aiki, ko da kun ninka tsawon dosing bisa ga mafi yawan kwanan nan da tattara sakamakon binciken da aka buga a cikin Yuli 2024 fitowar New England Journal of Medicine.
Yana sake tabbatar da wanda aka buga a baya rahoton rahoton makonni kadan bayan an amince da Paxlovid kuma aka baiwa Amurkawa suna nuna hakan mutanen da suka dauki Paxlovid ba sa samun sauki da wuri, idan aka kwatanta da wadanda ke shan placebo. Ƙungiyar likitoci ta sani, kuma rubuta game da Paxlovid ya sake dawowa wanda ya faru tun daga farkon.
Na bayanin kula, dawowa daga HCQ ba shi da yuwuwar faruwa sosai saboda tsayinsa, rabin rayuwar da aka ambata.
A yau, har ma da Fadar White House - 'yan jaridu yana nuna ba'a a fili game da amfani da Paxlovid don kamuwa da cutar Joe Biden a Yuli 2024 tare da Covid-19 a duka taken da hoton hoto daga business Insider A kasa:
Hoton da ke sama yana ba'a game da ci gaba da amfani da Paxlovid a cikin taken da taken da ke ƙasa, ya nuna tsohon shugaban ƙasa Joe Biden yana samun allurar mRNA, amma ya yi nuni da cewa yana karɓar Paxlovid don kamuwa da cutar ta Yuli 2024 tare da Covid-19. Ba kamar hydroxychloroquine ba, an kafa Paxlovid a matsayin wanda ba shi da tasiri sosai wajen inganta kusan dukkanin sakamakon Covid-19. An gwada wannan kuma an tabbatar da shi akai-akai, kwanan nan a cikin New England Journal of Medicine. Ko da ba likitanci ba, manyan wallafe-wallafe irin su business Insider da son zuciya ta siyasa bazawa Scientific American suna ba da rahoton rashin ingancinsa don hana kwantar da asibiti ko mutuwa. Paxlovid ya ci gaba da kasancewa a kasuwa, yana da tsada sosai, kuma ana tallata shi a fili (har zuwa ranar buga wannan littafin) ta manyan kantin sayar da kayayyaki ciki har da CVS da kuma Walgreens, da kuma inganta ta Ƙungiyar Ƙwararrun Amurka, da FDA, da CDC, da NIH, Pfizer, da manyan cibiyoyin kiwon lafiya ciki har da amma ba'a iyakance ga: da Mayo Clinic, Johns Hopkins, Da kuma Jami'ar Yale asibitoci da asibitoci.
Tsakanin $16 da $22 Tiriliyan Batar:
Kyautar HCQ da Trump ya bayar don rigakafin bayyanar da wuri, bayyanar da wuri, ko jiyya da wuri (a cikin mutanen da suka cancanta), da sun yi aiki fiye da Paxlovid kuma ana iya amfani da su don hana yawancin nau'ikan Covid-19 daga farkon.
Kuma dubun-dubatar biliyoyin daloli da aka yi hasarar akan Paxlovid da sauran manyan buhunan magunguna na Big Pharma sun kasance kajin kaji dangane da duk farashin cutar.
An kiyasta cewa cutar ta Covid-19 ta kashe Amurkawa a kalla Dala tiriliyan 16 a cewar masu binciken tattalin arzikin Harvard, $18 tiriliyan a cewar Malaman Gidauniyar Heritage, tare da wasu kiyasin kasancewa har ma mafi girma daga Cibiyar Ci gaba. Yana da wuya a yi tunanin nawa ko da dala tiriliyan 1 ne, amma ga misali ɗaya dangane da seconds ko kwanaki. Dangantakar motoci, ta amfani da kiyasin Harvard mafi ƙanƙanta na dala tiriliyan 16, adadin kuɗin zai iya sayan sabo. $30,000 Toyota Camry SE domin kowane dan Amurka daya (namiji, mace da yaro na kowane zamani) a Amurka da sama da dala tiriliyan 5 da suka rage. Maimakon haka, Amurkawa ba kawai ba ne ba samun sabuwar mota kirar Toyota Camry SE, amma a maimakon haka sai su rasa motocin da suke da su, sun rasa gidajensu, kuma ana fama da hauhawar farashin kayayyaki a kusan duk abin da suke bukata, ciki har da abinci, man fetur, madarar jarirai, da wutar lantarki.
Ba ƙari ba ne a faɗi cewa shawarar HCQ na Trump na iya hana yawancin mummunan tasirin kuɗi, zamantakewa, da tabin hankali na Covid-19 - ban da cututtuka da mace-mace. Dangane da meta-binciken nazarce-nazarce a cikin littafin tarihin da ke ƙasa, HCQ zai yi tasiri kuma yana iya yuwuwar gujewa yawancin kashewar dala tiriliyan 16.
Maganar ƙasa ita ce: Shugaba Trump ya yi daidai don tabbatar da gudummawar, kuma ya ba da shawarar yin amfani da HCQ ga mutanen da suka cancanta. Abubuwan da aka tattara mafi kyau na baya-bayan nan masu alaƙa da HCQ shaidu ne da ba za a iya musantawa ba cewa Amurkawa sun fi dacewa da an aiwatar da HCQ kuma an yi amfani da su a cikin jama'ar da suka cancanta.
Taƙaitaccen Hotunan Hydroxychloroquine:
Don cikakken bayani game da bayyana gaskiya, Ina haɗa da cikakken jerin binciken HCQ da aka kammala zuwa yau wanda ya ƙunshi meta-bincike da ke nuna inganci da amincin HCQ. Kowane nassoshi 400-plus sun haɗa da taƙaitaccen taƙaitaccen bayani da hanyar haɗi zuwa dogon bincike a c19 ku.
Littafin ya ƙunshi dukan bayanan asibiti ciki har da duka m da kuma korau binciken da ya aiwatar da yin allurai ba daidai ba, da ɗan gajeren lokaci, da kuma nazarin da suka yi amfani da jiyya na marigayi. Hakanan ya haɗa da binciken da bai kai ga ƙididdiga ba (p>0.05). Hakanan ana bayar da hanyoyin haɗin kai zuwa bayanan binciken na asali.
A wasu lokuta, mujallolin sun gudanar da nazarin asibiti daga wallafe-wallafe na tsawon lokaci sannan kuma sun ƙi takardun ba tare da bita ba (wasu mujallolin har yanzu sun ƙi yarda da masu tallafawa Big Pharma da / ko kuma sun kasance sun kasance. yayi barazanar tace bayanan su ta hanyar odar fadar White House). Ga wasu, mawallafa za su iya rasa izini daga ma'aikacin su don bugawa, ko kuma ƙila ba za su so su ci gaba da buga mujallu ba saboda tsoron mummunan tasiri a kan ayyukansu ko kuɗin kansu ko na ma'aikata. Hakanan wata yuwuwa ce ta musamman cewa wasu marubutan kawai sun ɓata wallafe-wallafen ci gaba kuma sun matsa zuwa wasu bincike ko ayyukan asibiti da ake buƙata daga gare su lokacin da Cutar sankara-19 da mace-mace sun ruguje sakamakon bullowar bambance-bambancen Omicron (a ƙarshen 2021) tare da bambance-bambancen da ke ƙasa.
Tare da bibliography, Ina kuma haɗa da ɓangarorin watsawa na HCQ da yawa waɗanda ke kwatanta adadin mummunan sakamako mai kyau daga c19 ku akan fa'ida gabaɗaya, da rushewar fa'idodin dangi daga rigakafin rigakafi, jiyya na farko da marigayi.
A cikin alkalumman da aka nuna a sama, da'irar BLUE da aka nuna sune nazarce-nazarce waɗanda ke dalla-dalla ingantaccen binciken binciken HCQ da da'irar RED mara kyau akan lokaci. (Hoto A da B su ne fassarar bayanai guda biyu). Akwai bayanan da ba su da kyau, amma ingantaccen binciken HCQ ya fi su duka biyun a cikin binciken yawa da karatu size (wanda aka kwatanta da girman da'irar), da kuma kan lokaci da kuma nuni, bisa ga bayanan nazarin meta da aka harhada a: c19ivm.org. Kusan duk bayanan da ba su da kyau da suka shafi aikace-aikacen MAGANIN MARIGAYI yayin aiwatar da daidaitattun MAGANIN FARKO yana da fa'ida koyaushe. Duka hotuna na farko da na biyu bayanai iri ɗaya ne, tare da hoto na biyu rugujewar lokacin fara jiyya.
Summary:
Mujallun kiwon lafiya na "Tip-tier", jaridu na yau da kullun, asibitoci, masu gudanarwa, kamfanonin inshora, Big Pharma, gwamnatin jaha / gundumomi, a saman kowace hukumar haruffa ta tarayya da sauran duk sun haɗu da haɓakar haɓaka babban ra'ayi na yarda da aka ƙera wanda ya lalata HCQ yayin da yake son sabon labari, ɗan gwadawa kaɗan, ingantaccen magani na kasuwanci mai tsada. The hade meta-bincike yanzu ya tabbatar da ingancin HCQ. Ba ƙari ba ne don bayyana cewa magudin bayanan da suka faru tare da HCQ (da sauran jiyya na miyagun ƙwayoyi) shine babban abin kunya a tarihin likitancin Amurka, kuma ɗayan manyan laifukan likita akan bil'adama.
Manufar kimiyya da masana kimiyya ita ce haɓaka tunani mai mahimmanci haɗe tare da shirye-shiryen almajiransa don daidaita tunaninsu kuma su yarda da rashin kuskure game da ra'ayoyin ko ra'ayoyin da ake dasu. A wasu kalmomi, sanin cewa babu wani kimiyya da ya taɓa "tsalle" gaba ɗaya don haka bai kamata a rufe shi ba.
- Tabbatar da son zuciya a cikin yin magana zaɓi HCQ RCTs ba kimiyya ba ne.
- Bayanan aminci na FDA akan HCQ ya ƙunshi bayanan da bai dace ba, ceri da aka zaɓa kuma ba kimiyya ba.
- Yin watsi da ƙa'idar kulawa da yawanci la'akari da marigayi da kuma marigayi da rashin dacewa allurai/lokacin jiyya na HCQ a matsayin hanyar wulaƙanta shawarar HCQ na Trump ba kimiyya ba ce.
- Yin shiru da ƙwararrun likitocin likita da na kimiyya masu sukar Fadar White House, FDA, da Big Pharma ba kimiyya ba ce.
- Ƙididdigar rashin cancantar 'yan jaridu da ƙimantawa na cikakkun bayanai na HCQ ba kimiyya ba ne.
- Labarai daga The Hill, Forbes ta, da kuma POLITICO wanda ya yi gaggawar faɗakar da zargi kan HCQ da Trump - amma bayan jajircewar karatu, ci gaba da samun labaransu akan layi kuma jama'a na ci gaba da samun damar yin amfani da su, ba kimiyya ba.
- Mujallun likitanci ba sa buƙatar gyare-gyaren latsawa kan abubuwan da aka sabunta/masu ja da baya dangane da gazawarta na “bita-bita” na ciki don tabbatarwa. ba sequitur Binciken HCQ ba kimiyya ba ne.
- Labarin asibiti game da HCQ da aka buga akan gidajen yanar gizon da ke fuskantar jama'a ba kimiyya ba ne.
- Rashin gazawar "bita-da-kullin takwarori" a mujallolin likitanci na "manyan matakin" don yin la'akari da kafaffen matakan jiyya na asibiti na jiyya na farko ba kimiyya ba.
- Ba da izinin “masu duba gaskiya” waɗanda ba kwararrun likitoci ba su yi tsokaci a kan rikitattun fannonin likitanci da fasaha na ilimin harhada magunguna da magani ba kimiyya ba ne.
- Hukunce-hukuncen masu harhada magunguna da likitocin al'umma don zabar da ya dace don bayarwa da rubuta HCQ don Covid-19 ba kimiyya ba ne.
- Neman "ijma'i" guda ɗaya kan yadda aka ba da izinin masu harhada magunguna da likitoci don kula da Covid-19 ba kimiyya ba ne.
- Wani jami'in tarayya (ko kowane mutum ɗaya) da yake magana da kansa musamman a matsayin "kimiyya" ba kimiyya ba.
Dubban ƙwararrun masana kimiyya da likitoci a gwamnatin tarayya na Amurka, jami'o'i, da saitunan asibitoci sun yi biris da tarihi, tsarin tantancewar kimiyya a hankali da magabata na kimiyya suka kafa. Babu ƙarya game da HCQ na Covid-19 ya yi girma sosai, kuma kowane murdiya na gaskiya ya zama barata kamar yadda ya cancanta, ba wai kawai don lalata HCQ ba, amma shawarar da Donald Trump kawai ya yi na amfani da HCQ ga majinyata masu cancanta.
Wannan shine yadda aka ƙirƙiri labarin anti-HCQ. Duk wanda ke da alhakin ya zama kamar sun haɗa kansu cikin sirri a cikin "ijma'i" da aka haɗa a kan HCQ.
A madadin HCQ, sabon, ɗan ƙaramin gwaji, tsada, mai rikitarwa, fasahar jiyya da ba kasafai ake amfani da shi ba Big Pharma ne ya gabatar da shi, sannan ba bisa ilimin kimiyya ba ta Fadar White House ta Biden, kuma an biya ta da bashi na batsa. Ƙarya game da HCQ da sauran jiyya da aka sake amfani da su kamar ivermectin gwamnati da kungiyoyin labarai ne suka inganta shi, suna mai da shi kamar alluran mRNA, masu haɓaka marasa iyaka da labari, hanyoyin kwantar da hankali na FDA sun kasance. kawai Hanyoyi masu yarda don hanawa ko magance Covid-19. Ƙarshen samfurin ƙarya da umarnin mRNA ya shafi kowane ɗan Amurka guda ɗaya, tare da wasu ƴan zaɓaɓɓu waɗanda suka sami riba mai ban mamaki, waɗanda ke bayan masu biyan haraji.
Haɗin gwiwar Donald Trump da RFK na kwanan nan da haɗin gwiwa don Samun Lafiyar Amurka Again (MAHA) a ƙarshe ya kamata ya haɗa da cikakken bincike kan toshewar HCQ a matsayin maganin da aka sake amfani da shi don Covid-19 don fahimtar da alama daidaitacce kuma gabaɗaya rashin dacewa.
Ba ƙari ba ne a faɗi cewa da an ƙyale Trump ya ci gaba da ƙoƙarinsa na rarraba HCQ don Covid-19 a cikin yawan marasa lafiya da ya dace, da za mu zauna a cikin Amurka ta daban. Abubuwan da aka tattara na aminci da inganci na yau akan bayanan HCQ hujja ce marar tabbas da ke bayyana fa'idodinta, musamman don farkon jiyya na Covid-19.
RA'AYI: KADA KA daina ko fara shan kowane magani ba tare da fara tattaunawa da likitan kantin magani ko likitan da ka sani kuma ka amince da shi ba.
Dokta David Gortler masanin harhada magunguna ne kuma masanin harhada magunguna. Shi tsohon Farfesa ne a Makarantar Magunguna ta Jami'ar Yale a fannin ilimin hada magunguna da fasahar kere-kere. Yayin da yake Yale, FDA ta ɗauke shi aiki don ya zama jami'in likita / babban manazarcin likita a Ofishin Sabbin Magunguna na FDA. Daga baya an nada shi a matsayin babban mai ba da shawara ga kwamishinan FDA kan amincin magunguna da manufofin kimiyyar FDA. A halin yanzu babban ɗan'uwa ne a Gidauniyar Heritage da ke Washington, DC, wanda a baya ya yi aiki a matsayin ɗan'uwa a Cibiyar Da'a da Harkokin Jama'a.
An jera kayan gado don dalilai na tantancewa kawai. Ra'ayoyin da aka bayyana a cikin wannan labarin na marubucin ne kuma ba sa nuna wani matsayi na hukuma na Heritage ko Kwamitin Amintattu.
Bibliography
1. Y. Su, Y. Ling, Y. Ma, L. Tao, Q. Miao, Q. Shi, J. Pan, H. Lu, da B. Hu, Ingantaccen maganin hydroxychloroquine na farko wajen hana cutar COVID-19 cutar huhu, gwaninta daga Shanghai, China Disamba 2020, Hanyoyin Kimiyya na BioScience, Juzu'i na 14, Fitowa ta 6, Shafi na 408-414
MAGANIN FARKO Nazarin jiyya na farko na HCQ: 85% ƙananan ci gaba (p=0.006), 24% haɓakawa cikin sauri (p=0.02), da 36% ingantacciyar kariya ta hoto (p=0.001).
85% ƙananan ci gaban cuta tare da farkon amfani da HCQ. Marasa lafiya na 616 na baya-bayan nan a China suna nuna ci gaba da aka daidaita, haɗarin haɗari 0.15, p = 0.006. https://c19p.org/su
2. Purwati, Budiono, B. Rachman, Yulistiani, A. Miatmoko, Nasronudin, S. Lardo, Y. Purnama, M. Laely, I. Rochmad, T. Ismail, S. Wulandari, D. Setyawan, A. Rosyid, H. Setiawan, P. Wulaningrum, T. Marfiwati, E. Endraswari. Lopinavir/Ritonavir-Doxycycline, da Azithromycin-Hydroxychloroquine ga Marasa lafiya da aka gano tare da Cututtuka masu sauƙi zuwa matsakaicin COVID-19 Fabrairu 2021, Biochemistry Research Int., Juzu'i na 2021, Shafi na 1-12
MAGANIN LAFIYA 754 mai haƙuri HCQ marigayi magani RCT: 66% ingantacciyar kariya ta hoto (p <0.0001).
RCT 754 marasa lafiya suna kwatanta HCQ + AZ tare da sauran kungiyoyin jiyya ta amfani da lopinavir / ritonavir da doxycycline zuwa ƙungiyar kulawa da ke ɗaukar AZ, suna samun saurin kamuwa da kwayar cuta tare da duk kungiyoyin jiyya. (Lura: Alamun da ke cikin Hoto 2 sun bayyana ana juyawa). https://c19p.org/purwati
3. T. Sulaiman, A. Mohana, L. Alawdah, N. Mahmoud, M. Hassanein, T. Wani, A. Alfaifi, E. Alenazi, N. Radwan, N. AlKhalifah, E. Elkady, M. Alanazi, M. Alqahtani, K. Abdullah, Y. Yousif, F. AboGazalah, F. Alfadah, Kem F. Alfadah, Kem, Al-Radwan A. AlJedai, H. Jokhdar, da F. Alrabiah, Tasirin Farkon Farkon Jiyya na Hydroxychloroquine a cikin Marasa lafiya na COVID-19 a cikin Saitunan Kula da Motoci: Nazarin Ƙungiya mai Tsara na Ƙasashe Satumba 2020, medRxiv
MAGANIN FARKO 7,892 mai haƙuri HCQ binciken farko na magani: 64% ƙananan mace-mace (p=0.01), 44% ƙananan mace-mace / shigar da ICU (p = 0.02), 37% ƙananan shigar da ICU (p = 0.13), da 39% ƙananan asibiti (p <0.0001).
Masu lura da marasa lafiya 5,541 masu zuwa, daidaita daidaiton mace-mace na HCQ KO 0.36, p = 0.012. Gyaran asibiti KO 0.57, p <0.001. An yi amfani da kari na zinc a kowane yanayi. Magani da wuri a asibitocin zazzabin gaggawa a Saudiyya. https://c19p.org/sulaiman
4. R. Seet, A. Quek, D. Ooi, S. Sengupta, S. Lakshminarasappa, C. Koo, J. So, B. Goh, K. Loh, D. Fisher, H. Teoh, J. Sun, A. Cook, P. Tambyah, da M. Hartman, Kyakkyawan tasiri na maganin poxichloroquine na baki da kuma maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin rigakafi. gwajin bazuwar lakabin buɗaɗɗen Afrilu 2021, Int. J. Cututtuka masu Yaduwa, Juzu'i na 106, Shafi na 314-322
1,051 mai haƙuri HCQ prophylaxis RCT: 35% ƙananan lokuta na alamomi (p=0.05) da 32% ƙananan lokuta (p=0.009).
Prophylaxis RCT a cikin Singapore tare da 3,037 marasa lafiya marasa haɗari, suna nuna ƙananan ƙananan lokuta, ƙananan alamun bayyanar cututtuka, da ƙananan tabbatar da shari'o'in Covid-19 tare da duk jiyya (ivermectin, HCQ, PVP-I, da Zinc + bitamin C) idan aka kwatanta da bitamin C. Kawai 71.4% ya ruwaito> 70% riko, iyakance tasiri. QTc bai bambanta sosai a ƙididdiga ba tsakanin tushe da karatun karatu (ma'ana 379 vs 378ms, t-test p=0.387). Meta-binciken bitamin C a cikin gwaje-gwajen da suka gabata 6 yana nuna fa'idar 16%, don haka ainihin amfanin ivermectin, HCQ, da PVP-I na iya zama mafi girma. Cluster RCT mai gungu 40. Ba a kwantar da su a asibiti ba kuma babu mace-mace. https://c19p.org/seeth
5. I. Simova, T. Vekov, J. Krasnaliev, V. Kornovski, da P. Bozhinov, Hydroxychloroquine don rigakafi da kula da COVID-19 a cikin ma'aikatan kiwon lafiya Nuwamba 2020, Sabbin ƙwayoyin cuta da Sabbin cututtuka, Juzu'i na 38, Shafi na 100813
MAGANIN FARKO 38 haƙuri HCQ binciken farko na jiyya: 94% ƙananan asibiti (p=0.01) da 96% ingantacciyar kariya ta hoto (p=0.001).
100% raguwa a asibiti da lokuta tare da magani da wuri ta amfani da HCQ+AZ+zinc. Takaitaccen rahoto kan ma'aikatan kiwon lafiya a Bulgaria. 0 asibiti tare da jiyya vs. 2 don kula da 0 PCR + a ranar 14 tare da jiyya vs. 3 don kula da marasa lafiya na 33 da marasa lafiya na 5. Babu mummunan al'amura mara kyau. Wannan takarda ta ba da rahoto game da PEP da farkon magani, mun raba karatun biyu. https://c19p.org/simova
6. H. Tsanovska, I. Simova, V. Genov, T. Kundurzhiev, J. Krasnaliev, V. Kornovski, N. Dimitrov, da T. Vekov, Hydroxychloroquine (HCQ) magani ga marasa lafiya na asibiti tare da COVID-19 Maris 2022, Cutar cututtuka - Manufofin Magunguna, Juzu'i na 22
MAGANIN LAFIYA 140 mai haƙuri HCQ marigayi magani PSM binciken: 58% ƙananan mace-mace (p=0.03), 74% ƙananan iska (p=0.0007), da 70% ƙananan shigar da ICU (p=0.0004).
Binciken PSM mai yiwuwa na marasa lafiya 260 Covid-19 a Bulgaria, yana nuna ƙarancin mace-mace, samun iska, da shigar da ICU tare da jiyya na HCQ. https://c19p.org/tsanovska
7. B. Yu, C. Li, P. Chen, J. Li, H. Jiang, da D. Wang, Tasiri masu fa'ida da hydroxychloroquine ke yi wajen kula da marasa lafiya na COVID-19 ta hanyar kare gabobin jiki da yawa. Agusta 2020, Kimiyyar Kimiyyar Rayuwa ta China, 2020 Agusta 3, Juzu'i na 64, Fitowa ta 2, Shafi na 330-333
MAGANIN LAFIYA 2,882 mai haƙuri HCQ marigayi nazarin jiyya: 83% ƙananan ci gaba (p=0.05) da 85% ƙananan mace-mace (p=0.02).
Marasa lafiya 2,882 na baya-bayan nan a China, matsakaicin shekaru 62, 278 suna karɓar HCQ, matsakaici Kwanaki 10 bayan asibiti, Yana nuna cewa maganin HCQ zai iya rage ƙumburi na tsarin kuma ya hana hadarin cytokine, don haka kare gabobin da yawa daga raunin da ya faru, irin su detoxification a cikin hanta da kuma rage raunin zuciya. Matakan IL-6 sun ragu sosai bayan jiyya na HCQ (p <0.05). Matsakaicin ƙarancin adadin da aka yi amfani da shi anan yana da yuwuwar alaƙa da abubuwan lura daban-daban daga sakamakon gwaji na SAKEWA. Marubuta sun ba da shawarar cewa ya kamata a fara magani da wuri-wuri. An ba da rahoton marasa lafiya 550 waɗanda ke fama da rashin lafiya a asali a cikin wata takarda ta dabam. Ga marasa lafiya marasa lafiya a asali, adadin marasa lafiya da suka yi rashin lafiya ya ragu sosai ga waɗanda aka yi wa HCQ. Ga rukunin marasa lafiya waɗanda suka fara jiyya na HCQ da wuri kawai 1.4% sun mutu a kan 3.9% don HCQ sun fara a ƙarshen kuma 9.1% don kulawa da marasa lafiya. https://c19p.org/yu2
8. K. Hong, J. Jang, J. Hur. Yuli 2020, Kamuwa da cuta. Chemother., 2020, Juzu'i na 52, Fitowa ta 3, Shafi na 396
MAGANIN FARKO 90 mai haƙuri HCQ binciken farko na jiyya: 65% ingantacciyar ƙwayar cuta (p=0.001).
HCQ kwanaki 1-4 daga ganewar asali shine kawai abin da ke da kariya daga zubar da jini mai tsawo da aka samu, KO 0.111, p=0.001. 57.1% kariya daga kamuwa da cuta tare da jinkirin kwanaki 1-4 vs. 22.9% don 5+ jinkirin jinkirin kwanaki. Marubuta sun ba da rahoton cewa farkon fara gudanar da HCQ yana inganta ɓoyayyen ɓoyewar cytokine mai kumburi kuma ya kamata a ba marasa lafiya COVID-19 HCQ da wuri-wuri. 42 marasa lafiya tare da HCQ 1-4 kwanaki daga ganewar asali, 48 tare da HCQ 5+ kwanaki daga ganewar asali. https://c19p.org/hong
9. Z. Chen, J. Hu, Z. Zhang, S. Jiang, S. Han, D. Yan, R. Zhuang, B. Hu, da Z. Zhang, Ingancin hydroxychloroquine a cikin marasa lafiya tare da COVID-19: sakamakon gwajin gwaji na asibiti bazuwar. Maris 2020, medRxiv doi: 10.1101/2020.03.22.20040758
MAGANIN LAFIYA 62 mai haƙuri HCQ marigayi magani RCT: 57% ƙananan ciwon huhu (p=0.04).
62 marasa lafiya. RCT yana nuna mahimmancin farfadowa da sauri tare da HCQ. 13% ya ci gaba zuwa lokuta masu tsanani a cikin ƙungiyar kulawa, tare da 0% don ƙungiyar kulawa. Mahimmanci mai mahimmanci da aka gani a cikin ciwon huhu a kan kirji CT don 61% na marasa lafiya da aka bi da su da 16% na marasa lafiya. https://c19p.org/chenrct
10. G. Reis, E. Moreira Silva, D. Medeiros Silva, L. Thabane, G. Singh, J. Park, J. Forrest, O. Harari, C. Quirino dos Santos, A. Guimarães de Almeida, A. Figueiredo Neto, L. Savassi, A. Milagres, M. Teixeira, M. Simplicio, da kuma E. Tasirin Jiyya na Farko Tare da Hydroxychloroquine ko Lopinavir da Ritonavir akan Hadarin Asibiti Tsakanin Marasa lafiya Tare da COVID-19 TARE da Gwajin Gaggawa na asibiti. Afrilu 2021, Kungiyar JAMA ta bude, Juzu'i na 4, fitowa ta 4, Shafi na e216468
MAGANIN LAFIYA 441 mai haƙuri HCQ marigayi magani RCT: 24% ƙananan asibiti (p = 0.57) da 4% inganta ƙwayar cuta (p=0.1).
An dakatar da RCT da farko a Brazil yana nuna ƙarancin mace-mace da asibiti tare da HCQ, amma bai kai ga mahimmancin ƙididdiga ba. Kodayake taken ya haɗa da "maganin farko" cewa magani ya yi latti, tare da yawancin marasa lafiya sun wuce kwanaki 5 daga farkon bayyanar cututtuka. Abubuwan da ba su da kyau sun kasance ƙasa a cikin ƙungiyar HCQ idan aka kwatanta da ƙungiyar kulawa. Wannan gwajin da alama an ƙare a 45% rajista yayin da yake nuna yuwuwar fifikon ≥70%. Ba a bayar da rahoton iyakar rashin amfani ba, amma zai zama sabon abu sosai don ya kasance kamar yadda 70%. Takardar ta nuna placebo talc,; duk da haka ka'idar gwaji ta nuna "placebo" a matsayin bitamin C, wanda akwai nazarin jiyya guda 7 na Covid-19 har zuwa Afrilu 2021 wanda ke nuna tasiri mai mahimmanci.. Sakamako ya bambanta sosai da waɗanda aka ruwaito kafin bugawa. Kafin bugawa, marubuta sun ba da rahoton wani RR don asibiti ko mutuwar 1.0 [0.45-2.21]. https://c19p.org/reis
11. M. Million, J. Lagier, H. Tissot-Dupont, I. Ravaux, C. Dhiver, C. Tomei, N. Cassir, L. Delorme, S. Cortaredona, S. Amrane, C. Aubry, K. Bendamardji, C. Berenger, B. Doudier, S. Edouard, M. C. Triquet S. Gentile Brouqui, da D. Raoult, Jiyya na Farko tare da Hydroxychloroquine da Azithromycin a cikin 10,429 COVID-19 Marasa lafiya na Jihohin: Nazarin Ƙungiya Mai Tsaya Tsakanin Monocentric Mayu 2021, Reviews a cikin Magungunan cututtukan zuciya, Juzu'i na 22, fitowa ta 3, shafi na 1063
MAGANIN FARKO 10,429 mai haƙuri HCQ binciken farko na jiyya: 83% ƙananan mace-mace (p=0.0007), 44% ƙananan shigar da ICU (p=0.18), da 4% ƙananan asibiti (p=0.77).
Marasa lafiya 10,429 na baya-bayan nan a Faransa, 8,315 da aka yi musu magani tare da HCQ+AZ matsakaicin kwanaki 4 daga farkon bayyanar cututtuka, yana nuna raguwar mace-mace tare da jiyya. https://c19p.org/million4
12. L. Chen, Z. Zhang, J. Fu, Z. Feng, S. Zhang, Q. Han, X. Zhang, X. Xiao, H. Chen, L. Liu, X. Chen, Y. Lan, D. Zhong, L. Hu, J. Wang, X. Yu, D. She, Y. Zhu, kuma Z. nau'in COVID-19: mai yiwuwa buɗaɗɗen lakabin da bazuwar binciken sarrafawa Juni 2020, medRxiv
MAGANIN LAFIYA 48 mai haƙuri HCQ marigayi magani RCT: 20% farfadowa da sauri (p = 0.51) da 71% saurin ƙwayar cuta (p=0.0004).
RCT 48 marasa lafiya a asibiti a kasar Sin suna nuna saurin murmurewa na asibiti da kariya daga kamuwa da cuta tare da CQ/HCQ. https://c19p.org/chen
13. A. Vaezi, E. Nasri, H. Fakhim, M. Salahi, S. Ghafel, S. Pourajam, A. Darakhshandeh, N. Kassaian, S. Sadeghi, B. Ataei, da S. Javanmard, Ingancin hydroxychloroquine a pre-bayyana tsananin m numfashi ciwo ma'aikatan kiwon lafiya na 2-prophylaper. Janairu 2023, Advanced Biomedical Research, Juzu'i na 12, Fitowa ta 1, Shafi na 3
143 sabar HCQ prophylaxis RCT: 92% ƙananan lokuta na alamomi (p=0.03).
Ma'aikatan kiwon lafiya na RCT 143 a Iran, suna nuna ƙananan lokuta tare da HCQ prophylaxis, ƙididdiga mai mahimmanci kawai ga matsakaita/masu tsanani. Ba a bayar da cikakkun bayanai na asali ba. https://c19p.org/nasri
14. T. Rouamba, E. Ouédraogo, H. Barry, N. Yaméogo, A. Sondo, R. Boly, J. Zoungrana, A. Ouédraogo, M. Tahita, A. Poda, A. Diendéré, A. Ouedraogo, I. Valea, I. Traoré, Z. Tarnagda, H. Dr. Tinto, da Time, A. Mutuwa, tsakanin marasa lafiya na COVID-19 da marasa lafiya, a ƙarƙashin jiyya tare da Hydroxychloroquine ko Chloroquine da Azithromycin Combination a Burkina Faso Fabrairu 2022, Int. J. Cututtuka masu Yaduwa
MAGANIN LAFIYA 864 mai haƙuri HCQ marigayi nazarin jiyya: 80% ƙananan mace-mace (p <0.0001), 20% ƙananan ci gaba (p=0.43), da kuma 31% saurin kariya daga kamuwa da cuta (p=0.26).
Majinyata 863 na Covid-19 na baya-bayan nan a Burkina Faso, suna nuna ƙarancin mace-mace, ƙarancin ci gaba ga marasa lafiya, da saurin kamuwa da kwayar cuta tare da maganin HCQ/CQ. Ƙananan mace-mace ne kawai ke da mahimmanci a ƙididdiga. Bayanin NCT04445441. https://c19p.org/rouamba
15. O. Mitjà, M. Corbacho-Monné, M. Ubals, A. Alemany, C. Suñer, C. Tebé, A. Tobias, J. Peñafiel, E. Ballana, C. Pérez, P. Admella, N. Riera-Martí, P. Laporte, J. Mitjà, M. Clua, M. Sarquer, S. J. Argimon, G. Cuatrecasas, P. Cañadas, A. Elizalde-Torrent, R. Fabregat, M. Farré, A. Forcada, G. Flores-Mateo, C. López, E. Muntada, N. Nadal, S. Narejos, A. Nieto, N. Prat, J. Puig, C. Quiñmís. Via Quiñmís. Reyes-Urueña, E. Riveira-Muñoz, L. Ruiz, S. Sanz, A. Sentís, A. Sierra, C. Velasco, R. Vivanco-Hidalgo, J. Zamora, J. Casabona, M. Vall-Mayans, C. González-Beiras, da B. Clotet-R na Hydrochloroquisteroquid Covid-19 Watsawa da Cuta Yuli 2020, NEJM, Juzu'i na 384, Fitowa ta 5, Shafi na 417-427
2,497 mai haƙuri HCQ prophylaxis RCT: 46% ƙananan mace-mace (p=0.39), 17% ƙananan asibiti (p=0.71), da 32% ƙananan lokuta (p=0.27).
Don alamun bayyanar cututtuka masu kyau, ana ganin sakamako mafi girma ga mazauna gida, RR = 0.49 [0.21 - 1.17], vs. gaba ɗaya 0.89, mai yiwuwa saboda an gano abubuwan da suka faru da sauri a cikin wannan mahallin, tare da bayyanar gida inda gwajin tushen zai iya zama jinkiri. Gwajin ya yi kadan don mahimmanci. Idan yanayin ya ci gaba da wannan sakamakon zai zama mahimmanci a p<0.05 bayan kusan 25% an ƙara ƙarin marasa lafiya. Akwai ƙungiyoyi biyu a cikin wannan binciken: PCR+ a asali (n=2) da PCR- a tushe (n=314), wanda ya kamata a raba kasancewar su jama'a daban-daban (yawan sakamako na farko 18.6% da 22.2% idan aka kwatanta da 3.0% da 4.3%). PCR + ya riga ya sami Covid-19, don haka binciken PEP ya kamata ya kasance na PCR 2,000, yana nuna alamun Covid-19 na 4.3% (control) da 3.0% (jiyya), RR 0.7, p=0.154. Takardar tana da ma'auni na RR daban-daban a nan, yana bayyana cewa an daidaita su don masu canjin matakin lamba. Ba a bayyana yadda ake lissafta su ba - RR da aka daidaita don samfurin gabaɗaya shine 4% ƙananan, don PCR + shine 20% ƙananan, amma ga PCR- yana da 107% mafi girma, kodayake PCR- yana wakiltar 86% na samfurin. Da fatan, ƙarin bayanai za su samar da ɓarna akan lamura a cikin wannan PCR- @samfurin tushe ta adadin kwanaki tun lokacin da aka fallasa, sannan kuma ya ba da sakamakon asibiti da ya dace. Rijistar ya kasance har zuwa kwanaki 7 bayan fallasa, tsaka-tsakin kwanaki 4. Ba a san jinkirin jiyya ba. Ba a cika daki-daki ba. Ya bayyana yana dogara ne akan kwanan wata tabbataccen gwaji don tuntuɓar, wanda mai yuwuwa zai yi yawa daga baya fiye da ainihin lokacin bayyanarwa. 13.1% sun riga sun kasance masu inganci a asali, wanda ya yi daidai da ainihin lokacin bayyanar da yake da muhimmanci a baya. Gwajin PCR yana da ƙima mai ƙima a matakin farko (misali, 100% a rana ta 1, 67% a rana ta 4, da 20% a rana ta 8), don haka yana yiwuwa kashi mafi girma ya kamu da cutar a lokacin da ba a sani ba kafin shiga. Ba a yi cikakken bayani game da gudanar da magani ba. Ba a bayar da hankali da ƙayyadaddun gwaje-gwajen ba. Ganin jinkirin gano lamuran fihirisa, jinkirin gwajin PCR, da ƙimar ƙimar PCR na ƙarya a farkon matakan, jinkirin jiyya gabaɗaya ya daɗe sosai kuma yana iya wuce makonni 2. RR don tabbataccen rashin PCR a asali shine 0.74. Ciki har da PCR-tabbatacce a marasa lafiya na asali sun rage wannan zuwa 0.89. Wannan kuma ya yi daidai da maganin da ya gabata yana da inganci. Takardar ba ta ambaci zinc ba. An ba da rahoton karancin Zinc a Spain a kashi 83%; wannan na iya rage tasiri sosai. HCQ wani zinc ionophore ne wanda ke haɓaka ɗaukar wayar salula, yana sauƙaƙe yawan adadin zinc a cikin salula, kuma an san zinc yana hana SARS-CoV RNA mai dogaro da RNA polymerase aiki, kuma shine. An yi imanin cewa yana da mahimmanci don tasiri tare da SARS-CoV-2. Wannan binciken yana mayar da hankali kan wanzuwar bayyanar cututtuka ko sakamako mai kyau na PCR; duk da haka tsananin bayyanar cututtuka ya fi mahimmanci. Bincike ya nuna adadin HCQ na iya zama yafi girma a cikin huhu idan aka kwatanta da plasma, wanda zai iya taimakawa rage yawan faruwar lokuta masu tsanani da mutuwa. Akwai alaƙar jinkirin jinkirin amsawa daidai da ingantaccen magani, duk da haka marubutan suna ba da jeri na 3 kawai kuma ba sa rushe lokutan jinkirin jiyya na farko.. Ma'anar alamun Covid-19 yana da faɗi sosai - kawai kasancewar ciwon kai kaɗai ko ciwon tsoka kaɗai an ɗauki Covid-19. Akwai gabaɗaya ƙananan adadin da aka tabbatar da Covid-19 (lambobi 138 a duka biyun hannu). Babu wasu munanan abubuwan da suka faru da aka yanke hukunci a matsayin suna da alaƙa da magani. Marubuta sun ware waɗanda ke da alamun cutar a cikin makonni biyu da suka gabata; duk da haka, waɗanda ke da alamun cutar har zuwa watanni da yawa kafin su iya gwada PCR-tabbatacce ko da yake ba za a iya samun kwayar cutar ba. Ya bayyana akwai bayanan da ba daidai ba. Tebur 2, sakamako na biyu, sarrafawa, bayanan asibiti / mahimman bayanai sun nuna cewa 8 na 1042 shine 9.7% (ƙididdigar su zama 0.8%). Abubuwan da ke nazarin nauyin ƙwayar cuta na Nasopharyngeal sun haɗa da gwada rashin dogaro da bambance-bambance na lokaci-lokaci a cikin zubar da kwayar cuta. Bayanai daga wannan binciken An yi amfani da shi don nuna cewa kwayar cutar kwayar cuta ita ce farkon abin da ke watsawa. https://c19p.org/mitjapep
16. J. Beltran Gonzalez. Guerra, inganci da amincin Ivermectin da Hydroxychloroquine a cikin Marasa lafiya masu tsananin COVID-19: Gwajin Sarrafa Bazuwar Fabrairu 2021, Rahoton Cututtuka masu Yaduwa, Juzu'i na 14, Fitowa ta 2, Shafi na 160-168
MAGANIN LAFIYA 70 mai haƙuri HCQ marigayi magani RCT: 63% ƙananan mace-mace (p=0.27) da 25% ƙananan ci gaba (p=0.57).
RCT mai tsanani na ƙarshen zamani (93% SOFA ≥ 2, 96% APACHE ≥ 8) marasa lafiya marasa lafiya na asibiti a Mexico tare da 33 HCQ da 37 masu kula da marasa lafiya ba su sami bambance-bambance masu mahimmanci ba. Saukewa: NCT04391127. https://c19p.org/beltrangonzalezh
17. D. Rathod, K. Kargirwar, M. Patel, V. Kumar, K. Shalia, P. Singhal, Abubuwan Haɗari da ke da alaƙa da Marasa lafiya na COVID-19 a Indiya: Nazarin Ƙungiyar Ƙwararrun Ƙwararrun Ƙwararru guda ɗaya Mayu 2023, J. Ƙungiyar Likitocin Indiya
MAGANIN FARKO 565 haƙuri HCQ binciken farko na jiyya: 73% ƙananan mace-mace (p=0.02).
Marasa lafiya 565 Covid-19 na baya-bayan nan a Indiya, suna nuna ƙarancin mace-mace tare da jiyya na HCQ+AZ. Yawancin marasa lafiya (66%) suna da ƙananan cututtuka a asali. https://c19p.org/rathod2
18. E. Heras, P. Garibaldi, M. Boix, O. Valero, J. Castillo, Y. Curbelo, E. Gonzalez, O. Mendoza, M. Anglada, J. Miralles, P. Llull, R. Llovera, da J. Piqué, COVID-19 abubuwan haɗarin mace-mace a cikin tsofaffi a cibiyar kulawa ta dogon lokaci. Satumba 2020, Magungunan Geriatric na Turai, juzu'i na 12, fitowa ta 3, Shafi na 601-607
MAGANIN FARKO 100 haƙuri HCQ binciken farko na jiyya: 96% ƙananan mace-mace (p=0.004).
Na baya-bayan nan 100 COVID+ tsofaffi marasa lafiya na gida, HCQ+AZ mace-mace 11.4% vs. iko 61.9%, RR 0.18, p<0.001. Tsakanin shekaru 85. https://c19p.org/heras
19. M. Bernabeu-Wittel, J. Ternero-Vega, M. Nieto-Martín, L. Moreno-Gaviño, C. Conde-Guzmán, J. Delgado-Cuesta, M. Rincón-Gómez, P. Díaz-Jiménez, L. Giménez-Miranda, J. Lomas-Guzmán, S. Caña. Calzón-Fernández, da M. Ollero-Baturone, Ingantacciyar Shirin Kiwon Lafiyar Yanar Gizo don Gidajen Ma'aikatan Jiyya tare da Barkewar COVID-19 Yuli 2020, J. Gerontol. A Biol. Sci. Med. Sci., Juzu'i na 76, Fitowa ta 3, Shafi na e19-e27
MAGANIN FARKO 272 haƙuri HCQ binciken farko na jiyya: 94% ƙananan mace-mace (p=0.001).
Mazauna gidajen jinya 272 na baya-bayan nan suna nuna ingantacciyar rayuwa bayan kafa shirin jiyya da suka haɗa da HCQ tare da ko ba tare da lopinavir/ritonavir ba tare da ƙari na adjuvant da maganin ƙwayoyin cuta dangane da yanayi. HCQ (marasa lafiya 114), HCQ+LPV/RTV (marasa lafiya 18), da HCQ+AZ (majiyyata 7). Cikakkun bayanai suna cikin ƙarin bayani. https://c19p.org/bernabeuwittel
20. R. Polo, X. García-Albéniz, C. Terán, M. Morales, D. Rial-Crestelo, M. Garcinuño, M. García del Toro, C. Hita, J. Gómez-Sirvent, L. Buzón, A. Díaz de Santiago, J. Pérez Arellano, E. Díaz-Brito, M. Masiá, A. Hernández-Torres, J. Guerra, J. Santos, P. Arazo, L. Muñoz, J. Arribas, P. Martínez de Salazar, S. Moreno, M. Hernán, J. Del Amo, J. Del Amo, Rosa Polo, S. Martín, J. Moreno, J. Moreno, J. Moreno, J. Moreno, J. M. P. Martínez de Salazar, X. García de Albéniz, M. Iradier, I. Jarrín, J. Zamora, A. Rivero, C. Menéndez, E. Conde, J. Montes, C. Terán, B. Flores, M. Elena Choque, J. Peñaranda, G. Gorena, M. Faarno et al. disoproxil fumarate / emtricitabine da hydroxychloroquine don pre-exposure prophylaxis na COVID-19: wani makafi mai makafi wanda aka sarrafa bazuwar gwaji a cikin ma'aikatan kiwon lafiya Agusta 2022, Clinical Microbiology da Kamuwa da cuta
435 mai haƙuri HCQ prophylaxis RCT: 51% ƙananan lokuta na alamomi (p=0.79) da 27% ƙananan lokuta (p=0.31).
Farkon dakatar da ma'aikacin kiwon lafiya prophylaxis RCT a cikin Spain, yana nuna ƙananan haɗarin lokuta na alamun bayyanar cututtuka tare da rigakafin HCQ, ba tare da mahimmancin ƙididdiga ba saboda ƙananan adadin abubuwan da suka faru. https://c19p.org/polo
21. V. Dubée, P. Roy, B. Vielle, E. Parot-Schinkel, O. Blanchet, A. Darsonval, C. Lefeuvre, C. Abbara, S. Boucher, E. Devaud, O. Robineau, P. Rispal, T. Guimard, E. D'Anglejean, S. Diamantis, A. Brallier. P. Codron, J. Lemée, V. Pichon, R. Dhersin, G. Urbanski, C. Lavigne, R. Courtois, H. Danielou, J. Lebreton, R. Vatan, N. Crochette, J. Lainé, L. Perez, S. Blanchi, H. Hitoto, L. Bernard, F. Maillot, J. Marchand, P. Motte-Vincent, M. Morrier, D. Merrien, Y. Bleher, M. Flori, A. Ducet-Boiffard, O. Colin, R. Février, P. Thill, M. Tetart, F. Demaeght et al., Hydroxychloroquine a cikin matsakaici-zuwa-matsakaici COVID-19 gwajin gwaji sau biyu Oktoba 2020, Clinical Microbiology da Kamuwa da cuta, Juzu'i na 27, Fitowa ta 8, Shafi na 1124-1130
MAGANIN LAFIYA 247 mai haƙuri HCQ marigayi magani RCT: 46% ƙananan mace-mace (p=0.21) da 26% ƙananan mace-mace / intubation (p=0.48).
Ƙananan farkon ƙare ƙarshen mataki (60% akan oxygen) RCT a Faransa yana nuna 46% ƙananan mace-mace. Mutuwa a kwanakin 28 hadarin dangi RR 0.54 [0.21-1.42] hadewar mace-mace / intubation a kwanakin 28 hadarin dangi RR 0.74 [0.33-1.70]. Idan ba a tsaya da wuri ba kuma ana ci gaba da irin wannan yanayin, za a kai ga mahimmancin ƙididdiga akan mutuwar kwanaki 28 bayan ~ 550 marasa lafiya (an shirya marasa lafiya 1,300). Ba a bayar da sakamakon mace-mace don ƙungiyoyin ƙasa ba. Don ƙananan ƙungiyoyi masu karɓar AZ: Ba a gano matsalolin tsaro ba. An gabatar da wannan binciken a matsayin mara kyau; duk da haka sakamakon bai goyi bayan hakan ba. https://c19p.org/dubee
22. R. Amaravadi, L. Giles, M. Carberry, M. Hyman, I. Frank, S. Nasta, J. Walsh, E. Wileyto, P. Gimotty, M. Milone, E. Teng, N. Vyas, S. Balian, J. Kolansky, N. Abdulhay, S. McGovern, S. Gamblin. O. Callahan, da kuma P. SARS-CoV-2 tabbataccen marasa lafiya an keɓe su a gida: Nazarin wucin gadi na farko na gwajin asibiti bazuwar da aka gudanar Fabrairu 2021, medRxiv
MAGANIN FARKO 29 mai haƙuri HCQ farkon jiyya RCT: 60% inganta farfadowa (p=0.13).
Ƙananan 34 mai haƙuri RCT da aka ƙare da wuri don jiyya na asibiti yana nuna saurin murmurewa tare da jiyya (ba ƙididdiga ba). Duk marasa lafiya sun murmure (masu kula da marasa lafiya 3 sun murmure bayan hayewa zuwa hannun jiyya) - kamar yadda sakamakon tsakiyar farfadowa yana da fifiko. Babu mace-mace kuma asibiti guda ɗaya kawai a ranar 0 kafin magani. Ba a sami mummunan bala'i ba. https://c19p.org/amaravadi
23. S. Azhar, J. Akram, W. Latif, N. Cano Ibanez, S. Mumtaz, A. Rafi, U. Aftab, S. Iqtadar, M. Shahzad, F. Syed, B. Zafar, N. Fatima, S. Saadat Afridi, S. Javed Akram, M. Afzal Chaudhary., Sadiq. Ashraf, H. Akrma, da T. Khaliq, Tasirin magungunan farko na magunguna a cikin alamun alamun COVID-19 marasa lafiya: Gwajin asibiti bazuwar Maris 2024, Pakistan J. Kimiyyar Lafiya, Juzu'i na 40, Mas'ala ta 5
MAGANIN FARKO 471 mai haƙuri HCQ farkon jiyya RCT: 71% ƙananan mace-mace (p=0.03), 4% mafi girman haɓakawa (p=0.64), da 10% ingantacciyar kariya ta hoto (p=0.52).
RCT 471 marasa lafiya na Covid-19 masu sauƙi a Pakistan ba su nuna wani bambance-bambance a cikin haɓakar asibiti da kawar da kwayar cuta tsakanin HCQ, azithromycin, oseltamivir, da haɗuwa. Mutuwar ta ragu sosai a cikin HCQ vs. makamai marasa HCQ. An ga sakamako mafi kyau don kawar da kwayar cutar hoto da inganta lafiyar asibiti tare da haɗuwa da duk jiyya. Babu ƙungiyar kulawa. Ba a sami rahoton mummunan aukuwa ba. Duk marasa lafiya suna da Covid-19 mai sauƙi kuma takarda ta nuna jiyya da wuri, duk da haka ba a ba da rahoton lokaci daga farkon ba kuma an ba da ƙarancin bayanan tushe. https://c19p.org/azhar
24. R. Derwand, M. Scholz, da V. Zelenko, COVID-19 Marasa lafiya - Jiyya na Farko-Tsarin Haɗari tare da Zinc Plus Ƙananan Kashi Hydroxychloroquine da Azithromycin: Nazari Na Ci Gaba Yuli 2020, Int. J. Magungunan rigakafi, Juzu'i na 56, Fitowa ta 6, Shafi na 106214
MAGANIN FARKO 518 haƙuri HCQ binciken farko na jiyya: 79% ƙananan mace-mace (p=0.12) da 82% ƙananan asibiti (p=0.001).
79% ƙananan mace-mace da 82% ƙananan asibiti tare da farkon HCQ+AZ+Z. Babu illolin zuciya. Marasa lafiya 518 na baya-bayan nan (141 bi da su, kulawar 377). https://c19p.org/derwand
25. V. Guérin, P. Lévy, J. Thomas, T. Lardenois, P. Lacrosse, E. Sarrazin, N. Andreis, da M. Wonner, Azithromycin da Hydroxychloroquine Accelerate farfadowa da marasa lafiya tare da M / Matsakaici COVID-19 Mayu 2020, Asiyan J. Magunguna da Lafiya, Yuli 15, 2020, Shafi na 45-55
MAGANIN FARKO 88 haƙuri HCQ binciken farko na jiyya: 65% saurin farfadowa (p=0.0001).
Ma'anar lokacin dawowa na asibiti ya ragu daga kwanaki 26 (ma'auni na kulawa) zuwa kwanaki 9, p<0.0001 (HCQ+AZ) ko 13 days, p<0.0001 (AZ). Babu gubar zuciya. Ƙananan nazarin baya-bayan nan na marasa lafiya na 88 tare da nazarin nazarin yanayin tare da marasa lafiya da suka dace. https://c19p.org/guerin
26. T. Tarjoman, M. Valizadeh. Cutar COVID-19 a cikin yawan jama'ar asymptomatic: Gwajin asibiti bazuwar Janairu 2024, Damalancin Lafiya na Lafiya, Juzu'i na 10, Fitowa Vol. 10 (2024): Batun Ci gaba
1,000 marasa lafiya HCQ prophylaxis RCT: 80% ƙananan asibiti (p=0.25) da Ƙananan lokuta 43% (p=0.005).
RCT na mutane 1,000 suna nuna ƙananan haɗarin kamuwa da cutar Covid-19 tare da rigakafin HCQ. Babu wani bambanci mai mahimmanci a cikin sakamako masu illa ko rikowa, babu mummunan sakamako, kuma an kiyaye makanta da kyau. Akwai yanzu PrEP RCTs, yana nuna ingantaccen inganci ga shari'o'in Covid-19. https://c19p.org/chouhdari
27. C. Yilgwan, A. Onu, J. Ofoli, L. Dakum, N. Shehu, D. Ogoina, I. Okoli, D. Osisanwo, V. Okafor, A. Olayinka, I. Mamadu, A. Adebiyi, Clinical profile and Predictors of results of Asibiti marasa lafiya da Laboratory-Confirmed Severespekt Syndrome Nigeria: Analysis Jihohi 2 masu nauyi a Najeriya Mayu 2023, Likitan Najeriya J.
MAGANIN LAFIYA 3,462 mai haƙuri HCQ nazarin jiyya na ƙarshen: 93% ƙananan mace-mace (p <0.0001).
Kimanin mutane 3,462 da ke kwance a asibiti na Covid-19 a cikin jihohi 13 na Najeriya, wanda ke nuna karancin mace-mace tare da HCQ. Marubuta sun lura cewa ingantattun sakamako idan aka kwatanta da sauran karatun da yawa a ƙarshen mataki na iya zama alaƙa da kashi da ƙwarewar likitocin - a cikin wasu nazarin tasiri masu amfani na iya zama a kashe su ta hanyar sakamako masu illa na babban tarin allurai a cikin marasa lafiya na ƙarshen zamani. Har ila yau, marubutan sun lura da mummunan sakamako tare da haɗin CQ / HCQ da AZ na iya kasancewa da alaka da illar da ke zama mafi mahimmanci ga marasa lafiya marasa lafiya. https://c19p.org/yilgwan
28. B. Obrișcă, A. Vornicu, R. Jurubiță, V. Mocanu, G. Dimofte, A. Andronesi, B. Sorohan, C. Achim, G. Micu, R. Bobeică, C. Dina, da G. Ismail, Halayen SARS-CoV-2 Kamuwa da Ciwon Ciwon Ciwon Ciwon Ciki Satumba 2022, Magungunan ƙwayoyin cuta, Juzu'i na 10, Fitowa ta 10, Shafi na 2423
95 haƙuri HCQ nazarin prophylaxis: Ƙananan lokuta 87% (p=0.01).
Bincike mai zuwa na marasa lafiya Lupus Nephritis 95 a cikin Romania, yana nuna ƙarancin haɗarin Covid-19 tare da amfani da HCQ. https://c19p.org/obrisca
29. C. Loucera, R. Carmona, M. Esteban-Medina, G. Bostelmann, D. Muñoyerro-Muñiz, R. Villegas, M. Peña-Chilet, da J. Dopazo, Shaida ta gaske ta duniya tare da ƙungiyar 15,968 na COVID-19 marasa lafiya na asibiti suna ba da shawarar sabbin magunguna 21 Agusta 2022, Virology J., Juzu'i na 20, Mas'ala ta 1
15,968 haƙuri HCQ nazarin prophylaxis: 69% ƙananan mace-mace (p=0.0002).
A baya-bayan nan 15,968 Covid-19 marasa lafiya na asibiti a Spain, suna nuna ƙarancin mace-mace tare da amfani da magunguna da yawa waɗanda suka haɗa da metformin, HCQ, azithromycin, aspirin, bitamin D, bitamin C, da budesonide. Tunda marasa lafiya ne a asibiti kawai aka hada, Sakamakon ba ya nuna yiwuwar asibiti daban-daban a cikin jiyya. https://c19p.org/loucera3h
30. D. Badyal, S. Chandy, P. Chugh, A. Faruqui, Y. Gupta, A. Hazra, S. Kamat, V. Kamboj, R. Kaul, N. Kshirsagar, S. Maulik, B. Medhi, G. Menon, J. Ranjalkar, V. Rao, Y. Shetty, R. Trivila, SARS, Proxila, D. a cikin Ma'aikatan Kiwon Lafiya - Nazarin Ƙungiyoyin Ƙungiyoyin Maɗaukaki Masu Ƙaƙwalwar Ƙirar Ƙwarewa da Aminci Yuni 2021, J. Ƙungiyar Likitocin Indiya, Yuni 2021
2,090 haƙuri HCQ nazarin prophylaxis: Ƙananan lokuta 60% (p <0.0001).
Nazarin prophylaxis tare da ma'aikatan kiwon lafiya na Indiya 12,089, yana nuna ƙarancin haɗarin shari'o'in Covid-19 tare da jiyya, da ƙara ƙarancin haɗari na tsawon lokaci na HCQ prophylaxis. Abubuwan da aka haɗa ba su samuwa. https://c19p.org/badyal
31. J. Rojas-Serrano, A. Portillo-Vásquez, I. Thirion-Romero, J. Vázquez-Pérez, F. Mejía-Nepomuceno, A. Ramírez-Venegas, K. Pérez-Kawabe, da R. Pérez-Padilla, Hydroxychloroquine don gwajin ma'aikatan kiwon lafiya na COVID-19. Mayu 2021, KUMA KUMA, Juzu'i na 17, fitowa ta 2, Shafi na e0261980
127 mai haƙuri HCQ prophylaxis RCT: 82% ƙananan lokuta na alamomi (p=0.12).
An ƙaddamar da farko HCQ PrEP RCT tare da 62 HCQ da 65 marasa lafiya na placebo, suna nuna 82% ƙananan lokuta tare da magani, p = 0.12. Idan aka ci gaba da gwaji kuma aka lura da adadin abubuwan da suka faru. da an kai mahimmancin ƙididdiga bayan ƙara kusan marasa lafiya 16 a kowane hannu. https://c19p.org/rojasserrano
32. E. Corradini. M. Porta, P. Minuz. G. Arcidiacono, M. Podda, L. Muratori, C. Gabiati, F. Salinaro, M. Luciani, C. Barnini, S. Morra di Cella, A. Dalbeni, S. Friso, M. Luciani, F. Mearelli et al., Abubuwan da suka shafi asibiti da ke da alaƙa da mutuwa a cikin 3044 na asibiti na Italiyanci na COVID-19 sakamakon binciken da aka yi a cikin Italiyanci na COVID-19 da aka gudanar a cikin maganin COVID-XNUMX. Ƙungiyar Magungunan Ciki (SIMI) Afrilu 2021, Maganin Ciki da Gaggawa, juzu'i na 16, fitowa ta 4, Shafi na 1005-1015
MAGANIN LAFIYA 1,713 mai haƙuri HCQ nazarin jiyya na ƙarshen: 70% ƙananan mace-mace (p <0.0001).
A baya-bayan nan 3,044 marasa lafiya na Covid-19 na asibiti a Italiya, suna nuna HCQ da ke da alaƙa da rayuwa a cikin haske, mai laushi, da matsakaici a cikin bincike mai yawa, amma ba cikin yanayi mai tsanani ba. https://c19p.org/corradini
33. B. Cangiano, L. Fatti, L. Danesi, G. Gazzano, M. Croci, G. Vitale, L. Gilardini, S. Bonadonna, I. Chiodini, C. Caparello, A. Conti, L. Persani, M. Stramba-Badiale, da M. Bonomi, mace-mace a cikin gidan jinya na Italiyanci, D. D. kari, da iyakancewar gwaje-gwajen bincike Disamba 2020, tsufa, Juzu'i na 12, Fitowa ta 24, Shafi na 24522-24534
MAGANIN LAFIYA 98 mai haƙuri HCQ nazarin jiyya na ƙarshen: 73% ƙananan mace-mace (p=0.03).
Binciken 98 PCR+ mazauna gida a Italiya, yana nufin shekaru 90, yana nuna mutuwar HCQ RR 0.27, p = 0.03. Batun rikicewa ta hanyar contraindications. Takardar tana ba da ƙimar p don komawa baya amma ba girman tasirin ba. https://c19p.org/cangiano
34. E. Sheshah, S. Sabico, R. Albakr, A. Sultan, K. Alghamdi, K. Al Madani, H. Alotair, da N. Al-Daghri, Yawaitar Ciwon Ciwon Suga, Gudanarwa da Sakamako a Tsakanin Majinyata na Covid-19 An kwantar da su a Babban Asibiti na Musamman dake Riyadh, Saudi Arabia Nuwamba 2020, Binciken Ciwon sukari da Ayyukan Asibiti, Juzu'i na 172, Shafi na 108538
MAGANIN LAFIYA 300 mai haƙuri HCQ nazarin jiyya na ƙarshen: 80% ƙananan mace-mace (p=0.001).
Marasa lafiya na asibiti 300 na baya-bayan nan a cikin Saudi Arabiya suna nuna HCQ daidaita daidaiton rabo 0.12, p <0.001. https://c19p.org/sheshah
35. I. Simova, T. Vekov, J. Krasnaliev, V. Kornovski, da P. Bozhinov, Hydroxychloroquine don rigakafi da kula da COVID-19 a cikin ma'aikatan kiwon lafiya Nuwamba 2020, Sabbin ƙwayoyin cuta da Sabbin cututtuka, Juzu'i na 38, Shafi na 100813
204 haƙuri HCQ nazarin prophylaxis: Ƙananan lokuta 93% (p=0.01).
Rage 100% a lokuta tare da HCQ+ zinc prophylaxis bayan fallasa. Takaitaccen rahoto ga ma'aikatan kiwon lafiya a Bulgaria. 0 lokuta tare da jiyya vs. 3 don sarrafawa. 156 jiyya marasa lafiya da 48 kula da marasa lafiya. Babu mummunan al'amura mara kyau. Wannan takarda ta ba da rahoto game da PEP da farkon magani, mun raba karatun biyu. https://c19p.org/simovapep
36. V. Hande, S. Matthai, da V. Behera, Hydroxychloroquine a matsayin pre-exposure prophylaxis a kan COVID-19 a cikin ma'aikatan kiwon lafiya: Kwarewar cibiyar guda ɗaya Nuwamba 2020, J. Marine Medical Society, Juzu'i na 0, Fitowa ta 0, Shafi na 0
604 haƙuri HCQ nazarin prophylaxis: Ƙananan lokuta 90% (p <0.0001).
Rage 90% a lokuta tare da HCQ pre-exposure prophylaxis. Ma'aikatan kiwon lafiya 604 na baya-bayan nan. https://c19p.org/mathai
37. J. Nogueira López, C. Grasa Lozano, C. Ots Ruiz, L. Alonso García, I. Falces-Romero, C. Calvo, da M. García-López Hortelano, Telemedicine biyo bayan COVID-19: gogewa a cikin babban asibiti Nuwamba 2020, Annals of Pediatrics, Juzu'i na 95, Fitowa ta 5, Shafi na 336-344
MAGANIN LAFIYA 72 mai haƙuri HCQ nazarin jiyya na ƙarshen: 64% ƙananan ci gaba (p=0.02).
Marasa lafiya na yara 72 na baya-bayan nan suna nuna HCQ da ke hade da ɗan gajeren lokacin zazzabi (p=0.023), ƙarancin ci gaba (p=0.016), da ƙarancin komawa zuwa ER (p=0.017). https://c19p.org/lopez2
38. M. Lauriola, A. Pani, G. Ippoliti, A. Mortara, S. Milighetti, M. Mazen, G. Perseghin, D. Pastori, P. Grosso, da F. Scaglione, Tasirin hadewar maganin hydroxychloroquine da azithromycin akan mace-mace a cikin marasa lafiya na COVID-19 Satumba 2020, Clinical da Kimiyyar Fassara, Juzu'i na 13, Fitowa ta 6, Shafi na 1071-1076
MAGANIN LAFIYA 360 mai haƙuri HCQ nazarin jiyya na ƙarshen: 74% ƙananan mace-mace (p=0.001).
Marasa lafiya 377 na baya-bayan nan, 73% raguwa a cikin mace-mace tare da HCQ+AZ, daidaitaccen haɗarin haɗari 0.27 [0.17-0.41]. Matsakaicin shekaru 71.8. Babu mummunan al'amura mara kyau. Batun daidaitawa ga rashin cikawa ga masu rikicewa. https://c19p.org/lauriola
39. C. Ferri, D. Giuggioli, V. Raimondo, M. L'Andolina, A. Tavoni, R. Cecchetti, S. Guiducci, F. Ursini, M. Caminiti, G. Varcasia, P. Gigliotti, R. Pellegrini, D. Olivo, M. Colaci, G. Murtella, R. G. Murtella, G. Britella, G. Murtella, G. Spin A. Bellando-Randone, V. Aiello, S. Bilia, D. Giannini, T. Ferrari, R. Caminiti, V. Brusi, R. Meliconi, P. Fallahi, da A. Antonelli, COVID-19 da cututtuka na tsarin cututtuka na rheumatic autoimmune: rahoton babban jerin marasa lafiya na Italiya. Agusta 2020, Clinical Rheumatology, juzu'i na 39, fitowa ta 11, Shafi 3195-3204
1,641 haƙuri HCQ nazarin prophylaxis: Ƙananan lokuta 63% (p=0.02).
Binciken 1641 na marasa lafiya marasa lafiya na tsarin jiki wanda ke nuna csDMARD (HCQ da dai sauransu) RR 0.37, p=0.015. csDMARDs sun haɗa da HCQ, CQ, da wasu magunguna da yawa, don haka tasirin HCQ/CQ kaɗai zai iya zama mafi girma. Wannan binciken kuma ya tabbatar da cewa haɗarin Covid-19 ga masu cutar cututtukan ƙwayoyin cuta na ƙwayoyin cuta ya fi girma gabaɗaya, KO 4.42, p<0.001 (wannan shine haɗarin gaske na duniya wanda aka lura wanda yayi la'akari da dalilai kamar waɗannan marasa lafiya suna iya yin hankali don guje wa fallasa). (Sakamako na "tabbataccen + wanda ake zargi sosai" lokuta kuma an gabatar da babban sakamako a cikin takarda azaman OR don rashin ɗaukar csDMARDs, c19 ku canza wannan zuwa RR. https://c19p.org/ferri
40. A. Dubernet, K. Larsen, L. Masse, J. Allyn, E. Foch, L. Bruneau, A. Maillot, M. Lagrange-Xelot, V. Thomas, M. Jaffar-Bandjee, L. Gauzere, L. Raffray, K. Borsu, S. Dibernardo, S. Renaud, D. More, Jbot, N. R., N. J. N. R. Coolen-Allou, da N. Allou, Babban dabara don farkon jiyya na COVID-19 tare da azithromycin/hydroxychloroquine da/ko corticosteroids: sakamakon binciken lura na baya-bayan nan a sashen Faransa na ketare na Reunion Island Agusta 2020, J. Ƙwararrun Ƙwararrun Ƙwararru na Duniya, Juzu'i na 23, Shafi na 1-3
MAGANIN LAFIYA 36 mai haƙuri HCQ nazarin jiyya na ƙarshen: 88% ƙananan shigar da ICU (p=0.008).
Binciken na baya-bayan nan na marasa lafiya na asibiti 36 da ke nuna HCQ / AZ hade da ƙananan shigar da ICU, p=0.008. Tsakanin shekaru 66, babu mace-mace. Mai ban tsoro ta hanyar nuni; duk da haka, marasa lafiya da ciwon huhu na hypoxemic ne aka yi musu magani tare da HCQ/AZ. Ba a yi wa marasa lafiya magani da HCQ/AZ ba idan ba sa buƙatar maganin iskar oxygen. Ko da a wancan ƙarshen matakin, ya nuna inganci. https://c19p.org/dubernet
41. M. Soneja, H. Kadnur, A. Aggarwal, K. Singh, A. Mittal, N. Nischal, P. Tirlangi, A. Khan, D. Desai, A. Gupta, A. Kumar, P. Jorwal, A. Biswas, R. Pandey, N. Wig, da R. Guleria, ma'aikatan kiwon lafiya na hydroxis-chloroquine a tsakanin ma'aikatan kiwon lafiya na COVID-chloroquine. Kwarewar farko daga Indiya Yuli 2020, J. Magungunan Iyali da Kulawa na Farko, Juzu'i na 11, Fitowa ta 3, Shafi na 1140
358 haƙuri HCQ nazarin prophylaxis: Ƙananan lokuta 62% (p=0.01).
Nazarin prophylaxis tare da ma'aikatan kiwon lafiya masu ƙarancin haɗari 334 a Indiya, yana nuna ƙarancin haɗarin lokuta tare da jiyya. Marasa lafiya masu alamun sun sami sakamakon PCR, amma wasu marasa lafiya asymptomatic ne kawai suka yi, don haka ƙila an sami ƙarin maganganun asymptomatic. Ba a sami mummunan bala'i ba. https://c19p.org/kadnur
42. J. Zhong, G. Shen, H. Yang, A. Huang, X. Chen, L. Dong, B. Wu, A. Zhang, L. Su, X. Hou, S. Song, H. Li, W. Zhou, T. Zhou, Q. Huang, A. Chu, Z. Braunstein, X. Rao, C. Ye, da COVID-19 a cikin cutar Hubi, da kuma L.XNUMX. Lardi, Sin: nazari na lura da na baya-bayan nan da yawa Yuli 2020, Lancet Rheumatology, Juzu'i na 2, Fitowa ta 9, Shafi na e557-e564
43 haƙuri HCQ nazarin prophylaxis: Ƙananan lokuta 91% (p=0.04).
Marasa lafiya na rheumatic akan HCQ suna da ƙarancin haɗarin Covid-19 fiye da waɗanda ke kan sauran magungunan rigakafin cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan da kuma fiye da waɗanda ke canza cutar., KO 0.09 (0.01-0.94), p=0.044 bayan daidaitawa don shekaru, jima'i, shan taba, lupus erythematosus, kamuwa da cuta a cikin sauran 'yan uwa, da kuma cututtuka. Majinyata 43 da ke fama da cutar rheumatic da bayyanar Covid-19. https://c19p.org/zhong
43. J. Rogado, C. Pangua, G. Serrano-Montero, B. Obispo, A. Marino, M. Pérez-Pérez, A. López-Alfonso, P. Gullón, da M. Lara, Covid-19 da ciwon huhu: Yawan mutuwa mafi girma? Mayu 2020, huhu Cancer, Juzu'i na 146, Shafi na 19-22
MAGANIN LAFIYA 17 mai haƙuri HCQ nazarin jiyya na ƙarshen: 92% ƙananan mace-mace (p=0.02).
A baya-bayan nan 17 marasa lafiya ciwon huhu na asibiti suna nuna ƙarancin mace-mace tare da HCQ+AZ Magani. https://c19p.org/rogado
44. S. Panda, P. Chatterjee, T. Anand, K. Singh, R. Rasaily, R. Singh, S. Das, H. Singh, I. Praharaj, R. Gangakhedkar, da B. Bhargava, ma'aikatan kiwon lafiya & kamuwa da SARS-CoV-2 a Indiya: Binciken kula da shari'a a lokacin COVID-19 Mayu 2020, Indiya J. Med. Res., Yuni 20, 2020, juzu'i na 151, fitowa ta 5, Shafi na 459
455 haƙuri HCQ nazarin prophylaxis: Ƙananan lokuta 67% (p=0.001).
4+ allurai na HCQ da ke da alaƙa da raguwa mai mahimmanci a cikin rashin daidaituwar kamuwa da cuta, dangantakar amsa kashi tana wanzu. https://c19p.org/chatterjee
45. M. Huang, M. Li, F. Xiao, P. Pang, J. Liang, T. Tang, S. Liu, B. Chen, J. Shu, Y. You, Y. Li, M. Tang, J. Zhou, G. Jiang, J. Xiang, W. Hong, S. He, Z. Wang, J. Feng, C., Lin. Z, Y. Z, Y. Z, Y. Z. Sun, Z. Hong, J. Liu, H. Chen, X. Wang, Z. Li, D. Pei, L. Tian, J. Xia, S. Jiang, N. Zhong, da H. Shan, shaida ta farko daga wani bincike mai zurfi na bincike na aminci da ingancin chloroquine don maganin COVID-19 Mayu 2020, Binciken Kimiyya na Ƙasa, nwaa113, Juzu'i na 7, Fitowa ta 9, Shafi na 1428-1436
MAGANIN LAFIYA 373 mai haƙuri HCQ marigayi nazarin jiyya: 67% saurin kamuwa da cutar hoto (p=0.0001).
197 CQ marasa lafiya, 176 sarrafawa. Ma'anar lokacin da ba za a iya gano kwayar cutar RNA ba da kuma tsawon lokacin zazzabi ya ragu sosai. Babu mummunan al'amura mara kyau. https://c19p.org/huangnsr
46. B. Yu, C. Li, P. Chen, N. Zhou, L. Wang, J. Li, H. Jiang, da D. Wang, Karancin Kashi na Hydroxychloroquine Yana Rage Mutuwar Marasa Lafiya Masu Mutuwar COVID-19 Mayu 2020, Kimiyyar Rayuwar Kimiyya ta Sin, 2020 Mayu 15, 1-7, juzu'i na 63, fitowa ta 10, Shafi na 1515-1521
MAGANIN LAFIYA 550 mai haƙuri HCQ nazarin jiyya na ƙarshen: 60% ƙananan mace-mace (p=0.002).
A baya, 550 marasa lafiya marasa lafiya. 19% m ga HCQ a kan 47% ga wadanda ba HCQ, RR 0.395, p=0.002. Matakan cytokine mai kumburi IL-6 sun ragu sosai daga 22.2 pg / mL zuwa 5.2 pg / mL (p <0.05) a ƙarshen jiyya a cikin ƙungiyar HCQ amma babu canji a cikin ƙungiyar kulawa. https://c19p.org/yu
47. A. Pate, A. Shankarkumar, S. Shinde, M. Pruthi, H. Patil, da M. Madkaikar, Sero-bincike na ma'aikatan kiwon lafiya yana ba da tabbataccen shaida don ingancin maganin Hydroxychloroquine akan kamuwa da cutar COVID-19 Satumba 2020, ResearchGate
500 haƙuri HCQ nazarin prophylaxis: 82% ƙananan asibiti (p=0.01) da 42% ƙananan lokuta (p=0.05).
Binciken seroprevalence na ICMR na ma'aikatan kiwon lafiya 500 a Indiya, 279 suna ɗaukar rigakafin HCQ, yana nuna ƙarancin haɗari tare da jiyya, da ƙarancin ƙarfi. https://c19p.org/yadav3
48. M. Mokhtari, M. Mohraz, M. Gouya, H. Namdari Tabar, J. Tabrizi, K. Tayeri, S. Aghamohamadi, Z. Rajabpoor, M. Karami, A. Raeisi, H. Rahmani, da H. Khalili, Sakamakon Clinical na marasa lafiya tare da m COVID-19 bayan jiyya tare da hydroxychloroquine. Afrilu 2021, Int. Immunopharmacology, juzu'i na 96, shafi na 107636
MAGANIN FARKO 28,759 haƙuri HCQ binciken farko na jiyya: 70% ƙananan mace-mace (p <0.0001) da 35% ƙananan asibiti (p <0.0001).
A baya-bayan nan 28,759 manya marasa lafiya marasa lafiya tare da ƙarancin Covid-19 a Iran, 7,295 an yi musu magani tare da HCQ, yana nuna ƙananan ƙananan asibiti da mace-mace tare da magani. https://c19p.org/mokhtari
49. M. AlQahtani, N. Kumar, D. Aljawder, A. Abdulrahman, M. Mohamed, F. Alnashaba, M. Fayyad, F. Alshaikh, F. Alsahaf, S. Saeed, A. Almahroos, Z. Abdulrahim, S. Otoom, da S. Atkin, Randomized control trial na favipiravir, hydroxychloroquid da favipiravir, da kuma hydroxychloroqui. Cutar COVID-19 Maris 2022, Rahoton Kimiyya, Juzu'i na 12, Mas'ala ta 1
MAGANIN LAFIYA 103 mai haƙuri HCQ marigayi jiyya RCT: 4% inganta farfadowa (p=0.94) da 47% inganta ƙwayar cuta (p=0.13).
RCT tare da 54 favipiravir, 51 HCQ, da kuma 52 masu kula da marasa lafiya na asibiti a Bahrain, ba tare da nuna bambanci ba. Cirewar ƙwayar cuta ta inganta tare da jiyya guda biyu, amma bai kai ma'anar ƙididdiga ba tare da ƙaramin girman samfurin. https://c19p.org/alqahtani2
50. A. Ip. J. Ahn G. Mojares, M. Eagan, K. Ziontz, P. Mastrokyriakos, da S. Goldberg, Hydroxychloroquine a cikin kula da marasa lafiya marasa lafiya tare da alamun COVID-19 mai sauƙi: Nazarin kulawa da yawa. Agusta 2020, BMC Cututtuka masu Yaduwa, Juzu'i na 21, Mas'ala ta 1
MAGANIN FARKO 1,067 haƙuri HCQ binciken farko na jiyya: 55% ƙananan mace-mace (p=0.43) da 37% ƙananan asibiti (p=0.04).
Marasa lafiya na 1,274 na baya-bayan nan, 47% raguwa a cikin asibiti tare da HCQ tare da dacewa da dacewa, HCQ KO 0.53 [0.29-0.95]. Nazarin hankali ya bayyana ƙungiyoyi iri ɗaya. Abubuwan da ba su da kyau ba a ƙara su ba (2% QTc al'amuran tsawaitawa, 0% arrhythmias). https://c19p.org/ip
51. F. Cadegiani, A. Goren, C. Wambier, da J. McCoy, Farkon COVID-19 Therapy tare da azithromycin da nitazoxanide, ivermectin ko hydroxychloroquine a cikin Saitunan Marassa lafiya Ingantacciyar sakamako na COVID-19 idan aka kwatanta da Sanannun sakamako a cikin marasa lafiya da ba a kula da su ba. Nuwamba 2020, Sabbin ƙwayoyin cuta da Sabbin cututtuka, Juzu'i na 43, Shafi na 100915
296 mai haƙuri HCQ binciken farko na jiyya: 81% ƙananan mace-mace (p=0.21), 95% ƙananan iska (p=0.0008), da 98% ƙananan asibiti (p <0.0001).
Kwatanta HCQ, nitazoxanide, da ivermectin suna nuna tasiri iri ɗaya don jimlar sakamakon asibiti a cikin Covid-19 idan aka yi amfani da shi kafin kwanaki bakwai na bayyanar cututtuka, kuma mafi girman gaske idan aka kwatanta da yawan jama'ar Covid-19 da ba a kula da su ba, har ma ga waɗancan sakamakon da tasirin placebo bai yi tasiri ba, aƙalla lokacin da aka haɗa shi da azithromycin, da bitamin C, D da zinc a mafi yawan lokuta. 585 marasa lafiya tare da jinkirin jinkiri na tsawon kwanaki 2.9. Babu asibiti, iskar injina, ko mace-mace tare da jiyya. Ƙungiyar kulawa ta 1 ta kasance ƙungiyar da aka dawo da ita na marasa lafiya marasa lafiya na yawan jama'a. https://c19p.org/cadegiani
52. D. Dhibar, N. Arora, D. Chaudhary, A. Prakash, B. Medhi, N. Singla, R. Mohindra, V. Suri, A. Bhalla, N. Sharma, M. Singh, P. Lakshmi, K. Goyal, da A. Ghosh, The 'myth of Hydroxychloroquine (HCQ) prophylaxis prophylaxis (HCQ) COVID-19' yayi nisa da gaskiya Janairu 2023, Rahoton Kimiyya, Juzu'i na 13, Mas'ala ta 1
1,168 mai haƙuri HCQ prophylaxis RCT: 27% ƙananan lokuta na alamomi (p=0.32) da 21% ƙananan lokuta (p=0.21).
Ƙananan ƙananan ƙananan ƙananan HCQ PEP RCT, yana nuna ƙananan alamun bayyanar cututtuka tare da magani, ba tare da mahimmancin ƙididdiga ba. Babu matsakaita ko mai tsanani. HCQ 800mg a rana ta daya ya biyo bayan 400mg sau ɗaya a mako don makonni 3. https://c19p.org/dhibar2
53. T. Ly, D. Zanini, V. Laforge, S. Arlotto, S. Gentile, H. Mendizabal, M. Finaud, D. Morel, O. Quenette, P. Malfuson-Clot-Faybesse, A. Midejean, P. Le-Dinh, G. Daher, B. Labarriere, A. Morel Cogiquet, P. Chabriere, D. Raoult, da P. Gautret, Tsarin kamuwa da cutar SARS-CoV-2 tsakanin tsofaffi mazauna mazaunan da ke zaune a gidajen ritaya a Marseille, Faransa, Maris-Yuni 2020 Agusta 2020, Int. J. Magungunan rigakafi, Juzu'i na 56, Fitowa ta 6, Shafi na 106219
MAGANIN FARKO 226 haƙuri HCQ binciken farko na jiyya: 56% ƙananan mace-mace (p=0.02).
Binciken baya na gidajen ritaya, HCQ+AZ>= mutuwar kwanaki 3 KO 0.37, p=0.02. Mazauna tsofaffi 1,690 (yana nufin shekaru 83), mazauna 226 da suka kamu da cutar, 116 an yi musu magani tare da HCQ+AZ> = kwanaki 3. Ganewa ta hanyar tantance yawan jama'a kuma ya nuna ingantaccen haɓakawa (16.9% vs. 40.6%, OR 0.20, p=0.001), yana nuna cewa ganowa da jiyya a baya ya fi nasara. https://c19p.org/ly
54. C. Skipper, K. Pastick, N. Engen, A. Bangdiwala, M. Abassi, S. Lofgren, D. Williams, E. Okafor. McDonald, T. Lee, R. Rajasingham, da D. Boulware, Hydroxychloroquine a cikin Manya marasa Asibiti Tare da Farkon COVID-19: Gwajin Rarraba Yuli 2020, Annals na Internal Medicine, Juzu'i na 173, Fitowa ta 8, Shafi na 623-631
465 marasa lafiya HCQ "maganin farko" RCT: 37% ƙananan haɗuwa da mace-mace / asibiti (p=0.58), 49% ƙananan asibiti (p=0.38), da 20% inganta farfadowa (p=0.21).
Babu cikakkun bayanai kan jinkirin jiyya. Wani marubuci ya ruwaito cewa Ba a rubuta lokacin fara magani ba. Ana ba da ƙididdiga masu rikice-rikice a cikin sharhi na labarin da bincike mai zaman kansa, tare da rahotannin da ke nuna bayanan da aka ɓace a cikin bayanan. Hakanan duba (gwajin PEP na abokin tarayya), da Pullen et al., wanda ya nuna jinkirin jigilar kayayyaki don waɗannan gwaje-gwajen na sa'o'i 19 - 68. Kashi ɗaya cikin uku na mahalarta sun kammala rajistar kwanakin mako tsakanin 8: 00 na safe zuwa 4: 00 na yamma, tare da 44% a waje da waɗannan sa'o'i a cikin mako, da 22% a cikin karshen mako. Tare da yin rajista har zuwa kwanaki 4 bayan bayyanar alamar, wannan yana nufin bayarwa 19 - 164 hours bayan farawa (awanni 19 na buƙatar rajista nan take). ~ 70 zuwa 140 hours (inc. jigilar kaya) jinkirin jiyya na waje tare da HCQ yana nuna ƙananan asibiti / mutuwa da saurin dawowa, amma bai kai ga mahimmancin ƙididdiga ba. Akwai mutuwar kulawa guda ɗaya a asibiti da kuma mutuwar HCQ ɗaya wanda ba a asibiti ba. Ba a san dalilin da ya sa aka samu mutuwar ba a asibiti ba; abubuwan waje irin su rashin daidaitaccen kulawa na iya shiga ciki. Ban da wannan lamarin yana haifar da mutuwar sarrafawa ɗaya da mutuwar HCQ. Cikakkun bayanai game da asibiti da mace-mace kamar riko da magani da jinkirin jiyya da sun kasance da bayanai amma ba a bayar da su ba.. Jaridar ta bayyana cewa An canza ƙarshen ƙarshen don nuna tsanani saboda sun buƙaci mahalarta 6,000. Koyaya, idan adadin abubuwan da suka faru iri ɗaya ya ci gaba, za su buga mahimmancin 95% akan raguwar asibiti bayan ƙara ƙasa da marasa lafiya 500 a kowane hannu. Jiyya ya yi latti, ~ 70 zuwa 140 hours bayan bayyanar cututtuka, gami da jinkirin jigilar kaya. Takardar ba ta ambaci jinkirin jigilar kaya ba amma an ba da cikakkun bayanai a cikin ka'idar binciken. Ba su bayyana ba amma suna ba da shawara babu jigilar kaya a karshen mako kuma mai yuwuwar yankewa karfe 12 na dare don rabawa da aikawasiku na rana guda. Ba a yi la'akari da cin zarafi da ke faruwa yayin aika saƙon ba. Idan muka ɗauka cewa an rarraba rajista tsakanin 6 na safe zuwa 12 na safe kowace rana, muna samun matsakaicin jinkirin jigilar kayayyaki na sa'o'i 46. Bincike ya nuna maganin da aka yi amfani da shi a hannun kulawa (folic acid a cikin Amurka wanda shine mafi yawan marasa lafiya) na iya samun tasiri mai mahimmanci ga Covid-19.Deschasaux-Tanguy, Farag], don haka tasirin gaske na HCQ na iya zama mafi girma fiye da lura. Hakanan duba wannan. Lura cewa an annabta folic acid zai ɗaure ga sunadaran SARS-CoV-2 da yawa, matakan folic acid sun yi ƙasa a cikin marasa lafiya na Covid-19 da ke da mummunar cuta., Kariyar folic acid na iya taimakawa tare da hauhawar jini mai alaƙa da Covid-19 da hyperhomocysteinemia, kuma bambance-bambance a cikin enzyme mai alaƙa da folic acid na iya yin tasiri ga bambancin yanayi na Covid-19. Takardar ta kwatanta jinkirin 0 - 36 na jinkiri tare da oseltamivir (an yi amfani da shi don mura) da ~ 70 zuwa 140 jinkirin jinkiri tare da HCQ (Covid-19), lura da cewa oseltamivir ya zama mafi tasiri. Duk da haka, wani binciken da ya fi kama da shi shine McLean (2015) wanda ya nuna cewa 48 - 119 hours jinkirin jiyya tare da oseltamivir ba shi da wani tasiri. Wannan yana nuna cewa HCQ ya fi tasiri fiye da oseltamivir, kuma HCQ na iya samun tasiri mai mahimmanci ga wasu adadin jinkiri fiye da jinkiri inda oseltamivir ke da tasiri. An haɗa mutane 6 waɗanda suka yi rajista tare da> alamun 4d, kodayake ba su dace da ƙa'idodin haɗar binciken ba. Wannan yana rage tasirin gani. Takardar ta ce 56% (236) an yi rajista a cikin kwana 1 na alamun bayyanar cututtuka, amma sakamakon ya nuna kawai 40% na "<1d"… 56% yana yiwuwa na <48hrs, ana buƙatar bayani. Marasa lafiya a cikin wannan binciken suna da ƙanana kuma yawancinsu suna murmurewa ba tare da taimako ba. Wannan yana rage ɗakin don magani don ingantawa. Za a sa ran mafi girman haɓakar ingantaccen magani kafin duk marasa lafiya su kusanci farfadowa. Marubuta sun mayar da hankali kan sakamakon ƙarshe inda yawancin sun murmure, amma yana da ƙarin bayani don bincika lanƙwasa da maƙasudin mafi girman tasiri. Marubuta ba su tattara bayanai na kowace rana amma suna da sakamakon wucin gadi na kwanaki 3, 5, 10. Sakamakon ya yi daidai da magani mai mahimmanci kuma yana nuna haɓakar ƙididdiga mai mahimmanci, p = 0.05, a ranar 10 (sauran kwanakin da ba a ba da rahoto ba na iya nuna karuwar tasiri). Sakamako kuma yana nuna babban tasirin jiyya ga waɗanda> 50, ba a ƙididdige su ba saboda ƙaramin samfurin, amma an lura da haɗarin Covid-19 yana ƙaruwa sosai da shekaru. Tasirin na iya zama mafi bayyane a nan saboda ƙananan marasa lafiya na iya a matsakaita suna da ƙarin lokuta masu laushi tare da ƙarancin ɗaki don ingantawa. Gabaɗaya, marasa lafiya a cikin wannan binciken suna da ƙarancin bayyanar cututtuka a matsakaici, yana iyakance damar da za a lura da haɓakawa. Binciken ya dogara ne akan binciken Intanet. An ƙaddamar da binciken binciken karya da aka sani ga irin wannan gwajin PEP kuma za a iya samun adadin da ba a san adadin binciken karya ba a cikin duka gwaje-gwajen. RCT na marasa lafiya 423 tare da binciken Intanet. Binciken farko na marasa lafiya marasa lafiya; marubuta sun lura cewa sakamakon ba zai yiwu ba ga yawan masu haɗarin Covid. https://c19p.org/skipper
55. Smith et al., Kimanta ingancin Hydroxychloroquine da Azithromycin don Hana Asibiti ko Mutuwa a cikin Mutane masu COVID-19 Yuli 2020, NCT04358068
MAGANIN FARKO 16 mai haƙuri HCQ farkon jiyya RCT: 64% ƙananan asibiti (p=1) da 10% jinkirin dawowa.
An dakatar da NIAID RCT da wuri don HCQ. Marasa lafiya> 60 sun kasance kawai a hannun HCQ. 57% na marasa lafiya sun kasance masu haɗari a cikin hannun HCQ vs. 22% don sarrafawa. An fara magani har zuwa kwanaki 20 bayan bayyanar cututtuka. https://c19p.org/smith2
56. M. Kim, S. Jang, Y. Park, B. Kim, T. Hwang, S. Kang, W. Kim, P. Kyu, H. Park, W. Yang, J. Jang, da M. An, Amsar Jiyya ga Hydroxychloroquine, Lopinavir/Ritonavir, da Magungunan rigakafi don Matsakaici na COVID 19: Rahoton Farko na Koriya ta Kudu Mayu 2020, medRxiv
MAGANIN LAFIYA 97 mai haƙuri HCQ nazarin jiyya na ƙarshen: 51% gajarta asibiti (p=0.01) da 56% saurin izinin kamuwa da cuta (p=0.005).
A baya-bayan nan na 97 matsakaicin lokuta. Lokaci don kawar da kwayar cuta ya fi guntu don maganin rigakafi na HCQ+. An cire riga-kafi da ke jiran bitar takwarorinsu. https://c19p.org/kim
57. Novartis et al., Hydroxychloroquine Monotherapy kuma a cikin Haɗuwa Tare da Azithromycin a cikin Marasa lafiya tare da Matsakaici da Cutar COVID-19 Jul 2020, Novartis, NCT04358081
MAGANIN LAFIYA 12 mai haƙuri HCQ marigayi magani RCT: 71% mafi girma fitarwa na asibiti (p=0.42), 71% mafi girma ingantawa (p=0.42), da kuma 79% mafi muni kamuwa da kwayar cuta (p=0.56).
An dakatar da RCT da farko tare da marasa lafiya 20 kawai. https://c19p.org/novartis
58. I. Núñez-Gil, L. Ayerbe, C. Fernandez-Pérez, V. Estrada, C. Eid, R. Arroyo-Espliguero, R. Romero, V. Becerra-Muñoz, A. Uribarri, G. Feltes, D. Trabattoni, M. Molina, M. Agudo. Astrua, E. Alfonso, A. Castro-Mejía, S. Raposeiras-Roubin, L. Buzón, C. Paeres, A. Mulet, N. Lal-Trehan, E. Garcia-Vazquez, O. Fabregat-Andres, I. Akin, F. D'Ascenzo, P. Gomez. C. Macaya, Hydroxychloroquine da Mutuwa a cikin Cutar SARS-Cov-2; Rijistar HOPE-Covid-19. Satumba 2022, Agents Anti-Infective, Juzu'i na 20
MAGANIN LAFIYA 6,217 mai haƙuri HCQ marigayi magani PSM binciken: 53% ƙananan mace-mace (p <0.0001).
Makin da ya dace daidai da binciken baya na 6,217 marasa lafiya na asibiti a Spain, yana nuna ƙarancin mace-mace tare da HCQ. Mafi girman inganci da aka ruwaito tare da kiba hade da high serum cholesterol matakan ya dace da Babban ingancin HCQ an annabta ga marasa lafiya tare da babban cholesterol. https://c19p.org/nunezgil2
59. M. Ugarte-Gil, G. Alarcón, Z. Izadi, A. Duarte-García, C. Reátegui-Sokolova, A. Clarke, L. Wise, G. Pons-Estel, M. Santos, S. Bernatsky, S. Ribeiro, S. Al Emadi, J. Sparks, T. Patel. Valenzuela-Almada, A. Jönsen, G. Landolfi, M. Fredi, T. Goulenok, M. Devaux, X. Mariette, V. Queyrel, V. Romão, G. Sequeira, R. Hasseli, B. Hoyer, R. Voll, C. Specker, R. Baez, V. Castro-Coello, H. F. Re. O. Monticielo, E. Sirotich, J. Liew, J. Hausmann, P. Sufka, R. Grainger, S. Bhana, W. Costello, Z. Wallace, L. Jacobsohn, T. Taylor, C. Ja, A. Strangfeld, E. Mateus, K. Hyrich et al., Halayen da ke da alaƙa da rashin lafiya a cikin tsarin COVID-19. COVID-19 Global Rheumatology Alliance Fabrairu 2022, Annals na Rheumatic Diseases, Shafi annrheumdis-2021-221636
895 haƙuri HCQ nazarin prophylaxis: 44% ƙananan lokuta masu tsanani (p=0.007).
Marasa lafiya 1,606 SLE na baya suna nuna ƙananan haɗarin sakamakon Covid-19 mai tsanani tare da amfani da HCQ/CQ. https://c19p.org/ugartegil
60. J. Lora-Tamayo, G. Maestro, A. Lalueza, M. Rubio-Rivas, G. Villarreal Paul, F. Arnalich Fernández, J. Beato Pérez, J. Vargas Núñez, M. Llorente Barrio, da C. Lumbreras Bermejo, Farkon Lopinavir/rito19 ba ya rage yawan sakamako na COVID-XNUMX. karatu Feb 2021, J. Kamuwa da cuta, juzu'i na 82, fitowa ta 6, Shafi na 276-316
MAGANIN LAFIYA 8,553 mai haƙuri HCQ nazarin jiyya na ƙarshen: 50% ƙananan mace-mace (p <0.0001).
Lopinavir/ritonavir nazari na baya-bayan nan kuma yana nuna sakamako iri ɗaya don HCQ, tare da ƙarancin mace-mace. https://c19p.org/loratamayo
61. A. Di Castelnuovo, A. Gialluisi, A. Antinori, N. Berselli, L. Blandi, M. Bonaccio, R. Bruno, R. Cauda, S. Costanzo, G. Guaraldi, L. Menicanti, M. Mennuni, I. My, G. Parruti, G. Patti, S. Pertilli, G. Stefanore, F. Stefanore, F. Stefanore Vergori, W. Ageno, A. Agodi, P. Agostoni, L. Aiello, S. Al Moghazi, R. Arboretti, F. Aucella, G. Barbieri, M. Barchitta, P. Bonfanti, F. Cacciatore, L. Caiano, F. Cannata, L. Carrozzi, A.stigo, G. Cascucio, G. Cascucio, A.stigo, A.stigo F. Cipollone, C. Colomba, C. Colombo, A. Crisetti, F. Crosta, G. Danzi, D. D'Ardes, K. De Gaetano Donati, F. Di Gennaro, G. Di Tano, G. D'Offizi, F. Fusco et al. Janairu 2021, J. Injiniya Kiwon Lafiya, Juzu'i na 2021, Shafi na 1-10
MAGANIN LAFIYA 4,270 mai haƙuri HCQ nazarin jiyya na ƙarshen: 40% ƙananan mace-mace (p <0.0001).
Marasa lafiya na asibiti 4,396 na baya-bayan nan a Italiya suna nuna ƙarancin mace-mace tare da jiyya na HCQ, da kuma gano mafi inganci ga rukunin marasa lafiya a cikin ƙididdigar tari. https://c19p.org/dicastelnuovo2
62. A. Strangfeld, M. Schäfer. Bachiller-Corral, S. Bhana, P. Cacoub, L. Carmona, R. Costello, W. Costello, L. Gossec, R. Grainger, E. Hachulla, R. Hasseli, J. Hausmann, K. Hyrich, Z. Izadi, L. Jacobsohn, P. Katz, L., Robinson, da kuma Robin P. Kearsley. Machado, Abubuwan da ke da alaƙa da mutuwar COVID-19 a cikin mutanen da ke fama da cututtukan rheumatic: sakamakon COVID-19 Global Rheumatology Alliance likita ya ba da rahoton rajista Janairu 2021, Annals na Rheumatic Diseases, Juzu'i na 80, Fitowa ta 7, Shafi na 930-942
1,165 haƙuri HCQ nazarin prophylaxis: 48% ƙananan mace-mace (p <0.0001).
Marasa lafiya na rheumatic 3,729 na baya-bayan nan suna nunawa ƙananan haɗarin mace-mace tare da amfani da HCQ/CQ (HCQ/CQ vs. babu maganin DMARD). https://c19p.org/strangfeld
63. J. Signes-Costa, I. Núñez-Gil, J. Soriano, R. Arroyo-Espliguero, C. Eid, R. Romero, A. Uribarri, I. Fernández-Rozas, M. Aguado, V. Becerra-Muñoz, J. Huang, M. Pepe, E. Rapoz, S. Gooz, A. Franco-Leon, L. Wang, E. Alfonso, F. Ugo, J. García-Prieto, G. Feltes, M. Abumayyaleh, C. Espejo-Paeres, J. Jativa, A. Masjuan, C. Macaya, J. Carbonell Asíns, da V. Estrada, marasa lafiya da ke fama da cutar COVID-30 kafin kamuwa da cutar sankarau. Disamba 2020, Archivos de Bronconeumología, Juzu'i na 57, Shafi na 13-20
MAGANIN LAFIYA 5,847 mai haƙuri HCQ nazarin jiyya na ƙarshen: 47% ƙananan mace-mace (p=0.0005).
47% ƙananan mace-mace tare da HCQ/CQ. Marasa lafiya 1,271 na baya-bayan nan da ke fama da cutar huhu a Kanada, China, Cuba, Ecuador, Jamus, Italiya, da Spain, 83% an yi musu magani tare da HCQ/CQ. Multivariable Cox regression HCQ/CQ hazarin mace-mace HR 0.53, p <0.001. https://c19p.org/signescosta
64. Ö. Polat, R. Korkusuz, da M. Berber, Amfani da Hydroxychloroquine akan Ma'aikatan Kiwon Lafiya da Aka Nunawa ga COVID-19 - Kwarewar Asibitin Cutar Cutar Satumba 2020, Likita J. Bakirkoy, 280-6
208 haƙuri HCQ nazarin prophylaxis: Ƙananan lokuta 57% (p=0.03).
Karamin nazarin prophylaxis na ma'aikatan kiwon lafiya 208 a Turkiyya, 138 tare da babban hadarin fallasa ya karbi HCQ, yayin da 70 tare da ƙananan haɗari da ƙananan haɗari ba su yi ba. Laifukan Covid-19 sun kasance ƙasa a cikin rukunin jiyya, haɗarin dangi RR 0.43, p = 0.026. Tun da ƙungiyar kulawa tana da ƙananan haɗari, ainihin amfanin zai iya zama mafi girma. https://c19p.org/polat
65. L. Ayerbe, C. Risco-Risco, da S. Ayis, Ƙungiyar jiyya tare da hydroxychloroquine da mutuwar asibiti a cikin marasa lafiya na COVID-19 Satumba 2020, Magungunan Ciki da Gaggawa, Juzu'i na 15, Fitowa ta 8, Shafi na 1501-1506
MAGANIN LAFIYA 2,075 mai haƙuri HCQ nazarin jiyya na ƙarshen: 52% ƙananan mace-mace (p=0.001).
2,075 marasa lafiya na asibiti a Spain suna nuna HCQ yana rage yawan mace-mace 52%, rashin daidaituwa OR 0.39, p<0.001, bayan daidaitawa don shekaru, jinsi, zafin jiki> 37 ° C, da jikewa na oxygen <90% jiyya tare da azithromycin, steroids, heparin, tocilizumab, hade da ritopinnavir da opinnavir. shiga (Duba samfurin 4). https://c19p.org/ayerbe
66. D. Pinato, A. Zambelli, J. Aguilar-Company, M. Bower, C. Sng, R. Salazar, A. Bertuzzi, J. Brunet, R. Mesia, E. Seguí, F. Biello, D. Generali, S. Grisanti, G. Rizzo, M. Libertini, A. Maconi, N.Berncetulli, B. D.vittani, B. D.vittani A. Carbó, R. Bruna, S. Benafif, A. Marrari, R. Wuerstlein, M. Carmona-Garcia, N. Chopra, C. Tondini, O. Mirallas, V. Tovazzi, M. Betti, S. Provenzano, V. Fotia, C. Cruz, A. Dalla Pria, F, J. D. Saoudi-Gonzalez, E. Felip, M. Galazi, I. Garcia-Fructuoso, A. Lee, T. Newsom-Davis, A. Patriarca, D. García-Illescas, R. Reyes, P. Dileo, R. Sharkey, Y. Wong, D. Ferrante et al., marasa lafiya na SARS-Cocin ciwon daji na Turai a cikin ciwon daji na Turai-Cocin Portrait. Agusta 2020, Gano Cancer, Juzu'i na 10, Fitowa ta 10, Shafi na 1465-1474
MAGANIN LAFIYA 890 mai haƙuri HCQ nazarin jiyya na ƙarshen: 59% ƙananan mace-mace (p=0.0001).
Tsinkaya Mutane 890 ne suka kamu da cutar ta Covid-19, Daidaita mace-mace HR don HCQ/CQ 0.41, p<0.0001. An tabbatar da kamuwa da cutar SARS-CoV-2, wanda zai iya taimakawa mai da hankali kan lokuta masu tsanani. Bincike tare da samfurin haɗari na daidaitattun Cox. Ƙwararru masu yuwuwar rashin aunawa. https://c19p.org/pinato
67. B. Davido, G. Boussaid, I. Vaugier, T. Lansaman, F. Bouchand, C. Lawrence, J. Alvarez, P. Moine, V. Perronne, F. Barbot, A. Saleh-Mghir, C. Perronne, D. Annane, da P. De Truchis, Tasirin kulawar likita a kan lokacin da marasa lafiya ke amfani da maganin rigakafin cutar COVID-19. Agusta 2020, Int. J. Magungunan rigakafi, 2020, Juzu'i na 56, Fitowa ta 4, Shafi na 106129
132 marasa lafiya HCQ MAGANIN LAFIYA nazari: 55% ƙananan haɗin intubation/ asibiti (p=0.04).
A baya bayan nan na marasa lafiya 132 da ke asibiti. HCQ+AZ(52)/AZ(28) rage mutuwa/ICU, HR=0.45, p=0.04. Daidaita don Charlson Comorbidity Index (ciki har da shekaru), kiba, O2, ƙididdigar lymphocyte, da jiyya. Ma'anar jinkiri daga shiga zuwa jiyya kwanaki 0.7. https://c19p.org/davido
68. S. Arshad, P. Kilgore, Z. Chaudhry, G. Jacobsen, D. Wang, K. Huitsing, I. Brar, G. Alangaden, M. Ramesh, J. McKinnon, W. O'Neill, M. Zervos, V. Nauriyal, A. Hamed, O. Nadeem, J. Swiderek, J. Swiderek. Gardner-Gray, A. Ackerman, J. Lezotte, J. Ruhala, R. Fadel, A. Vahia, S. Gudipati, T. Parraga, A. Shallal, G. Maki, Z. Tariq, G. Suleyman, N. Yared, E. Herc, J. Williams, O. Lanfranco, P.Trene Kharga, da Reyes Kharga. Azithromycin, da Haɗuwa a cikin Marasa lafiya da ke Asibiti tare da COVID-19 Juni 2020, Int. J. Kamuwa da cuta. Dis., Yuli 1 2020, juzu'i na 97, Shafi na 396-403
MAGANIN LAFIYA 2,541 mai haƙuri HCQ nazarin jiyya na ƙarshen: 51% ƙananan mace-mace (p=0.009).
HCQ yana rage mace-mace daga 26.4% zuwa 13.5% (HCQ) ko 20.1% (HCQ+AZ). Ƙaunar da ta dace da HCQ HR 0.487, p=0.009. Michigan 2,541 marasa lafiya na baya. Kafin dacewa da dacewa, matsakaicin shekarun ƙungiyar HCQ shine 5 shekaru ƙarami kuma yawan marasa lafiyar maza shine 4% mafi girma. wanda zai iya fifita maganin da sarrafawa bi da bi a cikin kafin-propensity matching sakamakon. Wasu iyakoki da aka ruwaito na wannan binciken ba daidai ba ne. An sarrafa corticosteroid na a cikin da multivariate da kuma abubuwan da ke tattare da su ne da kuma cadigaities gami da cutar cututtukan zuciya. Shekaru wani abu ne mai zaman kansa mai haɗari mai alaƙa da mace-mace. HCQ yana da alaƙa da kansa tare da raguwar mace-mace, bambanta da tasirin steroid. 91% na duk marasa lafiya sun fara magani a cikin kwanaki biyu na shiga. An yi amfani da HCQ a duk tsawon lokacin binciken, yana iyakance lokaci. Marasa lafiya da aka ba wa ƙungiyar HCQ suna da matsakaici da rashin lafiya mai tsanani a lokacin gabatarwa, wanda zai ba da sakamako mafi muni tare da HCQ. https://c19p.org/arshad
69. T. Mikami, H. Miyashita, T. Yamada, M. Harrington, D. Steinberg, A. Dunn, da E. Siau, Abubuwan Haɗari don Mutuwa a cikin Marasa lafiya tare da COVID-19 a cikin Birnin New York Yuni 2020, J. Gen. Intern. Med., Juzu'i na 36, Fitowa ta 1, Shafi na 17-26
MAGANIN LAFIYA 6,000 mai haƙuri HCQ nazarin jiyya na ƙarshen: 47% ƙananan mace-mace (p <0.0001).
HCQ yana rage yawan mace-mace, HR 0.53 (CI 0.41-0.67). Daidaitawar IPTW baya canza HR 0.53 (0.41-0.68). Marasa lafiya 6,000 na baya-bayan nan a cikin Birnin New York. https://c19p.org/mikami
70. A. Ferreira, A. Oliveira-e-Silva, da P. Bettencourt, Jiyya na yau da kullun tare da hydroxychloroquine da kamuwa da cutar SARS-CoV-2 Yuni 2020, J. Likitan Kwayoyin cuta, Yuli 9, 2020, Juzu'i na 93, Fitowa ta 2, Shafi na 755-759
26,815 haƙuri HCQ nazarin prophylaxis: Ƙananan lokuta 47% (p <0.0001).
Jiyya na yau da kullun tare da HCQ yana ba da kariya daga Covid, rabon rashin daidaituwa 0.51 (0.37-0.70). Wataƙila fa'idar ta kasance mafi girma saboda bincike ya nuna cewa haɗarin Covid-19 ga masu cutar cututtukan ƙwayoyin cuta na ƙwayoyin cuta ya fi girma gabaɗaya. Ferri et al. nuna KO 4.42, p<0.001 wanda shine abin da aka gani na haƙiƙanin haɗari, la'akari da dalilai kamar marasa lafiya da ke iya yin hankali don guje wa fallasa. https://c19p.org/ferreira
71. J. Lagier, M. Million, P. Gautret, P. Colson, S. Cortaredona, A. Giraud-Gatineau, S. Honoré, J. Gaubert, P. Fournier, H. Tissot-Dupont, E. Chabrière, A. Stein, J. Deharo, F. Fenollar, J. Rolain, A. Layin B. Brouqui, M. Drancourt, P. Parola, D. Raoult, S. Amrane, C. Aubry, M. Bardou, C. Berenger, L. Camoin-Jau, N. Cassir, C. Decoster, C. Dhiver, B. Doudier, S. Edouard, S. Gentile, K. Guillon-Lor M. Mailhe, I. Ravaux, M. Richez, Y. Roussel, P. Seng, C. Tomei, da C. Zandotti, Sakamako na majinyata 3,737 COVID-19 da aka yi wa maganin hydroxychloroquine/azithromycin da sauran magunguna a Marseille, Faransa: Binciken baya Yuni 2020, Tafiya Med. Kamuwa da cuta. Dis. 101791, Juni 25, 2020, juzu'i na 36, Shafi na 101791
MAGANIN LAFIYA 3,737 mai haƙuri HCQ nazarin jiyya na ƙarshen: 59% ƙananan mace-mace (p=0.05).
Jiyya na farko yana haifar da ingantaccen sakamako na asibiti da sauri da rage nauyin ƙwayar cuta. Madaidaicin samfurin mace-mace HR 0.41 p-darajar 0.048. Marasa lafiya 3,737 a baya. Wannan binciken ya ƙunshi duka marasa lafiya da marasa lafiya a asibiti. https://c19p.org/lagier
72. J. Sánchez-Álvarez, M. Fontán, C. Martín, M. Pelícano, C. Reina, Á. Prieto, E. Melilli, M. Barrios, M. Heras, da M. Pino, Matsayin kamuwa da cutar SARS-CoV-2 a cikin marasa lafiya akan maganin maye gurbin na koda. Rahoton Rahoton COVID-19 na Ƙungiyar Nephrology na Mutanen Espanya (SEN) Afrilu 2020, nephrology, Juzu'i na 40, Fitowa ta 3, Shafi na 272-278
MAGANIN LAFIYA 375 mai haƙuri HCQ nazarin jiyya na ƙarshen: 46% ƙananan mace-mace (p=0.005).
Binciken marasa lafiya 868 akan maganin maye gurbin koda. Ƙididdigar ƙididdiga mai mahimmanci a cikin mace-mace tare da HCQ ga marasa lafiya akan dialysis (OR 0.47, p=0.005). Ba a sami wani canji mai mahimmanci na ƙididdiga ga marasa lafiya da aka dasa ba (ba a ba da sakamakon ba amma mai yiwuwa girman samfurin ya yi ƙanƙara - adadin marasa lafiya da aka dasa shine rabin adadin marasa lafiya na dialysis). https://c19p.org/sanchezalvarez
73. R. Esper. azithromycin ga wadanda ake zargi da cutar COVID-19 ta hanyar telemedicine Afrilu 2020, Hana Babban Cibiyar, São Paulo, Brazil
636 haƙuri HCQ binciken farko na jiyya: 64% ƙananan asibiti (p=0.02).
636 marasa lafiya. HCQ+AZ ya rage asibiti 79% lokacin amfani da shi a cikin kwanaki 7 (65% gabaɗaya). Ba-zuba. https://c19p.org/esper
74. A. Agusti, E. Guillen, A. Ayora, A. Anton, C. Aguilera, X. Vidal, C. Andres, M. Alonso, M. Espuga, J. Esperalba, M. Gorgas, B. Almirante, da E. Ribera, Inganci da amincin hydroxychloroquine a cikin ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun ƙwararrun SARS-Cospective. Disamba 2020, Enfermedades Infecciosas da Microbiología Clínica, Juzu'i na 40, Fitowa ta 6, Shafi na 289-295
142 mai haƙuri HCQ binciken farko na jiyya: 68% ƙananan ci gaba (p = 0.21) da 32% saurin ƙwayar cuta.
Karamin gwaji na ƙananan HCQ ga ma'aikatan kiwon lafiya tare da SARS-CoV-2 mai sauƙi yana nuna 68% ƙananan ci gaba zuwa ciwon huhu, p = 0.21, kuma cikin sauri, amma ba a ƙididdige ƙididdigar ƙwayar cuta ba. Babu shigar ICU ko mace-mace. Binciken da ba a kayyade ba. https://c19p.org/agusti
75. A. Heberto, P. Carlos, C. Antonio, P. Patricia, T. Enrique, M. Danira, G. Benito, da M. Alfredo, Abubuwan da ke tattare da raunin zuciya a cikin marasa lafiya na asibiti na Mexico tare da cutar coronavirus 2019 (COVID-19) Satumba 2020, IJC Zuciya & Vasculature, Juzu'i na 30, Shafi na 100638
MAGANIN LAFIYA 254 mai haƙuri HCQ nazarin jiyya na ƙarshen: 54% ƙananan mace-mace (p=0.04) da 65% ƙananan samun iska (p=0.008).
Masu lura da marasa lafiya na asibiti 254 masu zuwa, HCQ+AZ rashin daidaituwar mace-mace KO 0.36, p = 0.04. Samun iska KO 0.20, p = 0.008. https://c19p.org/heberto
76. P. Gautret, J. Lagier, P. Parola, V. Hoang, L. Meddeb, M. Mailhe, B. Doudier, J. Courjon, V. Giordanengo, V. Vieira, H. Tissot Dupont, S. Honoré, P. Colson, E. Chabrière, B. La Scola, P. Hydroxychloroquine da azithromycin azaman maganin COVID-19: sakamakon buɗaɗɗen lakabin gwajin asibiti mara tsari. Maris 2020, Int. J. na Ma'aikatan Antimicrobial, Juzu'i na 56, Fitowa ta 1, Shafi na 105949
MAGANIN FARKO 36 haƙuri HCQ binciken farko na jiyya: 66% ingantacciyar kariya ta hoto (p=0.001).
HCQ yana da alaƙa da mahimmanci tare da raguwa / kawar da kwayar cutar hoto, wanda aka inganta tare da AZ. Analysis na wannan takarda da tashe dabara batutuwa. Ya kamata a duba wannan binciken a cikin mahallin mafi girman sakamako mai kyau a cikin ɗimbin sauran karatun. Sabuntawa ga wannan takarda, ciki har da asali cire marasa lafiya, ya tabbatar da tasiri na HCQ + AZ a kan kamuwa da kwayar cuta da kuma farkon fitarwa. Marubuta mai amsawa ga hanyoyin waje da kuma tambayoyin bayanai, sabanin sauran marubutan HCQ. https://c19p.org/gautretjaa
77. A. Ouédraogo, G. Bougma, A. Baguiya, A. Sawadogo, P. Kaboré, C. Minougou, A. Diendéré, S. Maiga, C. Agbaholou, A. Hema, A. Sondo, G. Ouédraogo, A. Sanou, da M. Ouedraogo, Abubuwan da ke da alaƙa da majinyata da ke fama da rashin lafiya a Burkinaso Fabrairu 2021, Jaridar Cututtukan Numfashi, Juzu'i na 38, Fitowa ta 3, Shafi na 240-248
MAGANIN LAFIYA 456 mai haƙuri HCQ marigayi nazarin jiyya: 33% ƙananan mace-mace (p=0.38) da 68% ƙananan lokuta masu tsanani (p=0.001).
Majinyata 456 na baya-bayan nan a Burkina Faso suna nuna ƙananan haɗarin rashin lafiya na numfashi (p=0.001) da mace-mace (p=0.38) tare da HCQ. https://c19p.org/ouedraogo
78. D. Dhibar, N. Arora, A. Kakkar, N. Singla, R. Mohindra, V. Suri, A. Bhalla, N. Sharma, M. Singh, A. Prakash, L. PVM, da B. Medhi, Prophylaxis Post Exposure Prophylaxis tare da Hydroxychloroquine (HCQ) don Rigakafin COVID-19, Gaskiyar? Nazarin PEP-CQ Nuwamba 2020, Int. J. Magungunan Kwayoyin cuta, Juzu'i na 56, Fitowa ta 6, Shafi na 106224
317 mai haƙuri HCQ nazarin prophylaxis: 44% ƙananan lokuta (p=0.21) da Ƙananan lokuta 50% (p=0.04).
Nazarin PEP mai ƙarancin ƙima tare da marasa lafiya HCQ 132 da marasa lafiya na sarrafawa 185, yana nuna ƙarancin ƙarancin Covid-19 tare da jiyya. Babu wani mummunan al'amura mara kyau. HCQ 800mg a rana ta daya ya biyo bayan 400mg sau ɗaya a mako don makonni 3. https://c19p.org/dhibar
79. K. Atipornwanich, S. Kongsaengdao, P. Harnsomburana, R. Nanna, C. Chtuparisute, P. Saengsayan, K. Bangpattanasiri, W. Manosuthi, N. Sawanpanyalert, A. Srisubat, S. Thanasithichai, B. Maneeton, N. Suthisiston, C.j. Akksilp, Haɗuwa Daban-daban na Favipiravir, Lopinavir-Ritonavir, Darunavir-Ritonavir, Oseltamivir mai girma, da Hydroxychloroquine don Maganin COVID-19: Gwajin Sarrafa Bazuwar (Nazarin FIGHT-COVID-19) Oktoba 2021, SSRN Electronic J.
MAGANIN LAFIYA 200 mai haƙuri HCQ marigayi magani RCT: 56% ƙananan mace-mace (p=0.07), 54% ƙananan ci gaba (p= 0.02), da 7% saurin ƙwayar cuta (p=0.51).
RCT 320 marasa lafiya a Tailandia, suna nuna ƙananan ci gaba tare da HCQ don marasa lafiya masu matsakaici / masu tsanani, da sauri da sauri tare da marasa lafiya marasa lafiya (ƙididdiga mai mahimmanci ga 800mg). Akwai nau'ikan sakamako guda biyu - don matsakaita / marasa lafiya, kuma ga marasa lafiya masu rauni. Babu mace-mace ga marasa lafiya marasa lafiya. https://c19p.org/atipornwanich
80. M. Goenka, S. Afzalpurkar, U. Goenka, S. Das, M. Mukherjee, S. Jajodia, B. Shah, V. Patil, G. Rodge, U. Khan, da S. Bandyopadhyay, Seroprevalence na COVID-19 Daga cikin Ma'aikatan Kula da Lafiya a Babban Asibitin Kulawa na Babban Birni daga Indiya Oktoba 2020, SSRN
962 mai haƙuri HCQ nazarin prophylaxis: 87% ƙananan ƙimar IgG (p=0.03).
Nazarin ƙwayoyin rigakafin SARS-CoV-2-IgG a cikin ma'aikatan kiwon lafiya 1122 a Indiya suna samun 87% ƙarancin inganci don isassun rigakafin HCQ, 1.3% HCQ da 12.3% don babu rigakafin HCQ. An bayyana isassun rigakafin rigakafi azaman 400mg 1/wk na> makonni 6. https://c19p.org/goenka
81. M. Lyngbakken, J. Berdal, A. Eskesen, D. Kvale, I. Olsen, C. Rueegg, A. Rangberg, C. Jonassen, T. Omland, H. Røsjø, da O. Dalgard Yuli 2020, Nature Communications, Juzu'i na 11, Mas'ala ta 1
MAGANIN LAFIYA 53 mai haƙuri HCQ marigayi magani RCT: 4% ƙananan mace-mace (p = 1) da 71% inganta yawan raguwar ƙwayar cuta (p=0.51).
Ƙananan RCT na nauyin ƙwayar cuta na nasopharyngeal baya nuna bambance-bambance masu mahimmanci. Matsakaicin raguwa na HCQ shine 0.24 [0.03-0.46] RNA kofe / mL / 24h, da 0.14 [-0.10-0.37] don ƙungiyar kulawa (71% da sauri tare da HCQ amma ba ƙididdiga ba tare da ƙananan samfurin 27 HCQ da 26 masu kula da marasa lafiya). Bincike sama da awanni 96 kawai. https://c19p.org/lyngbakken
82. R. Bhattacharya, S. Chowdhury, R. Mukherjee, M. Kulshrestha, R. Ghosh, S. Saha, da A. Nandi, Pre fallasa amfani da Hydroxychloroquine yana da alaƙa da rage haɗarin COVID19 a cikin ma'aikatan kiwon lafiya. Juni 2020, medRxix
106 mai haƙuri HCQ nazarin prophylaxis: 81% ƙananan lokuta (p=0.001).
HCQ ya rage lokuta daga 38% zuwa 7%. mutane 106. Babu mummunan tasiri. https://c19p.org/bhattacharya
83. Zhong Nanshan (钟南山) et al., Inganci da amincin chloroquine don maganin COVID-19. Buɗaɗɗen lakabin, cibiyoyi da yawa, gwaji marasa tsari Maris 2020, Zhong Nanshan
MAGANIN LAFIYA 197 mai haƙuri HCQ nazarin jiyya na ƙarshen: 80% ingantacciyar kariya ta hoto (p=0.0001).
marasa lafiya 197. CQ tasiri. Rana ta 10 kwayar cutar RNA mara kyau 91.4% HCQ da 57.4% iko. Lokacin tsaka-tsaki zuwa gwaji mara kyau kwanaki 3 da kwanaki 9 don sarrafawa. https://c19p.org/zhong2
84. C. Isnardi, K. Roberts, V. Saurit, I. Petkovic, R. Báez, R. Quintana, Y. Tissera, S. Ornella, MDAngelo Exeni, C. Pisoni, V. Castro Coello, G. Berbotto, M. Haye Salinas, E. Velozo, Á. Reyes Torres, R. Tanten, M. Zelaya, C. Gobbi, C. Alonso, M. De los Ángeles Severina, F. Vivero, A. Paula, A. Cogo, G. Alle, M. Pera, R. Nieto, M. Cosatti, C. Asnal, D. Pereira, J. Albiero, V. Gadon M, F. Gadon, F.Germá, Fa. Baños, J. Gallino Yanzi, M. Gálvez Elkin, J. Morbiducci, M. Martire, H. Maldonado Ficco, M. Schmid, J. Villafañe Torres, M. De los Ángeles Correa, M. Medina, M. Cusa, J. Scafati, S. Agüero, N. Lloves Sodemino et al. C. C. C.C. Abubuwan da ke da alaƙa da mummunan sakamakon COVID-19 a cikin marasa lafiya da cututtukan rheumatic: bayanai daga SAR-COVID Registry Oct 2022, Clinical Rheumatology
2,066 mai haƙuri HCQ nazarin prophylaxis: 34% ƙananan mace-mace (p=0.23), 48% ƙananan lokuta masu tsanani (p=0.02), da 17% ƙananan asibiti (p=0.09).
Marasa lafiya na rheumatic 1,915 na baya-bayan nan tare da Covid-19 a Argentina, suna nuna ƙarancin mace-mace, matsanancin buƙatun iskar oxygen, da kuma asibiti tare da CQ/HCQ (antimalarial) ana amfani da su a cikin sakamakon da ba a daidaita su ba, ƙididdiga mai mahimmanci kawai don buƙatar oxygen mai tsanani. https://c19p.org/isnardi
85. E. Sobngwi, S. Zemsi, M. Guewo, J. Katte, C. Kouanfack, L. Mfeukeu, A. Zemsi, Y. Wasnyo, A. Ntsama Assiga, A. Ndi Manga, J. Sobngwi-Tambekou, W. Ngatchou, C. Moussi Omgba,go, P.ngolo, Pngolo, Pngolo, J. Mbolo Doxycycline vs Hydroxychloroquine + Azithromycin a cikin Gudanar da Marasa lafiya COVID-19: Buɗaɗɗen Lakabin Gwajin Clinical Randomized a cikin Saharar Afirka (DOXYCOV) Yuli 2021, Cureus
MAGANIN FARKO 187 mai haƙuri HCQ farkon jiyya RCT: 52% inganta farfadowa (p = 0.44) da 3% inganta ƙwayar cuta (p=0.88).
RCT 194 m / asymptomatic marasa lafiya marasa lafiya a cikin Kamaru, 97 da HCQ + AZ da 97 aka yi musu magani tare da doxycycline, suna nuna marasa lafiya na 2.1% a ranar 10 tare da HCQ + AZ, tare da 4.3% tare da doxycycline, ba tare da mahimmancin ƙididdiga ba. Akwai kawai marasa lafiya 6 da alamun bayyanar cututtuka a rana ta 10. Babu mace-mace ko asibiti, kuma babu manyan abubuwan da suka faru. https://c19p.org/sobngwi
86. P. Sivapalan, C. Ulrik, T. Lapperre, R. Bojesen, J. Eklöf, A. Browatzki, J. Wilcke, V. Gottlieb, K. Håkansson, C. Tidemandsen, O. Tupper, H. Meteran, C. Bergsøe, E. Brøndum, U. Brøndum, U. Brøndum, U. Brøndum, U. B. Brøndum, U. B. Brøndum, U. B. Brøndum, U. B. B. B. B. B. B. B. B. B. B. B. B. L. Pedersen, A. Jordan, H. Priemé, C. Søborg, I. Steffensen, D. Høgsberg, T. Klausen, M. Frydland, P. Lange, A. Sverrild, M. Ghanizada, F. Knop, T. Biering-Sørensen, J. Lundgren, da kuma A asibitin hydrozichloride J. COVID-19–gwajin da aka sarrafa makafi biyu bazuwar Yuni 2021, Ƙwararrun numfashi na Turai J., Juzu'i na 59, Fitowa ta 1, Shafi na 2100752
MAGANIN LAFIYA 117 mai haƙuri HCQ marigayi magani RCT: 92% ƙananan mace-mace (p=0.32), 22% mafi girma ICU shigar (p=1), da 8% ƙananan asibiti (p=0.36).
An ƙare farkon matakin ƙarshen (kwanaki 8 daga farawa, 59% akan oxygen) RCT baya nuna bambance-bambance masu mahimmanci. https://c19p.org/sivapalan
87. A. Omrani, S. Patan, S. Thomas, T. Harris, P. Coyle, C. Thomas, I. Qureshi, Z. Bhutta, N. Mawlawi, R. Kahlout, A. Elmalik, A. Azad, J. Daghfal, M. Mustafa, A. Jeremijenko, H. Soub, M. Khattab, da kuma S.-Malied Random wuri M. gwajin hydroxychloroquine tare da ko ba tare da azithromycin don maganin virologic na Covid-19 mara ƙarfi Nuwamba 2020, Magungunan Magunguna, Juzu'i na 29-30, Shafi na 100645
MAGANIN FARKO 456 mai haƙuri HCQ farkon jiyya RCT: 12% ƙananan asibiti (p = 1), 26% inganta farfadowa (p = 0.58), da 10% mafi muni na kwayar cutar hoto (p=0.13).
RCT mai ƙarancin haɗari ga HCQ + AZ da HCQ vs. sarrafawa, ba tare da nuna wani bambance-bambance masu mahimmanci ba. Marubuta sun lura cewa sakamakon bai dace da majinyata masu haɗari masu haɗari ba, cewa ingantaccen PCR na iya kawai yin la'akari da gano ƙwayoyin cuta marasa aiki (marasa kamuwa da cuta), cewa madadin tsarin sashi na iya zama mafi inganci, kuma ba a san bin tsarin magani ba. Maganin HCQ shine 600mg/rana don mako 1, ba za a iya kai matakan warkewa na kwanaki da yawa ba. Babu mace-mace ko munanan al'amuran da suka faru. Nauyin kwayar cuta ya riga ya yi girma sosai a asali. https://c19p.org/omrani
88. T. Korkmaz, A. Şener, V. Gerdan, da İ. Kızıloglu, Tasirin amfani da Hydroxychloroquine saboda cututtukan rheumatic akan haɗarin kamuwa da cutar Covid-19 da hanyarta. Mayu 2021, Authorea
694 mai haƙuri HCQ nazarin prophylaxis: 82% ƙananan mace-mace (p=0.19) da Ƙananan lokuta 94% (p <0.0001).
An dawo da marasa lafiya 683 a cikin a sashen rheumatology, 384 masu amfani da HCQ na yau da kullum da 299 masu kula da marasa lafiya, suna nuna rashin mutuwa ga masu amfani da HCQ vs. 2 mutuwar a cikin ƙungiyar kulawa, kuma ƙananan lokuta ga masu amfani da HCQ. https://c19p.org/korkmaz
89. J. Finkelstein da X. Huo, Ingancin Amfani da Hydroxychloroquine na Tsawon Tsawon Lokaci a cikin Rigakafin COVID-19: Nazarin Ƙungiya mai Komawa. Jun 2023, Nazari a Fasahar Lafiya da Ilimi
110,038 mai haƙuri HCQ prophylaxis nazarin PSM: Ƙananan lokuta 21% (p=0.0007).
PSM na baya-bayan nan na SLE/RA marasa lafiya a cikin Amurka, yana nuna ƙananan shari'o'in Covid-19 tare da rigakafin HCQ. https://c19p.org/finkelstein
90. . Mayu 2023, Kamuwa da cuta a cikin Ayyuka, Juzu'i na 19, Shafi na 100229
MAGANIN LAFIYA 848 mai haƙuri HCQ ICU binciken: 35% ƙananan mace-mace (p=0.0001).
Marasa lafiya 848 ICU na baya-bayan nan a Saudi Arabiya, suna nuna ƙarancin mace-mace tare da HCQ a cikin sakamakon da ba a daidaita ba. https://c19p.org/alqadheeb
91. Ş. Bubenek-Turconi, S. Andrei, L. Văleanu, M. Ştefan, I. Grigoraş, S. Copotoiu, C. Bodolea, D. Tomescu, M. Popescu, D. Filipescu, H. Moldovan, A. Rogobete, C. Bălan, B. S. Răşanus da kuma abubuwan da suka shafi Clinical, D. tare da mace-macen ICU a cikin shekarar farko ta cutar ta SARS-Cov-2 a Romania Nuwamba 2022, Turai J. Anesthesiology, Volume Buga Gaban Buga
MAGANIN LAFIYA Nazarin HCQ ICU: 22% ƙananan mace-mace (p=0.01).
Nazarin mai zuwa na 9,058 Covid-19 ICU marasa lafiya a Romania, yana nuna ƙarancin mace-mace tare da jiyya na HCQ. https://c19p.org/bubenekturconi
92. R. Go da T. Nyirenda, Hydroxychloroquine, azithromycin da methylprednisolone kuma a cikin rayuwar asibiti a cikin tsananin COVID-19 ciwon huhu Satumba 2022, Faransanci a Pharmacology, Juzu'i na 13
MAGANIN LAFIYA Nazarin jiyya na marigayi HCQ: 55% ƙananan mace-mace (p=0.03).
Marasa lafiya na asibiti na 759 na baya-bayan nan a Amurka, suna nuna ƙarancin mace-mace tare da haɗin HCQ + AZ + methylprednisolone magani idan aka kwatanta da methylprednisolone monotherapy. https://c19p.org/go2
93. . Agusta 2022, Bude Dandalin Cututtuka masu Yaduwa
MAGANIN LAFIYA 4,631 mai haƙuri HCQ nazarin jiyya na ƙarshen: 20% ƙananan mace-mace (p=0.007).
A baya-bayan nan 4,631 marasa lafiya na asibiti a New York, suna nuna yawan mace-mace tare da remdesivir, da ƙarancin mace-mace tare da HCQ. Marubuta sun ba da shawarar cewa karuwar mace-mace a lokacin bullar cutar ta farko wani bangare ne saboda damuwa kan albarkatun asibiti, wanda watakila an kauce masa tare da shawarar Trump na HCQ a cikin mutanen da suka cancanta. https://c19p.org/bowen
94. A. Yadav, A. Kotwal, da S. Ghosh, Hydroxychloroquine/chloroquine prophylaxis tsakanin ma'aikatan kiwon lafiya: Shin da gaske yana yin rigakafi? - Shaida daga binciken giciye-sashe da yawa Yuli 2022, Indiya J. Magungunan Al'umma, Juzu'i na 47, Fitowa ta 2, Shafi na 202
2,224 mai haƙuri HCQ nazarin prophylaxis: 20% ƙananan seropositivity (p=0.1).
Ma'aikatan kiwon lafiya na 2,224 na baya a Indiya, suna nuna ƙananan haɗarin seropositivity tare da HCQ prophylaxis, ba tare da mahimmancin ƙididdiga ba. https://c19p.org/yadav4
95. M. Ebongue, D. Lemogoum, L. Endale-Mangamba, B. Barche, C. Eyoum, S. Simo Yomi, D. Mekolo, V. Ngambi, J. Doumbe, C. Sike, J. Boombhi, G. Ngondi, C. Biholong, J. Kamdem, L. Mbenoun, A. D. Tegemou, C. D. Kamdem, F. Ntock, L. Mfeukeu, E. Sobngwi, I. Penda, R. Njock, N. Essomba, J. Yombi, da W. Ngatchou. Maris 2022, Maganin Tafiya da Cututtuka masu Yaduwa, Shafi na 102292
MAGANIN LAFIYA 580 mai haƙuri HCQ nazarin jiyya na ƙarshen: 43% ƙananan mace-mace (p=0.04).
A baya-bayan nan 580 marasa lafiya na Covid+ na asibiti a Kamaru, suna nuna ƙarancin mace-mace tare da jiyya na HCQ+AZ. https://c19p.org/ebongue
96. C. Lavilla Olleros, C. Ausín García, A. Bendala Estrada, A. Muñoz, P. Wikman Jogersen, A. Fernández Cruz, V. Giner Galvañ, J. Vargas, J. Seguí Ripoll, M. Rubio-Rivas, R. Miranda Godoy, F. A. M. Arnalich Fernández, A. Artero, J. Loureiro Amigo, G. García García, L. Corral Gudino, J. Jiménez Torres, J. Casas-Rojo, da J. Millán Núñez-Cortés, Amfani da megadoses na glucocorticoids a cikin SARS-CoV-2 kamuwa da cuta a cikin SEMI-COVID-19 Janairu 2022, KUMA KUMA, Juzu'i na 17, fitowa ta 1, Shafi na e0261711
MAGANIN LAFIYA 14,921 mai haƙuri HCQ nazarin jiyya na ƙarshen: 36% ƙananan mace-mace (p <0.0001).
Marasa lafiya 14,921 na asibiti a Spain, suna nuna ƙarancin mace-mace tare da jiyya na HCQ. https://c19p.org/lavillaolleros
97. J. McKinnon, D. Wang, M. Zervos, M. Saval, L. Marshall-Nightengale, P. Kilgore, P. Pabla, E. Szandzik, K. Maksimowicz-McKinnon, da W. O'Neill, Tsaro da Haƙuri na rigakafin Hydroxychloroquine a cikin ma'aikatan kiwon lafiya da masu amsawa na farko na COVID-19 S. Disamba 2021, Int. J. Cututtuka masu Yaduwa
543 mai haƙuri HCQ prophylaxis RCT: 2% ƙananan lokuta na alamomi (p=1) da 51% ƙananan lokuta (p=0.6).
HCQ prophylaxis RCT tare da 201 mako-mako HCQ marasa lafiya, 197 kullum HCQ marasa lafiya, da 200 kula da marasa lafiya, kammala prophylaxis ne mai lafiya. Babu aji 3 ko 4 AEs, SAEs, ziyarar ER, ko asibiti. An tabbatar da shari'o'i 4 kawai, 2 a hannun placebo kuma ɗaya a cikin kowane hannun HCQ. 60% na marasa lafiya sun sami fallasa a asali. HCQ 400mg mako-mako ko HCQ 200mg kowace rana bayan nauyin kaya na 400mg akan rana 1. https://c19p.org/mckinnon
98. P. Panda, B. Singh, B. Moirangthem, Y. Bahurupi, S. Saha, G. Saini, M. Dhar, M. Bairwa, V. Pai, A. Agarwal, G. Sindhwani, S. Handu da R. Kant Satumba 2021, Clinical Pharmacology: Ci gaba da Aikace-aikace, Juzu'i na 13, Shafi na 185-195
MAGANIN LAFIYA 41 mai haƙuri HCQ marigayi magani RCT: 48% ƙananan mace-mace (p=0.45).
RCT 111 marasa lafiya a Indiya a cikin ƙungiyoyi 5: marasa lafiya masu tsanani: a) daidaitaccen magani, b) hydroxychloroquine + ribavirin + daidaitaccen magani, ko c) lopinavir + ritonavir + ribavirin + daidaitaccen magani, da marasa ƙarfi: a) daidaitaccen magani ko b) hydroxychloroquine + ribavirin. An canza marasa lafiya marasa lafiya zuwa rukuni mai tsanani akan ci gaba. https://c19p.org/panda2
99. S. Naggie A. Milstone C. Woods, K. Anstrom, da A. Hernandez, Hydroxychloroquine don rigakafin rigakafin COVID-19 a cikin ma'aikatan kiwon lafiya: Bazuwar, multicenter, gwajin sarrafa wuribo (HERO-HCQ) Agusta 2021, Int. J. Cututtuka masu Yaduwa
1,359 mai haƙuri HCQ prophylaxis RCT: 24% ƙananan lokuta na alamomi (p=0.18).
HCQ prophylaxis RCT yana ba da rahoton ƙananan ƙananan lamuran ƙididdiga yayin tattara sakamako tare da Covid PREP RCT, KO 0.74 [0.55-1.0] p = 0.046. Babu wasu muhimman batutuwan aminci. An dakatar da gwaje-gwajen da wuri wanda ya haifar da asarar iko; duk da haka haɗin yana nuna tasiri mai mahimmanci na HCQ. Lura cewa an tantance wannan sakamakon a cikin sigar jarida, duba asali a medrxiv.org NAN. Takardar mujallar har yanzu tana nuna takardar Covid PREP a cikin jerin abubuwan da aka ambata, amma an share bincike da tattaunawa. Sigar mujallar ta faɗi ƙarya: “Yin amfani da HCQ ta hanyar HCW yana da aminci amma ba shi da tasiri” yayin da takarda a zahiri tayi kiyasin KO 0.75, wanda ya zama mahimmancin ƙididdiga KO 0.74 lokacin da aka haɗa shi da Covid PREP. Preprint ɗin ya ƙunshi nau'i daban: "… amma bai samar da magani mai amfani ba." Ba a san dalilin da ya sa ~ 25% ƙananan lokuta ba za su yi amfani ba. Sun kuma bayyana "Wannan ɗayan karatu mara kyau ne" duk da haka sakamakon yana da kyau, kawai bai kai ga ƙididdiga ba kafin haɗawa da Covid PREP. Wannan marubucin (Susanna Naggie, MD) An buga wani bincike mai cike da tambaya, wanda ba shi da kyau a kan ivermectin. An tattauna ƙarin batutuwa tare da ivermectin nan kuma a nan: https://c19p.org/naggie
100. F. Taieb, K. Mbaye, B. Tall, N. Lakhe, C. Talla, D. Thioub, A. Ndoye, D. Ka, A. Gaye, V. Cissé Diallo, N. Dia, P. Ba, M. Cissé, M. Diop, C. Diagne, L. Fortes, M. Diop, N. Fall M., Barry Sar., Badia, A. Seck, P. Dubrous, O. Faye, I. Vigan-Womas, C. Loucoubar, A. Sall, da M. Seydi, Hydroxychloroquine da Azithromycin Jiyya na Majinyatan Asibiti da suka kamu da SARS-CoV-2 a Senegal daga Maris zuwa Oktoba 2020 Yuni 2021, J. Clin. Med. 2021, juzu'i na 10, fitowa ta 13, shafi na 2954
MAGANIN LAFIYA 926 mai haƙuri HCQ marigayi nazarin jiyya: 39% mafi girma fitarwa na asibiti (p=0.02).
Marasa lafiya 926 na baya-bayan nan a Senegal, 674 da aka yi musu magani tare da HCQ+AZ, suna nuna mahimmancin sallamar asibiti a ranar 15 tare da jiyya. https://c19p.org/taieb
101. J. Lagier, M. Million, S. Cortaredona, L. Delorme, .. Yuni 2021, Therapeutics da Clinical Risk Management, Juzu'i na 18, Shafi na 603-617
MAGANIN LAFIYA 2,111 mai haƙuri HCQ nazarin jiyya na ƙarshen: 32% ƙananan mace-mace (p=0.004).
A baya-bayan nan 2,011 marasa lafiya na asibiti a Faransa, matsakaicin shekaru 67, suna nuna ƙarancin mace-mace tare da HCQ + AZ, da ƙarin fa'ida tare da ƙari na zinc. https://c19p.org/lagier2
102. . Corcione, Abubuwan Haɗari don Mutuwa a cikin COVID-19 Marasa lafiya Asibiti a Piedmont, Italiya: Sakamako daga Multicenter, Regional, CORACLE Registry Afrilu 2021, J. Clin. Med., Juzu'i na 10, fitowa ta 9, Shafi na 1951
MAGANIN LAFIYA 1,538 mai haƙuri HCQ nazarin jiyya na ƙarshen: 35% ƙananan mace-mace (p=0.02).
Marasa lafiya na asibiti 1,538 na dawowa a Italiya, suna nuna HCQ kawai da ke da alaƙa da rage mace-mace. Marubuta suna nazarin mace-mace tsakanin waɗanda ke raye a rana ta 7 don guje wa son rai na lokacin rayuwa saboda rikodi na miyagun ƙwayoyi da ke buƙatar ƙaramin magani na kwanaki 5. https://c19p.org/derosa
103. Z. Alzahrani, K. Alghamdi, da A. Almaqati, Halayen asibiti da sakamakon COVID-19 a cikin marasa lafiya da cututtukan rheumatic Afrilu 2021, Rheumatology Int. , Juzu'i na 41, Fitowa ta 6, Shafi na 1097-1103
47 mai haƙuri HCQ nazarin prophylaxis: 59% ƙananan mace-mace (p=1), 81% ƙananan iska (p=0.54), da 33% ƙananan lokuta (p=0.7).
Marasa lafiya na cututtukan rheumatic na 47 na baya baya samun bambance-bambance masu mahimmanci tare da HCQ. https://c19p.org/alzahrani
104. N. Dev, R. Meena, D. Gupta, N. Gupta, da J. Sankar, Abubuwan haɗari da yawan COVID-19 tsakanin ma'aikatan kiwon lafiya a cibiyar kula da manyan makarantu a Indiya: nazarin shari'a Maris 2021, Ma'amaloli na Royal Society of Tropical Medicine and Hygiene, Juzu'i na 115, Fitowa ta 5, Shafi na 551-556
759 haƙuri HCQ nazarin prophylaxis: 26% ƙananan lokuta (p=0.003).
Nazarin kula da shari'ar na baya-bayan nan na ma'aikatan kiwon lafiya 3,100 a Indiya suna nuna ƙananan lokuta tare da rigakafin HCQ, da ƙungiyar juzu'i tsakanin adadin alluran HCQ da aka ɗauka da haɗarin shari'o'in Covid-19. Ƙananan yawan jama'a ba tare da mace-mace ba kuma babu wasu lokuta masu tsanani. https://c19p.org/dev
105. F. Taccone, N. Van Goethem, R. De Pauw, X. Wittebole, K. Blot, H. Van Oyen, T. Lernout, M. Montourcy, G. Meyfroidt, da D. Van Beckhoven, Matsayin halayen ƙungiyoyi akan sakamakon COVID-19 marasa lafiya da aka shigar da su ICU a Belgium Disamba 2020, Lafiyar Yanki na Lancet - Turai, Juzu'i na 2, Shafi na 100019
MAGANIN LAFIYA 1,747 mai haƙuri HCQ ICU binciken: 25% ƙananan mace-mace (p=0.02).
Marasa lafiya na 1,747 ICU na baya-bayan nan a cikin Belgium suna nuna ƙarancin mace-mace tare da HCQ, nazarin tasirin tasirin multivariate HCQ daidaita daidaiton rabo 0.64 [0.45-0.92]. https://c19p.org/taccone
106. J. Tan, Y. Yuan, C. Xu, C. Song, D. Liu, D. Ma, da Q. Gao, Kwatanta magungunan da ake yi da COVID-19 a baya. Dec 2020, Binciken Virus, Juzu'i na 294, Shafi na 198262
MAGANIN LAFIYA 285 mai haƙuri HCQ marigayi magani binciken: 35% guntu asibiti (p=0.04).
An sake dawo da marasa lafiya 333 a China, tare da kawai 8 marasa lafiya na HCQ, yana nuna ɗan gajeren lokaci na asibiti tare da HCQ. https://c19p.org/tan2
107. S. Szente Fonseca, A. De Queiroz Sousa, A. Wolkoff, M. Moreira, B. Pinto, C. Valente Takeda, E. Rebouças, A. Vasconcellos Abdon, A. Nascimento, da H. Risch, Hadarin Asibiti ga Ma'aikatan Jihohin Covid-19 da Aka Yi Magance da Magungunan Magunguna daban-daban a Brazil. Oktoba 2020, Maganin Tafiya da Cututtuka masu Yaduwa, Juzu'i na 38, Shafi na 101906
MAGANIN FARKO 717 haƙuri HCQ binciken farko na jiyya: 64% ƙananan asibiti (p=0.0008).
64% ƙananan asibiti tare da HCQ. Marasa lafiya na 717 na baya a Brazil tare da jiyya da wuri, daidaitawa KO 0.32, p=0.00081, don HCQ ba tare da magani ba, da OR 0.45, p=0.0065, don HCQ vs sauran jiyya daban-daban. https://c19p.org/fonseca
108. A. Lammers, R. Brohet, R. Theunissen, C. Koster, R. Rood, D. Verhagen, K. Brinkman, R. Hassing, A. Dofferhoff, R. El Moussaoui, G. Hermanides, J. Ellerbroek, N. Bokhizzou, H. Visser, M. Van den Berge., H., P. Baxd, D. Baxd, Early, D. Baxd, D. Bax, D. Baxd, D. Baxd, D. Bax, D.P, D. D., D. D. D. D., D. D. D. D., D. D. P. D. D. D. D. D., D. Baxd, D. Baxd, D. Bax, D. Baxd, D. Bax, D. Baxd, D. Baxd, D. Baxd, D. Baxd, D. Baxd, D. Baxd, D. Baxd, D. Baxd, D. BH. amma ba amfani da chloroquine ba yana rage shigar ICU a cikin marasa lafiya na COVID-19 Satumba 2020, Int. J. Cututtuka masu Yaduwa, Juzu'i na 101, Shafi na 283-289
MAGANIN LAFIYA 1,064 mai haƙuri HCQ nazarin jiyya na ƙarshen: 32% ƙananan haɗewar mace-mace/ shigar da ICU (p=0.02).
Nazarin lura 1,064 marasa lafiya na asibiti a cikin Netherlands, 53% rage haɗarin canja wuri zuwa ICU don samun iska tare da jiyya na HCQ farawa a ranar farko ta shiga.. Matsakaicin ma'aunin nauyi daidaita girman haɗarin haɗari don canjawa zuwa ICU tare da maganin HCQ, HR = 0.47, p = 0.008. Don CQ, HR = 0.8, p = 0.207. Sakamakon mace-mace a cikin wannan binciken na mace-mace ne kawai kafin canja wurin zuwa ICU. Haɗin ICU / mutuwa HR shine 0.68, p = 0.024 don HCQ, da 0.85, p = 0.224 don CQ. Na lura, cibiyar sadarwa da yawa, nazarin ƙungiyoyin marasa lafiya na COVID-19 na asibiti. 189 HCQ marasa lafiya, 377 CQ, 498 sarrafawa. https://c19p.org/lammers
109. M. Ashinyo, V. Duti, S. Dubik, K. Amegah, S. Kutsoati, E. Oduro-Mensah, P. Puplampu, M. Gyansa-Lutterodt, D. Darko, K. Buabeng, A. Ashinyo, A. Ofosu, N. Baddoo, S. Akoriyea, F., Ofei-Akoriyea, F., Ofei Akoriyea, F. Ofei Akoriyea, F.. na asibiti a tsakanin majinyatan COVID-19 a Ghana: nazari na baya-bayan nan Satumba 2020, Pan African Medical J., Juzu'i na 37
MAGANIN LAFIYA 307 mai haƙuri HCQ marigayi magani binciken: 33% guntu asibiti (p=0.03).
A baya-bayan nan 307 marasa lafiya na asibiti a Ghana suna nuna raguwar 33% a lokacin asibiti tare da HCQ, raguwa 29% tare da HCQ+AZ, da raguwa 37% tare da CQ+AZ. https://c19p.org/ashinyo
110. A. Castelnuovo, S. Costanzo, A. Antinori, N. Berselli, L. Blandi, R. Bruno, R. Cauda, G. Guaraldi, L. Menicanti, I. My, G. Parruti, G. Patti, S. Perlini, F. Santilli, C. Signorelli, E. Spinoni, G. Stefano, A.gori, A.gori, A.gori, A.gori, A.gori, A.gori, A.gori, A.gori, A.gori, A.gori, A.gori, A.gori, A.gori, A.gori, A.gori, A.gori, A.gori, A.gori, A.gori, A.gori, A.gori, A.gori, A.gori. Aiello, P. Agostoni, S. Moghazi, M. Astuto, F. Aucella, G. Barbieri, A. Bartoloni, M. Bonaccio, P. Bonfanti, F. Cacciatore, L. Caiano, F. Cannata, L. Carrozzi, A. Cascio, A. Ciccullo, F. Colsta C.C.C. Pra, G. Danzi, D. D'Ardes, K. Donati, P. Giacomo, F. Gennaro, G. Di Tano, G. D'Offizi, T. Filippini, F. Fusco, I. Gentile et al., Amfani da hydroxychloroquine a asibiti COVID-19 marasa lafiya yana da alaƙa da raguwar mace-mace: Binciken da aka yi daga binciken Italiyanci da yawa. Agusta 2020, Turai J. Magungunan Ciki, Juzu'i na 82, Shafi na 38-47
MAGANIN LAFIYA 3,451 mai haƙuri HCQ nazarin jiyya na ƙarshen: 30% ƙananan mace-mace (p <0.0001).
Marasa lafiya na asibiti na 3,451 na baya, 30% raguwa a cikin mace-mace tare da HCQ bayan daidaitawar haɓakawa, HR 0.70 [0.59-0.84]. https://c19p.org/dicastelnuovo
111. L. Catteau, N. Dauby, M. Montourcy, E. Bottieau, J. Hautekiet, E. Goetghebeur, S. Van Ierssel, E. Duysburgh, H. Van Oyen, C. Wyndham-Thomas, D. Van Beckhoven, K. Bafort, L. Belkhir, N. Bossum Capsuyt, P. Munda Capsuyt J. Deblonde, D. Delmarcelle, M. Delvalee, R. Demeester, T. Dugernier, X. Holemans, B. Kerzmann, P. Yves Machurot, P. Minette, J. Minon, S. Mokrane, C. Nachtergal, S. Noirhomme, D. Piérard, C.Sirle Scherri, F. Stan Rossi, F. Stan Rossi, F. F. Triest, N. Goethem, J. Praet, A. Vanhoenacker, R. Verstraete, da E. Willems, Ƙarƙashin Maganin Hydroxychloroquine da Mutuwa a cikin Marasa lafiya na Asibiti tare da COVID-19: Nazarin Dubawa na Ƙasashen Duniya na Mahalarta 8075 Agusta 2020, Int. J. Magungunan rigakafi, Juzu'i na 56, Fitowa ta 4, Shafi na 106144
MAGANIN LAFIYA 8,075 mai haƙuri HCQ nazarin jiyya na ƙarshen: 32% ƙananan mace-mace (p <0.0001).
Marasa lafiya na asibiti 8,075 na dawowa, 4,542 ƙananan HCQ, kulawar 3,533. 35% ƙananan mace-mace don HCQ (17.7% vs. 27.1%), gyara HR 0.68 [0.62-0.76]. Ƙananan ƙwayar HCQ monotherapy an haɗa shi da kansa tare da ƙananan mace-mace a cikin marasa lafiya na asibiti. An cire marasa lafiya da aka fallasa ga wasu hanyoyin kwantar da hankali (TCZ, AZ, LPV/RTV). Ƙungiya mai zaman kanta ta yi nazarin ƙididdiga. An yi la'akari da lokacin kalandar takardar sayan magani da son zuciya mara mutuwa. Dokokin Corticosteroids sun yi ƙasa a cikin ƙungiyoyin biyu. https://c19p.org/catteau
112. C. Chen Y. Lin kimanta inganci da jurewar hydroxychloroquine da nazari na baya-bayan nan a cikin manya marasa lafiya masu rauni zuwa matsakaicin cutar Coronavirus 2019 (COVID-19) Yuli 2020, KYAUTA DAYA, Juzu'i na 15, fitowa ta 12, Shafi na e0242763
MAGANIN LAFIYA 33 mai haƙuri HCQ marigayi magani RCT: 24% ingantacciyar kariya ta hoto (p=0.71).
2 ƙananan karatu tare da marasa lafiya a asibiti a Taiwan. RCT tare da jiyya na 21 da 12 daidaitattun marasa lafiya. Babu mace-mace, ko mummunar illa. Lokacin tsaka-tsaki zuwa mummunan RNA kwanaki 5 tare da daidaitattun kulawa na kwanaki 10, p=0.4. Hadarin PCR + a ranar 14, RR 0.76, p = 0.71. Ƙananan binciken da aka yi nazari tare da 12 na 28 HCQ marasa lafiya da 5 na 9 a cikin ƙungiyar kulawa da kasancewa PCR- a ranar 14, RR 1.29, p = 0.7. RCT da kuma sake dubawa karatu ana jera su daban. https://c19p.org/chen25
113. W. Tang. Hydroxychloroquine a cikin marasa lafiya da ke da cutar coronavirus mai laushi zuwa matsakaici 2019: buɗaɗɗen lakabin, gwajin sarrafa bazuwar Afrilu 2020, BMJ 2020, 369, Shafi na 1849
MAGANIN LAFIYA 150 mai haƙuri HCQ marigayi magani RCT: 21% ingantacciyar kariya ta hoto (p=0.51).
150 haƙuri sosai marigayi mataki RCT nuna babu wani gagarumin bambanci. Jiyya ya yi latti sosai, matsakaita na kwanaki 16.6 bayan bayyanar cutar. An share bayanan da suka dace da HCQ a sigar ta biyu, duba bincike a nan. "[HCQ] yana hanzarta [s] kawar da alamun asibiti"; "Ƙarin saurin rage bayyanar cututtuka na asibiti tare da ma'auni na kulawa da HCQ fiye da yadda ake kula da shi kadai an lura da shi a cikin mako na biyu tun lokacin da bazuwar"; "Ingancin HCQ akan rage alamun bayyanar cututtuka, HR 8.83 [1.09-71.3], ya fi bayyana lokacin da aka cire abubuwan da ke damun wasu magungunan rigakafin cutar." https://c19p.org/tang
114. O. Mitjà, M. Corbacho-Monné, M. Ubals, C. Tebé, J. Peñafiel, A. Tobias, E. Ballana, A. Alemany, N. Riera-Martí, C. Pérez, C. Suñer, P. Laporte, P. Admella, J. Mitjà, M. Clua, M. Sarquel, L. Sarquel J. Argimon, J. Casabona, G. Cuatrecasas, P. Cañadas, A. Elizalde-Torrent, R. Fabregat, M. Farré, A. Forcada, G. Flores-Mateo, E. Muntada, N. Nadal, S. Narejos, A. Nieto, N. Prat, J. Puig, C., Reyñess, C. Quiñess Ramírez-Viaplana, L. Ruiz, E. Riveira-Muñoz, A. Sierra, C. Velasco, R. Vivanco-Hidalgo, A. Sentís, C. G-Beiras, B. Clotet, da M. Vall-Mayans, Hydroxychloroquine don Farkon Jiyya na Manya tare da Marasa lafiya-19 Yuli 2020, Cututtukan Cututtuka na Clinical, ciaa1009, juzu'i na 73, fitowa ta 11, shafi e4073-e4081
MAGANIN FARKO 293 mai haƙuri HCQ farkon jiyya RCT: 16% ƙananan asibiti (p = 0.64), 34% inganta farfadowa (p=0.38), da 2% inganta ƙwayar cuta.
Wannan takarda tana da ƙima masu karo da juna, tebur S2 yana nuna asibitocin kulawa na 12, yayin da tebur 2 ya nuna 11. Rahoton asali na wannan takarda yana da ƙarin ƙididdiga masu rikice-rikice, tare da ƙididdiga da aka ruwaito a cikin Table 2 da kuma bayanin da ya dace da asibitocin kulawa na 12, yayin da wasu suka dace da asibitocin kulawa na 11. Lissafin da ke cikin tebur S2 shima bai dace ba; n = 290 an ba shi don ƙarshen ƙarshen biyu amma ƙungiyoyi uku sun haɗa zuwa n = 238. Ƙididdigar maƙasudin ƙarshen na biyu don ƙungiyar kulawa a cikin tebur 2 bai dace da girman rukuni ba. Mara lafiya ɗaya da ya ɓace yana iya zama asibiti na kulawa na 12 amma akwai ƙarin 2 da suka ɓace. An sami raguwar 16% a asibiti da 34% raguwa a cikin haɗarin rashin ƙaddamar da alamar alama, ba tare da mahimmancin ƙididdiga ba saboda ƙananan samfurori. Ba a san jinkirin jinkiri ba. Suna bayar da rahoton jinkirin har zuwa sa'o'i 120 bayan bayyanar cututtuka da ƙarin jinkirin da ba a bayyana ba inda aka ba da magani ga marasa lafiya a ziyarar farko ta gida.. Marubuta ba su amsa bukatar C19early.com don cikakkun bayanai ba. Marubuta ba sa karya sakamako ta hanyar jinkirin jiyya. Takardar ba ta ambaci zinc ba. An ba da rahoton karancin Zinc a Spain a kashi 83%, wannan na iya rage tasiri sosai. Hcq shine zinc ionophore wanda ke kara yawan UPTake, yana sauƙaƙe muhimmin taro na cikin zinc, da zinc an san shi da hana SARKIN SARKINS, kuma ana tsammanin yana da mahimmanci don tasirin HCQ a cikin SARS-CoV-2. An canza nauyin kwayar cutar da ba a iya ganowa zuwa 3 log10 kwafi/ml mai yuwuwar canza tasiri. Ga mawallafa masu ɗaukar hoto na hoto suna amfani da swabs na nasopharyngeal, mun lura cewa aikin ƙwayar cuta a cikin huhu na iya zama mahimmanci musamman ga COVID-19, kuma binciken ya nuna adadin HCQ na iya zama. yafi girma a cikin huhu idan aka kwatanta da plasma. Mun kuma lura da cewa gano kwayar cutar hoto ta PCR baya daidaita da kwayar cutar da za ta iya yiwuwa. Ba a bayar da daidaiton gwaje-gwajen ba. Abubuwan da ke nazarin nauyin ƙwayar cuta na nasopharyngeal sun haɗa da rashin amincin gwajin gwaji da bambance-bambancen lokaci-tsara a cikin zubar da kwayar cutar hoto. 293 marasa lafiya marasa lafiya ba tare da mutuwa ba. Babu mummunan al'amura mara kyau. C19early.com yayi ƙoƙari ya yi hulɗa tare da marubuta, yana neman ƙarin cikakkun bayanai game da jinkirin jiyya da canjin ƙwayar cuta amma bai sami amsa ba. Duba kuma wannan bude wasika. https://c19p.org/mitja
115. M. Chechter, G. Dutra da Silva, R. E Costa, T. Miklos, N. Antonio da Silva, G. Lorber, N. Vascncellos Mota, A. Dos Santos Cortada, L. De Nazare Lima da Cruz, P. De Melo, B. De Souza, F. Emmerich, P. De Andrade. a farkon cutar ta COVID-19 a São Paulo, Brazil: Nazarin farko na gwaji na asibiti da ba a bazu ba. Nuwamba 2021, heliyon, Shafi e15337
MAGANIN FARKO 72 haƙuri HCQ binciken farko na jiyya: 95% ƙananan asibiti (p=0.004).
Nazarin mai yiwuwa na marasa lafiya na telemedicine 187 a Brazil. 74 masu gabatar da matsakaicin bayyanar cututtuka an ba da magani tare da HCQ+AZ, 12 bai karɓi HCQ (ɗaukar AZ kawai), kafa ƙungiyar kulawa. Akwai ƙananan asibiti da kuma inganta murmurewa tare da magani. https://c19p.org/chechter
116. McCullough et al., Hydroxychloroquine a cikin Rigakafin COVID-19 a cikin Ma'aikatan Kiwon Lafiya Agusta 2021, NCT04333225
221 haƙuri HCQ nazarin prophylaxis: Ƙananan lokuta 52% (p=0.01).
Nazarin mai zuwa tare da ma'aikatan kiwon lafiya 221, yana nuna ƙarancin haɗarin COVID-19 tare da rigakafin HCQ. https://c19p.org/mccullough4
117. M. Modrák, P. Bürkner, T. Sieger, T. Slisz, M. Vašáková, G. Mesežnikov, L. Casas-Mendez, J. Vajter, J. Táborský, V. Kubricht, D. Suk, J. Horejsek, M. Jedlička, A. Mifroška, A. Mifroška, A. MIFROška Váchalová, R. Šín, M. Veverková, Z. Pospíšil, J. Vohryzková, R. Pokrievková, K. Hrušák, K. Christozova, V. Leos-Barajas, K. Fišer, da T. Hyánek, Cikakkun cututtukan ci gaba na 213 marasa lafiya An kwantar da su a asibiti tare da bincike na Jamhuriyar Czech. Disamba 2020, wannasura
MAGANIN LAFIYA 213 mai haƙuri HCQ nazarin jiyya na ƙarshen: 59% ƙananan mace-mace (p=0.04).
Marasa lafiya 213 na asibiti a cikin Jamhuriyar Czech suna nuna ƙarancin mace-mace tare da HCQ. Batun ruɗarwa ta hanyar nuni. https://c19p.org/modrak
118. A. Khurana, G. Kaushal, R. Gupta, V. Verma, K. Sharma, da M. Kohli, Yaduwa da alaƙar asibiti na barkewar COVID-19 tsakanin ma'aikatan kiwon lafiya a wani babban asibiti. Yuli 2020, wannasura
181 haƙuri HCQ nazarin prophylaxis: Ƙananan lokuta 51% (p=0.02).
Nazarin ma'aikatan kiwon lafiya na asibiti da ke nuna rigakafin HCQ yana rage COVID-19 sosai, KO 0.30, p=0.02. Ma'aikatan kiwon lafiya 94 masu inganci tare da samfurin da ya dace na gwaji 87 mara kyau. Cikakken tsarin rigakafin yana da mahimmanci a cikin wannan binciken wanda yayi amfani da a ƙananan kashi na 400mg / mako HCQ (800mg na mako 1), don haka yana iya ɗaukar lokaci mai tsawo don isa matakan warkewa. Ainihin fa'idar HCQ na iya zama babba saboda ba'a la'akari da tsananin alamun a nan amma HCQ kuma na iya rage tsananin. https://c19p.org/khurana
119. F. Membrillo de Novales, G. Ramírez-Olivencia, M. Estébanez, B. De Dios, M. Herrero, T. Mata, A. Borobia, C. Gutiérrez, M. Simón, A. Ochoa, Y. Martínez, A. Aguirre, F. Alcántara, P. Fernáz, E. Gonz, E. Navarro, da L. Ballester, Early Hydroxychloroquine Yana Haɗe da Ƙarfafa Rayuwa a cikin Marasa lafiya na COVID-19: Nazari Na Dubawa Mayu 2020, Preprints 2020, 2020050057
MAGANIN LAFIYA 166 mai haƙuri HCQ nazarin jiyya na ƙarshen: 55% ƙananan mace-mace (p=0.002).
Marasa lafiya 166 da aka kwantar da su a asibiti tare da COVID-19, HCQ ya haɓaka rayuwa sau 1.4 - 1.8 lokacin da aka shigar da marasa lafiya a farkon matakan. Farkon yana da alaƙa da shigar da asibiti a nan - duk marasa lafiya suna cikin mummunan yanayi. https://c19p.org/membrillo
120. R. Rajasingham, A. Bangdiwala, M. Nicol, C. Skipper, K. Pastick, M. Axelrod, M. Pullen, A. Nascene, D. Williams, N. Engen, E. Okafor, B. Rini, I. Mayer, E. McDonald, T. Lee, P. Li, L. Macen, D. Hull, D. Macken. Boulware, S. Lofgren, M. Abassi, A. Balster, L. Collins, G. Drobot, D. Krakower, S. Lother, D. MacKay, C. Meyer-Mueller, S. Selinsky, D. Solvason, R. Zarychanski, da R. Zash, Hydroxychloroquine a matsayin pre-xisized gwajin ma'aikatan kiwon lafiya na COVID-19phyladom prophylactic. Satumba 2020, Cututtukan Cututtuka na Clinical, Juzu'i na 72, Fitowa ta 11, Shafi na e835-e843
1,483 mai haƙuri HCQ prophylaxis RCT: 27% ƙananan lokuta (p=0.07).
PrEP RCT yana nuna ƙananan lokuta tare da HCQ prophylaxis. An dakatar da gwajin bayan yin rajista na 47%, p <0.05 za a kai a ~75% rajista idan an ci gaba da samun sakamako iri ɗaya. HR 0.66 / 0.68 don cikakken yarda da magani, 0.72 / 0.74, p = 0.18 / 0.22 gaba ɗaya (1x / 2x dosing). Ingancin masu amsawa na farko ya fi girma, KO 0.32, p = 0.01. Masu amsawa na farko sun sami mafi girman abin da ya faru, yana ba da damar mafi girma, da rage tasirin rikice-rikice kamar rashin ganewar wasu yanayi ko batutuwan bincike. Aiki yayi kama da hannun kulawa na makonni 3 na farko. Tasirin na iya zama mafi girma tare da tsarin sashi wanda ke cimma matakan warkewa cikin sauri. ~ 40% na mahalarta ana zargin suna da COVID-19 kafin gwaji, tasirin mutanen da ba su da COVID-19 na iya zama mafi girma.. Bincike ya nuna maganin da aka yi amfani da shi a hannun kulawa (folic acid) na iya samun tasiri mai mahimmanci ga COVID-19, don haka tasirin gaske na HCQ na iya zama mafi girma fiye da lura. Duba kuma wannan labarin dangane da foil acid. Lura cewa an annabta folic acid zai ɗaure ga sunadaran SARS-CoV-2 da yawa, Matakan folic acid sun yi ƙasa a cikin marasa lafiya na COVID-19 da ke da mummunar cuta, Kariyar folic acid na iya taimakawa tare da COVID-19 masu alaƙa da hauhawar jini da hyperhomocystinemia, kuma bambance-bambance a cikin enzyme mai alaƙa da folic acid na iya yin tasiri ga bambancin yanayin yanayin COVID-19. Marubuta sun lura cewa ba a da ikon yin gwajinAn ba da garantin yin bincike kan yawan allurai akai-akai, kuma mai yiwuwa adadin bai wadatar da shi ba babu mahalarta da suka cimma fiye da in vitro EC50. Binciken Intanet RCT dangane da son zuciya. Babu mace-mace ko shigar da ICU. Ƙananan ma'aikatan kiwon lafiya masu haɗari, matsakaicin shekaru ~ 40. 494 1x / mako dosing, 495 2x / mako dosing, 494 mahalarta masu kulawa (masu halartar 1x da 2x sun sami kashi ɗaya na gaba ɗaya). https://c19p.org/rajasingham
121. B. Singh, B. Moirangthem, P. Panda, Y. Bahurupi, S. Saha, G. Saini, M. Dhar, M. Bairwa, V. Pai, A. Agarwal, G. Sindhwani, S. Handu, da Ravikant, Tsaro da ingancin maganin rigakafi kadai ko a hade a cikin COVID-19 da aka sarrafa bazuwar gwaji Yuni 2021, wannasura
MAGANIN LAFIYA 74 mai haƙuri HCQ marigayi magani RCT: 48% ƙananan mace-mace (p=0.45) da 14% inganta farfadowa (p=0.76).
Ƙananan da wuri ya ƙare RCT a Indiya, yana nuna ƙananan mace-mace amma ba tare da mahimmancin ƙididdiga ba tare da ƙaramin girman samfurin. Ba a bayar da lokacin da aka fara bayyanar cututtuka ba. Adadin dawowa don rukunin B marasa ƙarfi (86.7%) bai dace da kowane adadin dawo da ba, mun yi amfani da lamba mafi kusa (15/17). https://c19p.org/singh2
122. S. Almazrou, Z. Almalki, A. Alanazi, A. Alqahtani, da S. Alghamd, Kwatanta tasirin tsarin tsarin Hydroxychloroquine da daidaitaccen magani akan sakamakon majiyyata na COVID-19: Nazarin ƙungiyar masu bibiya. Satumba 2020, Saudi Pharmaceutical J., Juzu'i na 28, Fitowa ta 12, Shafi na 1877-1882
MAGANIN LAFIYA 161 mai haƙuri HCQ marigayi nazarin jiyya: 65% ƙananan samun iska (p=0.16) da 21% ƙananan shigar da ICU (p=0.78).
Marasa lafiya na asibiti 161 na baya-bayan nan a Saudi Arabiya suna nuna ƙarancin samun iska da shigar da ICU tare da HCQ, amma ba ƙididdiga ba tare da ƙananan samfuran samfuran. https://c19p.org/almazrou
123. C. Gentry, M. Humphrey, S. Thind, S. Hendrickson, G. Kurdgelashvili, da R. Williams, Yin amfani da hydroxychloroquine na dogon lokaci a cikin marasa lafiya tare da yanayin rheumatic da ci gaba da kamuwa da cutar SARS-CoV-2: nazari na baya-bayan nan. Satumba 2020, Lancet Rheumatology, Juzu'i na 2, Fitowa ta 11, Shafi na e689-e697
32,109 mai haƙuri HCQ nazarin prophylaxis: 91% ƙananan mace-mace (p=0.1) da 21% ƙananan lokuta (p=0.27).
Marasa lafiya na baya-bayan nan tare da yanayin rheumatologic suna nuna sifili na 10,703 COVID-19 mutuwar COVID-7 ga majinyatan HCQ da 21,406 na 64.8 masu kusancin da suka dace da marasa lafiya (ba ƙididdiga ba). Matsakaicin shekarun marasa lafiya na HCQ ya ɗan ragu kaɗan 65.4 tare da kulawar 19. Abubuwan COVID-0.79 KO 0.27, p=XNUMX. Akwai bambance-bambance masu mahimmanci da yawa a cikin halayen da suka dace da marasa lafiya waɗanda zasu iya shafar sakamako, misali, 20.9% SLE da 24.7%. https://c19p.org/gentry
124. K. Said, A. Alsolami, F. Alreshidi, A. Fathuddin, F. Alsammari, F. Alrashid, A. Aljadani, R. Aboras, F. Alreshidi, M. Alghozwi, S. Alshammari, da N. Alharbi, Bayanan martaba na Ƙungiyoyin Masu zaman kansu-Comorbidity a cikin Babban Abokan Kula da Marasa lafiya a cikin Babban Abokan Kulawa da Marasa Lafiya. Low-Kashi Hydroxychloroquine akan Antivirals Afrilu 2023, J. Kula da Kiwon Lafiyar Jama'a, Juzu'i na 16, Shafi na 1215-1229
MAGANIN LAFIYA 840 mai haƙuri HCQ nazarin jiyya na ƙarshen: 78% ƙananan mace-mace (p <0.0001).
Majiyoyin COVID-750 19 na baya-bayan nan a Saudi Arabiya, suna nuna ƙarancin mace-mace tare da jiyya na HCQ a cikin sakamako mara kyau. Marubuta sun lura cewa rashin sakamako mara kyau a cikin wasu gwaje-gwajen na iya zama alaƙa da haɓakar allurai da jiyya daga baya. https://c19p.org/said2
125. E. Satti, M. Ostensen, S. Darrgham, N. Hadwan, H. Ashour, da S. AL Emadi, Halaye da Sakamakon Ciwon ciki a Mata masu Cutar Rheumatic Autoimmune A Yayin Cutar COVID-19 a Qatar Afrilu 2022, Cureus
80 haƙuri HCQ nazarin prophylaxis: Ƙananan lokuta 61% (p=0.04).
Marasa lafiya masu ciki 80 masu juna biyu a jere tare da cututtukan rheumatic autoimmune a Qatar, suna nuna ƙarancin haɗarin COVID-19 tare da rigakafin HCQ. https://c19p.org/satti
126. M. AbdelGhaffar, D. Omran, A. Elgebaly, E. Bahbah, S. Afify, M. AlSoda, M. El-Shiekh, E. ElSayed, S. Shaaban, S. AbdelHafez, K. Elkelany, A. Eltayar, O. Ali, L. Kamal, A. Heiba, da kuma H. El Askary a asibiti a Masar marasa lafiya tare da cutar Coronavirus-2019: Nazarin na baya-bayan nan da yawa Janairu 2022, KUMA KUMA, Juzu'i na 17, fitowa ta 1, Shafi na e0262348
MAGANIN LAFIYA 3,712 mai haƙuri HCQ nazarin jiyya na ƙarshen: 100% ƙananan mace-mace (p <0.0001).
Marasa lafiya 3,712 na asibiti a Masar, suna nunawa ƙananan mace-mace tare da maganin HCQ a cikin sakamakon da ba a daidaita ba. Bisa ga ka'idar jiyya ta hukuma, an ba da shawarar HCQ tare da haɗari mafi girma da/ko mafi muni. https://c19p.org/abdelghaffar
127. Y. Huang, Z. Chen, Y. Wang, L. Han, K. Qin, W. Huang, Y. Huang, H. Wang, P. Shen, X. Ba, W. Lin, H. Dong, M. Zhang, da S. Tu, Siffofin asibiti na marasa lafiya 17 masu COVID-19 da cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan fata. Yuni 2020, Annals na Rheumatic Diseases 2020:79, 1163-1169, Juzu'i na 79, Fitowa ta 9, Shafi na 1163-1169
1,255 haƙuri HCQ nazarin prophylaxis: 80% ƙananan asibiti (p=0.001).
Binciken marasa lafiya 1255 na COVID-19 a Asibitin Wuhan Tongji wanda ya gano kashi 0.61% tare da cututtuka na tsarin rigakafi, ya yi ƙasa da yadda marubutan ke tsammani (3% -10%). Marubuta suna hasashen cewa abubuwan kariya, kamar amfani da CQ/HCQ, suna rage asibiti. https://c19p.org/huangard
128. K. Oku, Y. Kimoto, T. Horiuchi, M. Yamamoto, Y. Kondo, M. Okamoto, T. Atsumi, da T. Takeuchi, Abubuwan haɗari don asibiti ko mace-mace ga COVID-19 a cikin marasa lafiya da cututtukan rheumatic: Sakamakon rajista na JCR COVID-19 na ƙasa a Japan Satumba 2022, Zamani Rheumatology
220 mai haƙuri HCQ nazarin prophylaxis: 92% ƙananan mace-mace (p=1) da 12% ƙananan asibiti (p=0.34).
Marasa lafiya 220 na COVID-19 na baya-bayan nan tare da cututtukan rheumatic a Japan, suna nuna ƙarancin mace-mace da asibiti tare da rigakafin HCQ, ba tare da mahimmancin ƙididdiga ba. https://c19p.org/oku
129. G. Ramírez-García, P. García-Molina, M. Flor-Cremades, B. Muñoz-Rojas, J. Moleón Moya, Hydroxychloroquine da Tocilizumab a cikin Jiyya na COVID-19: Nazari na Dogayen Dubawa Mayu 2021, Archivos de Medicina Jami'ar
MAGANIN LAFIYA 403 mai haƙuri HCQ nazarin jiyya na ƙarshen: 67% ƙananan mace-mace (p <0.0001) da 6% mafi girma shigar ICU (p=1).
Marasa lafiya 403 na asibiti a Spain, suna nuna ƙarancin mace-mace tare da jiyya, duk da haka marubuta ba su daidaita don bambance-bambance tsakanin kungiyoyin. Mai ruɗani ta hanyar nuni yana yiwuwa. https://c19p.org/ramirezgarcia
130. G. Meeus, F. Van Coile, H. Pottel, A. Michel, O. Vergauwen, K. Verhelle, S. Lamote, M. Leys, M. Boudewijns, da P. Samaey, Inganci da aminci na asibiti na asibiti na kamuwa da cuta na Covid-19 tare da ƙananan ƙwayar hydroxychloroquine da marasa lafiya na asibiti azithromycin. Satumba 2023, Sabbin ƙwayoyin cuta da Sabbin cututtuka, Shafi na 101172
MAGANIN LAFIYA 3,885 mai haƙuri HCQ nazarin jiyya na ƙarshen: 36% ƙananan mace-mace (p=0.005).
A baya-bayan nan 352 marasa lafiya na COVID-19 da ke asibiti a Belgium da marasa lafiya 3,533 masu kulawa daga rukunin Haɗin gwiwar Belgian na zamani, suna nuna ƙarancin mace-mace tare da jiyya na HCQ. Amfanin tsira ya yi daidai a kowane rukuni na shekaru. Ba a ga alamun torsade de pointes ko arrhythmias na ventricular ba. Ba a bayar da matsakaicin lokaci daga farkon ba, amma kashi 43% na marasa lafiya da aka sani sun fara shiga a tsakanin kwanakin 5, yin inganci daidai da tsammanin bisa jinkirin jinkiri. HCQ 800mg rana ɗaya, 200mg tayin kwana biyar, bisa ga jagororin ƙasa. Marubuta sun lura cewa rashin sakamako mai kyau a cikin gwajin SOLIDARITY/RECOVERY na iya kasancewa yana da alaƙa da yawan allurai da aka yi amfani da su. Yawancin marasa lafiya kuma sun sami AZ. Ana ba da ingantaccen sakamako ga duk marasa lafiya na HCQ kawai. An jinkirta bugawa sama da shekaru 3. Marubuta sun ruwaito a cikin 2021 cewa takarda ta kasance Editocin mujallu huɗu daban-daban sun ƙi. kafin a yi bitar takwarorinsu. https://c19p.org/meeus
131. C. Johnston, E. Brown, J. Stewart. A. Greninger, M. Huang, K. Jerome, M. Wener, A. Wald, J. Schiffer, C. Celum, H. Chu, R. Barnabas, da J. Baeten, Hydroxychloroquine tare da ko Ba tare da Azithromycin don Jiyya na Farko SARS-CoV-2 Kamuwa Daga Cikin Babban Haɗari na Waje: Marasa Lafiyar Ma'aikatan Lafiya Disamba 2020, Magungunan Magunguna, Juzu'i na 33, Shafi na 100773
MAGANIN LAFIYA 231 mai haƙuri HCQ marigayi magani RCT: 30% ƙananan asibiti (p=0.73), 2% inganta farfadowa (p=0.95), da kuma 29% saurin kamuwa da kwayar cutar hoto.
Ƙananan da aka ƙare marigayi magani RCT kwatanta bitamin C + folic acid, HCQ + folic acid, da HCQ+AZ, yana nuna rashin ƙididdige ƙananan asibiti tare da HCQ/HCQ+AZ, da sauri mai saurin kamuwa da cuta tare da HCQ. Rijista ta kasance tsaka-tsaki na kwanaki 5.9 bayan farawa (6.2 da 6.3 a cikin hannun jiyya). Matsakaicin lokaci zuwa kwayar cutar kwayar cuta don bitamin C + folic acid ya kasance kwanaki 8 a cikin preprint amma ya canza zuwa kwanaki 7 a cikin takarda da aka buga ba tare da bayani ba. Dukansu bitamin C da folic acid (nan da kuma nan) nuna inganci a cikin wasu gwaje-gwaje, don haka tasirin gaske na HCQ(+AZ) na iya zama sama da yadda aka gani. Ƙananan marasa lafiya, matsakaiciyar shekaru 37, babu mutuwa (ba ta dace da taken da ke da'awar "babban haɗari"). Bayan hoc ƙari na a sabon matakin zagayowar don ɓoye mahimmin ƙididdiga mai saurin sharewa. Babu bincike don lokaci daga bayyanar cututtuka. Marubuta sun gano (kwatankwacin) ƙananan ƙungiyoyi masu haɗari da haɗari, amma ba sa samar da ko dai zubar da hoto ko kuma sakamakon ƙudurin alama ga ƙungiyoyin. Saukewa: NCT04354428. https://c19p.org/johnston
132. A. Alshamrani, A. Assiri, da O. Almohammed, Cikakken kimantawa na shirye-shirye guda shida don marasa lafiya na asibiti tare da COVID-19: Binciken da ya dace da ƙima. Fabrairu 2023, Saudi Pharmaceutical J.
MAGANIN LAFIYA 814 mai haƙuri HCQ marigayi magani PSM binciken: 50% ƙananan mace-mace (p=0.18), 37% ƙananan ci gaba (p=0.21), 9% guntun shigar da ICU (p=0.66), da 3% tsawon asibiti (p=0.7).
PSM na baya-bayan nan asibitoci 29 a Saudi Arabiya, gano ƙananan mace-mace tare da HCQ, ba tare da cimma mahimmancin ƙididdiga ba (marubutan sun bayyana a matsayin "babu tasiri"). https://c19p.org/alshamrani
133. A. Avezum, G. Oliveira, H. Oliveira, R. Lucchetta, V. Pereira, A. Dabarian, R. D'O Vieira, D. Silva, A. Kormann, A. Tognon, R. De Gasperi, M. Hernandes, A. Feitosa, A. Piscopo, A. Souza, C. Miguel., C. Miguel, C. Miguel. . da O. Berwanger, Hydroxychloroquine tare da placebo a cikin kula da marasa lafiya marasa lafiya tare da COVID-19 (COPE - Coalition V): Makafi biyu, tsakiya, bazuwar, gwajin sarrafawa. Maris 2022, Lafiyar Yanki na Lancet - Amurka, Juzu'i na 11, Shafi na 100243
MAGANIN FARKO 1,372 mai haƙuri HCQ farkon magani RCT: 1% ƙananan mace-mace (p = 1), 32% mafi girma samun iska (p = 0.79), 16% ƙananan shigar da ICU (p = 0.61), da 23% ƙananan asibiti (p=0.18).
Marubuta ba su amsa buƙatar fom ɗin bayanan tushen C19early.com ba. RCT na waje tare da 687 HCQ da 682 masu kula da marasa lafiya a Brazil, suna nuna ƙananan asibiti tare da magani, ba su kai ga mahimmancin ƙididdiga ba. An ga inganci mafi girma tare da jiyya <4 kwanaki daga farkon, RR 0.61. Binciken meta mai alaƙa ya haɗa da yawancin nazarin jiyya na ƙarshe, misali a cikin jinkiri na tsaka-tsaki daga farawa ya ɓace kwanaki 7. Ƙididdiga don ba daidai ba - binciken ya nuna 4 asibitoci a cikin hannun kulawa - RR don wannan binciken ya kamata ya zama 0.58 maimakon 0.78. https://c19p.org/avezum
134. A. Delgado, B. Cornett, Y. Choi, C. Colosimo, V. Stahel, O. Dziadkowiec, da P. Stahel, Magungunan bincike a cikin marasa lafiya 9,638 da ke asibiti tare da COVID-19 mai tsanani: darussa daga dabarun "kasa-da-koyi" a lokacin raƙuman ruwa biyu na farko na cutar a cikin 2020 Fabrairu 2023, Dandalin bincike
MAGANIN LAFIYA 9,638 mai haƙuri HCQ nazarin jiyya na ƙarshen: 26% ƙananan mace-mace (p=0.002).
PSM na baya-bayan nan 9,638 marasa lafiya a cikin Amurka, yana nuna ƙarancin mace-mace tare da HCQ a farkon 2020 (masu fama da HCQ 1,157), kuma babu wani babban bambanci a ƙarshen 2020 (82 HCQ marasa lafiya). Ƙananan marasa lafiya da aka yi wa magani a cikin lokaci na gaba na iya kasancewa cikin yanayi mafi muni saboda ƙoƙarin da ake bukata don shawo kan siyasa da ƙididdiga a cikin ƙasar binciken. Marubuta suna yin la'akari da sakamakon su a matsayin "babu wani fa'ida mai dacewa a cikin mace-mace tsakanin masu cutar biyu." https://c19p.org/delgado
135. A. AlShehhi, T. Almansoori, A. Alsuwaidi, da H. Alblooshi, Yin amfani da koyo na inji don nazarin rayuwa don gano abubuwan haɗari don shigar da sashin kulawa mai zurfi na COVID-19: Nazarin ƙungiyar gama gari daga Hadaddiyar Daular Larabawa. Janairu 2024, KUMA KUMA, Juzu'i na 19, fitowa ta 1, Shafi na e0291373
MAGANIN LAFIYA 1,797 mai haƙuri HCQ nazarin jiyya na ƙarshen: 43% ƙananan shigar da ICU (p=0.001).
An dawo da marasa lafiya 1,787 na COVID-19 na asibiti a cikin Hadaddiyar Daular Larabawa, suna gano hydroxychloroquine azaman rage haɗarin shigar da ICU a cikin samfurin koyon injin. Sai kawai an ba da sakamakon ƙididdiga marasa daidaituwa, wanda kuma ke nuna fa'ida. https://c19p.org/alshehhi
136. M. Sahebari, Z. Mirfeizi, Z. Shariati-Sarabi, M. Moghadam, K. Hashemzadeh, da M. Firoozabadi, Tasirin magungunan ƙwayoyin cuta da na al'ada waɗanda ke canza cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan da da kuma kamuwa da cutar. Satumba 2022, Reumatologia/Rheumatology, Juzu'i na 60, Fitowa ta 4, Shafi na 231-241
512 haƙuri HCQ nazarin prophylaxis: Ƙananan lokuta 56% (p=0.02).
Majiyoyin cutar rheumatic 512 na baya-bayan nan a Iran, suna nuna ƙarancin haɗarin COVID-19 tare da amfani da HCQ. https://c19p.org/sahebari
137. D. MacFadden, K. Brown, S. Buchan, H. Chung, R. Kozak, J. Kwong, D. Manuel, S. Mubareka, da N. Daneman, Nuna Manyan Bayanan Kiwon Lafiyar Jama'a don Mahimman Magungunan COVID-19: Nazarin Ƙungiyar Magungunan Magunguna (PWAS) na Gabaɗaya. Maris 2022, Bude Dandalin Cututtuka masu Yaduwa
Nazarin prophylaxis na HCQ: 12% ƙananan lokuta (p=0.01).
Komawa 26,121 lokuta da 2,369,020 sarrafawa ≥65yo a Kanada, suna nuna ƙananan lokuta tare da amfani na yau da kullun na HCQ. https://c19p.org/macfadden
138. A. Ahmed, W. Alotaibi, M. Aldubayan, A. Alhowail, A. Al-Najjar, S. Chigurupati, da R. Elgharabawy, Abubuwan da suka Shafi Faruwa, Ci gaba, da Tsananin COVID-19 a cikin Nau'in Ciwon sukari na 1 Nuwamba 2021, BioMed Research Int., Juzu'i na 2021, Shafi na 1-9
100 haƙuri HCQ nazarin prophylaxis: Ƙananan lokuta 99% (p=0.08).
Masu ciwon sukari na nau'in 1 na baya-bayan nan a Saudi Arabiya suna nuna raguwar haɗarin lokuta tare da rigakafin HCQ. https://c19p.org/ahmed2
139. K. Shaw, L. Yin, J. Shah, R. Sally, K. Svigos, P. Adotama, H. Tuan, J. Shapiro, R. Betensky, da K. Lo Siccoa, COVID-19 a cikin daidaikun mutane da aka bi da su tare da Long Term Hydroxychloroquine: Ƙwararren Ƙwararren Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararru 2021, J. Magunguna a cikin Dermatology, Juzu'i na 20, Fitowa ta 8, Shafi na 914-916
144 mai haƙuri HCQ prophylaxis nazarin PSM: Ƙananan lokuta 13% (p=0.006).
PSM na baya-bayan nan 144 marasa lafiya alopecia a cikin Amurka, suna nuna ƙarancin haɗarin COVID-19 tare da rigakafin HCQ. Babu ƙarin kari. https://c19p.org/shaw
140. M. Barry, N. Althabit, L. Akkielah, A. AlMohaya, M. Alotaibi, S. Alhasani, A. Aldrees, A. AlRajhi, A. AlHiji, F. Almajid, A. AlSharidi, F. Al-Shahrani, N. Alotaibi, da A. AlHetheel, Asibiti da Ma'aikatan Lafiya na COVID19 Asibitin Tuntuɓar MERS-CoV yayin Ƙulun Cutar Maris 2021, Int. J. Cututtuka masu Yaduwa, Juzu'i na 106, Shafi na 43-51
MAGANIN LAFIYA 605 mai haƙuri HCQ marigayi nazarin jiyya: 99% ƙananan mace-mace (p=0.6).
605 marasa lafiya a asibiti a Saudi Arabiya ba su nuna mace-mace tare da HCQ (majiyyata 6 kawai sun sami HCQ). https://c19p.org/barry
141. R. Guner, I. Hasanoglu, B. Kayaaslan, A. Aypak, E. Akinci, H. Bodur, F. Eser, A. Kaya Kalem, O. Kucuksahin, I. Ates, A. Bastug, Y. Tezer Tekce, Z. Bilgic, F. Gursoy, H. Akca, S. Izdes, H. H.Er. D. H. H. D. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. H. D. . Kilic, M. Cıvak, S. Aydogan, da T. Buzgan, Kwatanta Adadin Shigar ICU na Marasa lafiya marasa ƙarfi/Matsakaici na COVID-19 da aka yi musu magani da Hydroxychloroquine, Favipiravir, da Hydroxychloroquine da Favipiravir Disamba 2020, J. Kamuwa da Lafiyar Jama'a, Juzu'i na 14, Fitowa ta 3, Shafi na 365-370
MAGANIN LAFIYA 704 mai haƙuri HCQ marigayi nazarin jiyya: 77% ƙananan shigar da ICU (p=0.16).
Marasa lafiya 824 da ke asibiti a Turkiyya sun nuna ƙasa Shigar da ICU don HCQ vs. favipiravir. https://c19p.org/guner
142. M. Falcone. A. Rachele, B. Rubia, B. Pietro, B. Martina, B. Matteo, B. Giulia, C. Valeria, C. Nicoletta, C. Francesco, C. Alessandro, D. Alessandra, D. Massimiliano, F. Giovanna, G. Marco, M. Fabrizio, M. Alessandro M., M. Fabrizio, M. Alessandro M., M. Stefano, M. Palo M. Palo Elia, P. Naria, P. Simone, P. Chiara, R. Francesca, S. Maria, S. Massimiliano, da S. Stefano, Matsayin heparin maras nauyi a cikin marasa lafiya na asibiti tare da ciwon huhu na SARS-CoV-2: nazari mai yiwuwa. Nuwamba 2020, Bude Dandalin Cututtuka masu Yaduwa, Juzu'i na 7, Mas'ala ta 12
MAGANIN LAFIYA 315 mai haƙuri HCQ marigayi magani PSM binciken: 65% ƙananan mace-mace (p=0.2).
Binciken mai yiwuwa na 315 marasa lafiya na asibiti a Italiya yana nuna 65% ƙananan mace-mace tare da HCQ. Matsakaicin jinkirin jinkiri shine kwanaki 6 ga waɗanda suka tsira da kwanaki 6.5 ga waɗanda ba su tsira ba. Haɗarin dangi na mace-mace: RR 0.35, p = 0.2, ƙimar haɓaka ta dace da RR 0.75, p = 0.36, multivariate Cox regression RR 0.43, p <0.001, univariate Cox regression https://c19p.org/falcone
143. G. Boari, G. Chiarini, S. Bonetti, P. Malerba, G. Bianco, C. Faustini, F. Braglia-Orlandini, D. Turini, V. Guarinoni, M. Saottini, S. Viola, G. Ferrari-Toninelli, G. Pasini, C. Mascadri, B. Bosensini, C. Zamattini, C. Nardin, da D. Rizzoni, Abubuwan haɓakawa da masu hasashen sakamako a cikin marasa lafiya tare da COVID-19 da ciwon huhu da ke da alaƙa: nazarin ƙungiyoyin baya-bayan nan. Nuwamba 2020, Biosci. Rep., Juzu'i na 40, Mas'ala ta 12
MAGANIN LAFIYA 258 mai haƙuri HCQ nazarin jiyya na ƙarshen: 55% ƙananan mace-mace (p=0.001).
Marasa lafiya 258 na asibiti a Italiya suna nuna ƙarancin mace-mace tare da jiyya na HCQ, Hadarin dangi mara daidaituwa RR 0.455, p <0.001. Bayanai na cikin ƙarin bayani. https://c19p.org/boari
144. D. Águila-Gordo, J. Martínez-del Río, V. Mazoteras-Muñoz, M. Negreira-Caamaño, P. Nieto-Sandoval Martín de la Sierra, da J. Piqueras-Flores, mace-mace da abubuwan da ke da alaƙa a cikin tsofaffi da tsofaffi da yawa marasa lafiya marasa lafiya na numfashi COVID-19 Nuwamba 2020, Revista Española de Geriatría da Gerontología, Juzu'i na 56, Fitowa ta 5, Shafi na 259-267
MAGANIN LAFIYA 416 mai haƙuri HCQ marigayi nazarin jiyya: 67% ƙananan mace-mace (p=0.1).
67% ƙananan mace-mace tare da HCQ. Marasa lafiya tsofaffi 416 na baya a Spain suna nuna daidaitaccen haɗarin mace-mace na HCQ HR 0.33, p = 0.1. https://c19p.org/aguilagordo
145. E. Coll. Facundo, I. Lorenzo, Í. Yañez, C. Galeano, A. Roca, M. Cabello, M. Gómez-Bueno, M. García-Cosío, J. Graus, L. Lladó, A. De Pablo, C. Loinaz, B. Aguado, D. Hernández, da B. Domínguez-Gil, Covid-19 gwaninta a cikin transplant. Oktoba 2020, Amurka J. Dasawa, Juzu'i na 21, Fitowa ta 5, Shafi na 1825-1837
MAGANIN LAFIYA 635 mai haƙuri HCQ nazarin jiyya na ƙarshen: 46% ƙananan mace-mace (p <0.0001).
Marasa lafiya masu karɓa na 652 na baya-bayan nan a Spain suna nuna ƙarancin mace-mace 46% ga marasa lafiya da aka yi wa HCQ, Hadarin dangi mara daidaituwa RR 0.54, p <0.0001. https://c19p.org/coll
146. B. Grau-Pujol, D. Camprubí-Ferrer, H. Marti-Soler, M. Fernández-Pardos, C. Carreras-Abad, M. Andrés, E. Ferrer, M. Muelas-Fernandez, S. Jullien, G. Barilaro, S. Ajanovic, I. Godon, Vera, N Rez, N. Cortes-Serra, M. Roldán, A. Arcos, I. Mur. Satumba 2020, gwaji, juzu'i na 22, fitowa ta 1
269 mai haƙuri HCQ prophylaxis RCT: 11% ƙananan lokuta (p=1).
Ƙananan PrEP RCT yana nuna cewa PrEP tare da HCQ yana da lafiya a adadin da aka yi amfani da shi. Babu mace-mace, asibiti, ko munanan abubuwan da suka faru. Takardar ta ce: “Daga cikin dukkan mahalarta gwaji a ƙarshen watan farko (n=253), Mahalarta ɗaya ne kawai daga hannun placebo (1/116, 0.8%), an gwada inganci don SARS-CoV-2 PCR da kuma gwajin serology na SARS-CoV-2. Ƙididdigar ta bayyana: "Mai shiga cikin kowane rukuni ɗaya ne kawai aka kamu da COVID-19." https://c19p.org/graupujol
147. J. Berenguer, P. Ryan, J. Rodríguez-Baño, I. Jarrín, J. Carratalà, J. Pachón, M. Yllescas, J. Arriba, E. Aznar Muñoz, P. Gil Divasson, P. González Muñiz, C. Muñoz Aguirre, J. Rapez-S. F. Tejerina, T. Aldámiz-Echevarría, C. Díez, C. Fanciulli, L. Pérez-Latorre, F. Parras, P. Catalán, M. García-Leoni, I. Pérez-Tamayo, L. Puente, J. Cedeño, J. Berenguer. Vicente, E. Trigo Esteban, M. Lago Núñez, R. De Miguel Buckley, J. Cadiñaños Loidi, C. Busca Arenzana, A. Mican, M. Mora Rillo, J. Ramos Ramos, B. Loeches Yagüe, J. Bernardino de la Serna, J. García Rodríba, Álvéz, A. Alonso, E. Izquierdo García, J. Torres Macho, G. Cuevas Tascon, J. Troya García, B. Mestre Gómez, E. Jiménez González de Buitrago et al., Halaye da masu hasashen mutuwa tsakanin 4035 a jere a asibiti marasa lafiya a Spain tare da COVID-19 Agusta 2020, Clinical Microbiology da Kamuwa da cuta, Juzu'i na 26, Fitowa ta 11, Shafi na 1525-1536
MAGANIN LAFIYA 3,995 mai haƙuri HCQ nazarin jiyya na ƙarshen: 18% ƙananan mace-mace (p=0.0001).
Marasa lafiya na asibiti 4035 na baya a Spain suna nuna raguwar mace-mace tare da HCQ (bayani yana cikin ƙarin bayani). https://c19p.org/berenguer
148. K. Faíco-Filho, D. Conte, L. De Souza Luna, J. Carvalho, A. Perosa, da N. Bellei, Babu fa'idar hydroxychloroquine akan rage ɗaukar hoto na SARS-CoV-2 a cikin marasa lafiya marasa mahimmanci na asibiti tare da COVID-19 Yuni 2020, Braz J Microbiol, Juzu'i na 51, Fitowa ta 4, Shafi na 1765-1769
MAGANIN LAFIYA 66 mai haƙuri HCQ marigayi nazarin jiyya: 81% inganta ƙimar rage ƙwayar cuta (p=0.4).
Kwatancen nauyin hoto na hoto don 34 HCQ da marasa lafiya masu sarrafawa 32 da ke asibiti tare da matsakaicin COVID-19. Duk marasa lafiya sun dawo da iyakance ɗakin don tasiri masu amfani. Duk da yake ba a cimma mahimmancin ƙididdiga ba, sakamakon yana nuna saurin murmurewa tare da HCQ. Ana ganin mafi girman fa'ida a tsakiyar farfadowa kamar yadda ake tsammani don ingantaccen magani: Δt7-12: 81% haɓaka tare da HCQ Δt <7: 24% haɓaka tare da HCQ Don Δt>12, kowa ya warke don haka babu inda za a gyara. Tun da ƙungiyar HCQ ta fara dan kadan mafi girma haɓaka ya ɗan ragu kaɗan. Yawancin mahalarta kuma sun fice ta wannan gwajin, tare da saura 6 HCQ da sarrafawa 9 (kuma yana ba da shawarar marasa lafiya na HCQ sun murmure da sauri). https://c19p.org/faicofilho
149. J. Mathew, S. Jain, T. Susngi, S. Naidu, V. Dhir, A. Sharma, S. Jain, da S. Sharma, Masu tsinkayar tsananin COVID-19 da sakamako a cikin marasa lafiya na Indiya tare da cututtukan rheumatic: nazari na gaba mai zuwa Fabrairu 2023, Ci gaban Rheumatology a cikin Ayyuka, Juzu'i na 7, Mas'ala ta 1
64 mai haƙuri HCQ nazarin prophylaxis: 20% ƙananan mace-mace (p=0.8), babu canji a asibiti (p=0.94), da 40% ƙananan ƙananan lokuta (p=0.37).
Binciken da ake shirin yi na masu cutar rheumatic guda 64 tare da COVID-19, wanda ke nuna babu wani babban bambanci a sakamakon amfani da HCQ. https://c19p.org/mathew
150. R. AlSulaiman, S. Alqatari, A. Nemer, M. Hasan, R. Bukhari, R. Al Argan, D. Al Khafaji, A. Alwaheed, A. Alzaki, M. Al-wazza, S. Al Warthan, A. Al Saeed, F. Albeladi, H. Almeer, da A. Abu Quren, Saudi Arabia masu fama da cutar Corona a cikin masu fama da cutar Ista na Saudi Arabiya masu fama da cutar Corona. Mayu 2023, J. Magani da Rayuwa, Juzu'i na 16, Fitowa ta 6, Shafi na 873-882
34 mai haƙuri HCQ nazarin prophylaxis: 89% ƙananan samun iska (p=0.13), 64% ƙananan shigar da ICU (p=0.14), da 64% ƙananan lokuta (p=0.14).
Majiyoyin cutar rheumatological 34 da ke da COVID-19 a Saudi Arabiya, suna nunawa ƙananan haɗari na lokuta masu tsanani tare da amfani da HCQ a cikin sakamakon da ba daidai ba, ba tare da mahimmancin ƙididdiga ba. https://c19p.org/alqatari
151. V. Raabe, A. Fleming, M. Samanovic, L. Lai, H. Belli, M. Mulligan, da H. Belmont, Hydroxychloroquine pre-exposure prophylaxis don hana SARS-CoV-2 tsakanin ma'aikatan kiwon lafiya da ke cikin haɗari ga bayyanar SARS-CoV-2: Gwajin da ba a sarrafa shi ba. Yuli 2022, wannasura
130 mai haƙuri HCQ nazarin prophylaxis: 82% ƙananan lokuta na bayyanar cututtuka (p=0.17).
Ƙananan nazarin prophylaxis tare da ma'aikatan kiwon lafiya 130 a cikin Amurka, suna nuna ƙananan alamun bayyanar cututtuka tare da HCQ prophylaxis, ba tare da mahimmancin ƙididdiga ba. Mahalarta HCQ sun kasance manya sosai. Majinyacin HCQ kawai mai alamar alama ya ruwaito ciwon kai kawai azaman yuwuwar alamar COVID-19. https://c19p.org/raabe
152. N. Sawanpanyalert, R. Sirijatuphat, P. Sangsayunh, O. Putcharoen, W. Manosuthi, P. Intalapaporn, N. Palavutitotai, W. Samritmanoporn, N. Jitrungruengnij, A. Maleesatharn, K. Chokephaibulkit na maganin rigakafin cutar COVID-19, Ƙididdiga da ƙayyadaddun ƙa'idodin maganin rigakafin cutar COVID-XNUMX. kalaman farko a Thailand Satumba 2021, Kudu maso Gabashin Asiya J. Magungunan Tropical da Lafiyar Jama'a
MAGANIN FARKO Binciken farko na HCQ: 42% ƙananan ci gaba (p=0.37).
Majiyoyin asibiti na 744 na baya-bayan nan a Tailandia, suna nuna ƙarancin ƙarancin sakamako mara kyau don jiyya na favipiravir a cikin kwanaki 4 na alamun farko. Jiyya na farko tare da CQ / HCQ da lopinavir / ritonavir ko darunavir / ritonavir suma sun nuna ƙananan haɗari, amma ba tare da mahimmancin ƙididdiga ba. Ba a bayar da girman samfurin adadin majinyata da aka yi wa magani a cikin kwanaki 4 na bayyanar cututtuka ba. https://c19p.org/sawanpanyalert
153. B. Adama, P. Armel, C. Kadari, S. Apoline K, O. Boukary, O. Abdoul Risgou, T. Alfred B, K. Pierre, B. Brice W, Z. Jacques, S. Adama, F. Souleymane, K. Flavien, S. Adama, da K. Séni, Effectne da Chloroquicin a kan A. COVID-19 Farfadowa da Mutuwar Marasa lafiya: Shaida daga Asibiti An Gudanar da Nazarin Ƙungiya ta Juya a Burkina Faso Fabrairu 2021, J. Cututtuka masu Yaduwa da Epidemiology, Juzu'i na 7, Mas'ala ta 2
MAGANIN LAFIYA 208 mai haƙuri HCQ marigayi nazarin jiyya: 44% ƙananan mace-mace (p=0.14) da 3% inganta farfadowa (p=0.91).
A baya-bayan nan 208 marasa lafiya COVID-19 da ke asibiti a Burkina Faso suna nuna ƙarancin mace-mace tare da jiyya na HCQ/CQ+AZ, ba tare da ma'anar ƙididdiga ba. Babu bambanci don murmurewa. https://c19p.org/baguiya
154. G. Lano, A. Braconnier, S. Bataille, G. Cavaille, J. Moussi-Frances, B. Gondouin, P. Bindi, M. Nakhla, J. Mansour, P. Halin, B. Levy, E. Canivet, K. Gaha, I. Kazes, N. Noel, A. Wynckel, A. Wynckel, A. Moal, R. Vial, V. Scarfoglière, M. Bobot, M. Gully, T. Legris, M. Pelletier, M. Sallee, S. Burtey, P. Brunet, T. Robert, da P. Rieu, Abubuwan haɗari ga tsananin COVID-19 a cikin marasa lafiya na dialysis na yau da kullun daga ƙungiyar Faransawa da yawa. Oktoba 2020, Clinical Kidney J., Oktoba 2020, 878-888, Juzu'i na 13, Fitowa ta 5, Shafi na 878-888
MAGANIN LAFIYA 122 mai haƙuri HCQ marigayi nazarin jiyya: 33% ƙananan mace-mace (p=0.28) da 39% ƙananan mace-mace / shigar da ICU (p=0.23).
33% ƙananan mace-mace tare da HCQ+AZ, p=0.28. Marasa lafiya dialysis na Faransa 122 na baya. 69% ƙananan haɗe-haɗe mace-mace/ICU, p=0.11, don rukunin rukunin baya buƙatar O2 akan ganewar asali (jiyya kaɗan kaɗan). https://c19p.org/lano
155. J. Nachega, D. Ishoso, J. Otokoye, M. Hermans, R. Machekano, N. Sam-Agudu, C. Bongo-Pasi Nswe, P. Mbala-Kingebeni, J. Madinga, S. Mukendi, M. Kolié, E. Nkwembe, G. Mbuyi, J. Nsio, T. Nsioshi, T. Nsioshi, T. Nsioshi, T. Nsio, T. Nsioshi, D. Nsio, D. Nsio, D. Nsio, D. Nsio, D. Nsio, D. Nsio, S. Ahuka-Mundeke, J. Muyembe-Tamfum, L. Mofenson, G. Smith, E. Mills, J. Mellors, A. Zumla, D. Mavungu Landu, da J. Kayembe, Halayen Asibiti da Sakamakon Marasa lafiya da aka kwantar da Asibiti don COVID-19 a Afirka: Farko Daga Jamhuriyar Demokradiyyar Kongo Oktoba 2020, The American J. Tropical Medicine da Tsafta, Juzu'i na 103, Fitowa ta 6, Shafi na 2419-2428
MAGANIN LAFIYA 766 mai haƙuri HCQ marigayi nazarin jiyya: 28% ƙananan mace-mace (p=0.17) da 26% mafi girma (p=0.13).
A baya-bayan nan 766 marasa lafiya na asibiti a DRC suna nuna mace-mace daga 29% zuwa 11%, kuma haɓakawa a cikin kwanaki 30 ya karu daga 65% zuwa 84%. Mutuwa cox regression gyara haɗari rabo aHR 0.26, p <0.001 Hadarin ba tare da inganta daidaita daidaito rabo 0.28, p <0.001 Yin amfani da gefe na tsarin nazari nazarin wadannan kasada sun zama: Mutuwar MSM daidaita daidaito rabo daidaita daidaito rabo 0.65, p0.166 0.65. Hadarin rashin ci gaba MSM daidaita daidaiton rabo daidaita daidaiton rabo = 0.132, p = 46 Tsakanin shekaru 630, XNUMX da aka yi wa magani tare da CQ+AZ. https://c19p.org/nachega
156. B. Kirenga, W. Muttamba, A. Kayongo, C. Nsereko, T. Siddharthan, J. Lusiba, L. Mugenyi, R. Byanyima, W. Worodria, F. Nakwagala, R. Nantanda, I. Kimuli, W. Katagira, B. Bagaya, E. Nasinghe, Rukamu A. Aange, H. A. Sekibira, E. Buregyeya, N. Kiwanuka, M. Muwanga, S. Kalungi, M. Joloba, D. Kateete, B. Byarugaba, M. Kamya, H. Mwebesa, da W. Bazeyo, Halaye da sakamakon shigar marasa lafiya da suka kamu da SARS-CoV-2 a Uganda Satumba 2020, BMJ Budaddiyar Binciken Numfashi, Juzu'i na 7, fitowa ta 1, Shafi na e000646
56 mai haƙuri HCQ binciken farko na jiyya: 26% farfadowa da sauri (p=0.2).
Marasa lafiya na 56 masu zuwa a Uganda, 29 HCQ da kulawar 27, suna nuna 25.6% saurin dawowa tare da HCQ, 6.4 vs. 8.6 kwanaki (p = 0.20). Babu shigar ICU, iskar inji, ko mutuwa. Ba a ƙayyade jinkirin magani ba amma aƙalla wani ɓangare na marasa lafiya ya bayyana cewa an yi musu magani da wuri. https://c19p.org/kirenga
157. P. Byakika-Kibwika, C. Sekaggya-Wiltshire, J. Semakula, J. Nakibuuka, J. Musaazi, J. Kayima, C. Sendagire, D. Meya, B. Kirenga, S. Nanzigu, A. Kwizera, F. Nakwagala, I. Kisuule, M. Wayewzeya, H. Amintacciya da Ingantaccen Hydroxychloroquine don Maganin COVID-19 mara ƙarfi a cikin Manya a Uganda: Tsarin Buɗaɗɗen Lakabi na Mataki na II na gwaji na asibiti Yuni 2021, Dandalin bincike
MAGANIN LAFIYA 105 mai haƙuri HCQ marigayi jiyya RCT: babu canji a farfadowa (p=0.91) da 29% inganta ƙwayar cuta (p=0.47).
Ƙananan RCT mai haƙuri na 105 a Uganda yana nuna babu bambanci. Ba a bayar da rahoton mace-mace ba. Marasa lafiya sun kasance ƙanana (tsakiyar shekaru 32), suna murmurewa a cikin tsaka-tsaki na kwanaki 3 tare da daidaitaccen kulawa, barin ƙaramin ɗaki don magani don yin gyare-gyare. Ba a kayyade lokacin da alamun bayyanar ba, amma rarraba bayyanar cututtuka a asali yana nuna cewa yin rajista ya yi jinkiri a cikin ƙungiyar marasa lafiya marasa haɗari. https://c19p.org/byakikakibwika
158. S. Budhiraja, A. Soni, V. Jha, A. Indrayan, A. Dewan, O. Singh, Y. Singh, I. Chugh, V. Arora, R. Pande, A. Ansari, da S. Jha, Bayanan Clinical na Farko na 1000 COVID-19 da aka yarda da su a Asibitocin Kula da Lafiya na Indiya da Mahimmancin Halin su. Nuwamba 2020, wannasura
MAGANIN LAFIYA 976 mai haƙuri HCQ nazarin jiyya na ƙarshen: 65% ƙananan mace-mace (p <0.0001).
Marasa lafiya na asibiti na 976 na baya-bayan nan tare da 834 da aka bi da su tare da HCQ+AZ suna nuna haɗarin mutuwar HCQ RR 0.35, p <0.0001. Lura cewa a cikin wannan yanayin an ba da shawarar HCQ don lokuta masu sauƙi/matsakaici, don haka mafi tsanani lokuta ƙila ba su sami HCQ ba (wanda kuma yana iya zama dalilin da ya sa suka zama lokuta masu tsanani). Mun lura cewa wannan ya saba wa son rai gama gari a cikin karatun HCQ - a yawancin lokuta an fi ba da HCQ ga lokuta masu tsanani. https://c19p.org/budhiraja
159. A. Aparisi, C. Iglesias-Echeverría, C. Ybarra-Falcón, I. Cusácovich, A. Uribarri, M. García-Gómez, R. Ladrón, R. Fuertes, J. Candela, W. Hinojosa, C. Dueñas, R. González, D. Noga-Mogales, Carra J. Román, I. Amat-Santos, da D. Andaluz-Ojeda, ƙananan ƙwayoyin lipoprotein cholesterol suna da alaƙa da mummunan sakamakon asibiti a cikin COVID-19 Oktoba 2020, wannasura
MAGANIN LAFIYA 654 mai haƙuri HCQ nazarin jiyya na ƙarshen: 63% ƙananan mace-mace (p=0.008).
Marasa lafiya na asibiti na 654 na baya sun mayar da hankali kan ƙananan matakan cholesterol na jini, kuma suna nuna sakamako ga HCQ tare da marasa lafiya na 605 HCQ, ƙarancin mutuwar kwanaki 30 da ba a daidaita ba RR 0.37, p = 0.008. https://c19p.org/aparisi
160. Belmont et al., COVID-19 PrEP HCW Nazarin HCQ Oktoba 2021, ClinicalTrials.gov, NCT04354870
80 mai haƙuri HCQ nazarin prophylaxis: 79% ƙananan lokuta na bayyanar cututtuka (p=0.21).
Nazarin mai yiwuwa na HCQ prophylaxis a cikin Amurka, tare da 56 HCQ marasa lafiya da 24 masu kula da marasa lafiya, ba tare da nuna bambanci ba. Saukewa: NCT04354870 https://c19p.org/belmont
161. M. Agarwal, R. Ranka, P. Panda, A. Kumar, G. Chikara, S. Sharma, R. Negi, R. Samanta, R. Walia, Y. Bahurupi, S. Saha, M. Dhar, P. Sharma, A. Gupta, U. Mishra, M. Gupta, da R. Kant, Low dose hydroxychloroquine prospective prophylaxis covid-19. Satumba 2021, medRxiv
484 mai haƙuri HCQ nazarin prophylaxis: 27% ƙananan ci gaba (p=0.21) da 5% ƙarin lokuta (p=0.81).
Ƙananan gwaji na prophylaxis tare da ƙananan kashi 29 na HCQ da 455 masu kula da ma'aikatan kiwon lafiya a Indiya, ba tare da nuna bambancin ƙididdiga ba. https://c19p.org/agarwal2
162. C. Scirocco, S. Ferrigno, L. Andreoli, M. Fredi, C. Lomater, L. Moroni, M. Mosca, B. Raffeiner, G. Carrara, G. Landolfi, D. Rozza, A. Zanetti, C. Scirè, da G. Sebastiani, COVID-19 tsinkayar amosanin gabbai da kuma tsarin lupus idan aka kwatanta da tsarin lupus. spondyloarthritis: Sakamako daga Nazarin CONTROL-19 na Ƙungiyar Italiyanci don Rheumatology Oct 2023, Lupus Science & Medicine, juzu'i na 10, fitowa ta 2, shafi e000945
627 mai haƙuri HCQ nazarin prophylaxis: 41% ƙananan haɗewar mace-mace / intubation (p=0.38).
A baya-bayan nan 103 SLE da 524 RA marasa lafiya a Italiya, suna nuna ƙananan mace-mace / samun iska tare da amfani da HCQ ga marasa lafiya na SLE, kuma babu wani bambanci ga marasa lafiya na RA a sakamakon da ba a daidaita ba. Marubuta ba su haɗa da HCQ a cikin bincike mai yawa ba, kawai gami da masu canji guda huɗu “wanda aka zaɓa daga cikin mafi dacewa a asibiti.” Bincike mai yawa na iya inganta sakamako mai mahimmanci ga marasa lafiya na RA saboda amfani da HCQ na iya daidaitawa tare da cututtuka mafi tsanani saboda amfani da marasa lafiya da suka kasa ko kuma ba su yarda da hanyoyin kwantar da hankali na farko ba. Ba a bayyana yadda aka zaɓi marasa lafiya ba - mafi girma ~ 25% samun iska / mace-mace ya nuna cewa yawancin an kwantar da marasa lafiya na COVID-19 a asibiti, wanda a cikin haka duk wani fa'idar HCQ na rage asibitocin ba zai bayyana a cikin sakamakon ba. Marubuta sun yi ƙarya cewa "nazarin da suka biyo baya sun tabbatar da cewa [HCQ] ba shi da alaƙa da hasashen COVID-19", yana ba da shawara mai mahimmanci, kuma yana iya nuna dalilin da ya sa aka cire HCQ a cikin sakamakon da aka ruwaito. Duk da yake irin wannan mummunan bayani yana da ma'ana bisa ga shaidar da aka samu don jinkirin mataki mai girma, nazarin jiyya na farko da rigakafin ba su dace ba. A gaskiya ma,% na duk nazarin yana nuna sakamako mai kyau, kuma% na farkon magani da% na nazarin prophylaxis yana nuna sakamako mai kyau. Binciken da aka sarrafa yana nuna sakamako mai mahimmanci na ƙididdiga don sakamako ɗaya ko fiye (ciki har da RCTs). https://c19p.org/scirocco
163. P. Sen, N.R, A. Nune, J. Day, M. Joshi, V. Agarwal, R. Aggarwal, da L. Gupta, yanayin Post-COVID-19 a cikin marasa lafiya da cututtukan rheumatic autoimmune: Nazarin COVID-19 a cikin Cututtukan Autoimmune (COVAD) Afrilu 2023, Lancet Rheumatology, Juzu'i na 5, fitowa ta 5, Shafi e247-e250
HCQ dogon nazarin COVID: 40% ƙananan PASC (p=0.08).
Na baya-bayan nan 755 marasa lafiya na rheumatic autoimmune, suna nuna ƙananan haɗarin PASC (dogon COVID) tare da amfani da HCQ, ba tare da mahimmancin ƙididdiga ba. https://c19p.org/sen2
164. A. Krishnan, R. Kumar, R. Amarchand, A. Mohan, R. Kant, A. Agarwal, P. Kulshreshtha, P. Panda, A. Bhadoria, N. Agarwal, B. Biswas, R. Nair, N. Wig, R. Malhotra, S. Bhatnagar, R. Aggarwal, K. Singh. Solanki, B. Rathod, V. Dutta, P. Mohapatra, M. Panigrahi, S. Barik, da R. Guleria, Masu Hasashen Mutuwa tsakanin Marasa lafiya da aka kwantar da Asibiti tare da COVID-19 yayin Wave na Farko a Indiya: Nazarin Gudanar da Harka na Multisite Afrilu 2023, The American J. Tropical Medicine and Hygiene, Juzu'i na 108, fitowa ta 4, Shafi na 727-733
MAGANIN LAFIYA 2,431 mai haƙuri HCQ nazarin jiyya na ƙarshen: 40% ƙananan mace-mace (p=0.05).
Nazarin kula da shari'a tare da marasa lafiya 2,431 na asibiti COVID-19 a Indiya, suna nuna ƙarancin mace-mace tare da jiyya na HCQ, ba tare da mahimmancin ƙididdiga ba. https://c19p.org/krishnan2
165. A. Aweimer. El-Battrawy, da A. Mügge, Adadin mace-mace na mummunar gazawar numfashi da ke da alaƙa da COVID-19 tare da kuma ba tare da iskar oxygenation ba a yankin Ruhr ta Tsakiya na Jamus. Mar 2023, Rahoton Kimiyya, Juzu'i na 13, fitowa ta 1
MAGANIN LAFIYA 149 mai haƙuri HCQ ICU binciken: 40% ƙananan mace-mace (p=0.12).
Marasa lafiya na 149 na baya-bayan nan a ƙarƙashin iskar injuna na inji a cikin Jamus suna nuna babu wani bambanci mai mahimmanci a cikin mace-mace tare da HCQ a cikin sakamakon da ba a daidaita ba. https://c19p.org/aweimerh
166. K. Chevalier, M. Genin, T. Jean, J. Avouac, R. Flipo, S. Georgin-Lavialle, S. El Mahou, E. Pertuiset, T. Pham, A. Servettaz, H. Marotte, F. Domont, P. Chazerain, M. Devaux, A. Mekinian, J. E. N. Costedoat-Chalumeau, C. Richez, E. Hachulla, X. Mariette, da R. Seror, CovAID: Gano abubuwan da ke da alaƙa da COVID-19 mai tsanani a cikin marasa lafiya tare da rheumatism mai kumburi ko cututtuka na autoimmune Mar 2023, Gaba a Magunguna, Juzu'i na 10
1,213 mai haƙuri HCQ nazarin prophylaxis: 35% ƙananan mace-mace (p=0.19) da 19% ƙananan asibiti (p=0.36).
Marasa lafiya na rheumatic 1,213 na baya-bayan nan a Faransa, suna nuna ƙarancin haɗarin mace-mace da lokuta masu tsanani tare da amfani da HCQ a cikin bincike na univariate, ba tare da mahimmancin ƙididdiga ba. https://c19p.org/chevalier
167. M. Opdam, S. Benoy, L. Verhoef, S. Van Bijnen, F. Lamers-Karnebeek, R. Traksel, P. Vos, A. Den Broeder, da J. Broen, Gano Abubuwan Haɗari don COVID-19 Asibiti a cikin Marasa lafiya tare da Magungunan Magungunan Rheumatic: Sakamako Na Farko Feb 2022, Clinical Pharmacology & Therapeutics
477 mai haƙuri HCQ nazarin prophylaxis: 45% ƙananan asibiti (p=0.18).
Abubuwan da suka faru na 81 da kuma 396 masu sarrafawa a tsakanin marasa lafiya na rheumatic a cikin Netherlands, suna nuna ƙananan haɗarin asibiti tare da HCQ prophylaxis, ba tare da mahimmancin ƙididdiga ba. https://c19p.org/opdam
168. R. Cordtz, S. Kristensen, L. Dalgaard, R. Westermann, K. Duch, J. Lindhardsen, C. Torp-Pedersen, da L. Dreyer, Abubuwan da suka faru na COVID-19 Asibiti a cikin Marasa lafiya tare da Lupus Erythematosus Systemic: Nazarin Ƙungiyar Ƙasa ta Ƙasa daga Denmark Agusta 2021, J. Magungunan asibiti, juzu'i na 10, fitowa ta 17, shafi na 3842
2,533 mai haƙuri HCQ nazarin prophylaxis: 40% ƙananan asibiti (p=0.39).
Marasa lafiya 2,533 na SLE na baya-bayan nan a Denmark ba su nuna wani babban bambanci a haɗarin asibiti don shari'o'in COVID-19 tare da jiyya na HCQ. https://c19p.org/cordtz2
169. Q. Li, C. Cui, F. Xu, J. Zhao, N. Li, H. Li, T. Wang, H. Zhang, N. Liu, Y. Wei, X. Niu, Y. Xu, J. Dong, X. Yao, X. Wang, Y. Chen, H. Li, C. Song, J. Qiao, D. na Shen, da Eva N da aminci, da Eva N. hydroxychloroquine idan aka kwatanta da chloroquine a cikin matsakaici da matsananciyar marasa lafiya tare da COVID-19 Jan 2021, Kimiyyar Rayuwar Kimiya ta Kasar Sin, juzu'i na 64, fitowa ta 4, Shafi na 660-663
MAGANIN LAFIYA 28 mai haƙuri HCQ marigayi nazarin jiyya: 50% mafi girma fitarwa na asibiti (p=0.09).
Ƙananan RCT yana kwatanta HCQ da CQ a China tare da 88 mataki sosai (kwanaki 17.6 daga farkon zuwa asibiti da ~ 10 kwanaki zuwa bazuwar) marasa lafiya. Sakamakon farko na asibiti (lokacin zuwa farfadowa na asibiti da kuma lokacin inganta aikin asibiti) ba su da bambanci sosai. Mawallafa sun lura cewa HCQ na iya samun ƙarin tasiri mai tasiri a cikin tsarin tsarin rigakafi, wanda aka nuna ta hanyar raguwar ferritin a cikin matsakaicin matsakaici da haɓaka ƙimar CT da ƙididdigar lymphocyte a cikin lokuta masu tsanani. An yi haƙuri da HCQ da CQ da kyau. Har ila yau, mawallafa suna kwatanta marasa lafiya na RCT zuwa samfurin da ya dace da marasa lafiya na RCT a cikin asibiti guda ɗaya, suna nuna ɗan gajeren lokaci don fitarwa tare da CQ / HCQ, amma ba ƙididdiga ba saboda ƙananan girman. https://c19p.org/li3
170. J. Matangila, R. Nyembu, G. Telo, C. Ngoy, T. Sakobo, J. Massolo, B. Muyembe, R. Mvwala, C. Ilunga, E. Limbole, J. Ntalaja, da R. Kongo, Siffofin asibiti na marasa lafiya na COVID-19 da aka kwantar da su a asibiti a Clinique Ngaliema, asibitin jama'a a Jamhuriyar Demokradiyyar Kongo a Kinsha. Dec 2020, PLoS DAYA, Juzu'i na 15, fitowa ta 12, Shafi e0244272
MAGANIN LAFIYA 160 mai haƙuri HCQ marigayi nazarin jiyya: 55% ƙananan mace-mace (p=0.21).
55% ƙananan mutuwa tare da HCQ+AZ. A baya-bayan nan 160 marasa lafiya na asibiti a Jamhuriyar Demokradiyyar Kongo, 92% suna karɓar HCQ+AZ, suna nuna gyara KO 0.24 [0.03-2.2]. https://c19p.org/matangila
171. S. Ozturk. Dolarslan S. Bakirdogen Kazancioglu, A. Oruc, E. Yuksel, E. Onan, K. Turkmen, N. Hasbal, A. Gurel, B. Yelken, T. Sahutoglu, M. Gok, N. Seyahi et al. Dec 2020, Nephrology Dialysis Transplantation, juzu'i na 35, fitowa ta 12, Shafi na 2083-2095
MAGANIN LAFIYA 1,150 mai haƙuri HCQ marigayi nazarin jiyya: 44% ƙananan mace-mace (p=0.14).
A baya bayan nan 1210 marasa lafiya da ke kwance a asibiti a Turkiyya sun mayar da hankali kan cututtukan koda, hemodialysis da masu dashen koda, amma kuma sun nuna. ƙananan mace-mace tare da HCQ. Batun ruɗarwa ta hanyar nuni. https://c19p.org/ozturk
172. G. Serrano, J. Rogado, C. Pangua, B. Obispo, A. Martin Marino, M. Perez-Perez, A. Lopez-Alfonso, da M. Lara, COVID-19 da kansar huhu: Menene muka sani? Satumba 2020, Ann. Oncol., 2020, Satumba, 31, S1026, juzu'i na 31, Shafi S1026
MAGANIN LAFIYA 22 mai haƙuri HCQ marigayi nazarin jiyya: 43% ƙananan mace-mace (p=0.15).
Ƙananan binciken da aka yi na baya-bayan nan na marasa lafiya na huhu na 22, 14 da aka bi da su tare da HCQ + AZ, yana nuna haɗarin mutuwar HCQ + AZ RR 0.57, p = 0.145. https://c19p.org/serrano
173. G. Bousquet. Jun 2020, Tsufa, 11306-11313, juzu'i na 12, fitowa ta 12, Shafi na 11306-11313
MAGANIN LAFIYA 108 mai haƙuri HCQ marigayi nazarin jiyya: 43% ƙananan mace-mace (p=0.15).
Masu lura da marasa lafiya na asibiti 108 da ke da shekaru 65 da haihuwa, suna nuna mutuwar HCQ KO 0.49, p = 0.15. https://c19p.org/bousquet
174. F. Fontana, F. Giaroni, M. Frisina, G. Alfano, G. Mori, L. Lucchi, R. Magistroni, da G. Cappelli, SARS-CoV-2 kamuwa da cuta a cikin marasa lafiya na dialysis a arewacin Italiya: gwaninta guda ɗaya. Juni 2020, Clinical Kidney J., 334–339
MAGANIN LAFIYA 15 mai haƙuri HCQ marigayi nazarin jiyya: 50% ƙananan mace-mace (p=0.53).
Ƙananan binciken lura da marasa lafiya 15 na dialysis yana nuna mace-macen HCQ RR 0.50, p = 0.53. https://c19p.org/fontana
175. F. Alberici, E. Delbarba, C. Manenti, L. Econimo, F. Valerio, A. Pola, C. Maffei, S. Possenti, B. Lucca, R. Cortinovis, V. Terlizzi, M. Zappa, C. Saccà, E. Pezzini, E. Calcaterra, P. Piaruni, F. Boeri A. Guerio, Gallic. Mucchetti, S. Affatato, S. Bove, M. Bracchi, E. Costantino, R. Zubani, C. Camerini, P. Gaggia, E. Movilli, N. Bossini, M. Gaggiotti, da F. Scolari, Rahoton daga Brescia Renal COVID Task Force game da halayen asibiti da kuma sakamakon gajeren lokaci marasa lafiya na SARS-Codialysis na hemo-Codialysis. Mayu 2020, Kidney Int., 20-26, Yuli 1, 2020, Juzu'i na 98, Fitowa ta 1, Shafi na 20-26
MAGANIN LAFIYA 94 mai haƙuri HCQ marigayi nazarin jiyya: 43% ƙananan mace-mace (p=0.12).
Binciken hemodialysis 94 masu inganci COVID-19, yana nuna ƙarancin mace-mace tare da jiyya na HCQ, rashin kai ma'anar ƙididdiga. https://c19p.org/alberici
176. J. Frontera, J. Rahimian, S. Yaghi, M. Liu, A. Lewis, A. Havenon, S. Mainali, J. Huang, E. Scher, T. Wisniewski, A. Troxel, S. Meropol, L. Balcer, da S. Galetta, Jiyya tare da Zinc yana Haɗe tare da Rage Mutuwar Mutuwar 19 Daga cikin Cibiyoyin Ciki na COVID-XNUMX Nazarin Ƙungiya Oct 2020, Dandalin Bincike
MAGANIN LAFIYA 3,473 mai haƙuri HCQ marigayi magani PSM binciken: 37% ƙananan mace-mace (p=0.02).
Marasa lafiya na asibiti 3,473 na baya bayan nan suna nuna ƙarancin mace-mace tare da HCQ+ zinc. https://c19p.org/frontera
177. A. Omma, A. Erden, H. Apaydin, M. Aslan, H. Çamlı, E. Şahiner, S. Güven, B. Armağan, S. Karaahmetoğlu, I. Ates da O. Kucuksahin Jan 2022, Kamuwar J. a Ƙasashe Masu tasowa, Juzu'i na 16, Fitowa ta 01, Shafi na 25-31
MAGANIN LAFIYA 393 mai haƙuri HCQ marigayi nazarin jiyya: 28% ƙananan mace-mace (p=0.3), 50% ƙananan shigar da ICU (p=0.004), da 17% guntu asibiti (p=0.007).
An dawo da marasa lafiya 393 na COVID-19 a asibiti a Turkiyya, suna nuna ƙarancin shigar ICU da ɗan gajeren lokacin asibiti tare da HCQ. Babu wani gagarumin bambanci ga mace-mace. Tsanani ya kasance mafi girma a cikin ƙungiyar HCQ tare da mafi girman samun iska, babban iskar oxygen, zazzabi, da dyspnea. https://c19p.org/omma
178. A. Patil, C.K, P. Shenoy, C. S, V. Haridas, S. Kumar, M. Daware, R. Janardana, B. Pinto, R. Subramaniam, N. S, Y. Singh, S. Singhai, R. Jois, V. Jain, S. C, B. Dharmanand, C. Dharmapalaiah, V. Shopete, S. KNha, da kuma Pro. Nazari Na Tsawon Jiki Yana Ƙimar Tasirin Magungunan rigakafi da sauran Abubuwa akan COVID-19 a cikin Cututtukan Rheumatic Autoimmune Agusta 2021, Dandalin Bincike
9,212 mai haƙuri HCQ nazarin prophylaxis: 66% ƙananan mace-mace (p=0.1) da 9% ƙananan lokuta (p=0.43).
Nazarin mai yiwuwa na 9,212 marasa lafiya na rheumatic marasa lafiya da ke nuna ƙananan mace-mace tare da HCQ, ba tare da kai ga mahimmancin ƙididdiga ba. Marubuta ba daidai ba sun faɗi “amfani da HCQ bai yi tasiri a kan abin da ya faru na COVID-19 ba (RR = 0.909, CI (0.715,1.154), p = 0.432) ko mace-mace (p = 0.097)." Adadin mace-macen ga marasa lafiya na rheumatic autoimmune ya ninka sau 4.6 fiye da na yawan jama'a daga yanki ɗaya.. https://c19p.org/patil
179. R. Mehrizi, A. Golestani, M. Malekpour, H. Karami, M. Nasehi, M. Effatpanah, H. Ranjbaran, Z. Shahali, A. Sari, da R. Daroudi, Tsarin rubutun magunguna da haɗin gwiwa tare da mace-mace da lokacin asibiti a cikin marasa lafiya na COVID-19: fahimta daga manyan bayanai Dec 2023, Gaba a Kiwon Lafiyar Jama'a, juzu'i na 11
MAGANIN LAFIYA 917,198 mai haƙuri HCQ nazarin jiyya na ƙarshen: 26% ƙananan mace-mace (p <0.0001).
Binciken baya-bayan nan na 917,198 na asibiti COVID-19 na COVID-26 wanda Hukumar Inshorar Lafiya ta Iran ta rufe sama da watanni XNUMX yana nuna cewa antithrombotics, corticosteroids, da antiviral sun rage mace-mace yayin da diuretics, maganin rigakafi, da masu ciwon sukari suka karu. Ruɗewa yana sa wasu sakamako ba su da aminci sosai. Alal misali, ana amfani da diuretics kamar furosemide don magance nauyin ruwa, wanda ya fi dacewa a cikin ICU ko ci gaba da cutar da ke buƙatar farfadowa mai tsanani. Tsawon asibiti ya karu da haɗari mai mahimmanci, misali tsayin daka a asibiti yana kara damar samun magani, kuma mutuwa na iya haifar da gajeriyar asibiti. Sakamakon mace-mace na iya zama abin dogaro. Rashin rudani ta hanyar nuni yana iya zama mahimmanci ga magunguna da yawa. Mawallafa gyare-gyare suna da taƙaitaccen bayanin tsanani (nau'in shigar da shi yana nufin ward vs. ER sashen a farkon isowa). Za mu iya ƙididdige tasirin rikicewa daga tsarin amfani na yau da kullun, mitar takardar sayan magani, da ragewa ko haɓaka haɗari ga ICU vs. duk marasa lafiya. Ga HCQ, mai yiwuwa an mai da hankali kan amfani da wuri a cikin bala'in cutar, amma in mun gwada da iri ɗaya a cikin tsananin majinyata na Iran da ke asibiti. Rashin rikicewa ta lokaci zai zama babban batu, tare da amfani da mayar da hankali a lokacin farkon lokacin tare da yawan mace-mace, duk da haka mawallafa sun daidaita ta hanyar shigar da watan, suna ba da shawarar cewa saura rikicewar ƙila ba zai canza sakamakon ba sosai. C19early.com ya lura cewa daidaitawa yayi daidai da abin da ake tsammanin rikicewa ta lokaci. https://c19p.org/mehrizi
180. J. Gómez, L. Pérez-Belmonte, M. Rubio-Rivas, J. Bascuñana, R. Quirós-López, M. Martínez, E. Hernandez, F. Roque-Rojas, M. Méndez-Bailón, da R. Gómez-Huelgas, marasa lafiya da cututtuka na SARS da hadarin mutuwa a cikin abubuwan da ke haifar da mutuwa. daga SEMI-COVID-2 rajista Oktoba 2022, Medicina Clínica
MAGANIN LAFIYA 1,799 mai haƙuri HCQ nazarin jiyya na ƙarshen: 36% ƙananan mace-mace (p <0.0001).
A baya-bayan nan 1,799 marasa lafiya na COVID-19 da ke asibiti tare da fibrillation a Spain, suna nuna ƙarancin mace-mace tare da jiyya na HCQ a cikin sakamakon da ba a daidaita ba. https://c19p.org/gomez
181. R. Rubio-Sánchez, E. Lepe-Balsalobre, da M. Viloria-Peñas, Abubuwan da ake iya ganowa don tsananin cutar SARS-CoV-2 Maris 2021, Ci gaba a Magungunan Laboratory / Avances en Medicina de Laboratorio, Juzu'i na 2, fitowa ta 2, Shafi na 253-258
MAGANIN LAFIYA 197 mai haƙuri HCQ nazarin jiyya na ƙarshen: 40% ƙananan lokuta masu tsanani (p=0.02).
A baya-bayan nan 197 marasa lafiya na COVID-19 na asibiti a Spain, suna nuna ƙananan ci gaba zuwa ciwon huhu tare da HCQ a cikin sakamakon da ba a daidaita ba. https://c19p.org/rubiosanchez
182. . Yuli 2022, medRxiv
11,468 haƙuri HCQ nazarin prophylaxis: Ƙananan lokuta 46% (p=0.001).
A baya-bayan nan 11,468 masu cutar rheumatic da aka yi wa allurar rigakafi a cikin Amurka, suna nuna ƙarancin haɗarin COVID-19 tare da amfani da HCQ/CQ idan aka kwatanta da duk sauran jiyya. Ana ba da ingantaccen sakamako dangane da takamaiman wasu jiyya kawai. https://c19p.org/patel4
183. C. Hernandez-Cardenas, I. Thirion-Romero, N. Rivera-Martinez, P. Meza-Meneses, A. Remigio-Luna, da R. Perez-Padilla, Hydroxychloroquine don maganin kamuwa da cututtukan numfashi mai tsanani ta COVID-19: gwajin da bazuwar sarrafawa Fabrairu 2021, medRxiv
MAGANIN LAFIYA 214 mai haƙuri HCQ marigayi magani RCT: 12% ƙananan mace-mace (p=0.66).
Matsayin marigayi RCT tare da marasa lafiya 214, yana nufin SpO2 65%, 162 akan iskar inji, yana nuna babu wani bambanci mai mahimmanci a cikin mace-mace. Marasa lafiya da ba a shigar da su ba a asali suna nuna haɓaka mafi girma, HR 0.43 [0.09-2.03]. Tebur na 4 yana nuna sakamako daban-daban ga taƙaitaccen bayanin - tebur 4 gyara HR 0.80 [0.51-1.23], m HR 0.88 [0.51-1.53]. Babu wani bambanci mai mahimmanci a cikin mummunan al'amura marasa kyau. https://c19p.org/hernandezcardenas
184. N. Bernaola, R. Mena, A. Bernaola, C. Carballo, A. Lara, C. Bielza, da P. Larrañaga, Nazarin Dubawa na Ingantacciyar Jiyya a cikin Marasa lafiya da ke Asibiti tare da Covid-19 a Madrid Yuli 2020, medRxiv
MAGANIN LAFIYA 1,645 mai haƙuri HCQ nazarin jiyya na ƙarshen: 17% ƙananan mace-mace (p <0.0001).
HCQ HR 0.83 [0.77-0.89] bisa la'akari da ƙima ya dace da bincike na baya na 1,645 marasa lafiya na asibiti. Prednisone HR 0.85 [0.82-0.88], 14 wasu magunguna sun nuna ko dai babu wani amfani mai mahimmanci ko mummunan tasiri. https://c19p.org/bernaola
185. M. Salesi da M. Sedarat, Alamomin asibiti, alamomi, da tsananin COVID-19 a cikin majinyata masu cututtukan rheumatic yayin barkewar COVID-19 Dec 2023, Immunopathologia Persa, juzu'i na 10, fitowa ta 1, shafi e40568
77 mai haƙuri HCQ nazarin prophylaxis: 85% ƙananan ƙananan lokuta (p=0.003) da 18% ƙananan matsakaici / lokuta masu tsanani (p=0.35).
Binciken da aka yi na baya-bayan nan na marasa lafiya 77 tare da cututtukan rheumatic da aka gano tare da COVID-19, yana nuna ƙananan haɗarin COVID-19 mai tsanani tare da amfani da HCQ a cikin sakamakon da ba a daidaita ba. https://c19p.org/salesi
186. P. Liu, M. Zhang, J. Li, Y. Peng, S. Yu, da R. Wu, abubuwan da suka shafi sakamakon COVID-19 daban-daban a cikin marasa lafiya da ke dauke da kwayar cutar lupus erythematosus a lokacin bala'in cutar ta biyu na COVID-19 a kasar Sin Fabrairu 2024, Lupus
301 mai haƙuri HCQ nazarin prophylaxis: 39% ƙananan ƙananan lokuta (p=0.26).
Marasa lafiya na SLE guda 301 a jere tare da COVID-19, suna nuna ƙananan haɗarin sakamako mai tsanani tare da amfani da HCQ, tare da mahimmancin ƙididdiga a cikin gyare-gyare mai yawa 1 amma ba samfurin 2 ba. https://c19p.org/liu18
187. S. Huang, X. Ma, J. Cao, M. Du, Z. Zhao, D. Wang, X. Xu, J. Liang, da L. Sun, Tasirin hanyoyin kwantar da tarzoma na gargajiya kan yaduwa da sakamakon asibiti na cutar coronavirus 2019 a cikin marasa lafiya na kasar Sin masu fama da cututtukan autoimmune. Dec 2023, J. Fassarar Autoimmunity, Shafi na 100227
432 mai haƙuri HCQ nazarin prophylaxis: 43% ƙananan asibiti (p=0.09) da 6% ƙarin lokuta (p=0.25).
A baya-bayan nan 432 marasa lafiya masu kamuwa da cutar kansa a kasar Sin suna nuna ƙananan asibiti tare da HCQ ba tare da ma'anar ƙididdiga ba (OR 0.566, p=0.085) a cikin sakamakon da ba a daidaita ba, ƙaramar COVID-19 kaɗan ba tare da mahimmancin ƙididdiga ba, da haɓaka tari idan aka kwatanta da CNI. https://c19p.org/huang7
188. A. Rabe, W. Loke, R. Kalyani, R. Tummala, H. Stirnadel-Farrant, J. Were, da K. Winthrop, Tasirin kamuwa da SARS-CoV-2 akan marasa lafiya tare da lupus erythematosus na yau da kullun a Ingila kafin a yi maganin alurar riga kafi: nazari na duban dan tayi. Nov 2023, BMJ Buɗe, Juzu'i na 13, fitowa ta 11, Shafi e071072
6,145 mai haƙuri HCQ nazarin prophylaxis: 29% ƙananan lokuta (p=0.22).
Ƙungiyar marasa lafiya 6,145 na SLE na baya-bayan nan suna nuna ƙarancin faruwar COVID-19 ga marasa lafiya da ke karɓar HCQ/CQ (maganin rigakafi), ba tare da mahimmancin ƙididdiga ba. Ƙungiya ba su daidaita ba kuma sakamakon zai iya yin tasiri da abubuwa kamar tsananin cuta. An yi amfani da HCQ / antimalarials a cikin matsakaici / masu tsanani SLE marasa lafiya, suna nuna cewa sakamakon da aka kiyasta zai yi la'akari da tasirin gaske. https://c19p.org/rabe
189. L. Dulcey, R. Caltagirone, J. Leon, F. Rangel, R. Strauch, V. Peña, M. Ciliberti, E. Blanco, Hydroxychloroquine na dogon lokaci da Ƙungiyarta tare da Cutar Covid-19, Nazarin Ƙungiya daga Asibitin Kudancin Amirka. Mayu 2023, J. Clinical Rheumatology, juzu'i na 29, fitowar 4S1, Shafi S1-S112
967 mai haƙuri HCQ nazarin prophylaxis: 21% ƙananan lokuta (p=0.27).
PSM na baya-bayan nan 322 marasa lafiya na rheumatological akan HCQ da 645 da suka dace da sarrafawa, suna nuna ƙananan haɗarin COVID-19 tare da jiyya, ba tare da mahimmancin ƙididdiga ba. Marubuta sun ambaci ƙarancin mace-mace tare da HCQ amma ba su ba da cikakkun bayanai ba. Abun zayyana kawai yana samuwa. https://c19p.org/dulcey
190. C. Sukumar, N. Bolanthakodi, A. Venkatramanan, R. Nagraj, da S. Vidyasagar, The Frontline War: Nazarin kula da abubuwan haɗari ga COVID-19 tsakanin ma'aikatan kiwon lafiya Nov 2022, F1000Bincike, Juzu'i na 11, Shafi na 1298
116 mai haƙuri HCQ nazarin prophylaxis: 38% ƙananan lokuta (p=0.3).
Nazarin kula da shari'ar ma'aikatan kiwon lafiya a Indiya, yana nuna ƙananan haɗarin lokuta tare da HCQ prophylaxis, ba tare da mahimmancin ƙididdiga ba. Duk da yake marubuta sunyi sharhi mara kyau, kamar yadda ake buƙata don bugawa, kuma wannan binciken kadai ba shi da mahimmanci, sakamakon ya kasance daidai da sakamako mai kyau a duk nazarin har zuwa yau. https://c19p.org/sukumar
191. K. Becetti, E. Satti, B. Varughese, Y. Al Rimawi, R. Sheikh Saleh, N. Hadwan, M. Gharib, M. Al Kahlout, E. Abuhelaiqa, H. Afif Ashour, R. Singh, da S. Emadi, Yawaitar cutar coronavirus 2019 a cikin rukunin marasa lafiya da yawa na marasa lafiya na Qatar da ke fama da ciwon kai. Agusta 2022, Qatar Medical J., Juzu'i na 2022, fitowa ta 3
700 mai haƙuri HCQ nazarin prophylaxis: 37% ƙananan lokuta (p=0.17).
Marasa lafiya 700 na baya-bayan nan masu fama da cutar rheumatic autoimmune a Qatar, suna nuna ƙarancin haɗarin COVID-19 tare da amfani da HCQ, ba tare da mahimmancin ƙididdiga ba. Ga marasa lafiya da ke da kusanci da shari'o'in COVID-19, an sami wata ƙungiya mai mahimmanci tare da amfani da HCQ da ƙananan haɗarin COVID-19 a cikin sakamakon da ba a daidaita ba. https://c19p.org/becetti
192. E. Osawa da A. Maciel, Halaye da abubuwan haɗari ga mace-mace a cikin marasa lafiya marasa lafiya tare da COVID-19 suna karɓar iskar injuna: ƙwarewar hanyar sadarwa mai zaman kanta a Sao Paulo, Brazil Jun 2022, Maganin Kulawa Mai Mahimmanci na J., juzu'i na 8, fitowa ta 3, Shafi na 165-175
MAGANIN LAFIYA 215 mai haƙuri HCQ ICU binciken: 29% ƙananan mace-mace (p=0.07).
A baya-bayan nan 215 marasa lafiya na COVID-19 da ke da iska a cikin injina a Brazil, 71 an yi musu magani tare da HCQ, suna nuna ƙarancin mace-mace tare da jiyya a cikin sakamakon da ba a daidaita ba, ba tare da mahimmancin ƙididdiga ba. Bayanan marubuta An yi amfani da HCQ da yawa wajen fara kamuwa da cutar, wanda zai iya haifar da ruɗani saboda ƙa'idodin ƙa'idodi gabaɗaya suna haɓaka kan lokaci, yana ba da shawarar cewa fa'ida na iya zama mafi girma.. https://c19p.org/osawa
193. L. Guglielmetti. COVID-19—binciken ƙungiyar daga Arewacin Italiya Oct 2021, Rahoton Kimiyya, Juzu'i na 11, fitowa ta 1
MAGANIN LAFIYA 600 mai haƙuri HCQ marigayi nazarin jiyya: 28% ƙananan mace-mace (p=0.1).
Marasa lafiya na asibiti na 600 na baya-bayan nan a Italiya, suna nuna ƙarancin mace-mace tare da jiyya na HCQ, ba tare da kai ma'anar ƙididdiga ba (p = 0.1). https://c19p.org/guglielmetti2
194. S. Bae, B. Ghang, Y. Kim, J. Lim, S. Yun, Y. Kim, S. Lee, da S. Kim, Amfani da Hydroxychloroquine na Kwanan nan Ba Ya Haɗe da Ingantacciyar Sakamako na PCR na SARS-CoV-2: Nazarin Kulawa na Kasa a Koriya ta Kudu Feb 2021, ƙwayoyin cuta 2021, juzu'i na 13, fitowa ta 2, Shafi na 329
3,441 mai haƙuri HCQ prophylaxis nazarin PSM: 30% ƙananan lokuta (p=0.18).
Binciken bayanan baya na baya-bayan nan na amfani da HCQ a Koriya ta Kudu, yana nuna rashin kididdigar ƙarancin mace-mace da lokuta tare da jiyya. https://c19p.org/bae
196. S. Jung, M. Kim, M. Kim, S. Choi, J. Chung, da S. Choi, Tasirin bayyanar hydroxychloroquine akan kamuwa da cuta tare da SARS-CoV-2 a cikin marasa lafiya na rheumatic: Nazarin ƙungiyar jama'a Dec 2020, Clinical Microbiology da Kamuwa da cuta, juzu'i na 27, fitowa ta 4, Shafi na 611-617
2,066 mai haƙuri HCQ nazarin prophylaxis: 59% ƙananan mace-mace (p=1) da 13% ƙarin lokuta (p=0.86).
Binciken ƙungiyoyi na baya-bayan nan na RA da marasa lafiya na SLE ba su nuna babban bambanci a cikin shari'o'in PCR + ba. PCR+ baya bambance yanayin asymptomatic ko tsanani. Mutuwa ɗaya ce kawai wacce ke cikin ƙungiyar kulawa. Babu wani bayani kan tsananin da aka bayar. 33% na ƙungiyar kulawa sunyi amfani da HCQ a cikin shekarar da ta gabata. Kasancewar rikicewa ta bambance-bambance a cikin yanayi da tsananin cutar rheumatic yana yiwuwa. https://c19p.org/jung
197. . nazarin guguwar annoba ta farko Dec 2020, J. Kamuwa da Lafiyar Jama'a, juzu'i na 14, fitowa ta 2, Shafi na 263-270
MAGANIN LAFIYA 218 mai haƙuri HCQ marigayi nazarin jiyya: 35% ƙananan mace-mace (p=0.22).
Marasa lafiya na asibiti na 218 na baya a Italiya suna nuna ƙarancin ƙididdiga na 35% ƙananan mace-mace tare da HCQ, haɗarin haɗari aHR 0.65 [0.33-1.30]. https://c19p.org/guglielmetti
198. B. Lambermont, M. Ernst, P. Demaret, S. Boccar, C. Gurdebeke, V. Cedric, M. Quinonez, C. Dubois, T. Lemineur, T. Njambou, B. Akando, D. Wertz, J. Higny, P. Delanaye, da kuma B. Misset, Masu Hasashen Matattu na Matattu Tare da Cutar Coronavirus 2019: Nazarin Ƙungiyar Jama'a Nov 2020, Binciken Mahimmancin Kulawa, juzu'i na 2, fitowa ta 12, Shafi e0305
MAGANIN LAFIYA 247 mai haƙuri HCQ marigayi nazarin jiyya: 32% ƙananan mace-mace (p=0.46).
Marasa lafiya 247 da ke da iska na injina na baya-bayan nan suna nuna ƙarancin mace-mace tare da HCQ, amma ba ƙididdiga ba akan koma bayan Cox da yawa. Takardar ta ba da ƙimar p don mahara Cox (0.46) da kuma Cox mai sauƙi (0.02), amma bai ƙayyade ƙimar haɗarin da aka daidaita ba. https://c19p.org/lambermont
199. C. Rodriguez-Gonzalez, E. Chamorro-de-Vega, M. Valerio, M. Amor-Garcia, F. Tejerina, M. Sancho-Gonzalez, A. Narrillos-Moraza, A. Gimenez-Manzorro, S. Manrique-Rodriguez, M. Machado, V. Escudero, C. Olmedo Villanueva-Bueno, B. Torroba-Sanz, A. Melgarejo-Ortuño, J. Vicente-Valor, A. Herranz, E. Bouza, P. Muñoz, da M. Sanjurjo, COVID-19 a cikin marasa lafiya na asibiti a Spain: nazarin ƙungiyar a Madrid Nuwamba 2020, Int. J. Magungunan Kwayoyin cuta, Juzu'i na 57, Fitowa ta 2, Shafi na 106249
MAGANIN LAFIYA 1,208 mai haƙuri HCQ marigayi nazarin jiyya: 23% ƙananan mace-mace (p=0.26).
Marasa lafiya 1255 na baya-bayan nan a Spain suna nuna ƙarancin mace-mace tare da HCQ. Batun ruɗarwa ta hanyar nuni. https://c19p.org/rodriguezgonzalez
200. R. Nov 2020, BMC Infect Dis., juzu'i na 20, fitowa ta 1
MAGANIN LAFIYA 319 mai haƙuri HCQ nazarin jiyya na ƙarshen: 32% ƙananan mace-mace (p=0.05).
Marasa lafiya na asibiti 319 na baya-bayan nan a Belgium suna nuna ƙarancin mace-mace tare da HCQ. https://c19p.org/vanhalem
201. B. Revollo, C. Tebe, J. Peñafiel, I. Blanco, N. Perez-Alvarez, R. Lopez, L. Rodriguez, J. Ferrer, P. Ricart, E. Moret, C. Tural, A. Carreres, J. Matllo, S. Videla, B. Clotet, da J. Llibre, COVID-19 pre-carecare proxy a kiwon lafiya. ma'aikata Nov 2020, J. Maganin Chemotherapy Antimicrobial, Juzu'i na 76, Fitowa ta 3, Shafi na 827-829
487 mai haƙuri HCQ prophylaxis nazarin PSM: 23% ƙananan lokuta (p=0.52).
Binciken PrEP na baya tare da ma'aikatan kiwon lafiya na 69 akan PrEP HCQ, da kulawar 418. Marubuta suna ba da rahoton sakamakon PCR da IgG, ba tare da wani sakamako na asali na ko ɗaya ba. Marubuta sun lura da su "An gano 69 HCWs suna karɓar HCQ" yayin da ba su ba da bayanin dalilin ko lokacin da suka fara HCQ ba. Ba za a iya yanke shawara daga wannan binciken saboda yawancin ma'aikata na iya kasancewa masu inganci kafin fara HCQ. Kashi 14% kawai na ma'aikata sun zaɓi yin amfani da HCQ kuma ƙila an motsa su don yin hakan saboda suna da kamuwa da cuta. Marubuta suna yin gyare-gyare daban-daban, suna samun sakamako daban-daban. Ba a bayar da bayani kan mutuwa, asibiti, alamu, ko tsanani da aka bayar. Ba a bayar da cikakkun bayanai kan lokacin serology da matsayin serology na asali ba. Yiwuwar son zuciya saboda zaɓin kai don haɗari. An gano kashi 25% na kamuwa da cuta kafin kwanaki 7, wanda ke nuna cewa a zahiri sun faru a baya (tabbacin karya na PCR yana da girma da farko). Wataƙila yawancin cututtuka sun kasance kafin HCQ ya isa matakan warkewa. https://c19p.org/revollo
202. D. Datta, S. Ghosal, B. Sinha, S. Datta, T. Chakraborty, K. Gangopadhyay, A. Dutta, Babu Rawar HCQ a cikin COVID-19 Prophylaxis: Bincike tsakanin Likitocin Indiya Nov 2020, J. Alurar rigakafi & Alurar riga kafi, S6: 1000002
281 mai haƙuri HCQ nazarin prophylaxis: 22% ƙananan lokuta (p=0.47).
Binciken likitocin Indiya ba su sami wani gagarumin tasiri na rigakafin HCQ ba. https://c19p.org/datta
203. P. Behera, B. Patro, A. Singh, P. Chandanshive, RSR, S. Pradhan, S. Pentapati, G. Batmanabane, P. Mohapatra, B. Padhy, S. Bal, S. Singh, da R. Mohanty, Matsayin ivermectin a cikin rigakafin SARS-CoV-2 kamuwa da cuta tsakanin ma'aikatan kiwon lafiya a Indiya. Nov 2020, PLoS DAYA, Juzu'i na 16, fitowa ta 2, Shafi e0247163
372 mai haƙuri HCQ nazarin prophylaxis: 28% ƙananan lokuta (p=0.29).
Binciken da aka yi a baya-bayanan da ya dace don HCQ, ivermectin, da bitamin C tare da ma'aikatan kiwon lafiya 372, yana nuna ƙarancin COVID-19 ga duk jiyya, tare da ƙimar ƙididdiga ta kai ga ivermectin. HCQ KO 0.56, p = 0.29 ivermectin KO 0.27, p <0.001 bitamin C KO 0.82, p = 0.58 https://c19p.org/behera
204. S. Ñamendys-Silva, P. Alvarado-Ávila, G. Domínguez-Cherit, E. Rivero-Sigarroa, L. Sánchez-Hurtado, A. Gutiérrez-Villaseñor, J. Romero-González, H. Rodríguez-Bautista, A.-Brio-Garcnes-Boutista, Garcnes, C.C. Cruz-Ruiz, M. González-Herrera, F. García-Guillén, M. Guerrero-Gutiérrez, J. Salmerón-González, L. Romero-Gutiérrez, J. Canto-Castro, da V. Cervantes, Sakamako na marasa lafiya tare da COVID-19 a cikin Cibiyar Kula da Lafiya ta Mexico Oct 2020, Zuciya & Huhu, juzu'i na 50, fitowa ta 1, Shafi na 28-32
MAGANIN LAFIYA 164 mai haƙuri HCQ ICU binciken: 32% ƙananan mace-mace (p=0.19).
Marasa lafiya na ICU na 164 na baya a Mexico suna nuna ƙarancin mace-mace 32% tare da HCQ+AZ da 37% ƙasa tare da CQ. HCQ + AZ vs. ba HCQ ko CQ dangi hadarin RR 0.68, p = 0.03 CQ vs. ba HCQ ko CQ dangi hadarin RR 0.63, p = 0.02 HCQ + AZ ko CQ vs. ba dangi hadarin RR 0.65, p = 0.006 https://c19p.org/namendyssilva
205. P. Guisado-Vasco, S. Valderas-Ortega. Malo-Benages, M. Monforte-Gómez, R. Diez-Munar, E. Merino-Lanza, L. Comeche-Casanova, M. Remirez-de-Esparza-Otero, M. Correyero-Plaza, M. Recio-Rodríguez, M. Rodríguez-Lóchez. Thuissard-Vasallo, J. María-Tomé, da D. Carnevali-Ruiz, Halayen asibiti da sakamako a tsakanin manya da ke asibiti tare da COVID-19 mai tsanani an shigar da su zuwa cibiyar kiwon lafiya ta jami'a kuma suna karɓar maganin rigakafi, antimalarials, glucocorticoids, ko immunomodulation tare da tocilizumab ko cyclosporine: Binciken sake dubawaCO Oktoba 2020, EClinicalMedicine, juzu'i na 28, Shafi 100591
MAGANIN LAFIYA 607 mai haƙuri HCQ marigayi nazarin jiyya: 20% ƙananan mace-mace (p=0.36).
607 marasa lafiya na baya-bayan nan suna ba da rahoton sakamakon HCQ na farko da aka yi amfani da su tare da rashin daidaituwa na mace-mace OR 0.092 [0.022-0.381], p = 0.001 (65 marasa lafiya), kuma don amfani da asibiti, rashin daidaituwa na mace-mace OR 0.737 [0.38-1.41], p. Tsakanin shekaru 0.36. https://c19p.org/guisadovasco
206. J. Piñana, R. Martino, I. García-García, R. Parody, M. Morales, G. Benzo, I. Gómez-Catalan, R. Coll, I. De La Fuente, A. Luna, B. Merchan, A. Chinea, D. De Miguel, A. Serrano, C., C.Péz, C.Péz R. Bailen, T. Zudaire, D. Martínez, M. Jurado, M. Calbacho, L. Vázquez, I. Garcia-Cadenas, L. Fox, A. Pimentel, G. Bautista, A. Nieto, P. Fernandez, J. Vallejo, C. Solano, M. Valero, I. Saligado, J. R.S Jimenez, M. Trabazo, M. Gonzalez-Vicent, N. Fernández, C. Talarn, M. Montoya, A. Cedillo, da A. Sureda, Abubuwan haɗari da sakamakon COVID-19 a cikin marasa lafiya da cututtukan jini. Agusta 2020, Gwajin Hematology & Oncology, Juzu'i na 9, fitowa ta 1
Nazarin prophylaxis na HCQ: 36% ƙananan mace-mace (p=0.11).
Binciken da aka yi na baya-bayan nan na marasa lafiyar jini 367 tare da COVID-19 a Spain. Daga cikin marasa lafiya 216 masu tsananin COVID-19, an sami raguwar mace-mace tare da jiyya azithromycin. Har ila yau, mace-mace ya kasance ƙasa da HCQ, amma ba tare da mahimmancin ƙididdiga ba. https://c19p.org/pinana
207. A. D'Arminio Monforte, A. Tavelli, F. Bai, G. Marchetti, da A. Cozzi-Lepri, Tasirin Hydroxychloroquine a cikin cutar COVID-19: Halin da aka yi da ƙura? Yuli 2020, Int. J. Cututtuka masu Yaduwa, Juzu'i na 99, Shafi na 75-76
MAGANIN LAFIYA 539 mai haƙuri HCQ marigayi nazarin jiyya: 34% ƙananan mace-mace (p=0.12).
HCQ+AZ gyara mutuwa HR 0.44, p=0.009. Makiyoyin haɓaka sun haɗa da asali na asali na rashin lafiyar COVID-19, shekaru, jinsi, adadin ƙwayoyin cuta, cututtukan zuciya-jijiya, tsawon alamun bayyanar cututtuka, ranar shigar, plasma CRP na asali. Inverse propensity weighting tantancewa. Nazarin baya-bayan nan na 539 COVID-19 marasa lafiya a asibiti a Milan, tare da jiyya matsakaicin kwana 1 bayan shigar da su. HCQ 197 marasa lafiya, HCQ + AZ 94, iko 92. Ƙungiyar kulawa ta karbi wasu magunguna daban-daban. Marubuta sun cire mutanen da ke karɓar wasu magunguna waɗanda zasu iya ɓata tasirin HCQ yayin amfani da su a hade. Ragowar rikicewa yana yiwuwa (misali, mutanen da ke da CVD sun fi yawan sarrafawa), duk da haka mutanen da ke cikin rukunin sun fi buƙatar samun iska. https://c19p.org/darminiomonforte
208. P. Luo, L. Qiu, Y. Liu, X. Liu, J. Zheng, H. Xue, W. Liu, D. Liu, da J. Li, Jiyya na Metformin yana da alaƙa da Ragewar mace-mace a cikin marasa lafiya na COVID-19 masu ciwon sukari a cikin Binciken Na baya. Mayu 2020, The American J. Tropical Medicine and Hygiene, Juzu'i na 103, fitowa ta 1, Shafi na 69-72
MAGANIN LAFIYA 283 mai haƙuri HCQ marigayi nazarin jiyya: 32% ƙananan mace-mace (p=0.72).
A baya-bayan nan 283 masu fama da cutar COVID-19+ masu ciwon sukari a China, suna nuna ƙarancin mace-mace marasa ƙididdiga tare da jiyya na HCQ/CQ. https://c19p.org/luo3h
209. N. Capsoni, D. Privitera, A. Mazzone, C. Airoldi, V. Albertini, L. Angaroni, M. Bergamaschi, A. Molin, E. Forni, F. Pierotti, E. Rocca, F. Vincenti, da A. Bellone, Jiyya na CPAP A cikin COVID-19 Marasa lafiya: Sashen Kulawa na Gaggawa Nov 2020, Dandalin Bincike
MAGANIN LAFIYA 52 haƙuri HCQ marigayi magani binciken: 40% ƙananan samun iska (p=0.3).
Ƙananan 52 mai haƙuri na nazari na baya-bayan nan na marasa lafiya tare da gazawar numfashi mai tsanani yana nuna ƙananan ƙimar intubation tare da HCQ. https://c19p.org/capsoni
210. T. Arleo, D. Tong, J. Shabto, G. O'Keefe, da A. Khosroshahi, Koyarwar Clinical da Sakamakon cutar Coronavirus 2019 (COVID-19) a cikin Cutar Rheumatic Marasa lafiya akan Immunosuppression: Nazarin Harka a Cibiyar Single tare da Mahimmancin Jama'a Oktoba 2020, medRxiv
70 mai haƙuri HCQ nazarin prophylaxis: 50% ƙananan mace-mace (p=0.67).
Marasa lafiya na cututtukan rheumatic na asibiti na baya-bayan nan suna nuna 50% ƙananan mace-mace ga marasa lafiya akan HCQ. https://c19p.org/arleo
211. L. Smith, N. Mendoza, D. Dobesh, da S. Smith, Nazari na Dubawa akan majinyatan Covid 255 na injina a farkon cutar ta Amurka. Mayu 2021, medRxiv
MAGANIN LAFIYA 255 mai haƙuri HCQ nazarin jiyya na ƙarshen: 27% ƙananan mace-mace (p=0.002).
A baya-bayan nan 255 marasa lafiya na samun iska a cikin Amurka, suna nuna hakan HCQ+AZ da aka daidaita nauyi ya inganta rayuwa da sama da 100%. Tsawaitawar QTc bai daidaita da adadin adadin HCQ ba ko matakin jini na HCQ. Kodayake marubutan sun ambaci son zuciya mara mutuwa, ba a bayar da cikakkun bayanai kan lokacin gwamnatin HCQ ba kuma wannan ba a cika yin magana ba. Ƙwayoyin tsira suna nuna rashin mutuwa son zuciya lokaci zai canza sakamako sosai, kodayake fa'idar da aka gani ya bayyana ya wuce yuwuwar son zuciya. https://c19p.org/smith
212. M. Ashraf, N. Shokouhi, E. Shirali, F. Davari-tanha, O. Memar, A. Kamalipour, A. Azarnoush, A. Mabadi, A. Ossareh, M. Sanginabadi, T. Azad, L. Aghaghazvini, S. Ghaderkhani, T. Poordast, A., Iran Pourdast cikakken bincike daga bayyanar da sakamakon magani Afrilu 2020, medRxiv doi:10.1101/2020.04.20.20072421
MAGANIN FARKO 100 mai haƙuri HCQ binciken farko na jiyya: 68% ƙananan mace-mace (p=0.15).
Ƙananan ƙananan gwaji tare da marasa lafiya 100 sun kammala cewa HCQ ya inganta sakamakon asibiti, OR 0.016 [0.002-0.11] a cikin bincike na farfadowa. https://c19p.org/ashraf
213. M. Lecronier, A. Beurton, S. Burrel, L. Haudebourg, R. Deleris, J. Le Marec, S. Virolle, S. Nemlaghi, C. Bureau, P. Mora, M. De Sarcus, O. Clovet, B. Duceau, P. Grisot, M. Pari, J. Claracau, D. Boux Delemazure, M. Faure, M. Decavele, E. Morawiec, J. Mayaux, A. Demoule, da M. Dres, Kwatanta hydroxychloroquine, lopinavir/ritonavir, da daidaitattun kulawa a cikin marasa lafiya marasa lafiya tare da ciwon huhu na SARS-CoV-2: nazari na baya-bayan nan. Jul 2020, Mahimman Kulawa, 2020, juzu'i na 24, fitowa ta 1
MAGANIN LAFIYA 80 mai haƙuri HCQ ICU binciken: 42% ƙananan mace-mace (p = 0.24), 6% ƙananan haɓakar jiyya (p = 0.73), da 15% inganta ƙwayar cuta (p=0.61).
Marasa lafiya 80 ICU na baya-bayan nan, 22 daidaitaccen kulawa, 20 lopinavir/ritonavir, 38 HCQ. Mutuwar kwana 28 24% (HCQ) da 41% (misali na kulawa), a 41% raguwa, amma ba ƙididdiga ba saboda ƙananan girman samfurin. Ba a sami bambance-bambancen ƙididdiga ba don haɓakar jiyya, kwanakin da ba su da iska, nauyin hoto, ko mace-mace. Marubuta suna la'akari da haɓakar jiyya mafi mahimmanci fiye da mace-mace, don dalilan da ba a sani ba. https://c19p.org/lecronier
214. H. Assad, Pharmacotherapy yana ba da tsari da sakamako ga marasa lafiya na asibiti tare da matsananciyar COVID-19 Oct 2022, Batutuwa na Yanzu a cikin Pharmacy da Kimiyyar Kiwon Lafiya, Juzu'i na 0, Fitowa ta 0
MAGANIN LAFIYA 291 mai haƙuri HCQ marigayi nazarin jiyya: 60% ƙananan mace-mace (p=0.002).
Majiyoyin asibiti na 346 na baya-bayan nan a Iraki, suna nuna ƙarancin mace-mace tare da HCQ a cikin sakamakon da ba a daidaita ba. Sakamakon HCQ ana ba da shi ne kawai a cikin kashi 93% na marasa lafiya da aka bi da su tare da enoxaparin. https://c19p.org/assad
215. S. Samajdar, S. Mukherjee, T. Mandal, J. Paul, Ivermectin da Hydroxychloroquine don Chemo-Prophylaxis na COVID-19: Binciken Tambayoyi na Hane-hane da Tsara Ayyuka na Likitoci vi-a-vis Sakamako Nov 2021, J. Associationungiyar Likitocin Indiya
309 haƙuri HCQ nazarin prophylaxis: Ƙananan lokuta 75% (p <0.0001).
Binciken likita a Indiya tare da 164 ivermectin prophylaxis, 129 HCQ prophylaxis, da marasa lafiya 81, yana nuna ƙananan ƙananan COVID-19 tare da magani. Ba a bayar da cikakkun bayanai game da jiyya da ƙungiyoyin kulawa da ma'anar lokuta ba, kuma sakamakon yana ƙarƙashin son zuciya. Marubuta kuma suna ba da rahoto game da rigakafin al'umma amma suna gabatar da sakamakon ivermectin/HCQ kawai. https://c19p.org/samajdarh
216. I. Núñez-Gil, C. Fernández-Pérez, V. Estrada, V. Becerra-Muñoz, I. El-Battrawy, A. Uribarri, I. Fernández-Rozas, G. Feltes, M. Viana-Llamas, D. Trabattoni, J. López.jí, R. País. E. Cerrato, T. Astrua, F. D'Ascenzo, O. Fabregat-Andres, J. Moreu, F. Guerra, J. Signes-Costa, F. Marín, D. Buosenso, A. Bardají, S. Raposeiras-Roubín, J. Elola, Á. Molino, J. Gómez-Doblas, M. Abumayyaleh, Á. Aparisi, M. Molina, A. Guerri, R. Arroyo-Espliguero, E. Assanelli, M. Mapelli, J. García-Acuña, G. Brindicci, E. Manzone, M. Ortega-Armas, M. Bianco, C. Trung, M. Núñez, C. Casch, Vcíz, Garcíz-N. Cabello-Clotet, K. Jamhour-Chelh, M. Tellez, A. Fernández-Ortiz, da C. Macaya, kimanta haɗarin mutuwa a Spain da Italiya, fahimtar HOPE COVID-19 rajista Nov 2020, Intern. Emerg Med., Juzu'i na 16, fitowa ta 4, Shafi na 957-966
MAGANIN LAFIYA 954 mai haƙuri HCQ marigayi nazarin jiyya: 8% ƙananan mace-mace (p=0.005).
Binciken bayanan baya-bayan nan na marasa lafiya 1,021 a Ecuador, Jamus, Italiya, da Spain, yana nuna ƙimar ƙimar HCQ daidaitaccen ƙimar mace-mace daidaita daidaiton rabo 0.88, p=0.005. https://c19p.org/nunezgil
217. M. Maldonado, M. Ossorio, G. Del Peso, C. Santos, L. Álvarez, R. Sánchez-Villanueva, B. Rivas, C. Vega, R. Selgas, da M. Bajo, COVID-19 abin da ya faru da kuma sakamakon a cikin wani gida dialysis na gida a Madrid (Spain) a tsayin cutar. Nov 2020, Nefrología, Juzu'i na 41, Fitowa ta 3, Shafi na 329-336
MAGANIN LAFIYA 12 mai haƙuri HCQ marigayi nazarin jiyya: 91% ƙananan mace-mace (p=0.17).
Ƙananan baya-bayanan marasa lafiya 12 suna nuna mutuwar 1/11 tare da HCQ da 1/1 ba tare da HCQ ba. https://c19p.org/maldonado
218. R. Niwas, A.S, M. Garg, V. Nag, P. Bhatia, N. Dutt, N. Chauhan, J. Charan, S. Asfahan, P. Sharma, P. Bhardwaj, M. Banerjee, P. Garg, B. Sureka, G. Bohra, M. Gopalakrishnan, da S., bayanin martaba na COVID-19 da amsawar Clinical, da kuma sakamakon lafiya na Clinico chlorqui, Clinical sakamako. marasa lafiya - gwaninta na farko Oktoba 2020, Ci gaba a Magungunan Numfashi, juzu'i na 88, fitowa ta 6, Shafi 515-519
MAGANIN LAFIYA 29 mai haƙuri HCQ nazarin jiyya na ƙarshen: 29% saurin farfadowa (p=0.008).
Marasa lafiya na asibiti na 12 na baya a Indiya da aka bi da su tare da CQ da sarrafa 17, suna nuna saurin dawowa tare da jiyya. Babu wani muhimmin bambanci a kawar da kwayar cuta. Ƙungiyar CQ tana nufin shekaru 41.3 vs. 47.6 don sarrafawa. https://c19p.org/niwas
219. B. Abella, E. Jolkovsky, B. Biney, J. Uspal, M. Hyman, I. Frank, S. Hensley, S. Gill, D. Vogl, I. Maillard, D. Babushok, A. Huang, S. Nasta, J. Walsh, E. Wiletyo, P. Gimotty, M. Miadilone, da kuma Efficy Amarya vs. Placebo don Pre-bayyana SARS-CoV-2 Prophylaxis Tsakanin Ma'aikatan Kula da Lafiya Satumba 2020, JAMA Magungunan Ciki, Juzu'i 181, Fitowa ta 2, Shafi na 195
125 mai haƙuri HCQ prophylaxis RCT: 5% ƙananan lokuta (p=1).
Ƙananan ƙananan-ƙarewa da wuri mara ƙarfi PrEP RCT tare da 64/61 HCQ / kula da marasa lafiya da cututtuka 8 kawai, Yawan kamuwa da cuta na HCQ 6.3% tare da kulawa 6.6%, RR 0.95 [0.25 - 3.64]. Babu asibiti ko mutuwa, babu wani gagarumin bambanci a cikin QTc, babu wani mummunan yanayi, babu abubuwan da suka faru na zuciya (misali, syncope da arrhythmias) da aka gani. Rikon magani ya kasance 81%. Matakan jiyya na HCQ ƙila ba a kai ga lokacin kamuwa da cuta a cikin makon farko ba. An ba da rahoton cututtuka na 2 bayan an dakatar da maganin, amma marubutan ba su bayyana ko wane hannu ba ne a ciki. A zahiri, idan waɗannan duka biyun suna cikin hannun HCQ, sakamakon RR don magani zai zama ƙasa da ƙasa. https://c19p.org/abella
220. N. Alamdari, S. Afaghi, F. Rahimi, F. Tarki, S. Tavana, A. Zali, M. Fathi, S. Besharat, L. Bagheri, F. Pourmotahari, S. Irvani, A. Dabbagh, da S. Mousavi, Abubuwan Hadarin Mutuwar Mutuwa tsakanin Cibiyoyin Asibiti a Cibiyoyin Kula da Cututtuka na COVID-19 a Iran Satumba 2020, Tohoku J. Exp. Med., 2020, 252, 73-84, juzu'i na 252, fitowa ta 1, Shafi na 73-84
MAGANIN LAFIYA 459 mai haƙuri HCQ marigayi nazarin jiyya: 55% ƙananan mace-mace (p=0.03).
Marasa lafiya 459 na baya-bayan nan a Iran tare da kashi 93% ana bi da su tare da HCQ, suna nuna mace-macen HCQ RR 0.45, p = 0.028. HCQ shine kawai maganin rigakafi wanda ya nuna bambanci mai mahimmanci. Akwai ƙananan marasa lafiya masu sarrafawa kuma sakamakon yana ƙarƙashinsa mai ruɗani da nuni. Matsakaicin jinkirin shiga kwanaki 5.72. https://c19p.org/alamdari
221. C. Santos, C. Morales, E. Álvarez, C. Castro, A. Robles, da T. Sandoval, Ƙayyade tsananin cutar COVID-19 a cikin marasa lafiya da ke fama da cututtukan rheumatic Jul 2020, Clinical Rheumatology, juzu'i na 39, fitowa ta 9, Shafi 2789-2796
38 mai haƙuri HCQ nazarin prophylaxis: 92% ƙananan mace-mace (p=0.19).
Binciken da ake shirin yi na marasa lafiya na cututtukan rheumatic na asibiti guda 38 tare da COVID-19 a cikin Spain, wanda ke nuna babu mace-mace tare da amfani da HCQ na yanzu idan aka kwatanta da 32% ba tare da kaiwa ga mahimmancin ƙididdiga ba. Mawallafa kuma suna ba da rahoto game da amfani da HCQ/CQ bayan an kwantar da su a asibiti. An jera maganin rigakafi da sakamakon jiyya a baya daban. https://c19p.org/santos
222. A. Cavalcanti, F. Zampieri, R. Rosa, L. Azevedo, V. Veiga, A. Avezum, L. Damiani, A. Marcadenti, L. Kawano-Dourado, T. Lisboa, D. Junqueira, P. De Barros e Silva, L. Tramujas, E. Abreu-Siljeira, L. Sorqueira, A. A. Pereira, F. Freitas, O. Gebara, V. Dantas, R. Furtado, E. Milan, N. Golin, F. Cardoso, I. Maia, C. Hoffmann Filho, A. Kormann, R. Amazonas, M. Bocchi de Oliveira, A. Serpa-Neto, M. Falavigna, F. Hydroxychloroquine tare da ko ba tare da Azithromycin a cikin M-zuwa-Matsakaici Covid-19 Jul 2020, NEJM, Juzu'i na 383, Fitowa ta 21, Shafi na 2041-2052
MAGANIN LAFIYA 667 mai haƙuri HCQ marigayi magani RCT: 16% ƙananan mace-mace (p=0.77) da 28% mafi girma asibiti (p=0.3).
Late mataki RCT na 667 marasa lafiya na asibiti tare da har zuwa kwanaki 14 na alamun bayyanar cututtuka a rajista da kuma samun ƙarin oxygen zuwa lita 4 a minti daya, rashin samun sakamako mai mahimmanci bayan kwanaki 15. Mawallafa sun lura: "gwajin ba za ta iya yanke hukunci ba ko dai wani fa'ida mai mahimmanci na magungunan gwajin ko kuma wata illa mai yawa", girman samfurin sun yi ƙanƙanta. Ttakarda ya yi amfani da kalmomi masu sauƙi da matsakaici, duk da haka duk marasa lafiya suna da mummunar cutar da za a kwantar da su a asibiti, kuma 14% an bazu a cikin ICU. Gwajin yana da manyan sauye-sauye na ƙa'idodi da ƙarancin bin magunguna da ba a saba gani ba. Bazuwar ya haifar da 64.3% maza marasa lafiya (HCQ) vs. 54.2% (control) wanda zai iya tasiri sosai sakamakon sakamakon haɗari mafi girma ga marasa lafiya maza. Mawallafa sun lura: "manufarmu ita ce ware marasa lafiya da suka riga sun sami tsawon lokaci kuma masu yiwuwa maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin ƙwararriyar ƙwararru . Yin nazarin waɗannan marasa lafiya maimakon ware su na iya bayyana tasiri tare da amfani da wuri kamar yadda aka nuna a wasu nazarin. Da farko gwajin ya buƙaci yin rajista a cikin sa'o'i 48 na shigarwa kuma an canza shi don cire wannan buƙatun, wannan canjin zai iya rage tasiri saboda an koma yin rajista daga baya, idan aka kwatanta da lokacin da cutar ta yi tsanani don kwantar da hankali a asibiti. Jimlar adadin HCQ 5.6g. A gyara don kurakurai 17 NEJM an buga gami da maganganun: "Rahoton kamar yadda aka buga bai bayar da cikakken bayani game da mita da tsawon lokacin amfani da hydroxychloroquine ko azithromycin a baya ba tsakanin mahalarta gwajin." A cikin sashe na Mahalarta Hanyoyi (shafi na 2), jumla ta farko yakamata ta fara, "Mun sanya majinyata waɗanda ko dai ƙungiyar gwaji ta tantance su ko kuma sun tura mu waɗanda shekarun su suka kai 18 ko fiye kuma an kwantar da su a asibiti…," maimakon "Gwajin ya haɗa da marasa lafiya a jere waɗanda shekarunsu suka kai 18 ko fiye kuma waɗanda aka kwantar da su a asibiti…." A cikin jumla ta biyu, kalmar "amfani da chloroquine, hydroxychloroquine, azithromycin, ko duk wani macrolide a baya fiye da sa'o'i 24 kafin yin rajista (kuma tun farkon bayyanar cututtuka)" yakamata a cire shi. A cikin jumla ta uku, kalmar ", gami da sharuɗɗa game da amfani da hydroxychloroquine ko azithromycin a baya," yakamata su bi kalmar "ma'auni na keɓancewa." A cikin sakin layi na biyu na Randomization, Intervention, da Bi-bi-bi-biyar ɓangaren Hanyoyi (shafi na 2), jumlar da ta fara "Gudanar da hydroxychloroquine ko chloroquine" yakamata a cire shi. A bayanin kula na ƙarshe da ke ƙasa Tebur 1 (shafi na 4), ya kamata a cire kalmar nan “a cikin sa’o’i 24”, kuma ya kamata a ƙare bayanin kula, “An ba da cikakkun bayanai a Ƙarin Karin bayani.” A cikin ɓangaren Ƙididdiga na Hanyoyi, a cikin jumla ta ƙarshe ta sakin layi da ta fara “Mun kuma yi…” (shafi na 5), ya kamata a ƙara jimlar “a lokacin da bazuwar lokacin jiyya” bayan “magungunan da aka karɓa.” A cikin sakin layi na farko na Halayen Sashe na Sakamako (shafi na 8), "bazuwar ranar 17 ga Mayu, 2020" yakamata ya kasance "… a ranar 18 ga Mayu, 2020." A ƙarshen wannan sashin, "Tables S5 da S6, bi da bi" yakamata su kasance "Tables S5 ta hanyar S7." A cikin sashe na Sakamako na Farko (shafi na 8), ambaton Tables S7, S8, da S9, yakamata su kasance Tables S8, S9, da S10, bi da bi. Jumla ta ƙarshe na wannan sashin yakamata ta ƙare tare da "(Table S11) ko a cikin ƙungiyoyi uku na post hoc waɗanda aka ayyana gwargwadon ranar rajistar gwaji ko kuma bisa ga amfani da hydroxychloroquine ko azithromycin (Table S12) a baya," maimakon "(Table S10)." A cikin sakin layi na biyu na sashin Sakamako na Sakandare (shafi na 8), abubuwan da aka ambata na Tebura S11 da Tebura S12 yakamata su kasance Table S13 da Table S14. A cikin jimla ta ƙarshe na sashin Safety na Sakamako (shafi na 9), ambaton Tables S13 da S14 yakamata su kasance Tables S15 da S16. A cikin jimla ta farko na bayanin kula na farko da ke ƙasa Tebur 3 (shafi na 11), ya kamata a ƙara furcin “a lokacin jiyya da bazuwar” bayan “bisa ga magungunan da aka karɓa.” A cikin sakin layi na ƙarshe na Tattaunawa (shafi na 11), jumlar da ta fara, "Shiryar da marasa lafiya ba tare da amfani da waɗannan magunguna a baya ba yana da ƙalubale ..." yakamata a maye gurbinsu da, "Ba mu bayyana a cikin ka'idar mu ba da keɓance irin waɗannan marasa lafiya har sai a ƙarshen lokacin gwajin, kuma a sakamakon haka, 9.3% na masu amfani da hydrochlore na baya sun yi amfani da 36.1% na gwajin da suka gabata. azithromycin. Duk da haka, a mafi yawan lokuta, tsawon lokacin amfani da baya shine kawai 24 zuwa 48 hours kafin yin rajista, musamman saboda, kafin 13 ga Mayu, muna buƙatar a shigar da marasa lafiya a cikin gwaji a cikin sa'o'i 48 bayan shigar da asibiti kuma saboda rashin amfani da waɗannan magungunan (kafin shigar da su) ba safai ba ne. Bayan 13 ga Mayu, mun ayyana cewa amfani da waɗannan magungunan sama da sa'o'i 24 wani ma'auni ne na keɓancewa." An kuma shafi Karin Bayanin. Manyan ɓangarorin sun ba da misali ne na rashin kulawar rubuce-rubucen rubuce-rubucen, rashin karantawa (daga mawallafa 34 daban-daban) kuma sun ƙara nuna cewa kaɗan zuwa wani ƙwararrun bita da takwarorinsu da NEJM ta yi. https://c19p.org/cavalcanti
223. D. Boulware, M. Pullen, A. Bangdiwala, K. Pastick, S. Lofgren, E. Okafor, C. Skipper, A. Nascene, M. Nicol, M. Abassi, N. Engen. McDonald, R. Rajasingham, T. Lee, da K. Hullsiek, Gwajin Bazuwar Hydroxychloroquine azaman Prophylaxis Postexposure don Covid-19 Jun 2020, NEJM, Yuni 3 2020, Juzu'i na 383, Fitowa ta 6, Shafi na 517-525
821 mai haƙuri HCQ prophylaxis RCT: 17% ƙananan lokuta (p=0.35).
RCT mai nisa prophylaxis bayan fallasa yana ba da rahoton cewa "[HCQ] bai hana cutar da ta dace da Covid-19 ba ko kuma tabbatar da kamuwa da cuta lokacin amfani da prophylaxis bayan fallasa a cikin kwanaki 4 bayan fallasa." Duk da haka, wannan magana ba daidai ba ne - an rage lokuta, kawai ba tare da mahimmancin ƙididdiga ba – ba zai yiwu a kammala cewa babu inganci. Bugu da ƙari, magani ba a cikin kwanaki 4 ba - an sami jinkirin jigilar kaya har zuwa awanni 68 kamar yadda a kasa. Har ila yau, 6 Mai zaman kansa na nazarin na data a cikin wannan binciken nuna inganci. An rage shari'o'in COVID-19 da [49%, 29%, 16%] bi da bi lokacin da aka ɗauka cikin sa'o'i [70, 94, 118] na fallasa (ciki har da jinkirin jigilar kaya). Dangantakar jinkirin jinkiri yana da mahimmanci a p=0.002. Don ƙarin cikakkun bayanai, duba wannan Labarin NEJM da kuma analysis. Marubuta sun kwatanta da jiyya tare da folic acid, amma ana tunanin folic acid zai ɗaure ga sunadaran SARS-CoV-2 da yawa, matakan folic acid sun yi ƙasa a cikin marasa lafiya na COVID-19 da ke da mummunar cuta, ƙarin folic acid na iya taimakawa tare da hauhawar jini da ke da alaƙa da COVID-19 da hyperhomocystinemia, kuma bambance-bambance a cikin folic acid enzyme enzyme na iya yin tasiri ga COVID-19 bambancin yanayin ƙasa. Lokacin dosing ya kasance ba a rubuta a cikin waɗannan gwaje-gwajen ba. Duba Weisman et al, Da kuma Pullen et al bayanan da ke nuna jinkirin jigilar kayayyaki don waɗannan gwaje-gwajen na sa'o'i 19 - 68. Tare da yin rajista har zuwa kwanaki 4 daga fallasa, wannan yana nufin bayarwa 19 – 164 hours bayan fallasa. https://c19p.org/boulwarepep
224. W. Hong, Y. Park, B. Kim, S. Park, J. Shin, S. Jang, H. Park, W. Yang, J. Jang, S. Jang, da T. Hwang, Amfani da haɗin gwiwar jiyya na 3rd-ƙarni cephalosporin, azithromycin da antiviral jamiái a kan matsakaici SARs-CoV-2 marasa lafiya a Koriya ta Kudu: A cohort retros Mayu 2022, PLOS ONE, juzu'i na 17, fitowa ta 5, shafi e0267645
MAGANIN LAFIYA 30 mai haƙuri HCQ marigayi magani PSM binciken: 25% farfadowa da sauri (p=0.45), 13% tsayin asibiti (p=0.75), kuma babu canji a cikin izinin hoto (p=0.99).
Marasa lafiya na asibiti na 25 na baya da aka bi da su tare da cephalosporin, azithromycin, da HCQ, da 217 marasa lafiya na kulawa a Koriya ta Kudu, ba da rahoton wani bambance-bambance masu mahimmanci. An cire marasa lafiya 5 da ke karɓar lopinavir / ritonavir da HCQ> 5 kwanaki don dalilan da ba a sani ba. An fara HCQ yawanci bisa ga ci gaba ko illa daga wani magani. An bayar da rahoton sakamako masu karo da juna. Teburin 2 yana nuna marasa lafiya na 15 CA / HCQ bayan daidaitawa, yayin da S2 ke nuna 25, kuma ƙididdigar 3 ba ta da komai. S2 ya bayyana yana nunawa ba daidai ba kafin sakamako daidai, kuma sakamakon madaidaicin ya ɓace a cikin Tebur 3. 200mg HCQ tayin ba a daidaita shi ba. https://c19p.org/hong2
225. A. Bassets-Bosch, J. Raya-Muñoz, N. Wörner-Tomasa, S. Melendo-Pérez, da S. González-Peris, Negativización de PCR a SARS-CoV-2 en muestra respiratoria en pacientes con necesidad de asistencia recurrente. Afrilu 2022, Anales de Pediatría, Juzu'i na 96, Fitowa ta 4, Shafi na 357-359
MAGANIN LAFIYA 15 mai haƙuri HCQ marigayi nazarin jiyya: 29% saurin kamuwa da cutar hoto (p=0.45).
Marasa lafiya na yara 15 na baya-bayan nan a cikin Spain, suna nuna saurin kamuwa da cuta tare da HCQ+AZ, ba tare da mahimmancin ƙididdiga ba. Ba a bayar da lokacin jiyya da cikakkun bayanai ba. https://c19p.org/bassetsbosch
226. L. Rangel, P. Shah, K. Lo Sicco, A. Caplan, da A. Femia, Nau'in Hydroxychloroquine Therapy da Sakamakon COVID-19: Binciken Nazari Na Ci gaba Jan 2021, J. Cibiyar Nazarin Kwayoyin cuta ta Amurka, juzu'i na 84, fitowa ta 6, Shafi na 1769-1772
153 mai haƙuri HCQ nazarin prophylaxis: 25% ƙananan mace-mace (p=0.77) da 22% ƙananan asibiti (p=0.29).
Marasa lafiya 50 na COVID-19 na baya-bayan nan waɗanda ke ɗaukar HCQ na yau da kullun, idan aka kwatanta da samfurin da ya dace na marasa lafiya waɗanda ba sa ɗaukar HCQ na yau da kullun, suna nuna ƙarancin mace-mace da shigar da ICU, da gajeriyar asibiti ga marasa lafiyar HCQ, amma ba ƙididdiga ba saboda ƙananan adadin abubuwan da suka faru. Ainihin fa'ida ga HCQ na iya zama mafi girma. Binciken bai yi magana game da haɗarin rashin lafiya isa ya ziyarci asibiti ba. Mai yiwuwa masu amfani da HCQ suna iya kamuwa da cututtukan cututtukan ƙwayoyin cuta na tsarin jiki kuma marubuta ba sa daidaitawa don haɗarin tushe daban-daban ga waɗannan marasa lafiya. Wani bincike ya nuna cewa haɗarin COVID-19 ga masu cutar cututtukan ƙwayoyin cuta sun fi girma gabaɗaya, Ferri et al. nuna KO 4.42, p<0.001. https://c19p.org/rangel
227. E. Synolaki, V. Papadopoulos, G. Divolis, E. Gavriilidis, G. Loli, A. Gavriil, C. Tsigalou, O. Tsahouridou, E. Sertaridou, P. Rafailidis, A. Pasternack, D. Boumpas, G. Germanidis, O. Ritvos, S, P. Meta. Activin/Follistatin-axis an soke shi sosai a cikin COVID-19 kuma yana da alaƙa da mace-mace a asibiti. Satumba 2020, medRxiv
MAGANIN LAFIYA 312 mai haƙuri HCQ marigayi nazarin jiyya: 24% ƙananan mace-mace (p=0.27).
Marasa lafiya 117 na baya-bayan nan, 58 HCQ yana nuna ƙarancin mace-mace ga marasa lafiya na HCQ. Shafin 1 na wannan takarda ya bayyana: "HCQ, AZ, [da ...] an gano suna da alaƙa da rayuwa yayin da aka fara jiyya a maki FACTCLINYCoD <3." https://c19p.org/synolaki
228. M. González, E. Gonzalo, I. Lopez, F. Fernández, J. Pérez, D. Monge, J. Núñez, R. Fenoll, C. Fernández, S. Castro, M. Bailon, I. Fraile, M. Madrazo, P. Fontan, J. Gamboa, A. Garcíiz, A. Garcíiz, A. Arostegui, A. Erdozain, C. Cilleros, J. Amigo, F. Epelde, C. Bermejo, da J. Santos, The Prognostic Value of Eosinophil farfadowa da na'ura a cikin COVID-19: A Multicentre, Retrospective Cohort Nazarin a kan Marasa lafiya Asibiti a Asibitocin Spain Agusta 2020, medRxiv
MAGANIN LAFIYA 9,644 mai haƙuri HCQ nazarin jiyya na ƙarshen: 27% ƙananan mace-mace (p=0.06).
Binciken na baya-bayan nan ya mayar da hankali kan farfadowa na eosinophil tare da 9,644 marasa lafiya na asibiti a Spain, yana nuna ƙananan mace-mace ga HCQ (14.7% vs 29.2%, p<0.001), da AZ (15.3% vs. 18.4%, p <0.001). Tare da nau'in nau'i-nau'i masu yawa ciki har da abubuwan da za su iya rikicewa, HCQ da AZ suna hade da ƙananan mace-mace, HCQ KO 0.662, p=0.057. https://c19p.org/gonzalez2
229. J. Trullàs, E. Ruiz, C. Weisweiler, G. Badosa, A. Serra, H. Briceño, S. Soler, da J. Bisbe, Babban mace-mace a asibiti sakamakon COVID-19 a wani asibitin al'umma a Spain: nazari mai zuwa na lura. Jul 2020, Dandalin Bincike
MAGANIN LAFIYA 100 mai haƙuri HCQ marigayi nazarin jiyya: 36% ƙananan mace-mace (p=0.12).
Marasa lafiya 100 na asibiti a Spain suna nuna ƙarancin mace-mace tare da HCQ+AZ. https://c19p.org/trullas
230. N. Klebanov, V. Pahalyants, J. Said, W. Murphy, N. Theodosakis, J. Scarry, S. Duey, M. Klevens, E. Lilly, da Y. Semenov, Antimalarials ba su da tasiri kamar Pre-Exposure Prophylaxis for COVID-19: A Retrospective Matched Control Stule Jun 2023, J. Drugs in Dermatology, juzu'i na 22, fitowa ta 8, Shafi na 840-843
62,069 mai haƙuri HCQ nazarin prophylaxis: 31% ƙananan mace-mace (p=0.8) da 6% ƙarin lokuta (p=0.7).
Marasa lafiya 3,074 na baya bayan nan tare da rubutattun maganin zazzabin cizon sauro da kuma 58,955 masu dacewa da sarrafawa, suna nuna babu wani bambance-bambance mai mahimmanci tare da rigakafin cutar maleriya don lokuta PCR + (99% HCQ). Marubuta suna ba da sakamakon PCR + kawai da sakamakon mace-mace, kuma ba sa samar da matsakaicin sakamakon asibiti wanda zai iya nuna fa'ida mai mahimmanci. Marubuta ba sa daidaitawa don mabambantan haɗarin asali ga marasa lafiya na tsarin rigakafi. Wani bincike ya nuna cewa haɗarin COVID-19 ga masu cutar cututtukan ƙwayoyin cuta sun fi girma gabaɗaya, Ferri et al. nuna KO 4.42, p<0.001 (ga cututtukan cututtuka). https://c19p.org/klebanov
231. K. Cárdenas-Jaén, S. Sánchez-Luna, A. Vaillo-Rocamora, M. Castro-Zocchi, L. Guberna-Blanco, D. Useros-Brañas, J. Remes-Troche, A. Ramos-De la Medina, B. Priego-Parra, J. Velarde-Ruiztísco, P.yaztísco, P.yaztísco, P.yaztísco, P.yaztísco, Pa. Urzúa, D. Guiñez-Francois, K. Pawlak, K. Kozłowska-Petriczko, I. Gorroño-Zamalloa, C. Urteaga-Casares, I. Ortiz-Polo, A. Del Val Antoñana, E. Lozada-Hernández, E. Obregón. Domper-Arnal, D. Casas-Deza, E. Esteban-Cabello, L. Díaz, A. Riquelme, H. Martínez-Lozano, F. Navarro-Romero, I. Olivas, G. Iborra-Muñoz, A. Calero-Amaro, I. Caravaca-García, Ra. Lapeña-Muñoz, V. Sastre-Lozano, N. Pizarro-Vega, L. Melcarne, M. Pedrosa-Aragon, J. Mira, A. MStat, I. Carrillo, da E. De-Madaria, Gastrointestinal bayyanar cututtuka da rikice-rikice a cikin marasa lafiya da aka kwantar da su a asibiti saboda COVID-19, nazarin haɗin gwiwa na duniya da yawa) Jun 2023, Gastroenterología y Hepatología, juzu'i na 46, fitowa ta 6, Shafi na 425-438
MAGANIN LAFIYA 829 mai haƙuri HCQ marigayi nazarin jiyya: 56% ƙananan ƙananan lokuta (p=0.13).
A baya-bayan nan 829 marasa lafiya na COVID-19 da ke asibiti a Spain sun mai da hankali kan alamun gastrointestinal, suna nuna ƙananan haɗarin COVID-19 mai tsanani tare da jiyya na HCQ a cikin nazarin bivariate, ba tare da mahimmancin ƙididdiga ba. https://c19p.org/cardenasjaen
232. W. Hafez, H. Saleh, Z. Al Baha, M. Tariq, S. Hamdan, da S. Ahmed, Antiviral An Yi Amfani da shi a Tsakanin Laifukan COVID-19 marasa Mutunci dangane da Lokaci har zuwa Ciwon Kwayar cuta: Nazarin Ƙungiya mai Komawa. Afrilu 2022, Magungunan rigakafi, Juzu'i na 11, fitowa ta 4, Shafi na 498
MAGANIN LAFIYA 1,486 mai haƙuri HCQ marigayi nazarin jiyya: 12% saurin kamuwa da cutar hoto (p=0.59).
Marasa lafiya na asibiti na dawowa a cikin Hadaddiyar Daular Larabawa, ba su nuna wani bambanci mai mahimmanci a cikin kawar da kwayar cuta tare da haɗuwa daban-daban na HCQ, AZ, favipiravir, da lopinavir/ritonavir. https://c19p.org/hafez
233. A. Beaumont D. Vignes C. Guillet-Caruba, J. Téglas, da S. Abgrall, Abubuwan da ke da alaƙa da shigar da asibiti da sakamako mara kyau ga COVID-19: Matsayin abubuwan zamantakewa da kulawar likita Feb 2022, Cututtuka Masu Yaduwa Yanzu
MAGANIN LAFIYA 296 mai haƙuri HCQ marigayi nazarin jiyya: 14% ƙananan haɗewar mace-mace / intubation (p=0.55).
Marasa lafiya na asibiti na 296 na baya-bayan nan a Faransa, suna nuna babu wani bambanci mai mahimmanci tare da jiyya na HCQ. https://c19p.org/beaumont
234. H. Uygun, Tasirin Amfani da Hydroxychloroquine akan Tsawon Zaman Asibiti a Yara da Aka Gano Tare da Covid 19 Satumba 2021, Northern Clinics na Istanbul
MAGANIN LAFIYA 40 mai haƙuri HCQ marigayi nazarin jiyya: 12% saurin kamuwa da cutar hoto (p=0.05).
Marasa lafiya na asibiti na yara 40 na baya-bayan nan, 15 da aka bi da su tare da HCQ, suna nuna 7.2 vs. 8.2 kwanaki har PCR-, ba a kai ga mahimmancin ƙididdiga ba. https://c19p.org/uygen
235. M. Gonenli, I. Kayi, N. Alpay-Kanitez, T. Baydas, M. Kose, E. Nalbantoglu, M. Keskinler, T. Akpinar, da O. Ergonul, Analysis na Prophylactic amfani da Hydroxychloroquine a farkon cutar COVID-19 a tsakanin Likitoci. Dec 2020, Cututtuka masu Yaduwa da Ƙwayoyin Halitta na Clinical, Juzu'i na 4, Fitowa ta 4, Shafi na 236-243
564 mai haƙuri HCQ nazarin prophylaxis: 30% ƙananan ci gaba (p=0.77) da 19% ƙarin lokuta (p=0.58).
Ƙananan binciken prophylaxis yana nuna ƙananan, amma ba ƙididdiga ba, ci gaba zuwa ciwon huhu (3 na 148 HCQ, 12 na 416 iko), RR 0.70, p = 0.77. An sami mafi yawan lokuta na lokuta tare da HCQ, OR 1.19, p = 0.58, wanda zai iya zama saboda ra'ayin binciken, zaɓin magani, da kuma tsarin da ba daidai ba. Haɓakawa akan tsananin ƙila yana da alaƙa da mafi girman maida hankali na HCQ a cikin nama na huhu, kuma yana nuna cewa PCR na binary baya bambanta kwafi-ƙwarewa. Cikakkun bayanai na lambobin ciwon huhu don magani / sarrafawa daga marubucin, ba a san dalilin da yasa ba a ba da rahoton ƙananan ci gaba zuwa ciwon huhu a cikin takarda ba. https://c19p.org/gonenli
236. L. Orioli, T. Servais, L. Belkhir, P. Laterre, J. Thissen, B. Vandeleene, D. Maiter, J. Yombi, da M. Hermans, Halittu na asibiti da kuma tsinkayar gajeren lokaci na marasa lafiya da ciwon sukari da kuma COVID-19: Nazarin sake dubawa daga cibiyar ilimi a Belgium Dec 2020, Ciwon sukari & Ciwon Jiki: Bincike na Clinical & Reviews, Juzu'i 15, fitowa ta 1, Shafi na 149-157
MAGANIN LAFIYA 73 mai haƙuri HCQ marigayi nazarin jiyya: 13% ƙananan mace-mace (p=1).
Ƙananan nazarin baya na 73 masu ciwon sukari a Belgium, 55 marasa lafiya na HCQ, suna nuna HCQ RR 0.87, p = 1.0. https://c19p.org/orioli
237. S. Peng, H. Wang, X. Sun, P. Li, Z. Ye, Q. Li, J. Wang, X. Shi, L. Liu, Y. Yao, R. Zeng, F. He, J. Li, S. Ge, X. Ke, Z. Zhou, E. Dong, H. Wang, G. Xu, L. Zhang, da kuma farkon ciwon koda a tsakanin marasa lafiya da cutar COVID-19 da marigayi Zha. karatu na multicenter daga Wuhan, China Dec 2020, Nephrology Dialysis Transplantation, juzu'i na 35, fitowa ta 12, Shafi na 2095-2102
MAGANIN LAFIYA 4,020 mai haƙuri HCQ marigayi nazarin jiyya: 11% ƙananan ci gaba (p=0.63).
Marasa lafiya 4020 da ke asibiti a China na baya-bayan nan suna nuna ƙarancin ƙarancin haɗarin rauni na koda tare da HCQ. https://c19p.org/peng
238. A. Rodríguez, G. Moreno, J. Gómez, R. Carbonell, E. Picó-Plana, C. Benavent Bofill, R. Sánchez Parrilla, S. Trefler, E. Esteve Pitarch, L. Canadell, X. Teixido, L. Claverias, da M. Bodí, da cutar sankara-Coronavirus na SARS-Corona. babban asibiti tare da marasa lafiya na COVID-2 yayin bala'in 19 Nov 2020, Medicina Intensiva, juzu'i na 44, fitowa ta 9, Shafi na 525-533
MAGANIN LAFIYA 43 mai haƙuri HCQ marigayi nazarin jiyya: 59% ƙananan mace-mace (p=0.23).
Ƙananan binciken da ake tsammani na marasa lafiya na asibiti na 43 tare da 39 suna shan HCQ, yana nuna haɗarin mace-mace da ba a daidaita ba RR 0.41, p=0.23. https://c19p.org/rodriguez
239. M. Rivera-Izquierdo, M. Valero-Ubierna, J. R-delAmo, M. Fernández-García, S. Martínez-Diz, A. Tahery-Mahmoud, M. Rodríguez-Camacho, A. Gámiz-Molina, N. Barba-Gyengo, P. Gyeroz, Cabrezari, C. P. Guirado-Ruiz, D. Martín-Romero, A. Láinez-Ramos-Bossini, M. Sánchez-Pérez, J. Mancera-Romero, M. García-Martín, L. Martín-delosReyes, V. Martínez-Ruiz, da kuma E. Jiménez-Mentes ujíra te238, A. Jiménez-Mejis, A. pacientes hospitalizados por COVID-19 y su relación con la mortalidad Jul 2020, Medicina Clínica, juzu'i na 155, fitowa ta 9, Shafi na 375-381
MAGANIN LAFIYA 238 mai haƙuri HCQ marigayi nazarin jiyya: 19% ƙananan mace-mace (p=0.75).
Marasa lafiya na asibiti na 238 na baya-bayan nan a Spain suna nuna ƙarancin mace-mace tare da HCQ, daidaitaccen haɗarin haɗari 0.81 [0.24-2.76]. https://c19p.org/riveraizquierdo
240. . Pourcher, Tausayi amfani da hydroxychloroquine a cikin aikin asibiti ga marasa lafiya masu rauni zuwa mai tsanani Covid-19 a wani asibitin jami'ar Faransa Jun 2020, Cututtukan Magunguna na asibiti, juzu'i na 73, fitowa ta 11, shafi e4064-e4072
MAGANIN LAFIYA 89 mai haƙuri HCQ marigayi nazarin jiyya: 11% ƙananan mace-mace (p=0.88).
A baya-bayan nan na 89 marasa lafiya na asibiti, rayuwa HR 0.89 [0.23-3.47], ba mahimmanci ba. Marubuta sun lura cewa ƙila masu rikicewar da ba a auna ba sun dawwama (ba a ƙididdige ƙididdige ƙididdige ƙima mai ƙima ba) kuma binciken na iya zama mara ƙarfi. https://c19p.org/paccoud
241. S. Hraiech, J. Bourenne, K. Kuteifan, J. Helms, J. Carvelli, M. Gainnier, F. Meziani, da L. Papazian, Rashin izinin kamuwa da kwayar cutar ta hanyar haɗin hydroxychloroquine da azithromycin ko lopinavir da ritonavir a cikin SARS-CoV-2 da ke da alaka da rashin lafiya na numfashi mai tsanani. Mayu 2020, Ann. Kulawa Mai Tsanani, juzu'i na 10, fitowa ta 1
MAGANIN LAFIYA 32 mai haƙuri HCQ ICU binciken: 65% ƙananan mace-mace (p=0.21) da 3% mafi muni mai saurin kamuwa da cuta (p=1).
Marasa lafiya na ICU 45 na baya-bayan nan, 17 da aka yi musu magani tare da HCQ+AZ, ba su nuna wani bambanci mai mahimmanci a kawar da kwayar cutar ba bayan kwanaki 6, ko mace-macen kwanaki 6 daga matsanancin ciwo na numfashi. https://c19p.org/hraiech
242. J. Magagnoli, S. Narendran, F. Pereira, T. Cummings, J. Hardin, S. Sutton, da J. Ambati, Sakamako na amfani da hydroxychloroquine a Amurka tsoffin sojojin da ke asibiti tare da Covid-19 Afrilu 2020, Med, Juzu'i na 1, Fitowa ta 1, Shafi na 114-127.e3
MAGANIN LAFIYA 807 mai haƙuri HCQ marigayi nazarin jiyya: 11% ƙananan mace-mace (p=0.74).
Marasa lafiya na asibiti 807 na baya-bayan nan, babu raguwar ƙididdiga mai mahimmanci a cikin mace-mace ko buƙatar iskar injin inji tare da HCQ ko HCQ + AZ, ko don mutuwa tare da HCQ+AZ, HR 1.83, p=0.009 don mutuwar HCQ. The bayanin kula preprint cewa HCQ ya fi dacewa da za a rubuta wa marasa lafiya da cututtuka masu tsanani, duk da haka an goge wannan a cikin sigar da aka buga. Marasa lafiya 425 suna da yanayin mutuwa ko fitarwa a ƙarshen lokacin binciken don haka bai ci karo da batun tsawaita tsayuwar daka ba da bambance-bambancen adadin abubuwan lura da dama a tsakanin kungiyoyin.. Hakanan duba wannan yanki akan zargin "na ban mamaki" rashin da'ar kimiyya ta marubucin marubucin Jami'ar South Carolina Pharmacy Farfesa Farfesa Joseph Magagnoli, kuma bugu da žari yana misalta matalauta ko rashin cancantar tsarin bitar ɗan jarida. https://c19p.org/magagnoli
243. S. Yegorov, M. Goremykina, R. Ivanova, S. Good, D. Babenko, A. Shevtsov, K. MacDonald, da Y. Zhunussov, Epidemiological da Clinical Halayen, da Virologic Features na COVID-19 Marasa lafiya a Kazakhstan: Kasa-Wide, Retrospective Skill. Jan 2021, medRxiv
MAGANIN LAFIYA 1,072 mai haƙuri HCQ marigayi nazarin jiyya: 95% ƙananan mace-mace (p=1).
Marasa lafiya 1,072 na asibiti a Kazakhstan suna nunawa babu mace-mace ga marasa lafiya na HCQ, duk da haka marasa lafiya 23 ne kawai suka sami magani - wannan sakamakon ba shi da mahimmanci a kididdiga. https://c19p.org/yegerov
244. . Oktoba 2020, medRxiv
MAGANIN LAFIYA 3,322 mai haƙuri HCQ nazarin jiyya na ƙarshen: 18% ƙananan mace-mace (p <0.0001).
Retrospective database binciken na 5683 marasa lafiya, 692 samu HCQ/CQ+AZ, 200 samu HCQ/CQ, 203 samu ivermectin, 1600 samu AZ, 358 samu ivermectin + AZ, da kuma 2630 samu daidaitattun kulawa. Wannan binciken ya haɗa da duk wanda ke da lambobin ICD-10 COVID-19 wanda ya haɗa da marasa lafiya na PCR + asymptomatic, don haka yawancin marasa lafiya a cikin rukunin kulawa suna iya asymptomatic dangane da SARS-CoV-2, amma a asibiti don wani dalili. Ga waɗanda ke da alamun COVID-19, akwai kuma yuwuwar mahimmanci mai ruɗani da nuni. A cikin wannan binciken duk magunguna suna nuna yawan mace-mace a rana ta 30, wanda ya yi daidai da asymptomatic (na COVID-19) ko marasa lafiya marasa lafiya sun zama ruwan dare a cikin rukunin kulawa. Don ivermectin suna nuna mutuwar kwanaki 30 aHR = 1.39 [0.88 - 2.22]. KM masu lankwasa sun nuna cewa ƙungiyoyin jiyya sun kasance cikin mawuyacin hali, da kuma cewa bayan kimanin rana 35 tsira ya zama mafi kyau tare da ivermectin. Ranar ƙarshe don ivermectin yana nuna RR 0.83, p = 0.01. Fiye da jimlar yawan mace-mace ya faru a ranar farko. Wannan ya yi daidai da marasa lafiya da aka yi musu magani suna cikin yanayin da ya fi tsanani, kuma tare da da yawa daga cikin rukunin marasa lafiya suna asibiti don wani abu da bai da alaƙa da COVID-19. Marubuta suna amfani da a na'ura ta tushen tsarin makin ƙima wanda ya bayyana fiye da kima kuma mai yuwuwa ya haifar da gagarumin wuce gona da iri da sakamako mara inganci.. Ainihin, suna gwada duk hulɗar tsakanin covariates biyu da uku. Yanayin da adadi mai yawa na covariates yana nufin ana iya samun alaƙa da yawa bazuwar. Ba a amfani da tsananin COVID-19. Har ila yau, wannan binciken ba ya kwatanta jiyya tare da ƙungiyar kulawa ba ta karɓar magani ba - marubuta sun sanya marasa lafiya da ke karɓar jiyya bayan sa'o'i 48 a cikin ƙungiyar kulawa. Mawallafa sun bayyana cewa an cire sakamakon a cikin sa'o'i 24, duk da haka KM masu lankwasa suna nuna yawan mace-mace a rana ta 1 (kawai ga kungiyoyin jiyya). Da dama take hakkin yarjejeniya da bata data suna an kuma ruwaito a cikin wannan binciken. Mummunan ruɗani da ba a daidaita ba ta hanyar alama; ya haɗa da marasa lafiya na PCR+ waɗanda ke iya zama asymptomatic don COVID-19 amma suna kwance don wasu dalilai. https://c19p.org/sotobecerra
245. A. Shoaibi, S. Fortin, R. Weinstein, J. Berlin, da P. Ryan, Kwatancen Tasirin Famotidine a cikin Marasa lafiya na COVID-19 Satumba 2020, medRxiv
MAGANIN LAFIYA 29,451 mai haƙuri HCQ nazarin jiyya na ƙarshen: 15% ƙananan mace-mace (p=0.001).
Binciken bayanan da aka mayar da hankali kan Famotidine amma kuma yana nuna sakamako ga masu amfani da HCQ, tare da mutuwar da ba a daidaita ba. RR 0.85, p<0.001 (13.6% vs. 16.1%). https://c19p.org/shoaibi
246. K. Fung, S. Baik, F. Baye, Z. Zheng, V. Huser, da C. McDonald, Tasirin magunguna na yau da kullun akan haɗari da tsananin COVID-19 a cikin tsofaffi marasa lafiya. Satumba 2021, PLoS DAYA, juzu'i na 17, fitowa ta 4, shafi e0266922
Nazarin prophylaxis na HCQ: 13% ƙananan mace-mace (p=0.15), 3% ƙananan asibiti (p=0.63), da 9% ƙananan lokuta (p=0.02).
Binciken bayanan bayanan baya na marasa lafiya 374,229 a cikin Amurka, ba tare da nuna bambanci mai mahimmanci tare da amfani da HCQ ba, duk da haka mawallafa ba su daidaitawa ga mabambantan haɗari na asali ga marasa lafiya na tsarin jiki. Wani bincike ya nuna cewa haɗarin COVID-19 ga masu cutar cututtukan ƙwayoyin cuta sun fi girma gabaɗaya, Ferri et al. nuna KO 4.42, p<0.001. Marubuta sun kwatanta da marasa lafiya waɗanda basu taɓa amfani da HCQ ba kuma tare da marasa lafiya waɗanda suka yi amfani da HCQ a baya. https://c19p.org/fung
247. D. De Gonzalo-Calvo, M. Molinero, I. Benítez, M. Perez-Pons, N. García-Mateo, A. Ortega, T. Postigo, M. García-Hidalgo, T. Belmonte, C. Rodríguez-Muñoz, J. González, G. Torres, A.-Monie, C.-Mono, G. Torres. Estella, L. Tamayo Lomas, A. Martínez de la Gándara, L. Socias, Y. Peñasco, M. De la Torre, E. Bustamante-Munguira, E. Gallego Curto, I. Martínez Varela, M. Martin Delgado, P. Vidal-Cortés, J. Lórcé P.Garo, J. Lorcé, J. Galego Curto, J. Lórcé P. Capez, J. Capez, J. Galego Añón, A. Loza-Vázquez, N. Carbonell, J. Marin-Corral, R. Jorge García, C. Barberà, A. Ceccato, L. Fernández-Barat, R. Ferrer, D. Garcia-Gasulla, J. Lorente-Balanza, R. Menéndez, J. Mongolass Bermejo-Martin, A. Torres, da F. Barbé, Mai rarraba microRNA na jini don tsinkayar mace-macen ICU a cikin marasa lafiya na COVID-19: binciken tabbatarwa da yawa Jun 2023, Binciken Numfashi, juzu'i na 24, fitowa ta 1
MAGANIN LAFIYA 491 mai haƙuri HCQ ICU binciken: 38% ƙananan mace-mace (p=0.23).
Marasa lafiya na 491 ICU na baya-bayan nan a Spain suna nuna ƙarancin mace-mace tare da HCQ ba tare da ƙimar ƙididdiga ba a cikin sakamakon da ba a daidaita ba. https://c19p.org/degonzalocalvo
248. A. Fernández-Cruz, A. Puyuelo, L. Núñez Martín-Buitrago, E. Sánchez-Chica, C. Díaz-Pedroche, R. Ayala, M. Lizasoain, R. Duarte, C. Lumbreras, da J. Antonio Vargas, Mafi girma mace-mace na marasa lafiya da marasa lafiya marasa lafiya idan aka kwatanta da marasa lafiya marasa lafiya na COVID-19ematology. ta hanyar rikice-rikice na thrombotic da haɓakar ARDS: Nazarin ƙungiyoyin da suka dace da shekaru Jan 2022, Kamuwa da cuta a cikin Ayyuka, juzu'i na 13, Shafi 100137
MAGANIN LAFIYA 71 mai haƙuri HCQ marigayi nazarin jiyya: 27% ƙananan mace-mace (p=0.47).
A baya-bayan nan 71 marasa lafiya na hematologic na asibiti a Spain, suna nuna ƙarancin mace-mace tare da jiyya na HCQ a cikin sakamakon da ba a daidaita ba kuma ba tare da ƙididdiga ba. https://c19p.org/fernandezcruz
249. G. Menardi, L. Infante, V. Del Bono, L. Fenoglio, D. Collotta, P. Macagno, C. Bedogni, M. Rebora, C. Fruttero, da M. Collino, Wani nazari na baya-bayan nan game da hanyoyin magunguna ga marasa lafiya na COVID-19 a wani asibitin Italiyanci a farkon lokacin cutar. Satumba 2021, PharmAdvances, Juzu'i na 3, fitowa ta 3, Shafi na 576
MAGANIN LAFIYA 277 mai haƙuri HCQ marigayi nazarin jiyya: 35% ƙananan mace-mace (p=0.12).
Marasa lafiya na asibiti na 277 na baya-bayan nan a Italiya, suna nuna ƙarancin mace-mace tare da jiyya na HCQ, ba su kai ga mahimmancin ƙididdiga ba, kuma batun rikicewa ta nuni. https://c19p.org/menardi
250. M. Mahto, A. Banerjee, B. Biswas, S. Kumar, N. Agarwal, P. Singh, Seroprevalence na IgG a kan SARS-CoV-2 da ƙaddararsa a tsakanin ma'aikatan kiwon lafiya na wani asibiti na COVID-19 na Indiya. Fabrairu 2021, Binciken Jini na Amurka J
689 mai haƙuri HCQ nazarin prophylaxis: 27% ƙananan ƙimar IgG (p=0.38).
Ma'aikatan kiwon lafiya na 689 na baya-bayan nan a Indiya, suna nuna babu wani muhimmin bambanci a cikin ingancin IgG tare da rigakafin HCQ a cikin sakamakon da ba a daidaita ba. https://c19p.org/mahto
251. B. Purandare, P. Rajhans, S. Jog, P. Dalvi, P. Prayag, P. Marudwar, H. Pawar, B. Pawar, N. Mahale, V. Narasimhan, G. Oak, S. Marreddy, A. Bedekar, P. Akole, B. Bhurke, S. Chavan, V. Diwaghane, D. M. Gugale, da S. Bhor, Wani Nazari na Tuna Baya na Majiyoyin Cutar COVID-19 da ake Jiyya da Magungunan Immunomodulatory a Asibitin Kula da Manyan Makarantu. Dec 2020, Indiya J. Maganin Kulawa Mai Mahimmanci, juzu'i na 24, fitowa ta 11, Shafi na 1020-1027
MAGANIN LAFIYA 134 mai haƙuri HCQ marigayi nazarin jiyya: 29% ƙananan mace-mace (p=0.36).
A baya-bayan nan 134 marasa lafiya na COVID-19 na asibiti a Indiya, ba su nuna wani babban bambanci tare da jiyya na HCQ a cikin sakamakon da ba a daidaita ba. https://c19p.org/mahaleh
252. A. Chari, M. Samur, J. Martinez-Lopez, G. Cook, N. Biran, K. Yong, V. Hungria, M. Engelhardt, F. Gay, A. García Feria, S. Oliva, R. Oostvogels, A. Gozzetti, C. Rosenbaum, S. Kumar, E., H. K. K. Stand Beks Weisel. Dec 2020, Jini, juzu'i na 136, fitowa ta 26, Shafi na 3033-3040
MAGANIN LAFIYA 502 mai haƙuri HCQ marigayi nazarin jiyya: 33% ƙananan mace-mace (p=0.17).
Marasa lafiya myeloma da yawa na baya-bayan nan suna nuna ƙarancin mace-mace tare da jiyya na HCQ, RR 0.67 ba daidai ba, p = 0.17 (bayanai yana cikin ƙarin kayan). https://c19p.org/chari
253. R. Bielza, J. Sanz, F. Zambrana, E. Arias, E. Malmierca, L. Portillo, I. Thuissard, A. Lung, M. Neira, M. Moral, C. Andreu-Vázquez, A. Esteban, M. Ramírez, L. González, G. Carretero, R. M. Esteban-Ortega, I. García, M. Vaquero, A. Linares, A. Gómez-Santana, da J. Gómez Cerezo, Halayen asibiti, rashin ƙarfi da mace-mace na mazauna tare da COVID-19 a cikin gidajen kulawa na wani yanki na Madrid Dec 2020, J. Ƙungiyar Daraktocin Likitoci ta Amirka, juzu'i na 22, fitowa ta 2, Shafi na 245-252.e2
MAGANIN LAFIYA 630 mai haƙuri HCQ marigayi nazarin jiyya: 22% ƙananan mace-mace (p=0.09).
Marasa lafiya 630 tsofaffi marasa lafiya a Spain suna nuna ƙarancin mace-mace tare da jiyya na HCQ, haɗarin dangi mara daidaituwa RR 0.78, p = 0.09. An yi amfani da HCQ sau da yawa tare da marasa lafiya da aka kwantar da su a asibiti (24% da 3% amfani a cikin gidajen kulawa). Matsakaicin shekaru 87. https://c19p.org/bielza
254. W. Qin, F. Dong, Z. Zhang, B. Hu, S. Chen, Z. Zhu, F. Li, X. Wang, Y. Zhang, Y. Wang, K. Zhen, J. Wang, I. Elalamy, C. Li, Z. Zhai, B. Davidson, da C. Wang, Low kwayoyin nauyi marasa lafiya tare da cutar sankara 28-2019 kamuwa da cutar heparin. nazarin ƙungiyar a farkon zamanin annoba Nov 2020, Binciken Thrombosis, Juzu'i na 198, Shafi na 19-22
MAGANIN LAFIYA 749 mai haƙuri HCQ marigayi nazarin jiyya: 34% ƙananan mace-mace (p=0.61).
Ƙananan nazarin heparin na kwayoyin halitta kuma yana nuna sakamako don maganin HCQ, rashin daidaituwa na HCQ mutuwar dangi hadarin RR 0.66, p = 0.61. https://c19p.org/qin
255. C. Santos, C. Morales, E. Álvarez, C. Castro, A. Robles, da T. Sandoval, Ƙayyade tsananin cutar COVID-19 a cikin marasa lafiya da ke fama da cututtukan rheumatic Jul 2020, Clinical Rheumatology, juzu'i na 39, fitowa ta 9, Shafi 2789-2796
MAGANIN LAFIYA 38 mai haƙuri HCQ marigayi nazarin jiyya: 26% ƙananan mace-mace (p=0.6).
Binciken da ake shirin yi na marasa lafiya na cututtukan rheumatic na asibiti guda 38 tare da COVID-19 a cikin Spain, wanda ke nuna babu mace-mace tare da amfani da HCQ na yanzu idan aka kwatanta da 32% ba tare da kaiwa ga mahimmancin ƙididdiga ba. Mawallafa kuma suna ba da rahoto game da amfani da HCQ/CQ bayan an kwantar da su a asibiti. Prophylaxis da jiyya na marigayi sakamakon sune da aka jera daban. https://c19p.org/santos2
256. S. Krishnan, K. Patel, R. Desai, A. Sule, P. Paik, A. Miller, A. Barclay, A. Cassella, J. Lucaj, Y. Royster, J. Hakim, Z. Ahmed, da F. Ghoddoussi, Clinical commorbidities, halaye, da kuma sakamakon na inji ventilated marasa lafiya a cikin SARS-CoVa Jihar Michigan p. Jul 2020, J Clin Aneth., juzu'i na 67, Shafi na 110005
MAGANIN LAFIYA 152 mai haƙuri HCQ marigayi nazarin jiyya: 20% ƙananan mace-mace (p=0.48).
A baya-bayan nan 152 marasa lafiya da ke da iska a cikin injina a cikin Amurka suna nuna ƙarancin mace-mace tare da bitamin C, bitamin D, HCQ, da jiyya na zinc, ƙididdiga mai mahimmanci ga bitamin C kawai. https://c19p.org/krishnan
257. J. Martínez-López, M. Mateos, C. Encinas, A. Sureda, J. Hernández-Rivas, A. Lopez de la Guía, D. Conde, I. Krsnik, E. Prieto, R. Riaza Grau, M. Gironella, M. Blanchard, N. Caminoz. de Senin, La Senin, Fér. J. De la Puerta, E. Giménez, P. Martínez-Barranco, J. Mateos, L. Casado, J. Bladé, J. Lahuerta, J. De la Cruz, da J. San-Miguel, Multiple Myeloma da SARS-CoV-2 Kamuwa: Halayen Clinical da Prognostic Factors of Inpactsality Morning Jun 2020, Ciwon Jini J., juzu'i na 10, fitowa ta 10
MAGANIN LAFIYA 167 mai haƙuri HCQ marigayi nazarin jiyya: 33% ƙananan mace-mace (p=0.2).
Matsakaicin 167 mahara myeloma marasa lafiya a Spain, ba tare da nuna bambanci mai mahimmanci a cikin mace-mace tare da maganin HCQ a cikin sakamakon da ba a daidaita ba tare da cikakkun bayanai na rukuni ba. https://c19p.org/martinezlopez
258. J. Goldman, D. Lye, D. Hui, K. Marks, R. Bruno, R. Montejano, C. Spinner, M. Galli, M. Ahn, R. Nahass, Y. Chen, D. SenGupta, R. Hyland, A. Osinusi, H. Cao, C. Blair, X. Wei, A. Brañer, J. Gaggar, D. K. Mullane, F. Marty, K. Tashima, G. Diaz, da A. Subramanian, Remdesivir na tsawon kwanaki 5 ko 10 a cikin Marasa lafiya tare da Mummunan Covid-19 Mayu 2020, NEJM, Juzu'i na 383, Fitowa ta 19, Shafi na 1827-1837
MAGANIN LAFIYA 397 mai haƙuri HCQ marigayi nazarin jiyya: 22% ƙananan mace-mace (p=0.46).
Nazarin ya mayar da hankali kan remdesivir amma tare da sakamako na HCQ a cikin ƙarin bayani, yana nuna mutuwar 9% tare da HCQ tare da sarrafawa 12%, haɗarin dangi mara daidaita uRR 0.78, p = 0.46. https://c19p.org/goldmanh
259. M. Martin-Vicente, R. Almansa, I. Martínez, A. Tedim, E. Bustamante, L. Tamayo, C. Aldecoa, J. Gómez, G. Renedo, J. Berezo, J. Cedeño, N. Mamolar, P. Olivares, R. Hergerán, R. Orgerán, A. De la Fuente, J. Bustamante-Munguira, M. Muñoz-Gómez, M. González-Rivera, C. Puertas, V. Más, M. Vázquez, F. Pérez-García, J. Rico-Feijoo, S. Martín, A. Motos., Erat M. Fernan Dominguez-Gil, R. Ferrer, F. Barbé, D. Kelvin, J. Bermejo-Martin, S. Resino, da A. Torres, Rashin ko rashin isassun ƙwayoyin rigakafin SARS-CoV-2 S a shigar da ICU suna da alaƙa da babban nauyin hoto mai hoto a cikin plasma, antigenemia da mace-mace a cikin marasa lafiya na COVID-19 Maris 2021, medRxiv
MAGANIN LAFIYA 92 mai haƙuri HCQ ICU binciken: 59% ƙananan mace-mace (p=0.41).
Marasa lafiya na ICU 92 na baya-bayan nan tare da kusan duk waɗanda aka yi musu magani tare da HCQ kuma mara lafiya ɗaya kawai wanda ba HCQ ba wanda ya mutu, yana nuna ƙarancin mace-mace marasa mahimmanci tare da jiyya. https://c19p.org/martinvicente
260. R. Alqassieh, I. Bsisu, M. Al-Sabbagh, N. El-Hammuri, M. Yousef, M. El Jarbeh, A. Sharqawi, H. Smadi, S. Abu-Halaweh, da M. Abufaraj, Halayen asibiti da masu hasashen tsawon lokacin zaman asibiti a cikin marasa lafiya na COVID-19 a Jordan Dec 2020, F1000Bincike, Juzu'i na 9, Shafi na 1439
MAGANIN LAFIYA 131 mai haƙuri HCQ marigayi magani binciken: 18% guntu asibiti (p=0.11).
Nazarin lura mai yiwuwa na marasa lafiya 131 COVID-19 a cikin Jordan, yana nuna 18% gajarta zaman asibiti tare da HCQ, p = 0.11. https://c19p.org/alqassieh
261. A. Desbois, C. Marques, L. Lefèvre, S. Barmo, C. Lorenzo, M. Leclercq, G. Leroux, C. Comarmond, C. Chapelon, F. Domont, M. Vautier, D. Saadoun, da P. Cacoub, Yawaita da sifofin asibiti na marasa lafiya na COVID-19 a cikin babban haɗin gwiwa na 199idcohort. Jul 2020, Dandalin Bincike
199 mai haƙuri HCQ nazarin prophylaxis: 17% ƙananan lokuta (p=1).
Marasa lafiya na sarcoidosis na 199 na baya-bayan nan suna nuna HCQ RR 0.83 mara ƙididdiga, p=1.0. https://c19p.org/desbois
262. M. Shabrawishi, A. Naser, H. Alwafi, A. Aldobyany, da A. Touman, Negative nasopharyngeal SARS-CoV-2 PCR jujjuya don mayar da martani ga daban-daban na warkewa shisshigi. Mayu 2020, medRxix
MAGANIN LAFIYA 93 mai haƙuri HCQ marigayi nazarin jiyya: 15% inganta ƙwayar cuta (p=0.66).
Marasa lafiya na asibiti na 93 na baya-bayan nan a Saudi Arabiya suna nuna raguwar 15% mara ƙididdiga a cikin sakamako mai kyau na PCR a ranar 5, RR 0.85, p = 0.65. Ƙungiyar jiyya ta sami rashin lafiya mai tsanani da kuma yawan marasa lafiya na maza. https://c19p.org/shabrawishi
263. J. Chen, D. Liu, L. Liu, P. Liu, Q. Xu, L. Xia, Y. Ling, D. Huang, S. Song, D. Zhang, Z. Qian, T. Li, Y. Shen, H. Lu, Nazarin matukin jirgi na hydroxychloroquine a cikin kula da marasa lafiya da ke fama da cutar sankara-19 (COVID-19) Maris 2020, Jami'ar J. Zhejiang
MAGANIN LAFIYA 30 mai haƙuri HCQ marigayi magani RCT: 29% ƙananan ci gaba (p = 0.57) da 100% mafi muni mai saurin kamuwa da cuta (p=1).
Matsakaicin lokuta 30 na asibiti, duk sun warke. Lokaci zuwa RNA mara kyau kwatankwacinsa. Ƙananan ci gaba na rediyo tare da HCQ amma ba ƙididdiga ba. Ɗaya daga cikin majinyacin HCQ ya haɓaka zuwa wani yanayi mai tsanani. Ƙungiyar jiyya 4 shekaru da haihuwa da kuma tare da yawan hauhawar hauhawar jini. https://c19p.org/chenmedsci
264. R. Sarhan, H. Harb, A. Abou Warda, M. Salem-Bekhit, F. Shakeel, S. Alzahrani, Y. Madney, da M. Boshra, Ingantaccen magani na farko tare da tocilizumab-hydroxychloroquine da tocilizumab-remdesivir a cikin marasa lafiya na COVID-19 mai tsanani. Nov 2021, J. Kamuwa da Lafiyar Jama'a, juzu'i na 15, fitowa ta 1, Shafi na 116-122
MAGANIN LAFIYA 108 mai haƙuri HCQ marigayi magani RCT: 26% ƙananan mace-mace (p=0.39), 26% mafi girma fitarwa na asibiti (p=0.39), da 25% tsawon asibiti (p=0.06).
Ƙananan majiyyaci 108 RCT yana kwatanta HCQ vs. remdesivir a cikin jiyya na ƙarshen lokaci. Duk marasa lafiya sun sami tocilizumab. Akwai bambance-bambance masu mahimmanci waɗanda ba a daidaita su ba a cikin iska da shigar da ICU. Saukewa: NCT04779047. https://c19p.org/sarhan
265. P. Salvador, P. Oliveira, T. Costa, M. Fidalgo, R. Neto, M. Silva, C. Figueiredo, V. Afreixo, T. Gregório, da L. Malheiro, Siffofin Clinical da Abubuwan Hasashen Ma'aikatan Portugal 245 da ke Asibiti Tare da COVID-19 Maris 2021, Cureus
MAGANIN LAFIYA 245 mai haƙuri HCQ marigayi nazarin jiyya: 33% ƙananan mace-mace (p=0.1), 448% mafi girma samun iska (p=0.003), da 17% ƙananan haɗewar mace-mace / intubation (p=0.21).
Binciken da ake shirin yi na marasa lafiya na asibiti na 245, 121 da aka bi da su tare da HCQ, yana nuna ƙananan (ba tare da ƙididdiga ba) mace-mace da mafi girma samun iska a cikin kwanaki 30. Mai yiwuwa mai ruɗawa ta nuni. https://c19p.org/salvador
266. M. Naseem, H. Arshad, S. Hashmi, F. Irfan, da F. Ahmed, Hasashen mace-mace a cikin SARS-COV-2 (COVID-19) tabbataccen marasa lafiya a cikin marasa lafiya ta hanyar amfani da Novel Deep Neural Network Dec 2020, medRxiv
MAGANIN LAFIYA 1,214 mai haƙuri HCQ marigayi nazarin jiyya: 33% ƙananan mace-mace (p=0.34).
Marasa lafiya na asibiti na 1,214 a Pakistan, marasa lafiya na 77 HCQ, suna nuna 33% ƙananan mace-mace tare da HCQ, multivariate Cox HR 0.67, p = 0.34. https://c19p.org/naseem
267. E. Afşin, Abubuwan da ke shafar tsinkaya da mace-mace a cikin masu fama da cutar huhu na COVID-19 Yuli 2023, Acta Clinica Croatica
MAGANIN LAFIYA 80 mai haƙuri HCQ marigayi nazarin jiyya: 17% ƙananan mace-mace (p=0.5).
A baya-bayan nan an kwantar da marasa lafiya 80 masu tsanani na COVID-19 a asibiti a Turkiyya, ba tare da nuna wani bambanci mai mahimmanci tare da jiyya na HCQ a cikin sakamakon da ba a daidaita ba. Duk marasa lafiya sun sami favipiravir. https://c19p.org/afsin
268. A. Shukla, S. Atal, A. Banerjee, R. Jhaj, S. Balakrishnan, P. Chugh, D. Xavier, A. Faruqui, A. Singh, R. Raveendran, J. Mathaiyan, J. Gauthaman, U. Parmar, R. Tripathi, S. Kamat, N. Trivedi, P. Kumar, D. Badyal, M. Sharma, M. Singla, B. Medhi, A. Prakash, R. Joshi, N. Chatterjee, J. Cherian, V. Kamboj, da N. Kshirsagar, Wani bincike mai zurfi na COVID-19 a tsakanin ma'aikatan kiwon lafiya. Dec 2022, Lafiyar Yanki na Lancet - Kudu maso Gabashin Asiya, juzu'i na 10, Shafi na 100129
679 mai haƙuri HCQ nazarin prophylaxis: 5% ƙananan PASC (p=0.78).
Ma'aikatan kiwon lafiya 679 na baya-bayan nan sun biyo bayan sallamar COVID-19, 76 suna amfani da rigakafin HCQ, wanda ba ya nuna wani babban bambanci a cikin sequalae na bayan-wuta na covid. https://c19p.org/shukla
269. C. Hall, J. Jacobs, A. Stammers, J. St. Louis, J. Hayanga, M. Firstenberg, L. Mongero, E. Tesdahl, K. Rajagopal, F. Cheema, K. Patel, T. Coley, A. Sestokas, M. Slepian, da V. Badhwar, Multi-Cibiyoyin 505 na COVID-19 Taimakawa tare da Taimakon Ma'aikata na XNUMX. na Tsira Feb 2022, Littattafai na Surgery na Thoracic
MAGANIN LAFIYA 505 mai haƙuri HCQ ICU binciken: 11% ƙananan mace-mace (p=0.31).
Tsinkaya extracorporeal membrane oxygenation (mafi girman haɗarin likita sa baki) marasa lafiya da ke nuna babu bambanci mai mahimmanci a cikin mace-mace a sakamakon da ba a daidaita su ba. https://c19p.org/hall
270. H. Alwafi, M. Shabrawishi, A. Naser, A. Aldobyany, S. Qanash, da A. Touman, Juyawar Nasopharyngeal SARS-CoV-2 PCR a cikin Amsa ga Matsalolin Jiyya daban-daban Jan 2022, Cureus
MAGANIN LAFIYA 93 mai haƙuri HCQ marigayi nazarin jiyya: 15% inganta ƙwayar cuta (p=0.65).
Marasa lafiya na asibiti 93 na baya-bayan nan a Saudi Arabiya, 45 da aka yi musu magani tare da CQ/HCQ, ba su nuna wani bambanci mai mahimmanci a kawar da kwayar cutar ba. Ƙarin marasa lafiya da aka bi da su tare da CQ / HCQ suna da lokuta masu tsanani a asali (20% vs. 2%). https://c19p.org/alwafi
271. B. Tu, S. Lakoh, B. Xu, M. Lado, R. Cole, F. Chu, S. Hastings-Spaine, M. Jalloh, J. Zheng, W. Chen, da S. Sevalie, Abubuwan Haɗari ga Tsanani da Mutuwa a cikin Manyan Marasa lafiya An Tabbatar da COVID-19 a Saliyo S. Jan 2022, Cututtuka masu Yaduwa & rigakafi, juzu'i na 2, fitowa ta 2, Shafi na 83-92
MAGANIN LAFIYA 180 mai haƙuri HCQ marigayi nazarin jiyya: 17% ƙananan mace-mace (p=0.81).
A baya-bayan nan 180 marasa lafiya na COVID-19 da ke asibiti a Saliyo, ba su nuna wani bambanci mai mahimmanci tare da jiyya na HCQ a cikin sakamakon da ba a daidaita su ba, duk da haka HCQ ya kasance mai yuwuwa a yi amfani da shi ga marasa lafiya masu tsanani (33% vs. 12%). https://c19p.org/tu
272. M. Turrini, A. Gardellini, L. Beretta, L. Buzzi, S. Ferrario, S. Vasile, R. Clerici, A. Colzani, L. Liparulo, G. Scognamiglio, G. Imperiali, G. Corrado, A. Strada, M. Galletti, N. Castiglione, da kuma C. Factors Zangon da kuma Clinical Coctorsson, da kuma Clinic-C. Mutuwar majinyata 205 da ke dauke da cutar huhu ta SARS-CoV-2 a Como, yankin Lombardy, Italiya Jun 2021, Alurar riga kafi, juzu'i na 9, fitowa ta 6, shafi na 640
MAGANIN LAFIYA 205 mai haƙuri HCQ marigayi nazarin jiyya: 10% ƙananan mace-mace (p=0.15).
Marasa lafiya na 205 na baya-bayan nan a Italiya, 160 da aka bi da su tare da HCQ, suna nuna ƙarancin mace-mace tare da jiyya a cikin bincike mai yawa, amma ba kai ga mahimmancin ƙididdiga ba. https://c19p.org/turrini
273. M. Haji Aghajani, O. Moradi, H. Amini, H. Azhdari Tehrani, E. Pourheidar, M. Rabiei, da M. Sistanizad, Rage yawan mace-mace a asibiti da ke da alaƙa da maganin aspirin a cikin marasa lafiya na asibiti saboda tsananin COVID-19. Afrilu 2021, J. Likitan Virology, juzu'i na 93, fitowa ta 9, Shafi 5390-5395
MAGANIN LAFIYA 991 mai haƙuri HCQ marigayi nazarin jiyya: 19% ƙananan mace-mace (p=0.09).
Marasa lafiya na asibiti 991 na baya-bayan nan a Iran, suna nuna ƙarancin mace-mace tare da HCQ, ba su kai ga mahimmancin ƙididdiga ba. https://c19p.org/hajiaghajani
274. M. Haji Aghajani, O. Moradi, H. Amini, H. Azhdari Tehrani, E. Pourheidar, M. Rabiei, da M. Sistanizad, Rage Mutuwar Asibiti Tare da Gudanar da Aspirin a Majinyatan Asibiti Sakamakon Mummunan COVID-19 Afrilu 2021, J. Likitan Virology, juzu'i na 93, fitowa ta 9, Shafi 5390-5395
MAGANIN LAFIYA 991 mai haƙuri HCQ marigayi nazarin jiyya: 19% ƙananan mace-mace (p=0.09).
Marasa lafiya na asibiti 991 na baya-bayan nan a Iran suna mai da hankali kan amfani da aspirin amma kuma suna nuna sakamako ga HCQ, remdesivir, da favipiravir. https://c19p.org/aghajani
275. K. Pham, H. Torres, M. Satlin, P. Goyal, da R. Gulick, Kasawar hydroxychloroquine na yau da kullun don hana rikice-rikice na COVID-19 a cikin marasa lafiya da cututtukan rheumatic Maris 2021, Ci gaban Rheumatology a Aiki, juzu'i na 5, fitowa ta 1
42 mai haƙuri HCQ nazarin prophylaxis: 20% ƙananan mace-mace (p=0.77) da 35% mafi girma shigar ICU (p=0.61).
Ƙananan bayanan bayanan baya-bayan nan na marasa lafiyar COVID-19 na asibiti tare da cutar rheumatologic mai ɗauke da HCQ na yau da kullun 14 da marasa lafiya na sarrafawa 28. Marasa lafiya ba su da kyau sosai. Bias ga HCQ a bayyane yake a cikin taƙaitaccen bayanin wanda ya ambaci bambance-bambancen da ke son HCQ amma ya yi watsi da waɗanda ke son iko. (Babban bambance-bambance a cikin kabilanci, yanayin rheumatic, hauhawar jini, cututtukan jijiyoyin jini, masu karɓar dashen gabobin jiki, magungunan rigakafi). 61% na marasa lafiya kuma sun sami HCQ (?). Ba a bincika riko da marasa lafiya na HCQ na yau da kullun ba. Duk da manyan bambance-bambancen da ke tsakanin ƙungiyoyin, ba a yi gyara ba. Binciken ya yi iƙirarin cewa HCQ bai hana lokuta masu tsanani ba, amma binciken yana cikin marasa lafiya na asibiti, watau, sun riga sun sami lokuta masu tsanani don asibiti - wannan binciken ba zai iya gano wani sakamako mai kariya na HCQ ba wanda ya rage yiwuwar cututtuka mai tsanani don asibiti. https://c19p.org/pham
276. O. Ubaldo, J. Palo, da J. Cinco, COVID-19: Kwarewar ICU mai Cibiya Guda na Farko a Philippines Jan 2021, Bincike da Ayyuka na Mahimmanci, Ƙarfin 2021, Shafi na 1-12
MAGANIN LAFIYA 31 mai haƙuri HCQ ICU binciken: 18% ƙananan mace-mace (p=0.64).
Marasa lafiya na ICU na baya a cikin Philippines suna nuna HCQ RR 0.82 ba daidai ba, p = 0.64. https://c19p.org/ubaldo
277. S. Ortonobes Roig, N. Soler-Blanco, I. Torrente Jiménez, E. Van den Eynde Otero, M. Moreno-Ariño, da M. Gómez-Valent, Bayanan asibiti da magunguna a cikin COVID-19 marasa lafiya marasa lafiya na asibiti. Jan 2021, Revista Espanola de Quimioterapia, Juzu'i na 34, Fitowa ta 2, Shafi na 145-150
MAGANIN LAFIYA 79 mai haƙuri HCQ marigayi nazarin jiyya: 16% ƙananan mace-mace (p=0.76).
Marasa lafiya marasa lafiya na marasa lafiya na 79 na asibiti suna nuna rashin daidaituwar mace-macen HCQ RR 0.84, p = 0.76. https://c19p.org/roig
278. M. Khoubnasabjafari, A. Jouyban, A. Malek Mahdavi, L. Namvar, K. Esalatmanesh, M. Hajialilo, S. Dastgiri, M. Soroush, S. Safiri, da A. Khabbazi, Yawan COVID-19 a cikin marasa lafiya tare da rheumatoid amosanin gabbai (RA) an riga an yi la'akari da marasa lafiya tare da rheumatoid amosanin gabbai (RA) tare da hydroxyQnaquin. nazarin giciye-sashe da yawa Jan 2021, Likitan Digiri na gaba J., Juzu'i na 98, fitowar e2, Shafi e92-e93
1,858 mai haƙuri HCQ nazarin prophylaxis: 17% ƙananan lokuta (p=0.59).
Binciken bincike na 1,858 RA marasa lafiya a Iran, yana nuna babu wani bambanci mai mahimmanci a lokuta tare da HCQ prophylaxis. https://c19p.org/khoubnasabjafari
279. S. Tehrani, A. Killander, P. Åstrand, J. Jakobsson, da P. Gille-Johnson, Abubuwan haɗari ga mace-mace a cikin balagaggun marasa lafiya na COVID-19: rauni yana hasashen sakamako mai mutuwa a cikin tsofaffin marasa lafiya. Oktoba 2020, Int. J. Cututtuka masu Yaduwa, Juzu'i na 102, Shafi na 415-421
MAGANIN LAFIYA 255 mai haƙuri HCQ marigayi nazarin jiyya: 13% ƙananan mace-mace (p=0.63).
Marasa lafiya na asibiti na 255 na baya-bayan nan, 65 da aka bi da su tare da HCQ, suna nuna RR 0.87 ba daidai ba, p=0.63. Mai yiwuwa mai ruɗawa ta nuni. https://c19p.org/tehrani
280. . Agusta 2020, J. Maganin Chemotherapy Antimicrobial, Juzu'i na 75, Fitowa ta 11, Shafi na 3359-3365
MAGANIN LAFIYA 51 mai haƙuri HCQ ICU binciken: 16% ƙananan mace-mace (p=0.34).
Marasa lafiya 51 ICU na baya-bayan nan a ƙarƙashin iskar injina, 33 da aka bi da su tare da HCQ, suna nuna ƙarancin mace-mace marasa daidaituwa tare da jiyya. https://c19p.org/pasquini
281. A. Ip. D. Berry Rose, L. Tank, L. Jacobs, J. Korcak, S. Timmapuri, J. Underwood, G. Sugalski, C. Barsky, D. Varga, A. Asif, J. Landolfi, da S. Goldberg, Hydroxychloroquine da Tocilizumab Therapy a cikin marasa lafiya na COVID-19 - Nazarin Kulawa Mayu 2020, PLoS DAYA, Juzu'i na 15, Fitowa ta 8, Shafi e0237693
MAGANIN LAFIYA 2,512 mai haƙuri HCQ marigayi nazarin jiyya: 1% ƙananan mace-mace (p=0.93).
Binciken da aka yi amfani da shi na ƙarshen amfani da marasa lafiya na asibiti na 2,512 da ke nuna babu wani bambance-bambance a cikin mace-mace masu dangantaka da marasa lafiya da ke karɓar kowane HCQ a lokacin asibiti (HR, 0.99 [95% CI, 0.80-1.22]), HCQ kadai (HR, 1.02 [95% CI, 0.83-1.27%), ko 0.98% CI, 95-0.75% . CI, 1.28-XNUMX]). Rarraba ɓarna yana yiwuwa saboda taƙaita bayanan EHR na hannu. Sun lura da canje-canje a cikin tsarin tsarawa na HCQ yayin lokacin binciken. Mai ruɗani da nuni. https://c19p.org/ip2
282. S. Kamran, Z. Mirza, B. Naseem, F. Saeed, R. Azam, N. Ullah, W. Ahmad, da S. Saleem, Shareing the hazo: Shin HCQ yana da tasiri wajen rage ci gaban COVID-19: Gwajin da ba a sarrafa ba. Agusta 2020, medRxiv
MAGANIN LAFIYA 500 mai haƙuri HCQ marigayi nazarin jiyya: 5% ƙananan ci gaba (p = 1) da 26% inganta ƙwayar cuta (p=0.001).
Nazarin 349 marasa lafiya marasa lafiya a asibiti tare da 151 marasa yarda ko marasa cancanta da aka yi amfani da su azaman sarrafawa. Matsayin kulawa ya haɗa da zinc, bitamin C da bitamin D. An nuna ci gaba mai mahimmanci a cikin rashin daidaituwa na PCR a ranar 7 tare da maganin HCQ, 52.1% (HCQ) tare da 35.7% (control), p = 0.001, amma babu wani bambanci mai mahimmanci a ranar 14, ko a ci gaba. Marasa lafiya sun kasance ƙanana kuma babu mace-mace. Kashi 3% kawai na marasa lafiya sun sami ci gaba da cutar kuma duk marasa lafiya sun murmure, don haka akwai kaɗan idan wani ɗaki don fa'idar magani. Ci gaba a tsakanin marasa lafiya masu haɗari tare da cututtuka sun kasance ƙananan tare da jiyya (12.9% da 28.6%, p=0.3, ƙananan lokuta). Duk da take, wannan ba RCT ba ne tun da marasa lafiya sun zaɓi hannu da kansu ko kuma an zaɓi su bisa la'akari da rashin lafiyan halayen. Ƙungiyar jiyya tana da kusan sau biyu yawan adadin marasa lafiya tare da cututtuka. Ba a san jinkirin jinkiri ba - an rubuta shi amma ba a ruwaito shi a cikin takarda ba. Ba a auna nauyin ƙwayar cuta ba. Kamar yadda yake tare da sauran nazarin, PCR na iya gano ƙwayoyin nucleic acid wanda ba za'a iya maimaitawa ba, wannan ya fi dacewa a ranar 14. Ba a ba da cikakkun bayanai game da daidaiton gwajin ba, marubuta sun lura cewa hankalin RT-PCR ya fito daga 34-80%. https://c19p.org/kamran
283. M. Barra, N. Carlos Medinacelli, C. Meza Padilla, L. Di Rocco, R. Larrea, G. Gaudenzi, V. Mastrovincenzo, E. Raña, I. Moreno, D. Sörvik, A. Sarlingo, F. Dadomo, da M. Torrilla, COVID-19 a asibiti marasa lafiya a asibitin Sannos Isidro a Argentina Yuli 2021, medRxiv
MAGANIN LAFIYA 668 mai haƙuri HCQ marigayi nazarin jiyya: 11% ƙananan mace-mace (p=1).
Marasa lafiya na 668 na asibiti a Argentina, 18 da aka bi da su tare da HCQ, ba tare da nuna bambanci mai mahimmanci a cikin sakamakon da ba a daidaita ba. https://c19p.org/barra
284. M. An, M. Kim, Y. Park, B. Kim, S. Kang, W. Kim, S. Park, H. Park, W. Yang, J. Jang, S. Jang, da T. Hwang, Martanin Jiyya ga Hydroxychloroquine da Magungunan rigakafi don matsakaici zuwa matsakaici COVID-19: nazari na sake dubawa daga Koriya ta Kudu Yuli 2020, medRxiv
MAGANIN LAFIYA 226 mai haƙuri HCQ marigayi nazarin jiyya: 3% saurin kamuwa da cutar hoto (p=0.92).
A baya-bayan nan na marasa lafiya na asibiti tare da marasa lafiya na 31 HCQ da 195 daidaitattun marasa lafiya, ba tare da nuna bambanci mai mahimmanci ba dangane da ƙwayar cuta ko farfadowa. Babu mace-mace a kowane rukuni. "Abu ne sananne cewa HQ tare da rukunin maganin rigakafi sun sami mafi munin bayanan martaba na asibiti (watau mafi girman kaso na matsakaicin tsanani, ƙarin marasa lafiya da zazzabi>=37.5C, matsakaicin matsakaicin zafin jiki) da alamun tsinkaya kamar shekaru, LDH, ƙididdigar lymphocyte, da CRP."Mun lura da cewa propensity score matching cire kusan dukkan marasa lafiya maza a cikin ƙungiyar kulawa (40% zuwa 5%) amma ya karu da yawan marasa lafiya na maza a cikin ƙungiyar kulawa. Wannan yana ba da babbar fa'ida ga ƙungiyar kulawa saboda akwai a babban bambanci sosai a cikin tsanani da mace-mace dangane da jinsi. Dangane da kawar da kwayar cutar kwayar cutar RNA mun lura cewa wasu bincike sun gano cewa "kwafiyar kwayar cuta mai aiki tana raguwa da sauri bayan satin farko, kuma ba a sami kwayar cutar da za ta iya yiwuwa ba bayan mako na biyu na rashin lafiya duk da dacewar gano PCR na RNA” Nauyin kwayar cuta da aka auna ta PCR na iya zama ba daidai ba ne daidai da kwayar cutar da aka auna ta hanyar al'adar hoto. Porter et al. nuna cewa ƙwayar cuta a farkon kamuwa da cuta tana da alaƙa da ƙwayar cuta mai saurin kamuwa da cuta, amma nauyin ƙwayar cuta a ƙarshen kamuwa da cuta zai iya girma koda da ƙananan ƙwayar cuta ko kuma wanda ba a iya gano shi ba. Yin la'akari da nauyin ƙwayar cuta daga baya a cikin kamuwa da cuta na iya ƙididdige raguwar ƙwayoyin cuta tare da magani. https://c19p.org/an
285. S. Singh, A. Khan, M. Chowdhry, da A. Chatterjee, Sakamakon Jiyya na Hydroxychloroquine Tsakanin Marasa lafiya na COVID-19 da ke Asibiti a Amurka Mayu 2020, medRxiv
MAGANIN LAFIYA 1,820 mai haƙuri HCQ marigayi nazarin jiyya: 5% ƙananan mace-mace (p=0.72) da 19% ƙananan iska (p=0.26).
Binciken EHR na marasa lafiya 3,372 na COVID-19 na asibiti ba ya nuna bambanci mai mahimmanci ga mace-mace ko haɗarin iskar inji. Dangane da iyakokin bincike na EHR. Ba daidai ba ne mai yiwuwa. Mai yiwuwa mai ruɗawa ta nuni. https://c19p.org/singh
286. J. Macias, P. Gonzalez-Moreno, E. Sanchez-Garcia, R. Morillo-Verdugo, C. Dominguez-Quesada, A. Pinilla, M. Macho, M. Martinez, A. Gonzalez-Serna, A. Corma, L. Real, da J. Pineda, Kwatankwacin cutar Coronavirus 2019 (19) Ciwon ƙwayar cuta na XNUMX. cututtuka na rheumatic tare da kuma ba tare da maganin hydroxychloroquine ba Mayu 2020, medRxiv
722 mai haƙuri HCQ nazarin prophylaxis: 26% ƙananan asibiti (p=1) da 49% ƙarin lokuta (p=0.53).
Ƙananan binciken da aka yi nazari na marasa lafiya na rheumatic, girman samfurin ya yi ƙanƙara don mahimmancin ƙididdiga (HCQ 0.5-4.0%, no-HCQ 0.4-2.7%). An tabbatar da shari'o'in 1 HCQ da 2 babu-HCQ, an tabbatar da + yiwuwar lokuta 1 HCQ da 3 babu-HCQ. 1 HCQ da 2 marasa lafiya na HCQ an shigar da su asibiti. Ba ma tsammanin za a iya yanke hukunci bisa ga waɗannan nau'ikan samfuran. Akwai bambance-bambance masu mahimmanci tsakanin ƙungiyoyi, misali 30% na ƙungiyar HCQ suna da SLE vs. 2.5% na ƙungiyar no-HCQ. Marasa lafiya SLE suna da haɗarin ciwon huhu sau 5.7, yayin da Haɗarin dangi tare da glucocorticoids da masu hana TNF-α yana da ƙasa kaɗan. Biyu ƙarin binciken kwanan nan tare da cututtukan rheumatic / marasa lafiya na autoimmune suna ba da tabbaci mafi girma. https://c19p.org/macias
287. E. Sbidian, J. Josse, G. Lemaitre, I. Meyer, M. Bernaux, A. Gramfort, N. Lapidus, N. Paris, A. Neuraz, I. Lerner, N. Garcelon, B. Rance, O. Grisel, T. Moreau, A. Bellamine, P. Wolkenstein, G. Varoquaux, E. Laumeelle, E. Laumeelle, M. Audureau, Hydroxychloroquine tare da ko ba tare da azithromycin ba da mace-mace a asibiti ko fitarwa a cikin marasa lafiya da ke kwance a asibiti don kamuwa da cutar COVID-19: nazarin rukunin marasa lafiya 4,642 a Faransa Juni 2020, medRxiv
MAGANIN LAFIYA 4,642 mai haƙuri HCQ marigayi nazarin jiyya: 5% mafi girma mace-mace (p=0.74) da 20% mafi girma sallama asibiti (p=0.002).
A baya-bayan nan na marasa lafiya 4,642 na asibiti a Faransa suna nuna saurin fitarwa tare da HCQ da HCQ+AZ. Marasa lafiya da ke karɓar 'HCQ kaɗai' ko 'HCQ tare da AZI' sun fi zama ƙanana, maza, masu shan taba a halin yanzu kuma gabaɗaya an gabatar da su tare da ƙarin cututtukan haɗin gwiwa (kiba, ciwon sukari, kowane cututtukan huhu, cututtukan hanta). Babu wani tasiri mai mahimmanci da aka gani akan mace-mace na kwanaki 28, duk da haka yawancin marasa lafiya masu kulawa har yanzu suna asibiti a cikin kwanaki 28. An lura da ƙimar fitarwa mafi girma a gida a cikin marasa lafiya da HCQ ke jiyya. Sauran nazarin suna nuna ƙuduri mai sauri don HCQ, yana ba da shawarar za a sami ci gaba mai mahimmanci lokacin tsawaita kwanakin 28 da suka gabata. Lura cewa matsakaicin shekarun ya fi girma a cikin ƙungiyar ba a kula da HCQ ko AZ ba. Ga wasu batutuwa tare da gyara duba nan. https://c19p.org/sbidian
288. . Kwarewar Cibiyar Agusta 2021, Resistance Microbial Drug, juzu'i na 27, fitowa ta 9, Shafi na 1167-1175
MAGANIN LAFIYA 32 mai haƙuri HCQ ICU binciken: 5% ƙananan mace-mace (p=1).
Marasa lafiya na 32 ICU na baya-bayan nan, ba su nuna wani bambanci mai mahimmanci tare da jiyya na HCQ a cikin sakamakon da ba a daidaita su ba. https://c19p.org/karrulih
289. M. Shabani, M. Totonchi, O. Rezaeimirghaed, L. Gachkar, M. Hajiesmaeili, A. Khoshkar, M. Amirdosara, A. Saffaei, S. Shokouhi, M. Mardani, I. Alavi Darazam, A. Karami, M. Sharifi, M. Zaman, da E. Abedhe. Tasirin Hydroxychloroquine akan Mutanen da ke Kusa da Abokan hulɗa tare da Marasa lafiya tare da Covid-19 Agusta 2021, Kimiyyar Magungunan Huhu & Magunguna, Juzu'i na 70, Shafi 102069
113 mai haƙuri HCQ nazarin prophylaxis: 19% ƙananan lokuta na alamomi (p=1) da 6% ƙarin lokuta (p=1).
Ƙananan gwajin PEP tare da marasa lafiya na 51 HCQ, ba tare da nuna bambanci mai mahimmanci a lokuta ba. IRCT20130917014693N10. https://c19p.org/shabani
290. C. Roger, O. Collange, M. Mezzarobba, O. Abou-Arab, L. Teule, M. Garnier, C. Hoffmann, L. Muller, J. Lefrant, P. Guinot, E. Novy, P. Abraham, T. Clavier, J. Bourenne, G. Besch, L. Favier, M. Joutara, M. Fianit. Fischer, M. Leone, Y. Ait Tamlihat, J. Pottecher, P. Cordier, P. Aussant, M. Moussa, E. Hautin, M. Bouex, J. Julia, J. Cady, M. Danguy Des Déserts, N. Mayeur, T. Mura, da B. Allaouch Observation a kan SARS-Cibiyar Kulawa ta Faransa-Cibiyar Kulawa ta Faransa gudanarwa na farko: Nazarin CORONA na Faransa Jul 2021, Mahimmancin Kulawa na Anesthesia & Maganin Ciwo, Jul 40, Fitowa 4, Shafi na 100931
MAGANIN LAFIYA 966 mai haƙuri HCQ ICU binciken: babu canji a cikin mace-mace (p=0.94).
Nazarin mai yiwuwa na 966 ICU marasa lafiya a Faransa, 289 da aka bi da su tare da HCQ, ba tare da nuna bambanci mai mahimmanci tare da magani ba. An cire wannan binciken a cikin "bayan sakamakon cirewa" na ƙididdigar meta. Babban rikicewa ta lokaci mai yiwuwa saboda raguwar amfani a farkon matakan cutar lokacin da ƙa'idodin jiyya gabaɗaya suka inganta sosai. https://c19p.org/roger
291. J. Jacobs, A. Stammers, J. St Louis, J. Hayanga, M. Firstenberg, L. Mongero, E. Tesdahl, K. Rajagopal, F. Cheema, K. Patel, T. Coley, A. Sestokas, M. Slepian, da V. Badhwar, Multi-cibiyoyi Analysis na 200nts da kuma covid-comutEC da suka yi magani Jul 2021, Littattafai na Tiyatar Jiki, Juzu'i na 113, Fitowa ta 5, Shafi na 1452-1460
MAGANIN LAFIYA 200 mai haƙuri HCQ marigayi nazarin jiyya: 7% ƙananan mace-mace (p=0.74).
Nazarin mai yiwuwa na 200 extracorporeal membrane oxygenation (mafi girman haɗarin likita sa baki) marasa lafiya da ba su nuna bambanci mai mahimmanci a cikin sakamakon da ba a daidaita ba don maganin HCQ. https://c19p.org/jacobs
292. F. Çiyiltepe, Tasirin Jiyya na Hydroxychloroquine da aka riga aka shigar akan COVID-19 mai alaƙa da Ci gaba na Kulawa da Majinyatan Geriatric Afrilu 2021, Kudu. Clin. Ist. Yuro.
MAGANIN LAFIYA 147 mai haƙuri HCQ ICU binciken: 3% ƙananan mace-mace (p=0.85).
Marasa lafiya na ICU na 147 na baya-bayan nan a Turkiyya, suna nuna babu wani bambanci mai mahimmanci a cikin sakamako dangane da jiyya na HCQ kafin shigar da ICU. Wannan binciken bai ba da cikakken bayani ba, misali ba mu sani ba idan HCQ da aka yi wa marasa lafiya ba su da yuwuwar shigar da su zuwa ICU. https://c19p.org/ciyiltep
293. S. Spila Alegiani, S. Crisafulli, P. Giorgi Rossi, P. Mancuso, C. Salvarani, F. Atzeni, R. Gini, U. Kirchmayer, V. Belleudi, P. Kurotschka, O. Leoni, M. Ludergnani, E. Ferroni, S. Baracco, M. Massari, da COVID-19 asibiti a cikin G. na Trifi marasa lafiya na rheumatic da ake yi da hydroxychloroquine ko wasu DMARD na al'ada a Italiya Afrilu 2021, Rheumatology, juzu'i na 60, fitowar SI, Shafi SI25-SI36
Nazarin prophylaxis na HCQ: 8% mafi girman mace-mace (p=0.64) da 18% ƙananan asibiti (p=0.03).
Binciken bayanan bayanan baya-bayan nan nazarin yanayin kula da marasa lafiya na rheumatic. Idan aka kwatanta da sauran cDMARDs, Masu amfani da HCQ sun sami raguwa sosai a asibiti, duk da haka babu wani gagarumin bambanci a mace-mace. Sakamako ya bambanta sosai daga binciken da ya gabata, misali nuna mace-mace OR 0.94 [0.83-1.06] ga marasa lafiya da cututtukan rheumatic da mace-mace OR 0.88 [0.74-1.05] ga marasa lafiya tare da RA / SLE. Wani bincike ya nuna cewa haɗarin COVID-19 ga masu cutar cututtukan cututtukan ƙwayoyin cuta sun fi girma gabaɗaya. https://c19p.org/alegiani
294. N. Vernaz, T. Agoritsas, A. Calmy, A. Gayet-Ageron, G. Gold, A. Perrier, F. Picard, V. Prendki, J. Reny, C. Samer, J. Stirnemann, P. Vetter, M. Zanella, D. Zekry, da S. Baggio, farkon gwaji na asibiti na COVID-19s tare da haɗin gwiwa na gwaji na COVID-XNUMX da haɗin gwiwa. Dec 2020, Swiss Medical Weekly, juzu'i 150, fitowa ta 5153, Shafi w20446
MAGANIN LAFIYA 198 mai haƙuri HCQ ƙarshen jiyya haɓaka ƙimar madaidaicin binciken: 15% ƙananan mace-mace (p=0.71) da 49% tsayin asibiti (p=0.002).
Marasa lafiya na asibiti 840 na baya-bayan nan a Switzerland suna nuna ƙarancin mace-mace marasa ƙididdigewa tare da HCQ amma mafi tsayin lokutan asibiti. Mai yiwuwa mai ruɗawa ta nuni. Madaidaicin maki ya kasa daidaitawa don tsananin tare da 16% mafi girma da aka gyara makin gargaɗin farko na ƙasa don HCQ vs. daidaitattun kulawa a cikin ƙungiyar da ta dace. Mai yuwuwar rikiɗewar lokaci. HCQ ya zama mai kawo rigima kuma an dakatar da shi zuwa ƙarshen lokacin da aka yi nazari, don haka amfani da HCQ ya fi sau da yawa zuwa farkon lokacin binciken, lokacin da gabaɗayan ka'idojin jiyya sun kasance mafi muni. Marubutan sun lura: "Gaba ɗaya, an sami nuna son kai, tare da dalilin da aka rubuta takardar sayan magani da ke da alaƙa da sakamakon sha'awa. Lallai, marasa lafiya da ke da COVID-19 mai tsanani sun fi samun magungunan gwaji." https://c19p.org/vernaz
295. F. Annie, C. Sirbu, K. Frazier, M. Broce, da B. Lucas, Hydroxychloroquine a asibiti COVID-19 marasa lafiya: Ƙwarewar duniya ta ainihi tana tantance mace-mace Oct 2020, Pharmacotherapy, juzu'i na 40, fitowa ta 11, Shafi na 1072-1081
MAGANIN LAFIYA 734 mai haƙuri HCQ marigayi nazarin jiyya: 4% ƙananan mace-mace (p=0.83).
Binciken bayanan baya tare da PSM baya haɗa da tsananin COVID-19, gano mace-mace KO 0.95 [0.62-1.46] don HCQ, da 1.24 [0.70-2.22] don HCQ+AZ. Mai ruɗani da alama mai yiwuwa. https://c19p.org/annie
296. F. Albani, F. Fusina, A. Giovannini, P. Ferretti, A. Granato, C. Prezioso, D. Divizia, A. Sabaini, M. Marri, E. Malpetti, da G. Natalini, Tasirin Azithromycin da/ko Hydroxychloroquine akan Mutuwar Asibiti a COVID-19 Agusta 2020, J, Magungunan asibiti, juzu'i na 9, fitowa ta 9, Shafi na 2800
MAGANIN LAFIYA 816 mai haƙuri HCQ marigayi nazarin jiyya: 18% ƙananan mace-mace (p=0.15) da 9% mafi girma ICU shigar (p=0.7).
A baya-bayan nan 1376 marasa lafiya na asibiti a Italiya, 211 ana kula da su tare da HCQ da 166 tare da HCQ+AZ. https://c19p.org/albani
297. C. Salvarani, P. Mancuso, F. Gradellini, N. Viani, P. Pandolfi, M. Reta, G. Carrozzi, G. Sandri, G. Bajocchi, E. Galli, F. Muratore, L. Boiardi, N. Pipitone, G. Cassone, S. Croci, A. Marata, da kuma P. Costansibility a cikin Marasa lafiya da Aka Yi musu Maganin Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Ciwon Jiki: Wani Nazari Akan Yawan Jama'a a Emilia-Romagna, Arewacin Italiya. Agusta 2020, Arthritis & Rheumatology, juzu'i na 73, fitowa ta 1, Shafi na 48-52
Nazarin prophylaxis na HCQ: 6% ƙananan lokuta (p=0.75).
Kwatanta masu amfani da CQ/HCQ tare da yawan jama'a a wani yanki na Italiya, ba tare da nuna wani muhimmin bambanci a yuwuwar COVID-19 ba. Masu amfani da CQ/HCQ galibi sun kasance marasa lafiya na cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan ƙwayoyin cuta kuma marubuta ba su daidaitawa ga haɗarin tushe daban-daban ga waɗannan marasa lafiya. Wani bincike ya nuna cewa haɗarin COVID-19 ga masu cutar cututtukan ƙwayoyin cuta na tsarin jiki ya fi girma gabaɗaya, Ferri et al. nuna KO 4.42, p<0.001. https://c19p.org/salvarani
298. Z. Gendebien, C. Von Frenckell, C. Ribbens, B. André, M. Thys, M. Gangolf, L. Seidel, M. Malaise, da O. Malaise, Binciken tsari na COVID-19 kamuwa da cuta da bayyanar cututtuka a cikin tsarin lupus erythematosus yawan: daidaitawa tare da halayen cututtuka, amfani da hydroxychloropressive da maganin rigakafi Jun 2020, Littattafai na Cututtukan Rheumatic, juzu'i na 80, fitowa ta 6, Shafi na e94-e94
225 mai haƙuri HCQ nazarin prophylaxis: 4% ƙananan lokuta (p=0.93).
Ƙananan binciken marasa lafiya na SLE suna shan HCQ tare da binciken waya don alamun alamun COVID-19. Akwai asibiti guda 2 (ba a gano ƙungiyar ba) kuma babu ICU ko mutuwar mutuwa. An ba da rahoton irin wannan kashi na cututtukan da ake zargi ga masu amfani da HCQ da waɗanda ba masu amfani da HCQ ba, RR 0.96, p = 0.93. Ba a tantance tsananin ba don sanin ko HCQ da aka yi wa majinyata lafiya. Babu daidaitawa ga magunguna masu haɗuwa ko tsananin SLE. An tabbatar da shari'o'i 5 kawai PCR. https://c19p.org/gendebien
299. M. Gianfrancesco, K. Hyrich, S. Al-Adely, L. Carmona, M. Danila, L. Gossec, Z. Izadi, L. Jacobsohn, P. Katz, S. Lawson-Tovey, E. Mateus, S. Rush, G. Schmajuk, J. Simard, A. Strangfeld, K.W. R. Grainger, J. Hausmann, J. Liew, E. Sirotic, P. Sufka, Z. Wallace, J. Yazdany, P. Machado, da P. Robinson, Halayen da ke da alaƙa da asibiti don COVID-19 a cikin mutanen da ke fama da cututtukan rheumatic: bayanai daga COVID-19 Global Rheumatology Alliance Likitan da aka ba da rahoto. Mayu 2020, Annals of the Rheumatic Diseases, 859-866, juzu'i na 79, fitowa ta 7, Shafi na 859-866
600 mai haƙuri HCQ nazarin prophylaxis: 3% ƙananan asibiti (p=0.82).
Binciken marasa lafiya na cututtukan rheumatic da ke nuna babu wata ƙungiya mai mahimmanci tsakanin maganin maleriya da kuma asibiti, OR = 0.94 [0.57-1.57], p = 0.82 bayan gyare-gyare. https://c19p.org/gianfrancesco
300. M. Konig, A. Kim, M. Scheetz, E. Graef, J. Liew, J. Simard, P. Machado, M. Gianfrancesco, J. Yazdany, D. Langguth, da P. Robinson, Baseline amfani da hydroxychloroquine a cikin tsarin lupus erythematosus na systemic lupus erythematosus baya hana SARS-CoV-2 Mayu 2020, Littattafai na Cututtukan Rheumatic, Juzu'i na 79, Fitowa ta 10, Shafi na 1386-1388
80 mai haƙuri HCQ nazarin prophylaxis: 3% ƙananan asibiti (p=0.88).
Binciken marasa lafiya 80 SLE da aka gano tare da COVID-19, yana nuna adadin asibiti bai bambanta tsakanin mutane masu amfani da maganin zazzabin cizon sauro da waɗanda ba masu amfani ba (55% (16/29) vs 57% (29/51). https://c19p.org/konig
301. O. Gendelman, H. Amital, N. Bragazzi, A. Watad, da G. Chodick, Ci gaba da Hydroxychloroquine ko Colchicine Therapy Baya Hana Kamuwa da SARS-CoV-2: Hanyoyi Daga Babban Binciken Bayanai na Kiwon Lafiya Mayu 2020, Bita na Ƙarfafa Kai, Yuli 2020, Juzu'i na 19, Fitowa ta 7, Shafi na 102566
14,520 mai haƙuri HCQ nazarin prophylaxis: 8% ƙananan lokuta (p=0.88).
Ƙananan binciken cututtukan rheumatic / marasa lafiya na autoimmune ba su nuna wani bambanci ba amma tare da lokuta 3 na kullum na HCQ marasa lafiya. Ana la'akari da mutanen da aka gwada kawai a lokacin da aka gwada farkon alamun bayyanar cututtuka. Wani bincike ya nuna cewa haɗarin COVID-19 ga masu cutar cututtukan ƙwayoyin cuta sun fi girma gabaɗaya, Ferri et al. nuna OR 4.42, p <0.001 wanda shine haɗarin gaske na duniya, la'akari da dalilai kamar waɗannan marasa lafiya na iya yin hankali sosai don guje wa fallasa. Daidaita don bambanci a cikin haɗarin asali ta amfani da sakamakon a Ferri et al. yana nuna fa'ida mai mahimmanci ga HCQ, RR 0.211, amma tare da lokuta 3 HCQ kawai sakamakon bai cika ba. Ƙarin karatu na baya-bayan nan tare da cututtukan rheumatic / marasa lafiya na autoimmune suna ba da tabbaci mafi girma. https://c19p.org/gendelman
302. A. Rao, S. Veluswamy, B. Shankarappa, R. Reddy, N. Umesh, L. John, L. Mathew, da N. Shetty, Hydroxychloroquine a matsayin pre-exposure prophylaxis a kan COVID-19 kamuwa da cuta tsakanin ma'aikatan kiwon lafiya: mai yiwuwa binciken ƙungiyar. Dec 2021, Binciken Kwararru na Maganin Cutar Cutar
1,294 mai haƙuri HCQ nazarin prophylaxis: 11% ƙananan lokuta (p=0.68).
Nazarin PrEP mai zuwa tare da ƙananan ma'aikatan kiwon lafiya masu haɗari a Indiya suna nuna RR = 0.89 [0.53-1.52]. Babu wani tasiri mara kyau. An ba da ma'anar shekaru da rarraba jinsi kawai don halayen asali, ba a bayar da cikakkun bayanai ba, kuma ba a yi gyare-gyare ba. Marubuta suna nazarin amfani da HCQ don <8 vs. ≥8 makonni, lura da rashin mahimmancin ƙididdiga, amma ba samar da sakamakon ba. https://c19p.org/rao
303. K. Cortez, B. Demot, S. Bartolo, D. Feliciano, V. Ciriaco, I. Labi, D. Viray, J. Casuga, K. Camonayan-Flor, P. Gomez, M. Velasquez, T. Cajulao, J. Nigos, M. De Leon, D. Solimen., Pizar, A. Gomez. V. Mangati, C. Palaganas, M. Genuino, K. Cutiyog-Ubando, K. Tadeo, M. Longid, N. Catbagan, J. Bongotan, B. Dominguez-Villa, da J. Dalao, Halin asibiti da sakamakon COVID-19 marasa lafiya a wani babban asibiti a Baguio City, Philippines Nov 2021, Yammacin Pacific Sa ido da Martani J., juzu'i na 12, fitowa ta 4, Shafi na 71-81
MAGANIN LAFIYA 280 mai haƙuri HCQ marigayi nazarin jiyya: 15% ƙananan mace-mace (p=1).
Marasa lafiya 280 na asibiti a Philippines, 25 an yi musu magani tare da HCQ, baya nuna wani gagarumin bambance-bambance a cikin sakamakon da ba a daidaita ba. https://c19p.org/cortez
304. K. Fitzgerald, C. Mecoli, M. Douglas, S. Harris, B. Aravidis, J. Albayda, E. Sotirchos, A. Hoke, A. Orbai, M. Petri, L. Christopher-Stine, A. Baer, J. Paik, B. Adler, E. Tiniakou, H. Timlin, P. Bhargary, V, T. V. Lloyd, C. Pardo, B. Stern, M. Lazarev, B. Truta, S. Saidha, E. Chen, M. Sharp, N. Gilotra, E. Kasper, A. Gelber, C. Bingham, A. Shah, da E. Mowry, Abubuwan Haɗari don Kamuwa da Tasirin Lafiyar Jama'a tare da Cutar Cutar Cutar ta COVID-19. Fabrairu 2021, medRxiv
4,666 mai haƙuri HCQ nazarin prophylaxis: 9% ƙananan lokuta (p=0.54).
Mutane 4666 na baya-bayan nan da ke da cututtukan autoimmune ko yanayin kumburi, suna nuna haɗarin HCQ da aka daidaita na COVID-19 KO 0.91 [0.68-1.23]. Ba a daidaita sakamakon don babban haɗari daban-daban na COVID-19 dangane da nau'i da tsananin yanayin cutar kansa ko kumburi. https://c19p.org/fitzgerald
305. A. Wang, X. Zhong, da Y. Hurd, Ƙaddamarwa da Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararru na COVID-19 a cikin Tsarin Kiwon Lafiya na Birane na Amurka Juni 2020, medRxiv
MAGANIN LAFIYA 7,592 mai haƙuri HCQ marigayi nazarin jiyya: 6% ƙananan mace-mace (p=0.63).
Binciken bayanai na marasa lafiya 7,592 a cikin NYC, yana nuna daidaitaccen rabon mace-mace na HCQ KO 0.96, p = 0.82, da HCQ+AZ KO 0.94, p = 0.63 https://c19p.org/wangrx
306. E. Lamback, M. Oliveira, A. Haddad, A. Vieira, A. Neto, T. Maia, J. Chrisman, P. Spineti, M. Mattos, da E. Costa, Hydroxychloroquine tare da azithromycin a cikin marasa lafiya da aka kwantar da su a asibiti don COVID-19 mai sauƙi da matsakaici. Feb 2021, Cutar Cutar J. Brazilian, juzu'i na 25, fitowa ta 2, Shafi na 101549
MAGANIN LAFIYA 193 mai haƙuri HCQ marigayi nazarin jiyya: 9% ƙananan mace-mace (p=0.83), 20% mafi girman shigar da ICU (p=0.61), da 12% guntu asibiti.
Marasa lafiya na asibiti 193 na baya-bayan nan a Brazil ba su sami babban bambanci tare da HCQ ba. Ƙungiyar kulawa ta ƙunshi marasa lafiya da ke ƙin HCQ ko tare da contraindications. Mai yuwuwar rikicewar lokaci saboda HCQ ya zama mafi yawan rigima a Brazil tsawon lokacin da aka rufe (Maris - Jun 2020), yayin da ka'idojin jiyya gabaɗaya a wannan lokacin sun inganta sosai, watau ƙarin kulawa da marasa lafiya (waɗanda suka ƙi HCQ) mai yiwuwa su zo daga baya a cikin lokacin da ka'idojin jiyya suka inganta sosai. Takardar ba ta ambaci kalmar “mai ruɗani” ko yin wani gyara ba. https://c19p.org/lamback
307. S. Roy, S. Samajdar, S. Tripathi, S. Mukherjee, da K. Bhattacharjee, Sakamako na Matsalolin Jiyya daban-daban a cikin Marasa lafiya COVID-19 marasa lafiya a cikin Clinic OPD guda ɗaya na West Bengal: Nazarin Nazari Maris 2021, medRxiv
MAGANIN FARKO 29 mai haƙuri HCQ binciken farko na jiyya: 2% farfadowa da sauri (p=0.96).
Binciken bayanan baya-bayan nan na marasa lafiya COVID-56 masu sauƙi 19, duk waɗanda aka yi musu magani tare da bitamin C, bitamin D, da zinc, kwatanta ivermectin + doxycycline (n=14), AZ (n=13), HCQ (n=14), da daidaitattun kulawa (n=15), gano cewa duk ƙungiyoyi suna murmurewa da sauri, kuma babu wani gagarumin bambanci tsakanin ƙungiyoyin. https://c19p.org/royh
308. Xia et al., Ingantacciyar Chloroquine da Lopinavir / Ritonavir a cikin cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan hai da cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan hai da kuma sauran nau'ikan cutar sankara (CoVID-19) na chloroquine da Lopinavir / Ritonavir a cikin cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan hai da sauran cututtukan da ke haifar da cutar sankara. Fabrairu 2020, ChiCTR2000029741
MAGANIN LAFIYA 25 mai haƙuri HCQ marigayi nazarin jiyya: 38% inganta ƙwayar cuta (p=0.17).
Sakamakon farko daga ƙaramin gwaji, wanda aka ruwaito a cikin aikace-aikacen don gwaji na gaba. An bayar da cikakkun bayanai kaɗan, amma mun haɗa wannan a matsayin sakamakon farko da aka buga. Ga marasa lafiya na COVID-19 masu fama da ciwon huhu, ƙimar canjin ƙwayar cuta mara kyau shine 50% (5/10) tare da CQ akan 20% (3/15) tare da lopinavir/ritonavir. https://c19p.org/xia
309. O. Küçükakkaş da T. Aydın, Tasirin hydroxychloroquine akan kamuwa da cutar SARS-CoV-2 a cikin marasa lafiya na arthritis na rheumatoid Jul 2021, Dandalin Bincike
17 mai haƙuri HCQ nazarin prophylaxis: 43% mafi girma shigar ICU (p=1).
Na baya-bayan nan guda 17 na rheumatoid amosanin gabbai COVID-19+, 7 akan jiyya na HCQ, ba su nuna wani bambance-bambance ba. Suna nazarin rahotanni kawai ciki har da marasa lafiya na asibiti, amma sakamakon ya haɗa da marasa lafiya marasa asibiti. Sakamako baya nuna yuwuwar bambance-bambance a cikin yuwuwar cewa shari'ar ta yi tsanani da aka gwada kuma an gano ta. Ana ba da cikakkun bayanan rukuni kaɗan (har ma da shekarun marasa lafiya a kowace ƙungiya ba a ƙayyade ba). https://c19p.org/kucukakkas
310. M. Salehi, M. Mohammadi, S. Abtahi, S. Ghazi, A. Sobati, R. Bozorgmehr, S. Manshadi, S. Siahkali, M. Mohammadi, B. Badie, da E. Rahimi, Abubuwan haɗari na mutuwa a cikin marasa lafiya na COVID-19 na inji: nazari mai zurfi da yawa. Maris 2022, Dandalin Bincike
MAGANIN LAFIYA 125 mai haƙuri HCQ ICU binciken: 14% mafi girma mace-mace (p=0.44).
Tsinkaya 125 injina da iska Marasa lafiya na ICU a Iran, ba su nuna wani muhimmin bambanci tare da jiyya na HCQ a cikin sakamakon da ba a daidaita su ba. https://c19p.org/salehih
311. F. Alhamlan, R. Almaghrabi, E. Devol, A. Alotaibi, S. Alageel, D. Obeid, B. Alraddadi, S. Althawadi, M. Mutabagani, da A. Al-Qahtani, Cututtuka da Halayen Clinical a cikin Mutane tare da Tabbatar da SARS-CoV-2 a cikin Saudi Arabiya a Farko na COVID-19 Yuli 2021, medRxiv
MAGANIN LAFIYA HCQ marigayi nazarin jiyya: 52% mafi girma mace-mace (p=0.58).
Marasa lafiya a asibiti na baya-bayan nan a Saudi Arabiya suna nuna yawan mace-mace tare da yawancin jiyya duk da cewa ba su kai ga ƙididdiga ba. Ƙarfafawa ta hanyar nuni, lokaci, ko wasu dalilai yana yiwuwa (haɗari 19x mafi girma tare da lopinavir / ritonavir da 3.5x mafi girma tare da azithromycin ba a goyan bayan wasu nazarin misali). Ba a bayar da adadin marasa lafiyar da aka yi wa HCQ ba. https://c19p.org/alhamlan
312. S. Sarfaraz, Q. Shaikh, S. Saleem, A. Rahim, F. Herekar, S. Junejo, da A. Hussain, Masu tantance mace-macen asibiti a cikin COVID-19; wani bincike mai zuwa daga Pakistan Jan 2021, medRxiv
MAGANIN LAFIYA 186 mai haƙuri HCQ marigayi nazarin jiyya: 45% mafi girma mace-mace (p=0.07).
Marasa lafiya na asibiti 186 na baya-bayan nan a Pakistan suna nuna rashin daidaituwar mace-macen HCQ RR 1.45, p = 0.07. Mai yiwuwa mai ruɗawa ta nuni. https://c19p.org/sarfaraz
313. A. Abdulrahman, I. AlSayed, M. AlMadhi, J. AlArayed, S. Mohammed, A. Sharif, K. Alansari, A. AlAwadhi, da M. AlQahtani, Inganci da amincin hydroxychloroquine a cikin marasa lafiya na COVID19: ƙungiya mai zaman kanta ta ƙasa da yawa. Nov 2020, medRxiv
MAGANIN LAFIYA 446 mai haƙuri HCQ ƙarshen jiyya ya dace da binciken ƙima: 17% ƙananan mace-mace (p=1) da 75% mafi girma haɗuwa mace-mace / intubation (p=0.24).
Binciken na baya-bayan nan game da marasa lafiya na gaggawa a Bahrain ba tare da nuna wani tasiri mai mahimmanci na HCQ ba. Mai yiwuwa mai ruɗawa ta nuni. Daidaitawa ya bayyana bai dace ba don tsananin tsanani. 17.5% na marasa lafiya na HCQ sun buƙaci oxygen yayin da kawai 12.6% na marasa lafiya na kulawa sun yi. https://c19p.org/abdulrahman
314. F. Ader, N. Peiffer-Smadja, J. Poissy, M. Bouscambert-Duchamp, D. Belhadi, A. Diallo, C. Delmas, J. Saillard, A. Dechanet, N. Mercier, A. Dupont, T. Alfaiate, F. Lescure, F. Raffi, F. J. Goehringier, S. Kimurenguier, S. S. Nseir, F. Danion, R. Clere-Jehl, K. Bouiller, J. Navellou, V. Tolsma, A. Cabie, C. Dubost, J. Courjon, S. Leroy, J. Mootien, R. Gaci, B. Mourvillier, E. Faure, V. Pourcher, S. Laux, K. Laux, O. Makinson, G. Martin-Blondel, L. Bouadma, E. Botelho-Nevers, A. Gagneux-Brunon, O. Epaulard, L. Piroth, F. Wallet, J. Richard, J. Reuter, T. Staub, B. Lina, M. Noret et al., An bude-lakabin bazuwar, gwajin gwaji na lopinnavir, da ƙari na lopinnaviravir. IFN-beta-1a da hydroxychloroquine a cikin marasa lafiya na asibiti tare da COVID-19 - Sakamakon ƙarshe daga gwajin DisCoVeRy Oktoba 2020, medRxiv
MAGANIN LAFIYA 299 mai haƙuri HCQ marigayi jiyya RCT: 15% mafi girma mace-mace (p=0.7) da 24% inganta ƙwayar cuta (p=0.68).
Farko ya ƙare sosai a ƙarshen mataki (95% akan oxygen a tushe) Gwajin DisCoVeRy. 4% ƙarin marasa lafiya suna kan samun iska a tushe a cikin ƙungiyar HCQ. Wannan preprint ɗin yana ba da ƙarin sakamako na baya-bayan nan fiye da labarin jaridar da ta gabata. https://c19p.org/discovery
315. F. Shamsi, M. Karimi, Z. Nafei, da E. Akbarian, Rayuwa da Mutuwar Yara a Asibiti masu fama da COVID-19: Kwarewar Cibiyar Koyarwa a Yazd, Iran Jul 2023, Kanada J. Cututtuka masu Yaduwa da Kwayoyin Halitta na Likita, Jul 2023, Shafi na 1-12
MAGANIN LAFIYA 183 mai haƙuri HCQ marigayi nazarin jiyya: 39% mafi girma mace-mace (p=0.51).
A baya-bayan nan 183 marasa lafiya na COVID-19 na asibiti na asibiti a Iran, ba su nuna wani babban bambanci a cikin mace-mace tare da sakamakon da ba a daidaita ba. https://c19p.org/shamsih
316. P. Kamstrup, P. Sivapalan, J. Eklöf, N. Hoyer, C. Ulrik, L. Pedersen, T. Lapperre, Z. Harboe, U. Bodtger, R. Bojesen, K. Håkansson, C. Tidemandsen, K. Armbruster, A. Browatzki, H. Meteran, K. Lasseer, K. Lundgren, T. Biering-Sørensen, da J. Jensen, Hydroxychloroquine a matsayin wakili na farko na rigakafin cutar sars-cov-2: nazarin ƙungiyar. Mayu 2021, Int. J. Cututtuka masu Yaduwa, Juzu'i na 108, Shafi na 370-376
60,334 mai haƙuri HCQ nazarin prophylaxis: 44% asibiti mafi girma (p=0.25) da 10% ƙananan lokuta (p=0.23).
Masu amfani da HCQ na baya-bayan nan a Denmark, ba su nuna bambanci mai mahimmanci ba, duk da haka mawallafa ba su daidaitawa ga mabambantan haɗari na asali ga marasa lafiya na cututtuka na autoimmune. Marubuta sun bayyana ba su da masaniya game da bincike a yankin, alal misali suna cewa "a halin yanzu, babu wata alaƙa da ke tsakanin sanannen cututtukan rheumatological da haɗarin kamuwa da SARS-CoV-2." Takardu da yawa sun nuna cewa haɗarin COVID-19 ga masu cutar cututtukan ƙwayoyin cuta sun fi girma gabaɗaya, misali, Ferri et al. nuna KO 4.42, p<0.001. Babu ƙarin bayanai. https://c19p.org/kamstrup
317. A. El-Solh, U. Meduri, Y. Lawson, M. Carter, da K. Mergenhagen, Nazarin asibiti da sakamakon COVID-19 m ciwon numfashi na numfashi: bayanai daga ma'ajiyar kasa Oktoba 2020, medRxiv
MAGANIN LAFIYA 643 mai haƙuri HCQ marigayi nazarin jiyya: 18% mafi girma mace-mace (p=0.17).
Binciken bayanan baya-bayan nan na 7,816 Veterans Affairs an kwantar da marasa lafiya a asibiti suna nazarin ci gaba zuwa matsananciyar wahala ta numfashi da mace-mace na kwanaki 30 daga matsanancin ciwo na numfashi. Mai yiwuwa mai ruɗawa ta nuni. Mai yiyuwa ne son zuciya na lokaci-lokaci, tare da HCQ mafi kusantar a yi amfani da su a baya, kafin ingantacciyar haɓakawa a cikin jiyya gabaɗaya. Babu wani sakamako da aka bayar don HCQ don ci gaba zuwa matsananciyar wahala ta numfashi. https://c19p.org/solh
318. S. Saleemi, A. Alrajhi, M. Alhaji, A. Alfattani, da F. Albaiz, Lokacin zuwa PCR mara kyau daga farkon bayyanar cututtuka a cikin marasa lafiya na COVID-19 akan Hydroxychloroquine da Azithromycin - Kwarewar duniya ta gaske Agusta 2020, medRxiv
MAGANIN LAFIYA 85 mai haƙuri HCQ marigayi nazarin jiyya: 21% jinkirin jinkirin ƙwayar cuta (p=0.05).
Mai zuwa 65 HCQ + AZ, 20 masu kula da marasa lafiya, suna nuna lokacin tsaka-tsaki zuwa PCR mara kyau na kwanaki 23 don HCQ + AZ vs. 19 kwanaki don sarrafawa. Mai ruɗani da nuni. 100% na wadanda ba HCQ kungiyar suna da m cuta vs. 63% na kungiyar HCQ+AZ. Ƙarin cututtuka da alamun cututtuka a cikin ƙungiyar HCQ+AZ. https://c19p.org/saleemi
319. B. Alosaimi, H. Alshanbari, M. Alturaiqy, H. AlRawi, S. Alamri, A. Albujaidy, A. Bin Sabaan, A. Alrashed, A. Alamer, F. Alghofaili, K. Al-Duraymih, A. Alshalani, da W. Alturaiki, Analying the Difference in Moverate in the COVID-19 Marasa lafiya Suna Karɓan Hydroxychloroquine ko Favipiravir Nov 2022, Pharmaceuticals, Juzu'i na 15, fitowa ta 12, Shafi na 1456
MAGANIN LAFIYA 74 mai haƙuri HCQ marigayi magani PSM binciken: 400% mafi girma mace-mace (p=0.49), 43% guntun asibiti (p=0.63), da 29% mafi girma sallamar asibiti (p=0.74).
An dawo da marasa lafiya 200 na COVID-19 a asibiti a Saudi Arabiya, ba tare da nuna wani gagarumin bambanci a sakamako tsakanin HCQ da favipiravir ba. https://c19p.org/alosaimi
320. A. Lyashchenko, Y. Yu, D. McMahon, R. Bies, M. Yin, da S. Cremers, Bayyanar Tsarin Halittu ga Hydroxychloroquine da dangantakarta da sakamakon a cikin marasa lafiya na COVID-19 marasa lafiya a cikin New York City Agusta 2022, British J. Clinical Pharmacology
MAGANIN LAFIYA 3,256 mai haƙuri HCQ marigayi nazarin jiyya: 48% mafi girma mace-mace (p <0.0001).
A baya-bayan nan an kwantar da marasa lafiya a asibiti a New York a lokacin tashin farko, wanda ke nuna babu wata muhimmiyar alaƙa tsakanin matakan HCQ da sakamako. Mawallafa sun lura cewa marasa lafiya da bayanai sun kasance marasa lafiya marasa lafiya. https://c19p.org/lyashchenko
321. A. Malundo, C. Abad, M. Salamat, J. Sandejas, J. Poblete, J. Planta, S. Morales, R. Gabunada, A. Evasan, J. Cañal, J. Santos, J. Manto, M. Mercado, R. Rojo, E. Ornos, da M. Alejandria, Masu tsinkaya na Rashin Mutuwa a cikin Mutuwar Mutuwa 19 a cikin Mutuwar Mutuwa. Cibiyar a Philippines Jul 2022, Yankunan IJID
MAGANIN LAFIYA 1,215 mai haƙuri HCQ marigayi nazarin jiyya: 24% mafi girma mace-mace (p=0.32).
Marasa lafiya 1,215 da aka dawo da su a asibiti a Philippines, ba su nuna wani bambanci mai mahimmanci a cikin sakamako tare da remdesivir ko amfani da HCQ a cikin sakamakon da ba a daidaita shi ba yana fuskantar ruɗani ta hanyar nuni. https://c19p.org/malundo
322. A. Soto, D. Quiñones-Laveriano, J. Azañero, R. Chumpitaz, J. Claros, L. Salazar, O. Rosales, L. Nuñez, D. Roca, da A. Alcantara, Mutuwa da abubuwan haɗari masu alaƙa a cikin marasa lafiya da ke asibiti saboda COVID-19 a cikin wani asibiti na Peruvian. Maris 2022, PLOS ONE, Juzu'i na 17, Fitowa ta 3, Shafi e0264789
MAGANIN LAFIYA 1,418 mai haƙuri HCQ marigayi nazarin jiyya: 6% mafi girma mace-mace (p=0.46).
Komawa 1,418 Matsakaicin marigayi (46% mace-mace) marasa lafiya a Peru, ba su nuna wani bambanci mai mahimmanci tare da HCQ ba. Akwai rudani mai ƙarfi ta nuni, misali 48% na marasa lafiya tare da asali SpO2 <70% an bi da su idan aka kwatanta da 22% don SpO2>95%. Hakanan ana iya samun babban ruɗani ta lokaci tare da ƙayyadaddun kulawa da ke canzawa sosai a cikin 'yan watannin farko na cutar. https://c19p.org/sotoh
323. M. Albanghali, S. Alghamdi, M. Alzahrani, B. Barakat, A. Haseeb, J. Malik, S. Ahmed, da S. Anwar, Halayen Clinical da Sakamakon Magani na marasa lafiya na Covid-19 masu sauƙi zuwa matsakaici a Saudi Arabia: Nazarin Cibiya Guda. Feb 2022, J. Kamuwa da Lafiyar Jama'a, juzu'i na 15, fitowa ta 3, Shafi na 331-337
MAGANIN LAFIYA 811 mai haƙuri HCQ marigayi nazarin jiyya: 35% mafi girma mace-mace (p=0.46).
A baya-bayan nan 811 marasa lafiya na COVID+ na asibiti a Saudi Arabiya, suna nuna yawan mace-mace tare da jiyya na HCQ a cikin sakamakon da ba a daidaita ba wanda ke da rudani ta nuni. https://c19p.org/albanghali
324. S. Alghamdi, Halayen asibiti da sakamakon jiyya na marasa lafiya na COVID-19 masu tsanani (ICU) a Saudi Arabia: Nazarin cibiya guda ɗaya Agusta 2021, Saudi Pharmaceutical J., juzu'i na 29, fitowa ta 10, Shafi na 1096-1101
MAGANIN LAFIYA 171 mai haƙuri HCQ ICU binciken: 39% mafi girma mace-mace (p=0.52).
Marasa lafiya na ICU na 171 na baya-bayan nan a Saudi Arabiya suna nuna ba su da bambanci ga jiyya na HCQ a cikin sakamakon da ba a daidaita su ba. https://c19p.org/alghamdi2
325. K. Gadhiya, P. Hansrivijit, M. Gangireddy, da J. Goldman, Halayen asibiti na marasa lafiya na asibiti tare da COVID-19 da kuma tasiri akan mace-mace: hanyar sadarwa guda ɗaya, nazarin ƙungiyoyin koma baya daga jihar Pennsylvania. Afrilu 2021, BMJ Buɗe, Juzu'i na 11, fitowa ta 4, Shafi e042549
MAGANIN LAFIYA 271 mai haƙuri HCQ marigayi nazarin jiyya: 5% mafi girma mace-mace (p=0.89).
Marasa lafiya 283 na baya-bayan nan a cikin Amurka suna nuna yawan mace-mace tare da duk jiyya (ba ƙididdiga ba). Mai yiwuwa mai ruɗawa ta nuni. A cikin ƙarin bayani, marubuta sun lura cewa yawanci ana ba da jiyya ga marasa lafiya waɗanda ke buƙatar maganin iskar oxygen. Maganin iskar oxygen da shigar da ICU (wataƙila, takarda ta haɗa da shigar da ICU don ƙirar 2 a wasu wurare amma ba wasu ba) sune kawai masu canji waɗanda ke nuna tsananin da aka yi amfani da su a cikin gyare-gyare. Mai yuwuwar rikicewar lokaci saboda HCQ ya zama ƙarar cece-kuce kuma ba a yi amfani da shi ba tsawon lokacin da aka rufe (Maris 1 zuwa Mayu 31, 2020), yayin da gabaɗayan ka'idojin jiyya a wannan lokacin sun inganta sosai, watau, ƙarin kulawar marasa lafiya na iya zuwa daga baya a cikin lokacin da aka inganta ka'idojin magani. https://c19p.org/gadhiya
326. E. Mulhem, A. Oleszkowicz, da D. Lick, 3219 marasa lafiya na asibiti tare da COVID-19 a kudu maso gabas Michigan: nazari na sake dubawa Afrilu 2021, BMJ Buɗe, Juzu'i na 11, fitowa ta 4, Shafi e042042
MAGANIN LAFIYA 3,219 mai haƙuri HCQ marigayi nazarin jiyya: 28% mafi girma mace-mace (p=0.1).
Binciken bayanan baya na 3,219 marasa lafiya a asibiti a Amurka. Sakamakon daban-daban a cikin bincike na lokaci (Table S2), da kuma sakamakon da ya bambanta da sauran nazarin don magunguna iri ɗaya (misali, heparin KO 3.06 [2.44-3.83]) ya ba da shawara. mahimmancin rudani ta hanyar nuni da rikicewa ta lokaci. https://c19p.org/mulhem
327. S. Alghamdi, B. Barakat, I. Berrou, A. Alzahrani, A. Haseeb, M. Hammad, S. Anwar, A. Sindi, H. Almasmoum, da M. Albanghali, Ingantaccen Lafiyar Hydroxychloroquine a cikin Marasa lafiya tare da COVID-19: Bincike daga Binciken Kwatancen Kwatancen a Saudi Arabia Maris 2021, Magungunan rigakafi, juzu'i na 10, fitowa ta 4, Shafi na 365
MAGANIN LAFIYA 775 mai haƙuri HCQ marigayi nazarin jiyya: 7% mafi girma mace-mace (p=0.88).
Marasa lafiya 775 na asibiti a Saudi Arabiya na baya-bayan nan ba su nuna wani bambanci ba. Babu daidaitawa ga tsanani ko cututtuka. Mai yiwuwa mai ruɗawa ta nuni. https://c19p.org/alghamdi
328. N. Rosenthal, Z. Cao, J. Gundrum, J. Sianis, da S. Safo, Abubuwan Haɗari da ke Haɗe da Mutuwar Asibiti a cikin Samfurin Marasa lafiya na Ƙasar Amurka tare da COVID-19 Dec 2020, JAMA Network Bude, juzu'i na 3, fitowa ta 12, Shafi e2029058
MAGANIN LAFIYA HCQ marigayi nazarin jiyya: 8% mafi girma mace-mace (p=0.13).
Binciken bayanan baya na 64,781 marasa lafiya a asibiti a Amurka, yana nunawa ƙananan mace-mace tare da bitamin C ko bitamin D (marubuta ba su bambanta tsakanin su biyu ba), kuma mafi girman mace-mace tare da zinc da HCQ, ƙididdiga mai mahimmanci ga zinc. Marubuta sun cire ziyarar marasa lafiya ta asibiti, ba tare da bayani ba. Mai yuwuwar rikicewa ta nuni, gyare-gyare ba su bayyana sun haɗa da kowane bayani game da tsananin COVID-19 a tushe ba.. https://c19p.org/rosenthal
329. S. Aboulenain, N. Dewaswala, F. Ramos, P. Torres, A. Abdallah, M. Abdul Qader, B. Al-Abbasi, C. Bornmann, K. Dziadkowiec, K. Chen, J. Pino, R. Chait, da K. De Almeida, Tasirin Hydroxychloroquine a cikin Mutuwar Halittu. Nov 2020, HCA Healthcare J. Magani, juzu'i na 1, fitowa ta 0
MAGANIN LAFIYA 175 mai haƙuri HCQ marigayi nazarin jiyya: 15% mafi girma mace-mace (p=0.72).
A baya-bayan nan 175 marasa lafiya na COVID-19 na asibiti a cikin Amurka, ba su nuna wani babban bambanci a cikin mace-mace tare da HCQ. Marubuta sun lura cewa "marasa lafiya da aka yi musu magani tare da HCQ a cikin rukuninmu sun fi yin rashin lafiya a asali." https://c19p.org/aboulenain
330. G. Rodriguez-Nava, M. Yanez-Bello, D. Trelles-Garcia, C. Chung, S. Chaudry, A. Khan, H. Friedman, da D. Hines, Halayen asibiti da abubuwan haɗari ga mace-mace na marasa lafiya na asibiti tare da COVID-19 a cikin asibitin al'umma: Nazarin haɗin gwiwa na baya-bayan nan. Nov 2020, Ci gaba na Asibitin Mayo: Sabuntawa, Inganci & Sakamako, juzu'i na 5, fitowa ta 1, Shafi na 1-10
MAGANIN LAFIYA 313 mai haƙuri HCQ marigayi nazarin jiyya: 6% mafi girma mace-mace (p=0.77).
Marasa lafiya na 313 na baya-bayan nan, galibin matakan mahimmanci kuma galibi suna buƙatar tallafin numfashi, suna nuna RR 1.06 ba daidai ba, p = 0.77. Mai ruɗani da alama mai yiwuwa. https://c19p.org/rodrigueznava
331. E. Salazar, P. Christensen, E. Graviss, D. Nguyen, B. Castillo, J. Chen, B. Lopez, T. Eagar, X. Yi, P. Zhao, J. Rogers, A. Shehabeldin, D. Joseph, F. Masud, C. Leveque, R. Olsen, D. Bernard, J. Mortlysser a cikin Significat Den, J. Muhür, Den Gülhar, da kuma J. Mortality Den. Babban Ƙungiyar Cutar Coronavirus 2019 (COVID-19) An Bayar da Marasa lafiya da wuri tare da Plasma Convalescent Mai ɗauke da High-Titer Anti-Magungunan Cutar Cutar Cutar Coronavirus 2 (SARS-CoV-2) Spike Protein IgG Nov 2020, The American J. Pathology, Volume 191, fitowa ta 1, Shafi na 90-107
MAGANIN LAFIYA 903 mai haƙuri HCQ marigayi nazarin jiyya: 37% mafi girma mace-mace (p=0.28).
Nazarin plasma convalescent kuma yana nuna mace-mace dangane da jiyya na HCQ, haɗarin haɗari mara daidaituwa uHR 1.37, p = 0.28. Mai yiwuwa mai ruɗawa ta nuni. https://c19p.org/salazar
332. M. Choi, M. Kang, S. Shin, J. Noh, H. Cheong, W. Kim, J. Jung, da J. Song, Kwatanta tasirin antiviral don shari'ar COVID-19 mai sauƙi zuwa matsakaici tsakanin lopinavir/ritonavir da hydroxychloroquine. Oktoba 2020, Int. J. Cututtuka masu Yaduwa, Juzu'i na 102, Shafi na 275-281
MAGANIN LAFIYA 1,402 mai haƙuri HCQ marigayi nazarin jiyya: 22% jinkirin jinkirin ƙwayar cuta (p=0.0001).
Binciken bayanan inshorar lafiya ya kasa daidaitawa don tsananin cutar kuma rashin samun babban bambanci cikin lokaci zuwa PCR- na LPV/r da HCQ. Akwai manyan bambance-bambance a cikin tsanani a cikin ƙungiyoyi. Marubutan sun yi daidai da maki mai ƙima amma ya zaɓi kada ya ba da fifiko ga tsanani, yana haifar da ƙungiyoyi marasa misaltuwa, misali, ciwon huhu na asali na 44% a cikin ƙungiyar HCQ da 15% a cikin ƙungiyar kulawa (bayan PSM). Marubuta sun lura da wannan amma ba su bayar da bayani don rashin gyara ga tsanani: "Duk da haka, tsananin cutar da adadin ciwon huhu da ke tare da ita har yanzu sun kasance mafi girma a cikin ƙungiyar LPV/r da HCQ." https://c19p.org/choi
333. C. Rentsch, N. DeVito, B. MacKenna, C. Morton, K. Bhaskaran, J. Brown, A. Schultze, W. Hulme, R. Croker, A. Walker, E. Williamson, C. Bates, S. Bacon, A. Mehrkar, H. Curtis, D. Evans, K. Wing,, R. Ingles A. Dr. H. McDonald, J. Cockburn, H. Forbes, J. Parry, F. Hester, S. Harper, L. Smeeth, I. Douglas, W. Dixon, S. Evans, L. Tomlinson, da B. Goldacre, Tasirin pre-bayyana amfani da hydroxychloroquine akan marasa lafiya da ke fama da cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan da kuma cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan hai ko kuma tare da cututtukan cututtukan. erythematosus ta amfani da dandalin OpenSAFELY Satumba 2020, Lancet Rheumatology, Juzu'i na 3, fitowa ta 1, Shafi na e19-e27
194,637 mai haƙuri HCQ nazarin prophylaxis: 3% mafi girma mace-mace (p=0.83).
Binciken bayanan kulawa na RA / SLE marasa lafiya a cikin Birtaniya, 194,637 RA / SLE marasa lafiya tare da 30,569 da ciwon> = 2 HCQ takardun shaida a cikin watanni 6 da suka gabata, HCQ HR 1.03 [0.80-1.33] (HR 0.78 kafin daidaitawa). Marasa lafiya 70 tare da rubutattun HCQ sun mutu. Wata babbar matsala ita ce akwai babu ilimin yarda ga waɗannan marasa lafiya 70 alal misali, mai yiyuwa ne cewa suna cikin adadin da ake tsammani na marasa lafiya waɗanda ba su sha magani kamar yadda aka tsara ba, suna bata sakamakon. Sauran iyakoki sun haɗa da ruɗe ta hanyar amfani da bDMARDs da ruɗani ta tsananin cutar rheumatological. https://c19p.org/rentsch
334. M. Fried, J. Crawford, A. Mospan, S. Watkins, B. Munoz, R. Zink, S. Elliott, K. Burleson, C. Landis, K. Reddy, da R. Brown, Halayen Marasa lafiya da Sakamako na 11,721 Marasa lafiya tare da COVID19 Asibiti a fadin Amurka Agusta 2020, Cutar Cutar Cutar Kwalara, juzu'i na 72, fitowa ta 10, Shafi e558-e565
MAGANIN LAFIYA 11,721 mai haƙuri HCQ marigayi nazarin jiyya: 27% mafi girma mace-mace (p=0.001).
Binciken bayanan bayanai na 11,721 marasa lafiya na asibiti, 4,232 akan HCQ. Shaida mai ƙarfi don ruɗani ta hanyar nuni da jin ƙai na amfani da HCQ. 24.9% na marasa lafiya na HCQ sun kasance akan iskar injina akan sarrafa 12.2%. Yawan mace-macen iska ya kasance 70.5% a kan 11.6%. Wannan binciken baya daidaitawa don bambance-bambance a cikin yanayin haɗuwa da rashin lafiya, sabili da haka baya yin ƙarshe. Mutuwar HCQ da ba a daidaita ba ta kasance 24.8% sabanin sarrafawa 19.6%. Daidaita don samun iska kawai yana ba mu 17.7% HCQ daidai da 19.6% iko (daidaita ƙungiyar HCQ don samun daidaitattun ma'aikatan iska), RR 0.90. Da fatan marubuta za su iya yin cikakken nazarin daidaitawa. Kwayoyin cututtuka na iya ba da izinin sarrafawa, yayin da marasa lafiya da suka rage a asibiti (5.3%) na iya jin dadin HCQ (wasu nazarin sun nuna ƙuduri mai sauri ga marasa lafiya na HCQ). An sami rashin daidaiton bayanai a cikin wannan binciken, misali 99.4% na marasa lafiya da aka yi musu magani tare da HCQ an yi musu magani a asibitocin birane, idan aka kwatanta da 65% na marasa lafiya marasa lafiya (Ƙarin Ƙarin 3), yayin da ake rarraba marasa lafiya cikin daidaito tsakanin asibitocin koyarwa ko marasa koyarwa, da kuma a mafi yawan biranen (Arewa maso Gabas) da ƙananan birane (Midwest) na Amurka. https://c19p.org/fried
335. E. Peters D. Collard Den Bergh, I. Vlasveld, da J. Sikkens, Sakamako na Mutane Tare da COVID-19 a Asibitoci Tare da Ba tare da Daidaitaccen Jiyya Tare da (Hydroxy) chloroquine Agusta 2020, Ƙwararrun Ƙwayoyin Halitta da Kamuwa da cuta, Juzu'i na 27, fitowa ta 2, Shafi na 264-268
MAGANIN LAFIYA 1,949 mai haƙuri HCQ marigayi nazarin jiyya: 9% mafi girma mace-mace (p=0.57).
Nazarin baya na HCQ amfani a asibitoci 9 a cikin Netherlands, yana nuna babu wani bambanci mai mahimmanci a cikin mace-mace tare da HCQ/CQ ko dexamethasone. Marigayi mataki (an shigar da shi a asibiti tare da gwaji mai kyau ko CT scan rashin daidaituwa). Asibitoci 4 cikin 7 sun fara jinya ne bayan sun kara tabarbarewa. Kwanaki ashirin da daya (21 days) - wasu binciken sun nuna an magance matsalolin marasa lafiya da sauri da kuma ƙarin kulawa da marasa lafiya da suka rage a asibiti a wannan lokacin. A cikin preprint, 58 daga cikin 341 masu kulawa sun mutu. A cikin sigar jarida, 53 na 353 masu kulawa sun mutu. Mahimman bambance-bambance tsakanin asibitoci - asibitocin HCQ suna da manya manya marasa lafiya tare da ƙarin cututtuka. Asibitocin da ba na HCQ ba “cibiyoyin ilimi ne na manyan makarantu” yayin da asibitocin HCQ “asibitocin kula da sakandare ne.” Ragowar rudani mai yiwuwa. Wannan binciken ya kwatanta asibitocin yau da kullun masu cunkoso da asibitocin ilimi marasa cunkoso. An cire rukunin marasa lafiya saboda canja wurin zuwa wasu asibitoci. Wannan yana gabatar da son zuciya saboda marasa lafiya da ke cikin mawuyacin hali ba a canza su ba. Misali, marasa lafiya da ke amfana daga jiyya na HCQ na iya canjawa wuri zuwa cibiyoyin manyan makarantu kuma an cire su daga bincike, suna ƙara yawan adadin lokuta masu mahimmanci a cikin asibitocin sakandare. Daga cikin asibitocin CQ/HCQ guda bakwai, lokacin fara maganin CQ/HCQ ya bambanta; Asibitoci uku sun fara ne a daidai lokacin da aka gano cutar ta COVID-19, huɗu sun fara bayan ganewar asali amma sai lokacin da marasa lafiya suka tabarbare a asibiti misali, lokacin da aka sami karuwar yawan numfashi ko haɓakar amfani da ƙarin iskar oxygen. Yawancin marasa lafiya sun karɓi CQ maimakon HCQ mafi aminci, suna karɓar jinkiri tare da CQ. An ba marasa lafiya kashi na farko na 600mg CQ sannan kowane sa'o'i 12, don 5 kwanakin kashi na 300 MG, don jimlar 3600mg CQ, mai yiwuwa ya zama mai guba. Marubuta sun ambaci wani yanki na asibitocin da aka fara jiyya a baya, wanda da alama yanki ne mafi mahimmanci don tantancewa, amma ba a bayar da sakamako ba. https://c19p.org/peters
336. S. Roomi, W. Ullah, F. Ahmed, S. Farooq, U. Sadiq, A. Chohan, M. Jafar, M. Saddique, S. Khanal, R. Watson, da M. Boigon, Ingancin hydroxychloroquine da tocilizumab a cikin marasa lafiya tare da COVID-19: Tsare-tsare na sake dubawa na tsakiya guda ɗaya. Agusta 2020, J. Binciken Intanet na Likita, juzu'i na 22, fitowa ta 9, Shafi e21758
MAGANIN LAFIYA 176 mai haƙuri HCQ marigayi nazarin jiyya: 38% mafi girma mace-mace (p=0.54).
Marasa lafiya na asibiti na 176 na baya-bayan nan (144 HCQ, kulawar 32) yana nuna babu bambance-bambance masu mahimmanci tare da HCQ ko TCZ. Mai ruɗani da nuni. https://c19p.org/roomi
337. M. Singer, D. Kaelber, da M. Antonelli, Hydroxychloroquine ba shi da tasiri don rigakafin COVID-19 a cikin lupus da arthritis na rheumatoid Agusta 2020, Littattafai na Cututtukan Rheumatic, Juzu'i na 81, Fitowa ta 9, Shafi na e161-e161
32,758 mai haƙuri HCQ nazarin prophylaxis: 9% ƙarin lokuta (p=0.62).
Kwatanta yawan adadin marasa lafiya na SLE/RA akan magungunan rigakafi waɗanda ke shan HCQ, don gano COVID-19 tare da wasu cututtuka ko ziyarar marasa lafiya, gano irin wannan kaso a kowane hali.. Ba a bayar da bayanin mutuƙar tsanani don sanin ko HCQ da aka yi wa majinyata lafiya ba. Babu daidaitawa ga magunguna masu haɗuwa ko tsanani. https://c19p.org/singer
338. S. Gupta, S. Hayek, W. Wang, L. Chan, K. Mathews, M. Melamed, S. Brenner, A. Leonberg-Yoo, E. Schenck, J. Radbel, J. Reiser, A. Bansal, A. Srivastava, Y. Zhou, A. Sutherland, A., Green, A. Gojata, A. Shehata, J. S. Shaefi, C. Parikh, J. Arunthamakun, A. Athavale, A. Friedman, S. Short, Z. Kibbelaar, S. Abu Omar, A. Admon, J. Donnelly, H. Gershengorn, M. Hernán, M. Semler, D. Leaf, C. Walther, S. Anumudu, P. Ko. Nguyen, M. Krajewski, S. Shankar, A. Pannu, J. Valencia, S. Waikar, P. Hart, O. Ajiboye, M. Itteera, J. Rachoin, C. Schorr et al. Jul 2020, JAMA Intern. Med., Juzu'i na 180, fitowa ta 11, Shafi na 1436
MAGANIN LAFIYA 2,215 mai haƙuri HCQ marigayi nazarin jiyya: 6% mafi girma mace-mace (p=0.41).
Binciken marasa lafiya na sashin kulawa mai zurfi 2,215 da ke nuna babu bambance-bambance masu mahimmanci tare da wannan ƙarshen matakin amfani na HCQ. https://c19p.org/gupta
339. S. Juni 2020, Cir. 2020, 569-575, juzu'i na 88, fitowa ta 5
MAGANIN LAFIYA 56 mai haƙuri HCQ ICU binciken: 11% mafi girma mace-mace (p=1).
Ƙananan nazarin baya na 56 ICU marasa lafiya a Mexico suna nuna HCQ RR 1.1, p = 1.0. https://c19p.org/sosagarcia
340. J. Luo, H. Rizvi, I. Preeshagul, J. Egger, D. Hoyos, C. Bandlamudi, C. McCarthy, C. Falcon. Paik, G. Riely, C. Rudin, H. Yu, M. Zauderer, M. Donoghue, M. Łuksza, B. Greenbaum, M. Kris, da M. Hellmann, COVID-19 a cikin marasa lafiya da ciwon huhu. Jun 2020, Annals of Oncology, 1386-1396, juzu'i na 31, fitowa ta 10, Shafi na 1386-1396
MAGANIN LAFIYA 48 mai haƙuri HCQ marigayi nazarin jiyya: 2% mafi girma mace-mace (p=0.99).
Binciken marasa lafiya na huhu na asibiti tare da 35 na 48 suna ɗaukar HCQ, mace-mace KO 1.03, p = 0.99. https://c19p.org/luo
341. E. Bozzalla Cassione, G. Zanframundo, A. Biglia, V. Codullo, C. Montecucco, da L. Cavagna, COVID-19 kamuwa da cuta a cikin wani yanki na arewacin Italiya na tsarin lupus erythematosus wanda aka tantance ta hanyar telemedicine. Mayu 2020, Littattafai na Cututtukan Rheumatic, Juzu'i na 79, Fitowa ta 10, Shafi na 1382-1383
165 mai haƙuri HCQ nazarin prophylaxis: 50% ƙarin lokuta (p=0.59).
Binciken marasa lafiya 165 SLE, 127 akan HCQ. Majinyata 8 da ake zargin COVID-19 da 4 sun tabbatar da lamuran. Babu mace-mace, shari'ar ICU guda ɗaya. Marasa lafiya 7 ba su da alamun cutar duk da tuntuɓar mai haƙuri da COVID-19. Babu daidaitawa ga magunguna masu haɗuwa ko tsananin SLE. Mai ruɗani da nuni. https://c19p.org/cassione
342. J. Geleris, Y. Sun, J. Platt, J. Zucker, M. Baldwin, G. Hripcsak, A. Labella, D. Manson, C. Kubin, R. Barr, M. Sobieszczyk, da N. Schluger, Nazarin lura da Hydroxychloroquine a Asibiti masu fama da Covid-19 Mayu 2020, NEJM, Mayu 7, 2020, Juzu'i na 382, Fitowa ta 25, Shafi na 2411-2418
MAGANIN LAFIYA 1,446 mai haƙuri HCQ marigayi nazarin jiyya: 4% mafi girma haɗuwa mace-mace / intubation (p=0.76).
Kafin daidaitawa, 38 masu kulawa suna da hauhawar jini. Bayan daidaitawar haɓakawa, marasa lafiya 146 suna da hauhawar jini (Table 1). Ko da duk abin da ya dace da kulawa da marasa lafiya suna da hauhawar jini, Yawan sarrafawa zai zama 14% kawai idan aka kwatanta da 49% don magani. Tunda marasa lafiya da hauhawar jini a mafi girman haɗarin mutuwa (HR 2.12), wannan da alama yana ɓata sakamakon. Nazarin lura da marasa lafiya na asibiti na 1,446 da ke nuna ba su da wani tasiri mai mahimmanci akan haɗakar intubation / sakamakon mutuwa don ƙarshen jiyya. Koyaya, bincike na biyu ya nuna An ɓoye nasarar HCQ ta hanyar haɗa intubation da mutuwa - mutuwa / (haɗin mutuwa / intubation) don HCQ shine 60% vs. iko 89%. RCT shawarar. Babu AZ ko Zinc. Ƙungiyar HCQ sun fi rashin lafiya - marasa lafiya sun riga sun kasance cikin matsanancin matsananciyar wahala na numfashi, yawancin ƙungiyar masu kulawa ba su cikin matsanancin damuwa na numfashi. Matsalolin sarrafawa sun sami wasu hanyoyin warkewa. https://c19p.org/geleris
343. J. De la Iglesia, N. Fernández, R. Flores, M. Gómez, F. González de Haro, M. González, E. Vicente, M. Gil de Gómez, M. Guisado, I. Gómez, A. Andrada, N. Cao, P. Figaredo, C. García, Á. Alcalde, da J. Rilo, Hydroxicloroquine don rigakafin rigakafin riga-kafi don SARS-CoV-2 Satumba 2020, medRxiv
1,375 mai haƙuri HCQ nazarin prophylaxis: 43% ƙarin lokuta (p=0.15).
Binciken marasa lafiya na marasa lafiya a kan HCQ, idan aka kwatanta da ƙungiyar kulawa daga yawancin jama'a (wanda ya dace da shekaru da jima'i, amma ba a daidaita shi ba don cutar ta jiki), yana nuna bambance-bambance maras muhimmanci tsakanin kungiyoyi. Wani bincike ya nuna cewa Haɗarin COVID-19 ga masu cutar cututtukan ƙwayoyin cuta na tsarin jiki ya fi girma gabaɗaya, Ferri et al. nuna KO 4.42, p<0.001, wanda shine abin da aka lura da shi a zahiri, la'akari da dalilai kamar waɗannan marasa lafiya na iya yin hankali sosai don guje wa fallasa. Idan an daidaita don haɗarin tushe daban-daban, Sakamakon mace-mace ya zama RR 0.35, p=0.23, yana ba da shawarar fa'ida mai yawa don maganin HCQ (kamar yadda aka nuna a wasu nazarin). https://c19p.org/delaiglesia
344. O. Uyaroğlu, M. Sönmezer, G. Telli Dizman, N. Çalık Başaran, S. Karahan, da Ö. Uzun, Kwatanta Favipiravir zuwa Hydroxychloroquine Plus Azithromycin a cikin Jiyya na Marasa lafiya tare da COVID-19 marasa Muhimmanci: Tsari-da-tsaki, Maimaitawa, Nazari mai daidaita Maki Maris 2022, Acta Medica, juzu'i na 53, fitowa ta 1, Shafi na 73-82
MAGANIN LAFIYA 84 mai haƙuri HCQ marigayi magani PSM binciken: 200% mafi girma mace-mace (p=1), 67% ƙananan shigar da ICU (p=1), da 10% guntu asibiti (p=0.9).
Bayanan Bayani na PSM260 marigayi mataki asibiti COVID-19 masu ciwon huhu a Turkiyya, bai nuna wani gagarumin bambanci tsakanin favipiravir da HCQ ba. https://c19p.org/uyaroglu
345. A. Erden, O. Karakas, B. Armagan, S. Guven, B. Ozdemir, E. Atalar, H. Apaydin, E. Usul, I. Ates, A. Omma, da O. Kucuksahin, Sakamakon COVID-19 a cikin marasa lafiya da ciwon antiphospholipid: nazari na sake dubawa Jan 2022, Bratislava Medical J., Juzu'i na 123, fitowa ta 02, Shafi na 120-124
9 mai haƙuri HCQ nazarin prophylaxis: 75% ƙananan asibiti (p=0.23).
Komawa 9 COVID-19 marasa lafiya tare da ciwon antiphospholipid a Turkiyya, ba tare da nuna bambance-bambance masu mahimmanci ba dangane da jiyya na HCQ. https://c19p.org/erden
346. P. Bhatt, V. Patel, P. Shah, da K. Parikh, Hydroxychloroquine Prophylaxis da Cutar Coronavirus-19: Sakamakon Kwarewa tsakanin Ma'aikatan Kula da Lafiya Agusta 2021, medRxiv
927 mai haƙuri HCQ nazarin prophylaxis: 49% ƙarin lokuta (p=0.02).
Binciken lura na 927 ma'aikatan kiwon lafiya masu ƙarancin haɗari a Indiya, 731 masu aikin sa kai don rigakafin HCQ na mako-mako, suna nuna mafi girma lokuta tare da jiyya a sakamakon da ba a daidaita ba. Sakamakon asibiti ya kasance a cikin yarjejeniya, duk da haka ba a bayar da bayanin abin da marasa lafiya ke da alamun bayyanar cututtuka ba. Ba a sami wata matsala ba kuma babu asibiti ko mace-mace. Biyayya ya yi ƙasa sosai, yana raguwa mako-mako, tare da kusan dukkanin mahalarta sun daina zuwa mako 11. Yawancin cututtuka sun faru ne a cikin makonni masu zuwa lokacin da rashin yarda da haƙuri ya yi ƙasa sosai, kuma babu kowane bincike na yarjejeniya. #ECR/206/Inst/GJ/2013/RR-20. https://c19p.org/bhatt
347. H. Li, M. Deng, J. Wang, L. Ma, da Z. Yang, Jiyya ga marasa lafiya COVID-19 tare da hydroxychloroquine ko chloroquine: Binciken baya Jan 2021, Dandalin Bincike
MAGANIN LAFIYA 37 mai haƙuri HCQ marigayi nazarin jiyya: 40% jinkirin jinkirin ƙwayar cuta (p=0.06).
37. Ƙididdigar ƙididdiga na ƙididdiga na ƙananan bayanai na XNUMX marasa lafiya marasa lafiya sun kwanta a asibiti a cibiyar kulawa mai zurfi a kasar Sin, ba a sami wani gagarumin bambanci a zubar da kwayar cutar ba. Marasa lafiya duk suna cikin mawuyacin hali. Mutuwa daya ce kawai amma ba a fayyace kungiyar ba. Mai ruɗani da nuni mai yiwuwa. https://c19p.org/li2
348. A. Komissarov, I. Molodtsov, O. Ivanova, E. Maryukhnich, S. Kudryavtseva, A. Mazus, E. Nikonov, da E. Vasilieva, Hydroxychloroquine ba shi da wani tasiri a kan SARS-CoV-2 kaya a cikin nasopharynx na marasa lafiya da m nau'i na COVID-19 Juni 2020, medRxiv
MAGANIN LAFIYA 36 mai haƙuri HCQ marigayi nazarin jiyya: 25% mummunan nauyin hoto (p=0.45).
Ƙananan mataki na ƙarshe (kwanaki 7-10 bayan bayyanar cututtuka) nazarin hanci swab RNA tare da kulawar 12 da marasa lafiya na 33, ba tare da nuna bambance-bambance masu mahimmanci ba (ana ganin raguwa mai yawa a cikin ƙwayoyin cuta a cikin ƙungiyoyi biyu). Ƙungiyoyin ba su dace da juna ba, tare da bambance-bambance masu mahimmanci da aka gani tsakanin marasa lafiya na asibiti da marasa lafiya. 9 na 10 marasa lafiya na asibiti sun kasance a cikin ƙungiyar HCQ kuma daya kawai a cikin ƙungiyar kulawa. An ƙara ƙarin majiyyatan kulawa guda 2 tsakanin sigar farko da ta biyu na wannan preprint (ciki har da majinyacin kulawa kawai a asibiti). https://c19p.org/komissarov
349. D. Guillaume, B. Magalie, E. Sina, S. Imène, V. Frédéric, D. Mathieu, M. Aurore, G. Yoni, E. Emma, B. Charlotte, F. Laura, S. Alain, N. Steven, Z. Pierre, F. Jean-Luc, C. Romain, G. Alice, M. Adrien, R. P., P. P., P. P., P. P., P., P., P. P., P. P., P. G., P. P., P. P., Pierre, P., P., P., P., P., P., P., P., P., P., P., P., P., P., Pierre, Pier, P., P., P., P., P., P., P., P., Pierre, Pierre, Pier, Pier. C. Catherine, B. Kevin, S. Thomas, da G. Damien, Tasirin Magungunan Magungunan Antirheumatic akan Faruwar Cutar COVID-19 a cikin Marasa lafiya na Ambulatory tare da Cututtukan Cutar Cutar Cutar Cutar Cutar Cutar: Nazarin Ƙungiyar Satumba 2021, Rheumatology da Therapy, juzu'i na 8, fitowa ta 4, Shafi 1887-1895
459 mai haƙuri HCQ nazarin prophylaxis: 2% asibiti mafi girma (p=1) da 3% ƙarin lokuta (p=0.96).
Tsinkaya 459 lupus, rheumatoid, SjS, ko psoriatic amosanin gabbai marasa lafiya a Faransa, ba tare da nuna bambanci mai mahimmanci tare da maganin HCQ ba. Duk da haka, da Ƙididdigar ƙididdiga ta nuna rashin daidaituwa tare da bincike na farko, wanda zai iya kasancewa saboda wuce gona da iri tare da ƙayyadaddun bayanai da ƙananan adadin abubuwan da suka faru. Misali, bincike ya kiyasta ƙananan haɗari KO 0.72 na shekaru, kuma yana nuna haɗarin dangi daban-daban na lupus, rheumatic, SjS, ko cututtukan psoriatic idan aka kwatanta da sauran bincike. Mun lura da rarraba cututtuka daban-daban a cikin ƙungiyoyi, alal misali akwai yawancin cututtuka na psoriatic a cikin ƙungiyar HCQ.. Ƙididdiga marasa daidaituwa na haɗari ga cututtuka daban-daban da kuma shekaru mai yiwuwa ya sa binciken da aka daidaita ba daidai ba ne. https://c19p.org/guillaume
350. M. Stewart, C. Rodriguez-Watson, A. Albayrak, J. Asubonteng, A. Belli, T. Brown, K. Cho, R. Das, E. Eldridge, N. Gatto, A. Gelman, H. Gerlovin, S. Goldberg, E. Hansen, J. Hirsch, Y. Ho, A. Ip, J, M. S. Jones, A. Justice Kuranz, C. Lam, Q. Mao, S. Mataraso, R. Mera, D. Posner, J. Rassen, A. Siefkas, A. Schrag, G. Tourassi, A. Weckstein, F. Wolf, A. Bhat, S. Winckler, E. Sigal, da J. Allen, da kuma J. Allen, da COVID-19 da aka kwatanta da AVID-19 bincike. ba tare da Azithromycin tsakanin marasa lafiya na COVID-XNUMX na asibiti ba Mar 2021, PLoS DAYA, Juzu'i na 16, Fitowa ta 3, Shafi e0248128
MAGANIN LAFIYA 11,157 mai haƙuri HCQ marigayi nazarin jiyya: 28% mafi girma mace-mace (p=0.03) da 29% mafi girma samun iska (p=0.09).
Binciken baya na bayanan bayanai guda bakwai a cikin Amurka, yana nuna mafi girman mace-mace tare da jiyya. Sakamako sun ci karo da kwakkwarar shaida daga gwaje-gwajen RECOVERY/ SOLIDARITY, suna ba da shawara ga ruɗani ta hanyar nuni.. Yiwuwar rikicewar lokaci saboda HCQ ya zama mai yawan cece-kuce kuma amfani ya ragu sosai a tsawon lokacin da aka rufe, yayin da gabaɗayan ka'idojin jiyya a wannan lokacin sun inganta sosai, watau, ƙarin kula da marasa lafiya mai yiwuwa su zo daga baya a cikin lokacin da aka inganta ka'idojin magani sosai. Wannan binciken ya haɗa da kowa PCR+ yayin ziyararsu ko kafin ziyarar, da duk wanda ke da lambobin ICD-10 COVID-19 waɗanda ya haɗa da marasa lafiya na PCR + masu asymptomatic, don haka wasu marasa lafiya a cikin rukunin kulawa na iya zama asymptomatic dangane da SARS-CoV-2, amma a asibiti saboda wani dalili. Marubuta ba su ambaci yuwuwar ɗayan waɗannan abubuwa masu ruɗawa ba. https://c19p.org/stewart
351. R. Vivanco-Hidalgo, I. Molina, E. Martinez, R. Roman-Viñas, A. Sánchez-Montalvá, J. Fibla, C. Pontes, da C. Velasco Muñoz, Abubuwan da suka faru na COVID-19 a cikin marasa lafiya da aka fallasa ga chloroquine da hydroxychloroquine: sakamako daga tushen yawan jama'a a cikin Cat2020. Maris 2021, Euro sa ido, juzu'i na 26, fitowa ta 9
20,238 mai haƙuri HCQ nazarin prophylaxis: 46% asibiti mafi girma (p=0.1) da 8% ƙarin lokuta (p=0.5).
Binciken bayanan bayanan baya na masu amfani da HCQ na yau da kullun da madaidaicin kulawar marasa lafiya, kasa daidaitawa ko daidaitawa ga haɗarin tushe daban-daban ga marasa lafiya na cututtukan autoimmune. Wani bincike ya nuna cewa hadarin COVID-19 ga masu cutar cututtukan cututtukan ƙwayoyin cuta sun fi girma gabaɗaya, Ferri et al. nuna KO 4.42, p<0.001. https://c19p.org/vivancohidalgo
352. M. Bosaeed, E. Mahmoud, A. Alharbi, H. Altayib, H. Albayat, F. Alharbi, K. Ghalilah, A. Al Arfaj, J. AlJishi, A. Alarfaj, H. Alqahtani, B. Almutairi, M. Almaghaslah, N. Alyahya, A. Bawazir, S. Alarfaj, J. Alqahtani, B. Almutairi, M. Almaghaslah, N. Alyahya, A. Bawazir, S. Alharbi, M. AlShamrani, S. Al Johani, M. Aljeraisy, M. Alzahrani, A. Althaqafi, H. Almarhabi, A. Alotaibi, N. Alqahtani, Y. Arabi, O. Aldibasi, da A. Alaskar, Favipiravir da Hydroxychloroquine Combination Therapy tare da Annabta a cikin Patien Buɗe Label, Multicenter, Randomized, Sarrafa Gwajin Afrilu 2021, Cutar. Dis. Can., Juzu'i na 10, fitowa ta 4, Shafi na 2291-2307
MAGANIN LAFIYA 254 mai haƙuri HCQ marigayi magani RCT: 4% ƙananan mace-mace (p=0.91), 8% mafi girma samun iska (p=0.78), 31% mafi girma ICU shigar (p=0.24), da 29% jinkirin dawowa (p=0.29).
Farashin 254 mataki na ƙarshe (93% akan oxygen, 17% a cikin ICU a asali) marasa lafiya na asibiti a Saudi Arabiya ba nuna bambance-bambance masu mahimmanci tare da maganin HCQ+favipiravir. SaO2 kawai <94% marasa lafiya sun cancanci, duk da haka Ba a bayar da ainihin SaO2 na marasa lafiya da aka yi rajista ba. https://c19p.org/bosaeed
353. D. De Luna, Y. Roque, N. Batlle, K. Gómez, M. Jáquez, B. Cabrera, L. De la Cruz, O. Tavárez, R. Belliard, da J. Sanchez, Halin Clinical da Demographic Halayen COVID-19 Marasa lafiya da aka shigar a Asibitin Kulawa na Jami'a a Jamhuriyar Dominican Dec 2020, medRxiv
MAGANIN LAFIYA 150 mai haƙuri HCQ marigayi nazarin jiyya: 105% mafi girma mace-mace (p=0.69).
Marasa lafiya 150 na baya-bayan nan a Jamhuriyar Dominican, 132 sun yi jinya tare da HCQ, yana nuna yawan mace-mace tare da jiyya a sakamakon da ba daidai ba. Mai yiwuwa mai ruɗawa ta nuni. https://c19p.org/deluna
354. D. Edwards da D. McGrail, Jerin shari'o'in COVID-19 a UnityPoint Health St. Luke's Hospital a Cedar Rapids, IA Yuli 2020, medRxiv
MAGANIN LAFIYA 75 mai haƙuri HCQ marigayi nazarin jiyya: 70% mafi girma mace-mace (p=0.69).
HCQ+AZ a farkon cutar ya sami nasara mai kyau tare da 'yan rikitarwa, 86% na marasa lafiya na HCQ sun tsira da 92% na marasa lafiya HCQ+AZ. Marasa lafiya da ba su karɓa ba suna da 93% na rayuwa amma ba a yi la'akari da su ba saboda ƙungiyoyin da aka yi musu magani sun fi rashin lafiya sosai (100% hypoxic at admission vs. 59%) kuma wannan binciken baya daidaitawa ga bambance-bambance. Canjawa daga dabarar shigar da ruwa na farko zuwa ga yin amfani da tsatsauran ra'ayi na cannula na hanci da kuma iskar iska (watau BiPAP) ya yi nasara wajen 'yantar da albarkatun ICU. https://c19p.org/mcgrail
355. J. Barbosa, D. Kaitis, R. Freedman, K. Le, X. Lin, Sakamakon Clinical na hydroxychloroquine a cikin marasa lafiya na asibiti tare da COVID-19: nazarin kwatancen da bazuwar Afrilu 2020, Preprint
MAGANIN LAFIYA 63 mai haƙuri HCQ marigayi nazarin jiyya: 147% mafi girma mace-mace (p=0.58).
Ƙananan nazarin baya-bayan nan tare da marasa lafiya 63 (32 da aka bi da su tare da HCQ), ba tare da wani tasiri ba, duk da haka yanayin tushen kowane hannu ya bambanta sosai. https://c19p.org/barbosa
356. S. Lotfy, A. Abbas, da W. Shouman, Amfani da Hydroxychloroquine a cikin Marasa lafiya tare da COVID-19: Nazari Na Farko Dec 2020, Turkiyya. Thorac. J., Juzu'i na 22, Fitowa ta 1, Shafi na 62-66
MAGANIN LAFIYA 202 mai haƙuri HCQ marigayi binciken jiyya: 25% mafi girma mace-mace (p=0.76), 41% mafi girma samun iska (p=0.34), da 17% mafi girma ICU shigar (p=0.53).
Marasa lafiya 202 na baya-bayan nan a Saudi Arabiya ba sa nuna bambance-bambance masu mahimmanci tare da magani. Ba a bayar da bayani kan yadda aka zaɓi marasa lafiya don magani ba, ana iya samun babban ruɗani ta hanyar nuni. Bambancin lokaci kuma yana iya yiwuwa yayin da HCQ ya zama rigima yayin lokacin nazarin, don haka Yiwuwar amfani da HCQ ya kasance akai-akai zuwa farkon lokacin, lokacin da ƙa'idodin jiyya gabaɗaya sun fi muni sosai. https://c19p.org/lotfy
357. E. Burhan. Semedi, M. Rayhan, T. Tarigan, N. White, G. Bassi, J. Suen, da J. Fraser, Halaye da sakamakon marasa lafiya da COVID-19 mai tsanani a Indonesia: Darussan daga tashin farko Satumba 2023, PLOS ONE, juzu'i na 18, fitowa ta 9, shafi e0290964
MAGANIN LAFIYA 559 mai haƙuri HCQ ICU binciken: 1% mafi girma mace-mace (p=0.91).
Na baya-bayan nan 559 COVID-19 marasa lafiya ICU a Indonesia, ba su nuna bambanci a cikin mace-mace tare da HCQ a cikin sakamakon da ba a daidaita ba. https://c19p.org/burhan
358. B. Silva. Obata, G. Bueno, F. Mundim, A. Oliveira-Scussel, I. Monteiro, Y. Ferreira, G. Machado, K. Ferreira-Paim, H. Moraes-Souza, M. Da Silva, V. Rodrigues Júnior, da C. Oliveira, Cutar Kwayar cuta tare da Matsalolin COVID-19 a cikin Sashin Lafiya na Brazil. Macroregion: Cututtuka da Magunguna Mayu 2022, Gaba a cikin Salon salula da Kamuwa da cuta Microbiology, Volume 12
MAGANIN LAFIYA 395 mai haƙuri HCQ marigayi nazarin jiyya: 46% mafi girma mace-mace (p=0.22).
Marasa lafiya na asibiti na 395 na baya-bayan nan a Brazil, suna nuna yawan mace-mace tare da jiyya na HCQ, ba tare da mahimmancin ƙididdiga ba. https://c19p.org/silva3
359. N. Kokturk, C. Babayigit, S. Kul, P. Duru Cetinkaya, S. Atis Nayci, S. Argun Baris, O. Karcioglu, P. Aysert, I. Irmak, A. Akbas Yuksel, Y. Sekibag, O. Baydar Toprak, E. Azakhadar, S. Mulamahmutorgel, B. B. Baran Ketencioglu. M. Tor, G. Gunluoglu, S. Altin, T. Turgut, T. Tuna, O. Ozturk, O. Dikensoy, P. Yildiz Gulhan, I. Basyigit, H. Boyaci, I. Oguzulgen, S. Borekci, B. Gemicioglu, F. Bayraktar, O. Elbek et al. marasa lafiya Afrilu 2021, Magungunan Numfashi, Juzu'i 183, Shafi 106433
MAGANIN LAFIYA 1,500 mai haƙuri HCQ marigayi nazarin jiyya: 4% mafi girma mace-mace (p=0.97).
A baya-bayan nan 1,500 da aka kwantar a asibiti a ƙarshen mataki (matsakaicin SaO2 87.7) marasa lafiya a Turkiyya, suna nuna babu wani bambanci mai mahimmanci tare da maganin HCQ. https://c19p.org/kokturk
360. D. Rivera S. Peters Fecher, C. Friese, M. Galsky, S. Goel, S. Gupta, T. Halfdanarson, B. Halmos, J. Hawley, A. Khaki, C. Lemmon, S. Mishra, A. Olszewski, N. Pennell, M. Puc, S. Revankar, L. Schapira, A. Shahwartz., G. Schmidt, G. Sch. Yeh, H. Zhu, Y. Shyr, G. Lyman, da J. Warner, Amfani da Jiyya na COVID-19 da Sakamakon Asibiti tsakanin Marasa lafiya da Ciwon daji: Nazarin Ƙungiyar COVID-19 da Cancer Consortium (CCC19) Jul 2020, Gano Ciwon daji, juzu'i na 10, fitowa ta 10, Shafi na 1514-1527
MAGANIN LAFIYA 506 mai haƙuri HCQ marigayi nazarin jiyya: 2% mafi girma mace-mace (p=0.92).
Marasa lafiya na ciwon daji na baya-bayan nan, suna nuna daidaitacce OR 1.03 [0.62-1.73] don HCQ. Binciken ya ba da rahoton adadin marasa lafiya na HCQ+AZ amma ba sa samar da sakamako ga HCQ+AZ (HCQ + duk wani magani kawai). Mahimman rudani ta hanyar nuni da amfani da tausayi yana yiwuwa. https://c19p.org/rivera
361. C. Chen Y. Lin kimanta inganci da jurewar hydroxychloroquine da nazari na baya-bayan nan a cikin manya marasa lafiya masu rauni zuwa matsakaicin cutar Coronavirus 2019 (COVID-19) Jul 2020, PLoS DAYA, Juzu'i na 15, Fitowa ta 12, Shafi e0242763
MAGANIN LAFIYA 37 mai haƙuri HCQ marigayi nazarin jiyya: 29% mafi muni mai saurin kamuwa da cuta (p=0.7).
2 ƙananan karatu tare da marasa lafiya a asibiti a Taiwan. RCT tare da jiyya na 21 da 12 daidaitattun marasa lafiya. Babu mace-mace, ko mummunar illa. Lokacin tsaka-tsaki zuwa mummunan RNA kwanaki 5 tare da daidaitattun kulawa na kwanaki 10, p=0.4. Hadarin PCR + a ranar 14, RR 0.76, p = 0.71. Ƙananan binciken da aka yi nazari tare da 12 na 28 HCQ marasa lafiya da 5 na 9 a cikin ƙungiyar kulawa da kasancewa PCR- a ranar 14, RR 1.29, p = 0.7. An jera RCT da nazari na baya daban [Chen, Chen]. https://c19p.org/chen26
362. V. Pawlotsky, M. Michel, E. Perrodeau, N. Carlier, N. Roche, V. De Lastours, C. Ourghanlian, S. Kerneis, P. Ménager, L. Mouthon, E. Audureau, P. Ravaud, B. Godeau, S. Gallien, da N. Costedoat, Clinical EHydroffixy-Chalucion, Clinical EHydroffixy Emerson covid-19 ciwon huhu wanda ke buƙatar oxygen: nazarin kwatancen kallo ta amfani da bayanan kulawa na yau da kullun Mayu 2020, BMJ 2020, shafi m1844
MAGANIN LAFIYA 173 mai haƙuri HCQ marigayi nazarin jiyya: 20% mafi girma mace-mace (p=0.75).
Binciken lura na 181 marasa lafiya da ci-gaba cuta bukatar oxygen nuna babu fa'ida ga HCQ. Ƙarfin nazarin ya yi ƙasa da ƙasa don tallafawa ƙarshe, bisa ga BMJ. Babu wani daga cikin marasa lafiya 15 da ke karɓar HCQ+AZ da aka canjawa wuri zuwa kulawa mai zurfi ko ya mutu idan aka kwatanta da 23% gabaɗaya. https://c19p.org/mahevas
363. E. Rosenberg, E. Dufort, T. Udo, L. Wilberschied, J. Kumar, J. Tesoriero, P. Weinberg, J. Kirkwood, A. Muse, J. DeHovitz, D. Blog, B. Hutton, D. Holtgrave, da H. Zucker, Ƙungiyar Jiyya tare da Hydroxychloroquine ko Tare da Azithality Morning COVID-19 a jihar New York Mayu 2020, JAMA, Mayu 11, 2020, Juzu'i na 323, Fitowa ta 24, Shafi na 2493
MAGANIN LAFIYA 1,483 mai haƙuri HCQ marigayi nazarin jiyya: 35% mafi girma mace-mace (p=0.31).
Binciken na baya-bayan nan na nazari a ƙarshen mataki a New York yana nuna babu bambance-bambance masu mahimmanci amma yana kira don gwaji na asibiti. Zervos et al. nuna manyan iyakoki waɗanda suka ce ya kamata a gyara akan rikodin: marasa lafiya da ke karɓar HCQ tare da ko ba tare da AZ sun fi rashin lafiya gaba ɗaya akan gabatarwa kuma suna da wasu abubuwan haɗari masu yawa ciki har da haɗari mafi girma dangane da kabilanci; marasa lafiya da ke karɓar HCQ sun fi zama masu kiba, masu ciwon sukari, suna da cututtukan huhu na yau da kullun, da yanayin cututtukan zuciya; duk da haka waɗannan majinyata marasa lafiya suna da kusan adadin mace-mace iri ɗaya idan aka kwatanta da marasa lafiya da ke da ƙananan yanayin cutar da ƙarancin haɗari. Koyaya, marubutan sun kammala cewa "babu wani fa'ida mai mahimmanci." Abin lura ne cewa HCQ yana da alaƙa da muhimmiyar fa'idar rayuwa a cikin ɗimbin ƙungiyar marasa lafiya daga Birnin New York kamar yadda Mikami ya ruwaito. Hakanan duba yanki na bincike a worldtribune.com. https://c19p.org/rosenberg
364. S. Auld, M. Caridi-Scheible, J. Blum, C. Robichaux, C. Kraft, J. Yakubu, C. Jabaley, D. Carpenter, R. Kaplow, A. Hernandez-Romieu, M. Adelman, G. Martin, C. Coopersmith, da D. Murphy, ICU da rashin lafiya na numfashi19 tare da mace-mace mai tsanani na COVID-XNUMX Afrilu 2020, Maganin Kulawa Mai Mahimmanci, juzu'i na 48, fitowa ta 9, Shafi e799-e804
MAGANIN LAFIYA 217 mai haƙuri HCQ marigayi nazarin jiyya: 3% mafi girma mace-mace (p=1).
Marasa lafiya 217 masu fama da rashin lafiya na baya-bayan nan, 114 suna karɓar HCQ, suna nuna babu wani bambanci mai mahimmanci a cikin mace-mace. https://c19p.org/auld
365. M. Souza-Silva, D. Pereira, M. Pires, I. Vasconcelos, A. Schwarzbold, D. Vasconcelos, E. Pereira, E. Manenti, F. Costa, F. Aguiar, F. Anschau, F. Bartolazzi, G. Nascimento, H. Vianna, J. Machado, Rus. Ferreira, L. Oliveira, L. Menezes, P. Ziegelmann, M. Tofani, M. Bicalho, M. Nogueira, M. Guimarães-Júnior, R. Aguiar, D. Rios, C. Polanczyk, and M. Marcolino, Dados de Vida Real sobre o Uso da Hidroxicloroquina Azitromicina em Pacientes com Covid-19: Uma Analise Retrospectiva no Brasil Satumba 2023, Arquivos Brasileiros de Cardiologia, juzu'i na 120, fitowa ta 9
MAGANIN LAFIYA 1,346 mai haƙuri HCQ marigayi nazarin jiyya: 5% mafi girma mace-mace (p=0.68), 21% mafi girma samun iska (p=0.08), 9% mafi girma ICU shigar (p=0.31), da 12% tsawo asibiti (p=0.03).
Marasa lafiya na asibiti 7,580 na baya-bayan nan a Brazil, suna nuna doguwar jinya, kuma babu wani babban bambanci a cikin mace-mace, iskar injina, da shigar da ICU tare da jiyya na HCQ. Marubuta suna lura da ruɗani ta hanyar nuni saboda zaɓaɓɓen amfani a cikin mahallin amfani mai tausayi. Marubuta suna daidaitawa kawai akan shekaru, jima'i, cututtukan zuciya da jijiyoyin jini, da kuma yin amfani da asibiti na corticosteroid, kuma kawai 10% na marasa lafiya sun karɓi HCQ/CQ, saboda haka rikicewa ta nuni yana iya zama mahimmanci. An haɗa jerin madaidaitan daban-daban a cikin rubutu, amma ba ya haɗa da tsananin COVID-19. A cikin layi na farko na marubutan rubutun ƙarya sun faɗi cewa babu wata shaida ta fa'ida don maganin HCQ. Yayin da ɓatar da binciken da ya gabata ya zama ruwan dare gama gari, wannan babban lamari ne kuma yana haifar da damuwa don ingancin bincike. A gaskiya ma, binciken da aka sarrafa yana nuna sakamako mai mahimmanci na ƙididdiga don sakamako ɗaya ko fiye (ciki har da RCTs). Tattaunawar marubutan bincike na baya yana nuna irin wannan son zuciya. https://c19p.org/souzasilva
366. K. Huh, W. Ji, M. Kang, J. Hong, G. Bae, R. Lee, Y. Na, da J. Jung, Ƙungiyar magunguna da aka tsara tare da haɗarin kamuwa da COVID-19 da tsanani tsakanin manya a Koriya ta Kudu Dec 2020, Int. J. Cututtuka masu Yaduwa, Juzu'i na 104, Shafi na 7-14
44,046 mai haƙuri HCQ nazarin prophylaxis: 251% ci gaba mafi girma (p=0.11) da 6% ƙananan lokuta (p=0.82).
Binciken bayanan baya-bayan nan tare da shari'o'in 17 don masu amfani da HCQ na yanzu da kuma lokuta 5 masu tsanani, ba su nuna bambanci mai mahimmanci ga lokuta da haɗari mafi girma ga lokuta masu tsanani. Koyaya, masu amfani da HCQ wataƙila suna da cututtukan cututtukan cututtukan cututtukan ƙwayoyin cuta da kuma mawallafa ba su daidaitawa don mabanbanta haɗarin asali ga waɗannan marasa lafiya. Wani bincike ya nuna cewa haɗarin COVID-19 ga masu cutar cututtukan cututtukan ƙwayoyin cuta sun fi girma gabaɗaya, Ferri et al. nuna KO 4.42, p<0.001. https://c19p.org/huh2
367. W. Ho, X. Wei, K. Tan, Y. Woh, M. Gill, A. Lok, S. Zulkifli, S. Idris, K. Khalid, L. Chee, da K. Ta yaya, Hydroxychloroquine don COVID-19: Cibiya Guda, Nazarin Ƙungiya Mai Komawa. Mar 2023, Malesiya J. Kimiyyar Magunguna da Kiwon Lafiya, juzu'i na 19, fitowa ta 2, Shafi na 8-13
MAGANIN LAFIYA 325 mai haƙuri HCQ marigayi nazarin jiyya: 890% ci gaba mafi girma (p=0.03).
An dawo da marasa lafiya 325 na COVID-19 a asibiti a Malaysia, suna nuna babban ci gaba tare da HCQ, duk da haka ƙungiyoyin ba su misaltuwa. 17 HCQ vs. 3 masu kula da marasa lafiya suna da nau'i mai tsanani ≥3 a asali (7 vs. 0 don tsananin ≥4). https://c19p.org/ho2
368. S. Civriz Bozdağ, G. Seval, İ. Yönal Hindilerden, F. Hindilerden, N. Andıç, M. Baydar, L. Aydın Kaynar, S. Toprak, H. Göksoy, B. Balık Aydın, U. Demirci, F. Can, V. Özkocaman, E. Gündüz, Z. Güven, Z. Özkurt, Demirci, Demirci M. İnce, U. Yılmaz, H. Eroğlu Küçükdiler, E. Abishov, B. Yavuz, Ü. Ataş, Y. Mutlu, V. Baş, F. Özkalemkaş, H. Üsküdar Teke, V. Gürsoy, S. Çelik, R. Çiftçiler, M. Yağcı, P. Topçuoğlu, Ö. Çeneli, H. Abbasov, C. Selim, M. Ar, O. Yücel, S. Sadri, C. Albayrak, A. Demir, N. Güler, M. Keklik, H. Terzi, A. Doğan, Z. Yegin, M. Kurt Yüksel, S. Sadri, İ. Yavaşoğlu, H. Beköz et al., Halayen Clinical da Sakamakon COVID-19 a cikin Marasa lafiya na Hematological na Turkiyya Satumba 2021, Turkiyya. J. Haematol., Juzu'i na 39, Fitowa ta 1, Shafi na 43-54
MAGANIN LAFIYA 175 mai haƙuri HCQ nazarin jiyya na ƙarshen: 399% mafi girman mace-mace (p=0.003).
Marasa lafiya 340 na baya-bayan nan tare da cututtukan jini a cikin Turkiyya, suna nuna mafi girman mace-mace tare da maganin HCQ. Rashin rikicewa ta lokaci yana iya yiwuwa saboda yawancin marasa lafiya na HCQ sun kasance a farkon lokacin lokacin da ka'idodin jiyya gabaɗaya sun fi muni.. https://c19p.org/civrizbozdag
369. M. Alotaibi, A. Ali, D. Bakhshwin, Y. Alatawi, S. Alotaibi, A. Alhifany, B. Alharthi, N. Alharthi, A. Alyazidi, Y. Alharthi, A. Alrafiah, Inganci da Tsaro na Favipiravir Idan aka kwatanta da Hydroxychloroquine don Gudanarwa na Covid-19 Satumba 2021, Int. J. General Medicine
MAGANIN LAFIYA 437 mai haƙuri HCQ marigayi nazarin jiyya: 134% mafi girma mace-mace (p=0.05).
Marasa lafiya na asibiti na baya-bayan nan a Saudi Arabiya, suna nuna ƙarancin mace-mace tare da favipiravir idan aka kwatanta da HCQ, ba su kai ma'anar ƙididdiga ba. Marubuta ba su nuna abubuwan da aka zaɓa a baya ba. Yana iya zama batun rikicewa mai mahimmanci ta hanyar nuni da rikicewa ta lokaci. https://c19p.org/alotaibi
370. R. Tamura, S. Said, L. De Freitas, da kuma I. Rubio, Sakamako da kasadar mutuwa na masu ciwon sukari tare da Covid-19 suna karɓar magungunan pre-asibiti da na asibiti na metformin Yuli 2021, Ciwon sukari & Ciwon Jiki, Jul 13, fitowa ta 1
MAGANIN LAFIYA 188 mai haƙuri HCQ nazarin jiyya na ƙarshen: 299% mafi girman mace-mace (p=0.04).
Marasa lafiya na asibiti 188 na baya-bayan nan a Brazil, suna nuna haɗarin mutuwa tare da HCQ. 'Yan kaɗan marasa lafiya sun sami HCQ. Sakamakon yana iya zama mai ruɗarwa ta hanyar nuni tare da jiyya mafi kusantar lokuta masu tsanani, kuma ba a yi amfani da tsanani a cikin gyare-gyare ba. Mai yiwuwa rikicewa ta lokaci, tare da raguwar amfani da HCQ da haɓaka ma'auni na kulawa a cikin lokacin binciken.. https://c19p.org/tamurah
371. A. Saib, W. Amara, P. Wang, S. Cattan, A. Dellal, K. Regieg, S. Nahon, O. Nallet, da L. Nguyen, Rashin ingancin hydroxychloroquine da azithromycin a cikin marasa lafiya da ke kwance a asibiti don COVID-19 ciwon huhu: Nazarin baya. Jun 2021, PLOS ONE, juzu'i na 16, fitowa ta 6, shafi e0252388
MAGANIN LAFIYA 104 mai haƙuri HCQ marigayi magani PSM binciken: 125% mafi girma hade mace-mace / intubation (p=0.23).
203 marasa lafiya a asibiti a Faransa, ba tare da nuna bambance-bambance masu mahimmanci tare da magani ba. Mai yiwuwa mai ruɗawa ta nuni. Marubuta ba su tattauna rikice-rikice ba. https://c19p.org/saib
372. D. Sammartino, F. Jafri, B. Cook, L. La, H. Kim, J. Cardasis, da J. Raff, Masu tsinkaya ga mace-macen marasa lafiya a lokacin tashin farko na cutar ta SARS-CoV-2: Binciken baya. Mayu 2021, PLOS One, Juzu'i na 16, Fitowa ta 5, Shafi e0251262
MAGANIN LAFIYA 328 mai haƙuri HCQ marigayi magani PSM binciken: 240% mafi girma mace-mace (p=0.002).
Marasa lafiya na asibiti 1,108 na baya-bayan nan a New York suna nuna yawan mace-mace tare da jiyya na HCQ. Yiwuwar rikicewar lokaci mai yuwuwa saboda HCQ ya zama ƙarar cece-kuce kuma ba a yi amfani da shi ba tsawon lokacin da aka rufe (Maris - Jun 2020), yayin da ka'idojin jiyya gabaɗaya a wannan lokacin sun inganta sosai, watau, ƙarin kulawar marasa lafiya na iya zuwa daga baya a cikin lokacin da aka inganta ka'idojin magani. Marubuta sun lura cewa kowane mako ko wata bayan an shigar da mutum, haɗarin mutuwa ya ragu da kashi 16% da 49%, bi da bi, duk da haka ba sa la'akari da rikicewar lokaci. https://c19p.org/sammartino
373. P. Mohandas, S. Periasamy, M. Marappan, A. Sampath, V. Garfin Sundaram, da V. Cherian, Binciken Clinical na marasa lafiya na COVID-19 da ke gabatar da wani asibiti mai zaman kansa na kula da kwata-kwata a Kudancin Indiya: Nazarin sake dubawa Afrilu 2021, Kimiyyar Cutar Kwayar cuta da Lafiya ta Duniya, Juzu'i na 11, Shafi 100751
MAGANIN LAFIYA 3,345 mai haƙuri HCQ marigayi nazarin jiyya: 81% mafi girma mace-mace (p=0.007).
A baya-bayan nan 3,345 marasa lafiya na asibiti a Indiya, 11.5% bi da su tare da HCQ, yana nuna rashin daidaituwa mafi girma na mace-mace tare da jiyya. Ƙarfafawa ta hanyar nuni da rikicewar lokaci (saboda raguwar amfani a tsawon lokacin lokacin da ka'idodin jiyya gabaɗaya suka inganta sosai) mai yiwuwa. https://c19p.org/mohandas
374. K. Sands, R. Wenzel, L. McLean, K. Korwek, J. Roach, K. Miller, R. Poland, L. Burgess, E. Jackson, da J. Perlin. Dec 2020, Int. J. Cututtuka masu Yaduwa, Juzu'i na 104, Shafi na 34-40
MAGANIN LAFIYA 1,669 mai haƙuri HCQ marigayi nazarin jiyya: 70% mafi girma mace-mace (p=0.01).
Binciken bayanan bayanan baya na marasa lafiya 1,669 a cikin Amurka yana nuna OR 1.81, p = 0.01. Mai yiwuwa mai ruɗawa ta nuni. An ƙaddara COVID-19 ta sakamakon PCR +, don haka marubutan sun haɗa da marasa lafiya asymptomatic don COVID-19, amma a asibiti saboda wasu dalilai. Yayin da marubuta suka daidaita don tsananin, hanyar da aka yi amfani da ita ba ta da kyau. 93.5% na marasa lafiya an rarraba su a matsayin "m" wanda shine marasa lafiya ba tare da rubutaccen kulawa ba a cikin sashin kulawa mai mahimmanci a cikin sa'o'i 8 na shiga. Saboda haka, kusan dukkan marasa lafiya suna cikin rukuni ɗaya, kuma waɗanda ke cikin nau'i daban-daban na iya zama saboda alamun da ba su da alaƙa da COVID-19. Ƙananan ƙiyayya ga maza marasa lafiya a cikin ƙungiyar kulawa kuma sun yarda da hasashen cewa ƙungiyar kulawa ta ƙunshi ƙarin mutane da ke asibiti don wani dalili. Tun da bincike ya ƙunshi farkon lokacin cutar a Amurka, da alama an yi amfani da HCQ sau da yawa a baya a lokacin bincike lokacin da ka'idojin jiyya suka yi muni sosai. Dogayen suka a kan manyan kasawa (da bayyane kurakurai) an lura da su a cikin International Journal of Infectious Disease buga wasiƙa zuwa ga editan. https://c19p.org/sands
375. G. Psevdos, A. Papamanoli, da Z. Lobo, Cutar Cutar Corona Virus-19 (COVID-19) a Asibitin Al'amuran Tsohon Sojoji a gundumar Suffolk, Long Island, New York Dec 2020, Bude Dandalin Cututtuka masu Yaduwa, juzu'i na 7, Matsalolin Kari_1, Shafi S330-S331
MAGANIN LAFIYA 67 mai haƙuri HCQ marigayi nazarin jiyya: 63% mafi girma mace-mace (p=0.52).
Marasa lafiya na asibiti 67 na baya-bayan nan a cikin Amurka suna nuna ƙarancin ƙididdiga waɗanda ba a daidaita su ba tare da HCQ. Mai yiwuwa mai ruɗawa ta nuni. Mai yuwuwar rikiɗewar lokaci. HCQ ya zama mai kawo rigima kuma an dakatar da shi a ƙarshen lokacin da aka yi nazari, sabili da haka amfani da HCQ ya fi sau da yawa zuwa farkon lokacin nazarin, lokacin da ka'idodin jiyya gabaɗaya ya fi muni. https://c19p.org/psevdos
376. C. Teixeira, H. Shiflett, D. Jandhyala, J. Lewis, S. Curry, da C. Salgado, Halaye da sakamakon COVID-19 marasa lafiya sun yarda da tsarin kiwon lafiya na yanki a kudu maso gabas Dec 2020, Bude Dandalin Cututtuka masu Yaduwa, juzu'i na 7, Matsalolin Kari_1, Shafi S251-S253
MAGANIN LAFIYA 161 mai haƙuri HCQ marigayi nazarin jiyya: 79% mafi girma mace-mace (p=0.1).
Marasa lafiya na asibiti 161 na baya-bayan nan a cikin Amurka suna nuna ƙarancin ƙididdiga waɗanda ba a daidaita su ba tare da HCQ. Mai yiwuwa mai ruɗani ta nuni. Mai yuwuwa bambance-bambancen lokaci rikicewa. HCQ ya zama rigima kuma an dakatar da shi zuwa ƙarshen lokacin da aka yi nazari, don haka amfani da HCQ ya kasance mai yiwuwa ya fi yawa zuwa farkon lokacin binciken, lokacin da ka'idodin jiyya gabaɗaya ya fi muni. https://c19p.org/teixeira
377. SolidarITY Trial Consortium et al., Sake dawo da magungunan antiviral don COVID-19; Sakamakon gwaji na wucin gadi na WHO SOLIDARITY Oktoba 2020, Ƙungiyar Gwajin SOLIDARITY, NEJM, Juzu'i na 384, Fitowa ta 6, Shafi na 497-511
MAGANIN LAFIYA 1,853 mai haƙuri HCQ marigayi magani RCT: 19% mafi girma mace-mace (p=0.23).
WHO SOLIDARITY gwajin buɗaɗɗen lakabi tare da 954 a ƙarshen mataki (64% akan oxygen / iska) marasa lafiya na HCQ, haɗarin mace-mace RR 1.19 [0.89-1.59], p=0.23. HCQ sashi sosai high kamar yadda yake a cikin FARUWA, 1.6g a cikin sa'o'i 24 na farko, 9.6g duka sama da kwanaki 10, kawai 25% kasa da babban adadin da Borba et al. nuna yana ƙara haɗari sosai (OR 2.8). Marubuta sun ce ba su san nauyin nauyi ko kiba na marasa lafiya ba don nazarin guba (tun da ba su daidaita sashi dangane da nauyin haƙuri, mai guba na iya zama mafi girma a cikin marasa lafiya na ƙananan nauyi). KM masu lankwasa suna nuna a karuwa a cikin kwanakin mace-macen HCQ 5-7, daidai da ~90% na jimlar yawan abin da aka gani a rana ta 28 (ana ganin irin wannan karu a cikin gwaji na SAMUN).. Kusan duk wuce gona da iri na mace-mace daga marasa lafiya ne da ke samun iska. Marubuta suna magana game da ƙarancin mace-mace a cikin ƴan kwanaki na farko don bayar da shawarar rashin guba, amma suna yin watsi da tsawon rabin rayuwar HCQ da tsarin allurai - matakan HCQ da yawa za a kai daga baya. Ƙara yawan mace-mace bayan kwanaki 2 na maganin HCQ a Borba et al. Kashi na marasa lafiya da ba a bayyana ba sun yi amfani da CQ mai guba. Ba a yi amfani da placebo ba. An yi amfani da allurai masu yawa komai nauyi, don haka maida hankali ya bambanta sosai a cikin kyallen takarda daban-daban kuma ƙwayar huhu na iya zama> 30x maida hankali na plasma. https://c19p.org/solidarity
378. M. Laplana, O. Yuguero, da J. Fibla, Rashin tasirin kariya na abubuwan da aka samo na chloroquine akan cutar COVID-19 a cikin samfurin Mutanen Espanya na marasa lafiya da aka yi musu jinya. Satumba 2020, PLOS ONE, juzu'i na 15, fitowa ta 12, shafi e0243598
638 mai haƙuri HCQ nazarin prophylaxis: 56% ƙarin lokuta (p=0.24).
Binciken marasa lafiya na cututtukan autoimmune guda 319 suna ɗaukar CQ/HCQ tare da 5.3% COVID-19 aukuwa, idan aka kwatanta da ƙungiyar kulawa daga yawan jama'a (wanda ya dace da shekaru, jima'i, da yanki, amma ba a daidaita shi don cutar ta autoimmune), tare da aukuwar 3.4%. Ba a bayyana dalilin da yasa marubuta ba su kwatanta da marasa lafiya na autoimmune ba akan CQ/HCQ ba. Wani bincike ya nuna cewa haɗarin COVID-19 ga masu cutar cututtukan cututtukan ƙwayoyin cuta sun fi girma gabaɗaya. Ferri et al. nuna OR 4.42, p <0.001, wanda shine haɗarin gaske na duniya, la'akari da dalilai kamar waɗannan marasa lafiya na iya yin hankali sosai don guje wa fallasa.. Idan muka daidaita don haɗarin tushe daban-daban, sakamakon ya zama RR 0.36, p <0.001, yana ba da shawarar fa'ida mai mahimmanci don maganin HCQ/CQ (kamar yadda aka nuna a cikin wasu nazarin). Hakanan ana iya samun mahimmanci binciken son zuciya - waɗanda ke fuskantar COVID-19 na iya zama da yuwuwar ba da amsa ga binciken. Mawallafa sun lura cewa "ba zai iya kawar da gaba ɗaya yiwuwar wasu son zuciya ba saboda ainihin yanayin mutanen da ke cikin rukunin masu jiyya waɗanda ke juyar da chloroquine ko magungunan ƙwayoyi na daban saboda wasu cututtukan da ke canza yanayin lafiyarsu kuma suna iya samun cututtuka daban-daban.” duk da haka za su iya ƙididdige ƙima guda ɗaya ta hanyar kwatanta da daidaitattun marasa lafiya na autoimmune. https://c19p.org/laplana
379. M. Kelly, R. O'Connor, L. Townsend, M. Coghlan, E. Relihan, M. Moriarty, B. Carr, G. Melanophy, C. Doyle, C. Bannan, R. O'Riordan, C. Merry, S. Clarke, da C. Bergin, Sakamakon Clinical da m abubuwan da suka faru a cikin marasa lafiya tare da COVID-19 da aka kwantar da su tare da marasa lafiya tare da hydroxychloraquid. azithromycin Jul 2020, British J. Clinical Pharmacology, juzu'i na 87, fitowa ta 3, Shafi na 1150-1154
MAGANIN LAFIYA 134 mai haƙuri HCQ marigayi nazarin jiyya: 143% mafi girma mace-mace (p=0.03).
Marasa lafiya na asibiti 82 na baya-bayan nan HCQ/AZ, 52 daidaitattun kulawa, rashin samun bambance-bambance masu mahimmanci. Ƙarfafawa ta hanyar nuni - marubuta sun lura cewa marasa lafiya na HCQ / AZ sun fi rashin lafiya, kuma kada ku yi ƙoƙarin daidaitawa ga masu rikici. https://c19p.org/kelly
380. P. Cravedi , S. Mothi, Y. Azzi Maggiore, I. Gandolfini, N. Agrawal, H. Patel, E. Akalin, da L. Riella, COVID-19 da dashen koda: Sakamako daga TANGO International Transplant Consortium Jul 2020, Jul na 20, fitowa ta 11, Shafi na 3140-3148.
MAGANIN LAFIYA 144 mai haƙuri HCQ marigayi nazarin jiyya: 53% mafi girma mace-mace (p=0.17).
Binciken marasa lafiya na 144 na asibiti da ke nuna mutuwar HCQ HR 1.53, p = 0.17. Batun ruɗarwa ta hanyar nuni. https://c19p.org/cravedi
381. N. Kuderer, T. Choueiri, D. Shah, Y. Shyr, S. Rubinstein, D. Rivera, S. Shete, C. Hsu, A. Desai, G. De Lima Lopes, P. Grivas, C. Painter, S. Peters, M. Thompson, Z. Bakouny, G. Batist, T. Bekaii. D. Castellano, S. Del Prete, D. Doroshow, P. Egan, A. Elkrief, D. Farmakiotis, D. Flora, M. Galsky, M. Glover, E. Griffiths, A. Gulati, S. Gupta, N. Hafez, T. Halfdanarson, J.. E. Hsu., C. A. Kammon, C. Ammonki, C. Ammonki, C., C. Hawlki Logan, T. Masters, R. McKay, R. Mesa, A. Morgans, M. Mulcahy, O. Panagiotou, P. Peddi, N. Pennell, K. Reynolds et al., Tasirin asibiti na COVID-19 akan marasa lafiya da ciwon daji (CCC19): nazarin ƙungiyar Mayu 2020, Lancet, Yuni 20, 2020, Juzu'i na 395, Fitowa ta 10241, Shafi na 1907-1918
MAGANIN LAFIYA 928 mai haƙuri HCQ marigayi nazarin jiyya: 134% mafi girma mace-mace (p <0.0001).
Masu ciwon daji na 928 na baya-bayan nan, suna nuna HCQ KO 1.06 [0.51-2.20]. HCQ+AZ KO 2.93 [1.79-4.79]. Matsalolin da ke tattare da hanyoyin kwantar da hankali daban-daban suna nuna cewa sakamakon yana da tasiri sosai ta hanyar rikicewa ta hanyar nuni. Lura na marubuta: HCQ+AZ bazai zama sanadin karuwar mace-mace ba, amma a maimakon haka an ba da waɗannan ga marasa lafiya masu tsananin COVID-19. https://c19p.org/kuderer
382. L. Trefond, E. Drumez, M. Andre, N. Costedoat-Chalumeau, R. Seror, M. Devaux, E. Dernis, Y. Dieudonne, S. El Mahou, A. Lanteri, I. Melki, V. Queyrel, M. Roumier, J. Schmidt, T. Barnetche, T., Thomas, A. Rich Better, A. Rich Be, P. da E. Hachulla, Effet d'un traitement par hydroxychloroquine prescrit comme traitement de fond de rhumatismes inflammatoires chroniques ou maladies auto-immunes systémiques sur les tests diagnostiques et l'évolution de l'kamuwa da marasa lafiya a SARS CoV-2 Jan 2021, Revue du Rhumatisme, Juzu'i na 89, Fitowa ta 2, Shafi na 192-195
262 mai haƙuri HCQ nazarin prophylaxis: 17% mafi girma mace-mace (p=0.8), 78% mafi girma haɗuwa mace-mace / shigar da ICU (p=0.21), da 45% asibiti mafi girma (p=0.12).
Na baya-bayan nan 71 marasa lafiya na HCQ na yau da kullun idan aka kwatanta da abubuwan sarrafawa guda 191, suna nazarin waɗanda ke da abin da ake zargi sosai ko kuma aka tabbatar da cutar ta COVID-19. Ba a sami wani gagarumin bambanci a cikin sakamako ba, duk da haka daidaitawa ya kasa tare da tsananin ruɗani - 77.5% na marasa lafiya na HCQ tare da cututtukan cututtuka na tsarin jiki vs. 21.5% na marasa lafiya masu kulawa. Wani bincike ya nuna cewa haɗarin COVID-19 ga masu cutar cututtukan ƙwayoyin cuta sun fi girma gabaɗaya, Ferri et al. nuna KO 4.42, p<0.001. https://c19p.org/trefond
383. RECOVERY Ƙungiyar Haɗin kai et al., Tasirin Hydroxychloroquine a cikin Marasa lafiya na Asibiti tare da COVID-19: Sakamakon farko daga cibiyar da yawa, bazuwar, gwajin sarrafawa Jun 2020, Ƙungiyar Haɗin kai, NEJM, juzu'i na 383, fitowa na 21, Shafi na 2030-2040
MAGANIN LAFIYA 4,716 mai haƙuri HCQ marigayi magani RCT: 9% mafi girma mace-mace (p=0.15) da 15% mafi girma samun iska (p=0.19).
Gwajin CIN GINDI baya samun wani fa'ida mai mahimmanci ga matuƙar mataki (kwanaki 9 bayan bayyanar bayyanar) marasa lafiya marasa lafiya. Sakamako na iya kasancewa saboda yawan adadin da ba a saba amfani da shi ba (9.2g duka a cikin kwanaki 10). Yawan adadin da aka yi amfani da shi shine kawai 23% kasa da babban adadin da Borba et al. amfani, wanda ke nuna babban haɓakar haɗari (OR 2.8). Marubuta ba sa bayar da rahoton sakamako dangane da nauyi, BMI, ko yanayi masu alaƙa kamar ciwon sukari, wanda zai iya ba da ƙarin shaida na allurai masu guba. Marubuta ba sa daidaita sashi dangane da nauyin haƙuri, don haka guba na iya zama mafi girma a cikin marasa lafiya na ƙananan nauyi. KM masu lankwasa suna nuna karuwa a cikin kwanakin mace-macen HCQ 5-8, daidai da ~ 85% na yawan abin da aka gani a ranar 28 (ana ganin irin wannan karu a cikin gwajin SOLIDARITY). Marubuta sun lura: “ba mu lura da yawan mace-mace ba a cikin kwanaki 2 na farko na jiyya…"amma suna yin watsi da tsawon rabin rayuwa na HCQ da tsarin maganin - za a kai ga matakin HCQ da yawa daga baya. Ƙaruwar mace-mace a Borba et al. ya faru bayan kwanaki 2. Marasa lafiya sun kasance marasa lafiya sosai (tsakiyar 9 kwanaki bayan bayyanar cututtuka, 60% na buƙatar oxygen da kuma ƙarin 17% na buƙatar samun iska / extracorporeal membrane oxygenation (mafi girman haɗarin likita), tare da yawan mace-mace da ba a saba gani ba a hannu biyu. 1,561 HCQ marasa lafiya, 3,155 daidaitattun kulawa. Wani bincike na biyu ya gano rashin daidaituwa da yawa a cikin bayanan. Hypoxia na iya hana shigar HCQ sel, yana sa ya zama ƙasa da tasiri don amfani da ƙarshen mataki. Duba a nan don ƙarin a kan wuce kima HCQ dosing, kuma lura da cewa maida hankali bambanta sosai a cikin daban-daban kyallen takarda da huhu maida hankali na iya zama> 30x plasma maida hankali. https://c19p.org/recovery
384. S. Juneja, P. Rana, P. Chawala, R. Katoch, K. Singh, S. Rana, T. Mittal, B. Kaur, da S. Kaur, Hydroxychloroquine pre-exposure prophylaxis yana ba da wani kariya daga COVID-19 tsakanin ma'aikatan kiwon lafiya: nazari na yanki a cikin wani babban asibitin kulawa a Arewacin Indiya. Jan 2022, J. Basic and Clinical Physiology and Pharmacology, Volume 0, fitowar 0
2,200 mai haƙuri HCQ nazarin prophylaxis: 142% mafi girman lokuta masu tsanani (p=0.59) da 6% ƙarin lokuta (p=0.67).
Ma'aikatan kiwon lafiya na 2,200 na baya-bayan nan a Indiya, 996 suna ɗaukar rigakafin HCQ, suna nuna babu bambance-bambance masu mahimmanci. Akwai manyan bambance-bambance a cikin aikin mahalarta sabili da haka fallasa, kuma marubutan ba su yin gyare-gyare. https://c19p.org/juneja
385. N. Awad, D. Schiller, M. Fulman, da A. Chak, Tasirin hydroxychloroquine akan ci gaban cuta da shigar da ICU a cikin marasa lafiya tare da kamuwa da cutar SARS-CoV-2. Feb 2021, American J. Health-System Pharmacy, juzu'i 78, fitowa ta 8, Shafi na 689-696
MAGANIN LAFIYA 336 mai haƙuri HCQ marigayi nazarin jiyya: 19% mafi girma mace-mace (p=0.6), 461% mafi girma samun iska (p <0.0001), da 463% mafi girma ICU shigar (p <0.0001).
Wannan takarda yana da ƙididdiga marasa daidaituwa - adadin jiyya da kulawa da marasa lafiya sun bambanta a cikin rubutu da Table 1, mun yi amfani da magani 188 da kuma kula da 148. Marasa lafiya na asibiti 336 na baya-bayan nan a Amurka suna nuna yawan mace-mace, shigar da ICU, da shigar da magani tare da jiyya. Mai yiwuwa mai ruɗawa ta nuni. Hakanan akwai yiwuwar rikicewar lokaci daban-daban saboda raguwar amfani a farkon lokacin lokacin da ka'idodin jiyya gabaɗaya su ma suna haɓaka sosai. Marubuta da masu bita da alama ba su saba da ɗayan waɗannan ba. https://c19p.org/awad
386. M. Oztas, M. Bektas, I. Karacan, N. Aliyeva, A. Dag, S. Aghamuradov, S. Cevirgen, S. Sari, M. Bolayirli, G. Can, G. Hatemi, E. Seyahi, H. Ozdogan, A. Gul, da S. Ugurlu, Frequency and Diversity of COVID-19 Kullum tare da Colchicine ko Hydroxychloroquine Maris 2022, J. Likitan Kwayoyin cuta
650 mai haƙuri HCQ nazarin prophylaxis: 215% asibiti mafi girma (p=0.36), 40% ƙarin alamun alamun (p=0.44), da 5% ƙarin lokuta (p=0.88).
Masu amfani da HCQ 317 na baya da kuma abokan hulɗa na gida 333, suna nuna haɗari mafi girma tare da HCQ. https://c19p.org/oztas
387. H. Gerlovin, D. Posner, Y. Ho, C. Rentsch, J. Tate, J. King, K. Kurgansky, I. Danciu, L. Costa, F. Linares, I. Goethert, D. Jacobson, M. Freiberg, E. Begoli, S. Muralidhar, R. Ramoni, G. Tourassi., Gano D. Chozi. Pharmacoepidemiology, Koyan Injin da COVID-19: Niyya-don-biyar da bincike na hydroxychloroquine, tare da ko ba tare da azithromycin ba, da sakamakon COVID-19 a tsakanin Tsohon Sojan Amurka da ke asibiti Jun 2021, American J. Epidemiology, juzu'i na 190, fitowa ta 11, Shafi na 2405-2419
MAGANIN LAFIYA 1,199 mai haƙuri HCQ marigayi nazarin jiyya: 22% mafi girma mace-mace (p=0.18) da 55% mafi girma samun iska (p=0.02).
Marasa lafiya 1,769 da ke asibiti a Amurka baya nuna ba su da bambance-bambance masu mahimmanci ga HCQ, da intubation mafi girma don HCQ+AZ. https://c19p.org/gerlovin
388. L. Shahrin, M. Mahfuz, M. Rahman, M. Hossain, A. Khandaker, M. Alam, D. Osmany, M. Islam, M. Chisti, C. Ahmed, da T. Ahmed, Nazarin Quasi-Gwaji na Asibiti akan Hydroxychloroquine Pre-Exposure Prophylaxis ga COVID-19 a cikin Ma'aikatan Lafiya Dec 2022, Rayuwa, juzu'i na 12, fitowa ta 12, Shafi na 2047
336 mai haƙuri HCQ nazarin prophylaxis: 88% ƙarin lokuta (p=0.09).
Ma'aikatan kiwon lafiya marasa haɗari na 230 na baya-bayan nan suna ɗaukar rigakafin HCQ, da 106 waɗanda suka ƙi, suna nuna mafi girma lokuta ba tare da mahimmancin ƙididdiga ba. Ba a bayar da bayanin tsananin yanayin ba. Ƙimar ma'anar ta fi son HCQ lokacin ware kwanakin 14 na farko da kuma haɗa da mahalarta waɗanda suka yi aiki na akalla kwanaki 16. Marubuta sun lura da muhimmiyar alaƙar amsa kashi. https://c19p.org/shahrin
389. H. Burdick, C. Lam, S. Mataraso, A. Siefkas, G. Braden, R. Dellinger, A. McCoy, J. Vincent, A. Green-Saxena, G. Barnes, J. Hoffman, J. Calvert, E. Pellegrini, da R. Das, Shin Injin Koyo Mafi Kyawu Don Gano COVID-19 Daga Maganin Hydroxychloroquine?—Gwamnatin Gano Nov 2020, J. Magungunan asibiti, juzu'i na 9, fitowa ta 12, Shafi na 3834
MAGANIN LAFIYA 290 mai haƙuri HCQ marigayi nazarin jiyya: 59% mafi girma mace-mace (p=0.12).
Gwajin lura da haƙuri na 290 a cikin Amurka, baya nuna babban bambanci tare da jiyya na HCQ gabaɗaya, amma yana nuna ƙarancin mace-mace a cikin rukunin marasa lafiya inda ake tsammanin HCQ zai kasance da fa'ida bisa ga na'urar koyo algorithm. https://c19p.org/burdick
390. J. Pablos, M. Galindo, L. Carmona, A. Lledó, M. Retuerto, R. Blanco, M. Gonzalez-Gay, D. Martinez-Lopez, I. Castrejón, J. Alvaro-Gracia, D. Fernández Fernández, A. Mera-Varela-, Vánaquez, Vánaquez, S.ri N. Man, da kuma A. Fernandez-Nebro, Sakamako na asibiti na marasa lafiya na asibiti tare da COVID-19 da cututtukan kumburi na yau da kullun da cututtukan rheumatic na autoimmune: nazarin ƙungiyoyi masu yawa da suka dace. Agusta 2020, Littattafai na Cututtukan Rheumatic, Juzu'i na 79, Fitowa ta 12, Shafi na 1544-1549
MAGANIN LAFIYA 228 mai haƙuri HCQ marigayi nazarin jiyya: 126% mafi girma lokuta masu tsanani (p=0.002).
Cutar cututtukan rheumatic 228 da 228 marasa lafiya marasa lafiya sun kwantar da marasa lafiya na COVID-19 a Spain, suna nuna babban haɗarin COVID-19 mai tsanani tare da jiyya na HCQ. https://c19p.org/pablos
391. M. Kalligeros, F. Shehadeh, E. Atalla, E. Mylona, S. Aung, A. Pandita, J. Larkin, M. Sanchez, F. Touzard-Romo, A. Brotherton, R. Shah, C. Cunha, da E. Mylonakis, Hydroxychloroquine da aka yi amfani da su a cikin marasa lafiya na asibiti tare da COVID-19: Nazarin covid-XNUMX Agusta 2020, J. Juriya na Ƙwayoyin cuta na Duniya, juzu'i na 22, Shafi na 842-844
MAGANIN LAFIYA 108 mai haƙuri HCQ marigayi nazarin jiyya: 67% mafi girma mace-mace (p=0.57).
Ƙananan nazarin bayanan bayanan baya na marasa lafiya 36 da ke karɓar HCQ ba su nuna bambance-bambance masu mahimmanci ba. Mai yiwuwa mai ruɗawa ta nuni. https://c19p.org/kalligeros
392. J. Mallat, F. Hamed, M. Balkis, M. Mohamed, M. Mooty, A. Malik, A. Nusair, da M. Bonilla, Hydroxychloroquine yana da alaƙa da raguwar ƙwayar cuta a cikin marasa lafiya na COVID-19 na asibiti tare da cuta mai laushi zuwa matsakaici: Nazarin baya. Mayu 2020, Magunguna, juzu'i na 99, fitowa ta 52, Shafi e23720
MAGANIN LAFIYA 34 mai haƙuri HCQ marigayi nazarin jiyya: 203% jinkirin jinkirin ƙwayar cuta (p=0.02).
Ƙananan ƙididdiga na baya-bayan nan na marasa lafiya 34 suna samun raguwar ƙwayar cuta ta PCR na binary tare da HCQ. Ba a bayar da bayani kan tsananin kulawa da kulawa ba. Babu mace-mace, shigar ICU, ko iskar injina. Binary PCR baya bambance kwafi-ƙwarewa. Maganin HCQ ya fara a makare ga yawancin marasa lafiya tare da> = 9 kwanaki don 25%. https://c19p.org/mallat
393. B. Tirupakuzhi Vijayaraghavan, V. Jha, D. Rajbhandari, S. Myatra, A. Ghosh, A. Bhattacharya, S. Arfin, A. Bassi, L. Donaldson, N. Hammond, O. John, R. Joshi, M. Kunigari, C. Amrutha, S. Husaini, S. Narajo, S. Narajo, H. Ghosh K. Shah, da B. Venkatesh, Hydroxychloroquine da kayan kariya na sirri tare da kayan kariya na sirri kawai don rigakafin kamuwa da cutar COVID-19 da aka tabbatar da dakin gwaje-gwaje a tsakanin ma'aikatan kiwon lafiya: cibiyar da yawa, rukunin rukuni-rukuni bazuwar gwaji daga Indiya. Mayu 2022, Buɗe BMJ, Juzu'i na 12, Fitowa ta 6, Shafi e059540
414 mai haƙuri HCQ prophylaxis RCT: 196% ci gaba mafi girma (p=1), 52% ƙananan asibiti (p=0.62), da 14% ƙananan lokuta (p=0.73).
Ƙarƙashin ƙwayar cuta RCT tare da ƙananan ma'aikatan kiwon lafiya masu haɗari a Indiya, ba tare da nuna bambanci ba. Ba a bayar da sakamakon alamun alamun ba. Biyan ya wuce watanni 6, duk da haka magani ya ƙare bayan watanni 3. 21% na marasa lafiya sun daina magani kafin watanni 3 (Table S2). https://c19p.org/tirupakuzhi
394. R. Ferreira, R. Beranger, P. Sampaio, J. Mansur Filho, da R. Lima, Sakamakon da ke da alaƙa da Hydroxychloroquine da Ivermectin a cikin marasa lafiya na asibiti tare da COVID-19: ƙwarewar cibiyar guda ɗaya. Nov 2021, Revista da Associação Médica Brasileira, Juzu'i na 67, Fitowa ta 10, Shafi na 1466-1471
MAGANIN LAFIYA 192 mai haƙuri HCQ marigayi nazarin jiyya: 151% mafi girma mace-mace (p=0.03) da 46% mafi girma hade mace-mace / intubation (p=0.23).
Marasa lafiya na asibiti 230 na baya-bayan nan a Brazil suna nuna yawan mace-mace tare da maganin HCQ. Marubuta sun lura cewa ana iya ba da jiyya ga marasa lafiya marasa lafiya. Marubuta sun lura cewa ba su sani ba idan an fara magani kafin ko bayan shigar da ICU da shigar da su. Ba a san adadin sashi ba. https://c19p.org/ferreira2h
395. A. Spivak, B. Barney, T. Greene, R. Holubkov, C. Olsen, J. Bridges, R. Srivastava, B. Webb, F. Sebahar, A. Huffman, C. Pacchia, J. Dean, da R. Hess, A Randomized Clinical Trial Testing Hydroxychloroquine don Ragewar Asibitin COVID-2 na Farko a cikin Asibiti-Covid-19. Kamuwa da cuta Mar 2023, Spectrum Microbiology, Juzu'i na 11, fitowa ta 2
MAGANIN LAFIYA 367 mai haƙuri HCQ marigayi magani RCT: 73% asibiti mafi girma (p = 0.54), 20% inganta farfadowa (p= 0.19), da 17% inganta ƙwayar cuta (p=0.19).
Jinkirin bugawa na farkon ƙarewar jiyya RCT tare da ƙananan haɗari (babu mace-mace) marasa lafiya a cikin Amurka, yana nuna babu wani bambanci mai mahimmanci tare da HCQ. Marubuta ba su ba da bayanan farkon alamun ba, amma bincike na rukuni ya nuna cewa ƙarin marasa lafiya na iya kasancewa a cikin rukunin kwanaki 5+. (ƙididdigar ƙungiyar 5+ tana da ƙaramin tazarar amincewa, kuma gabaɗayan ma'ana / matsakaici na HCQ ya fi kusa da ƙungiyar 5+). An fara jiyya kwana ɗaya bayan yin rajista bisa ga Table S1 (rahotan marubutan "fiye da kwana 1 bayan bazuwar"A cikin rubutu) Wannan yana nuna cewa yawancin marasa lafiya an yi musu magani kwanaki 6+ bayan farawa. Ana ba da bincike na rukuni don <5, ≥5 kwanaki kawai don tsawon lokacin zubar da kwayar cutar, kuma yana nuna ingantaccen sakamako don maganin farko. Rikodin ya kasance 66% kawai (Hoto 1). Bugawa ya kasance watanni 21 bayan kammala shari'ar. An canza sakamakon da aka yi rajista a Nuwamba 2022, Disamba 2022, da Janairu 2023, sama da shekara guda bayan kammala gwajin. Misali, a cikin Janairu 2023, an share sakamakon sayan gida a cikin kwanaki 28, ya bar kwanaki 14 kacal. Akwai nau'ikan tsarin ƙididdigar ƙididdiga guda 7, duk waɗanda aka yi kwanan watan bayan fara gwaji, da 5 kwanan wata bayan an kammala shari'ar. Yawancin sakamako a cikin SAP sun ɓace, ciki har da mutuwar watanni 6 da asibiti, QOL, da KM don asibiti / mace-mace. Musamman ma, mawallafa suna ba da ƙididdigar ƙungiyar shekaru don ƙididdige alamun alama da watsawa, amma ba sa ba da lokacin daga binciken farko. Rashin cikakkun bayanai na farkon alamun bayyanar, rashin nazarin rukunin rukunin farko don sakamakon asibiti, da iƙirarin kuskure na marubuta cewa babu ɗaya daga cikin RCTs har zuwa yau da ke nuna "ma'anar sakamako na asibiti" da ke nuna nuna son kai.. https://c19p.org/spivak
396. A. Schmidt, M. Tucker, Z. Bakouny, C. Labaki, C. Hsu, Y. Shyr, A. Armstrong, T. Beer, R. Bijjula, M. Bilen, C. Connell, S. Dawsey, B. Faller, X. Gao, B. Gartrell, D. Gill, S. Gulati. Menon, M. Morris, M. Puc, K. Russell, D. Shah, N. Shah, N. Sharifi, J. Shaya, M. Schweizer, J. Steinharter, E. Wulff-Burchfield, W. Xu, J. Zhu, S. Mishra, P. Grivas, B. Rini, J. Warner, T. Zhang, R. Choei. Cohen, A. Olszewski, A. Bardia, A. Daher, A. Brown, A. Yeh, A. Hsiao et al., Ƙungiyar Tsakanin Androgen Deprivation Therapy da Mutuwa Tsakanin Marasa lafiya da Ciwon Jiki na Prostate da COVID-19 Nov 2021, JAMA Network Buɗe, Juzu'i na 4, Fitowa ta 11, Shafi e2134330
MAGANIN LAFIYA 477 mai haƙuri HCQ marigayi magani PSM binciken: 333% mafi girma mace-mace (p=0.0001) da 613% mafi girma lokuta (p <0.0001).
Marasa lafiya 1,106 na cutar kansar prostate, suna nuna yawan mace-mace tare da maganin HCQ. https://c19p.org/schmidth
397. R. Barnabas, E. Brown, A. Bershteyn, H. Stankiewicz Karita, C. Johnston, L. Thorpe, A. Kottkamp, K. Neuzil, M. Laufer, M. Deming, M. Paasche-Orlow, P. Kissinger, A. Luk, K. Paolino, R. Landovitz, R. Hoffws, T. Hoffws, R. S. Morrison, H. Haugen, L. Kidoguchi, M. Wener, A. Greninger, M. Huang, K. Jerome, A. Wald, C. Celum, H. Chu da J. Baeten Dec 2020, Littattafan Likitan Ciki, Juzu'i na 174, Fitowa ta 3, Shafi na 344-352
829 mai haƙuri HCQ prophylaxis RCT: 27% ƙarin lokuta (p=0.33).
Tun da farko an dakatar da rigakafin pre-bayyana RCT kwatanta HCQ da bitamin C tare da marasa lafiya marasa lafiya 781 (83% na gida), ba da rahoton wani babban bambanci. An bayar da rahoton sakamako daban-daban a IDWeek taro vs. sama Annals na Internal Medicine bazawa. Binciken ya sanya mutane da bayyanar su ta ƙarshe a cikin kwanaki 4, watau, idan an fallasa wani na tsawon kwanaki 30 a jere, ana iya yin rajista a ko'ina daga rana ta 1 zuwa rana ta 34. Saboda haka, da yawa sun kamu da cutar kafin ranar rajista. Lura cewa PCR yana da ƙima mara kyau na ƙarya, misali, 100% a ranar 1 da 67% a ranar 4. An gano 50% na cututtuka ta rana ta 4. Tare da PCR karya karya da jinkirin jiyya yana yiwuwa yawancin cututtuka sun faru kafin yin rajista ko kafin HCQ na iya isa matakan warkewa. Mahimmanci mafi mahimmanci an kama su a asali a cikin ƙungiyar kulawa (54 vs. 29 don HCQ) kuma an cire su daga bincike. Gabatarwar farko ta bayyana cewa an fara farfaɗo kwana ɗaya bayan an aika da rajista da kayan karatu ga mahalarta “ko dai ta hanyar isar da sako ko ta wasiku."Takardar da aka buga ta canza wannan zuwa"isar da sako a cikin awanni 48." Gabaɗaya jinkiri ba a bayyana ba amma yana iya zama: lokaci tun bayyanar farko - lokaci marar iyaka daga bayyanar ƙarshe zuwa rajista - 10% an ruwaito kamar yadda > = Kwanaki 5 zuwa taron wayar tarho - kwana 1 (kwanaki 3 idan ranar Juma'a?) lokacin karbar magani - <48 hours (ciki har da karshen mako?) Alamun bayyanar cututtuka a cikin wannan binciken ya dogara ne akan bayyanar cututtuka na CDC wanda ya ƙunshi alamun bayyanar cututtuka wanda zai iya zama saboda HCQ. Ba a bayar da rahoton wasu sakamakon ba, gami da alamomi @ kwanaki 28. Nazarin yana amfani da ƙananan sashi na tsawon lokaci, matakan warkewa za a iya isa kawai kusa da ranar 14, idan a duka., Don haka sakamakon ranar 28 ya kamata ya zama ƙarin bayani lokacin da ake samuwa (ko da yake an yi wa lakabi da gwajin PEP, tare da ƙananan ƙididdiga da ci gaba da nunawa ga yawancin mahalarta shine mafi yawan gwajin PrEP / PEP inda za a iya ganin amfani daga baya yayin da matakan HCQ ya karu). Abubuwan ƙarshe sune: Sakamakon farko: PCR+ @ kwanaki 28 mITT - aHR 1.16 [0.77-1.73] PCR+ @ kwanaki 14 mITT - aHR 1.10 [0.73-1.66] Rahoton IDWeek ya bambanta: aHR 0.99 [0.64-1.52] PCR + [14-0.81] Sakandare na biyu: PCR+ alamar alama @ kwanaki 0.57 - HAR YANZU BA A RUWAITO BA tsawon lokacin zubar da ciki - HAR YANZU BA A RUWAITO BA. Ba a cikin ƙa'idar nazarin ba: PCR+ tara alamun alamun @14 kwanaki - aHR 1.23 [0.76-1.99]. Kashi a cikin sa'o'i 24 na farko - 0.8g (kwatanta da Boulware et al. 2g) Kashi a cikin kwanaki 5 na farko - 1.6g (kwatanta da Boulware et al. 3.8g) Wani bincike ya nuna cewa bitamin C na iya zama da amfani ga COVID-19. Ba a bayar da bayani kan tsananin lamurra ba. Binary PCR baya bambance kwafi-ƙwarewa. Akwai asibitocin COVID-2 guda 19, ɗaya a cikin kowane rukuni. Abubuwan illa sun kasance iri ɗaya ga HCQ da placebo. 83% bin magani a ranar 14. Gidauniyar Tallafin Farko ta Bill & Melinda Gates. COVID-19 PEP. Saukewa: NCT04328961. https://c19p.org/barnabas
398. W. Self, M. Semler, L. Leither, J. Casey, D. Angus, R. Brower, S. Chang, S. Collins, J. Eppensteiner, M. Filbin, D. Files, K. Gibbs, A. Ginde, M. Gong, F. Harrell, D. Hayden, C. Houghse, Khan, N. M. Moss, P. Park, T. Rice, B. Robinson, D. Schoenfeld, N. Shapiro, J. Steingrub, C. Ulysse, A. Weissman, D. Yealy, B. Thompson, da S. Brown, Tasirin Hydroxychloroquine akan Matsayin Asibiti a Kwanaki 14 a Asibiti 19 Marasa lafiya na Asibiti Nov 2020, JAMA, Juzu'i na 324, Fitowa ta 21, Shafi na 2165
MAGANIN LAFIYA 477 mai haƙuri HCQ marigayi magani RCT: 6% mafi girma mace-mace (p=0.85) da 3% mafi muni 7-ma'auni sakamakon sakamakon (p=0.87).
An ƙare da wuri matuƙar ƙarshen mataki (65% akan ƙarin oxygen) RCT tare da 242 HCQ da 237 masu kula da marasa lafiya ba su nuna wani bambanci mai mahimmanci a sakamakon. Don rukunin rukunin ba akan ƙarin oxygen ba a asali (dangantaka da farkon jiyya), ƙimar rashin daidaituwa ga ma'aunin sakamako na maki 7 shine: daidaita daidaiton rabo 0.61 [0.34-1.08]. https://c19p.org/self
399. R. Ulrich, A. Troxel, E. Carmody, J. Eapen, M. Bäcker, J. DeHovitz, P. Prasad, Y. Li, C. Delgado, M. Jrada, G. Robbins, B. Henderson, A. Hrycko, D. Delpachitra, V. Raabe, J. Austrian, Y. D. , da Treating-Dub Hydroxychloroquine (TEACH): A Multi-center, Biyu-Makafi, Gwajin Gudanar da Bazuwar a cikin Marasa lafiya na Asibiti Sep 2020, Dandalin Budaddiyar Cututtuka masu Yaduwa, juzu'i na 7, fitowa ta 10
MAGANIN LAFIYA 128 mai haƙuri HCQ marigayi magani RCT: 6% mafi girma mace-mace (p=1) da 173% mafi girma ICU shigar (p=0.13).
Ƙananan RCT akan amfani da ƙarshen mataki na HCQ, tare da 48% akan oxygen a asali. 67 HCQ marasa lafiya, 61 sarrafawa. Jihohin asali ba su kasance daidai ba - 82% ƙarin marasa lafiya na HCQ sun sami mafi girma a cikin asali, akwai 32% ƙarin marasa lafiya na HCQ maza, kuma 44% ƙarin marasa lafiya sun yi amfani da AZ.. Ƙungiyar HCQ kuma tana da ƙarin majiyyata da yawa masu fama da cututtukan cerebrovascular, cututtukan zuciya (rashin hawan jini), cututtukan koda (marasa dialysis), da tarihin dashen gabobin jiki. https://c19p.org/ulrich
400. C. Babayigit, N. Kokturk, S. Kul, P. Cetinkaya, S. Atis Nayci, S. Argun Baris, O. Karcioglu, P. Aysert, I. Irmak, A. Akbas Yuksel, Y. Sekibag, O. Baydar Toprak, E. Azak, S. Mulamahmutoglu, B. Cuhadar, C.. Ketencioglu. Tor, G. Gunluoglu, S. Altin, T. Turgut, T. Tuna, O. Ozturk, O. Dikensoy, P. Yildiz Gulhan, I. Basyigit, H. Boyaci, I. Oguzulgen, S. Borekci, B. Gemicioglu, F. Bayraktar, O. Elbek et al., The antiviral kwayoyi na COVID-19. nazarin ƙungiyar COVID-19 na ƙasa baki ɗaya Aug 2022, Gaba a Magunguna, Juzu'i na 9
MAGANIN LAFIYA 1,472 mai haƙuri HCQ marigayi nazarin jiyya: 112% mafi girma samun iska (p=0.21), 53% mafi girma shigar ICU (p=0.33), da 17% tsawon asibiti (p=0.05).
A baya-bayan nan 1,472 marasa lafiya na asibiti a Turkiyya, suna nuna haɗarin shigar ICU da samun iska tare da HCQ, ba tare da mahimmancin ƙididdiga ba. https://c19p.org/babayigith
401. O. Babalola, Y. Ndanusa, A. Ajayi, J. Ogedengbe, Y. Thairu, da O. Omede, A Randomized Controlled Trial of Ivermectin Monotherapy Versus Hydroxychloroquine, Ivermectin, and Azithromycin Combination Therapy in Covid-19 Patients in Nigeria Sep 2021, J. Cututtuka masu Yaduwa da Cutar Kwalara, juzu'i na 7, fitowa ta 10
MAGANIN LAFIYA 60 mai haƙuri HCQ marigayi magani RCT: 55% ƙananan fitarwa na asibiti (p = 0.2) da 10% inganta ƙwayar cuta (p=0.78).
Ƙananan RCT tare da marasa lafiya 61 a Najeriya, duk marasa lafiya sun yi amfani da ivermectin, zinc, da bitamin C, ba su nuna wani gagarumin ci gaba a farfadowa tare da ƙarin HCQ+AZ. https://c19p.org/babalola2h
402. F. Syed, M. Hassan, M. Arif, S. Batool, R. Niazi, U. Laila, S. Ashraf, da J. Arshad, Pre-exposure Prophylaxis Tare da Daban-daban na Hydroxychloroquine Daga cikin Ma'aikatan Kiwon Lafiya tare da Babban Haɗarin Bayyanawa ga COVID-19: Gwajin Sarrafa Bazuwar Mayu 2021, Cureus
101 mai haƙuri HCQ prophylaxis RCT: 60% ƙarin lokuta alamun bayyanar cututtuka (p=0.41) da 92% ƙarin lokuta (p=0.12).
Ƙananan PrEP RCT na ƙananan ma'aikatan kiwon lafiya masu haɗari, ba tare da nuna bambanci ba. Marubuta sun ba da rahoton cewa babu asibiti, kulawar ICU, ko mutuwa daga COVID-19, duk da haka tebur na 3 na preprint yana nuna munanan al'amura da aka lakafta a matsayin "bukatar asibiti" Sakamakon bayyanar cututtuka da tsananin cututtuka a cikin tebur 3 da 4 sun bayyana rashin daidaituwa.. Saukewa: NCT04359537. https://c19p.org/syed
403. J. Calderón, S. Padmanabhan, F. Salazar, D. Hernández, A. Martínez, C. Ortiz, H. Zerón, Jiyya tare da hydroxychloroquine vs nitazoxanide a cikin marasa lafiya tare da COVID-19: taƙaitaccen rahoto Nov 2021, PAMJ - Magungunan Asibiti
MAGANIN LAFIYA 44 mai haƙuri HCQ marigayi binciken jiyya: 215% mafi girma mace-mace (p=0.38), 652% mafi girma samun iska (p=0.15), 145% mafi girma ICU shigar (p <0.0001), da 107% tsawo asibiti (p=0.007).
Shirye-shiryen RCT na HCQ vs. HCQ+nitazoxanide wanda aka soke saboda yanzu. Janye takarda Surgisphere rubuta ta wulakanci, yanzu tsohon likita Sapan Desai. Mawallafa sun sake nazarin ƙananan ƙananan marasa lafiya na HCQ vs. nitazoxanide (waɗanda suka kasance ƙetare yarjejeniya a cikin RCT da aka tsara), suna nuna rage lokacin asibiti da shigar da ICU tare da nitazoxanide. https://c19p.org/calderon2h
404. . Agusta 2021, Int. J. Magungunan rigakafi, juzu'i na 58, fitowa ta 5, shafi na 106428
MAGANIN FARKO 84 mai haƙuri HCQ farkon jiyya RCT: 14% ingantacciyar kariya ta hoto (p=0.15).
RCT 84 ƙananan marasa lafiya, 42 da aka bi da su tare da HCQ / AZ, ba tare da nuna bambanci ba. Asibiti daya ne kawai wanda ke hannun jiyya. https://c19p.org/rodrigues
405. A. Llanos-Cuentas, A. Schwalb, J. Quintana, B. Delfin, F. Alvarez, C. Ugarte-Gil, R. Guerra Gronerth, A. Lucchetti, M. Grogl, da E. Gotuzzo, Hydroxychloroquine don hana SARS-CoV-2 kamuwa da cuta a tsakanin ma'aikatan kiwon lafiya, lokacin da aka gudanar da gwajin-ma'aikatan kiwon lafiya, ƙarshen gwaji na 3. Feb 2023, Bayanan Bincike na BMC, juzu'i na 16, fitowa ta 1
68 mai haƙuri HCQ prophylaxis RCT: 69% ƙarin lokuta (p=0.46).
Ma'aikacin kiwon lafiya da aka dakatar da farko PrEP RCT tare da marasa lafiya 68 kawai da shari'o'in 8, suna nuna babu wani bambanci mai mahimmanci tare da HCQ. Ba a bayar da bayani kan alamomin kowane rukuni, tsananin yanayin, ko lokacin lokuta da aka bayar. https://c19p.org/llanoscuentas
406. S. Florescu, D. Stanciu, M. Zaharia, A. Kosa, D. Codreanu, A. Kidwai, S. Masood, C. Kaye, A. Coutts, L. MacKay, C. Summers, P. Polgarova, N. Farahi, E. Fox, S. McWilliam, D. Hawcutt, L. J'D Jones, L. Radley R. Dore, P. Saunderson, O. Kelsall, N. Cowley, L. Wild, J. Thrush, H. Wood, K. Austin, J. Bélteczki, I. Magyar, Á. Fazekas, S. Kovács, V. Szőke, A. Donnelly, M. Kelly, N. Smyth, S. O'Kane, D. McClintock, M. Warnock, R. Campbell, E. McCallion, A. Azaiz, C. Charron, M. Godement, G. Geri, A. S., Hannaley Johnson, da dai sauransu. al., Sakamako na Dogon lokaci (kwana 180) a cikin Majinyata Masu Mummunan Ciki Tare da COVID-19 a cikin Gwajin Rarraba REMAP-CAP Dec 2022, JAMA
MAGANIN LAFIYA 352 mai haƙuri HCQ ICU RCT: 51% mafi girma mace-mace (p=0.06).
Bibiyar dogon lokaci don REMAP-CAP matuƙar matuƙar gwajin ICU, yana nuna haɗari mafi girma tare da HCQ, ba a kai ga mahimmancin ƙididdiga ba. https://c19p.org/higgins
407. A. Barratt-Due, I. Olsen, K. Nezvalova-Henriksen, T. Kåsine, F. Lund-Johansen, H. Hoel, A. Holten, A. Tveita, A. Mathiessen, M. Haugli, R. Eiken, A. Kildal, Å. Berg, A. Johannessen, L. Heggelund, T. Dahl, K. Skåra, P. Mielnik, L. Le, L. Thoresen, G. Ernst, D. Hoff, H. Skudal, B. Kittang, R. Olsen, B. Tholin, C. Ystrøm, N. Skei, T. A. Dussen, O. Dalgard, A. Finbråten, K. Tonby, B. Blomberg, S. Aballi, C. Fladeby, A. Steffensen, F. Müller, A. Dyrhol-Riise, M. Trøseid, da P. Aukrust, Ƙimar Tasirin Remdesivir da Hydroxychloroquine a kan COVID-19 Jul 2021, Littattafai na Magungunan Cikin Gida, juzu'i na 174, fitowa ta 9, Shafi na 1261-1269
MAGANIN LAFIYA 93 mai haƙuri HCQ marigayi magani RCT: 120% mafi girma mace-mace (p=0.35).
Ƙananan RCT a Norway tare da 52 HCQ da 42 marasa lafiya na remdesivir, ba su nuna wani bambanci mai mahimmanci tare da magani. Add-on gwaji ga WHO SOLIDARITY. Saukewa: NCT04321616. https://c19p.org/barratdue
408. I. Schwartz, M. Boesen, G. Cerchiaro, C. Doram, B. Edwards, A. Ganesh, J. Greenfield, S. Jamieson, V. Karnik, C. Kenney, R. Lim, B. Menon, K. Mponponsuo, S. Rathwell, K. Ryckborst, B. Stewart, L. Hillang, L. Yaskina, L. Yaskina, M. Hilla, M. Hill, da kuma M. Hill Messeng inganci da amincin hydroxychloroquine azaman jiyya na COVID-19: gwajin da bazuwar sarrafawa Jun 2021, CMAJ Buɗe, juzu'i na 9, fitowa ta 2, Shafi E693-E702
MAGANIN LAFIYA 179 mai haƙuri HCQ marigayi magani RCT: 37% inganta farfadowa (p=0.15).
Ƙananan da wuri da aka ƙare a ƙarshen jiyya RCT yana nuna babu bambance-bambance masu mahimmanci. Ƙungiyar HCQ ta kasance a Tsakanin kwanaki 7 daga farkon bayyanar cututtuka a asali, wanda bazai haɗa da jinkirin ba da magani ba. Daga asibitocin 4 na HCQ, daya ne kawai a cikin nazarin yarjejeniya, kuma an kwantar da majinyacin wata rana bayan bazuwar (marubuta ba su bayyana idan mai haƙuri ya karbi HCQ ba kafin asibiti). An dakatar da shari'ar da wuri saboda labarin Lancet na yaudara (kalmomi a nan sun sha bamban tsakanin nau'ikan da aka ƙaddamar da waɗanda aka buga). Binciken ƙa'idodin ƙa'ida, sigar da aka ƙaddamar, da sharhin nazari na takwarori (masu duba guda biyu, ɗaya kaɗai tare da ra'ayi mai mahimmanci) suna cikin ƙarin kayan. Lokacin da majiyyaci ya ba da rahoton wata alama, an tambaye su ko har yanzu suna fuskantar wannan alamar, kuma su zaɓi tsakanin waɗannan zaɓuɓɓuka guda uku yayin kwatanta alamar zuwa jiharsu ta COVID-19: (1) "Ee, wannan matsalar ta kasance iri ɗaya"; (2) "Eh, amma an sami WASU cigaba"; ko (3) "A'a, wannan ya dawo al'ada." An rarraba mai haƙuri a matsayin "babu ci gaba" a cikin shekaru 1 idan sun bayar da rahoton ≥1 alama a duka ziyarar, wanda ya nuna cewa matsalar ta kasance iri ɗaya a cikin shekaru 1. Dagewa yana nufin marasa lafiya suna ba da rahoton alamar ≥1 da ta bulla bayan COVID-19 kuma har yanzu tana nan a lokacin tantancewar. Don kasancewar alamun, mai haƙuri ya ba da rahoton alamar ≥1 da ta fito tare da ko bayan kamuwa da cutar ta COVID-19 a wani lokaci kafin lokacin tantancewa. https://c19p.org/schwartz2
409. A. Réa-Neto, R. Bernardelli, B. Câmara, F. Reese, M. Queiroga, da M. Oliveira, Buɗaɗɗen lakabin gwaji mai sarrafawa wanda ke kimanta ingancin chloroquine/hydroxychloroquine a cikin marasa lafiya na COVID-19 mai tsanani. Afrilu 2021, Rahoton Kimiyya, Juzu'i na 11, fitowa ta 1
MAGANIN LAFIYA 105 mai haƙuri HCQ marigayi magani RCT: 57% mafi girma mace-mace (p=0.2), 115% mafi girma samun iska (p=0.03), da 147% muni dawo (p=0.02).
An ƙare farkon matakin ƙarshe (99% akan oxygen, 81% a cikin ICU, 18% akan iskar injina a tushe) RCT tare da marasa lafiya na 24 CQ, 29 HCQ, da marasa lafiya na 52, suna nuna mummunan sakamako na asibiti tare da magani. Saukewa: NCT04420247. https://c19p.org/reanato
-
Dokta David Gortler masanin ilimin harhada magunguna ne, likitan harhada magunguna, masanin kimiyyar bincike kuma tsohon memba na Babban Jami'in Gudanarwa na FDA wanda ya zama babban mai ba da shawara ga Kwamishinan FDA akan al'amuran: Al'amuran ka'idoji na FDA, amincin magunguna da manufofin kimiyya na FDA. Shi tsohon jami'ar Yale ne da kuma jami'ar Georgetown didactic farfesa a fannin harhada magunguna da fasahar kere-kere, tare da sama da shekaru goma na koyar da ilimin kimiyya da bincike na benci, a zaman wani bangare na kwarewarsa ta kusan shekaru ashirin a ci gaban muggan kwayoyi. Shi babban ɗan'uwa ne a fannin kiwon lafiya da manufofin FDA a Gidauniyar Heritage a Washington DC da 2023 Brownstone Fellow.
Duba dukkan posts
